Towards subunit specific proteasome inhibitors by Linden, W.A. van der
Towards subunit specific proteasome inhibitors
PROEFSCHRIFT
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P. F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 22 december 2011
klokke 15:00 uur
door
Wouter Alexander van der Linden
Geboren te Rotterdam in 1983
Promotie commissie
Promotor: Prof. Dr. H. S. Overkleeft
Co-promotores: Prof. Dr. A. F. Kisselev
Dr. B. I. Florea
Overige leden: Prof. Dr. C. A. van Boeckel
Prof. Dr. M. Kaiser
Prof. Dr. J. Brouwer
Prof. Dr. G. A. van der Marel
Prof. Dr. M. Groll
The printing of this thesis was financially supported by the J. E. Jurriaanse stichting.
Typeset in LATEX
Printed by Wöhrman Print Service
Van wie moet dat dan?
Table of Contents
List of Abbreviations vi
1 General Introduction 1
1.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Ubiquitin Proteasome System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.3 Structure and function of the proteasome . . . . . . . . . . . . . . . . . . . . . . . 2
1.4 Proteasome inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.5 Natural occurring proteasome inhibitors . . . . . . . . . . . . . . . . . . . . . . . 4
1.6 Synthetic proteasome inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.7 Therapeutic implications of proteasome inhibition . . . . . . . . . . . . . . . . . 14
1.8 Subunit selective proteasome inhibitors . . . . . . . . . . . . . . . . . . . . . . . . 16
1.9 Aim and outline of this Thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2 Subunit selectivity of a proteasome inhibitor is influenced by the electrophile 23
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.4 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3 Proteasome selectivity towards Michael acceptor containing oligopeptide-based
inhibitors 39
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.4 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4 Syringolin ureido-peptide moiety containing inhibitors show tunable subunit
selectivity 63
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
4.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.4 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
5 Two-step bioorthogonal activity-based proteasome profiling using copper-free
click reagents: a comparative study 83
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
5.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
iv
5.4 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
6 Basicity at P1 and P3 induces β2 selectivity in proteasome inhibitors 91
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
6.2 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
6.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
6.4 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
7 Summary and Future Prospects 109
7.1 Experimental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
References 131
Samenvatting 147











Ada 1-adamantyl acetic acid
Ahx 6-aminohexanoic acid
AMC 7-amino-4-methyl coumarin
APT attached proton test
aq. aqueous
ATP adenosine triphosphate














DC dual colour molecular weight marker
DCM dichloromethane
dd double doublet











EL4 murine lymphoid cell line
























LMP2 low molecular weight protein 2, β1i
LMP7 low molecular weight protein 7, β5i
M molar
m multiplet






MHC I major histocompatibility complex
class I
min. minute(s)
MS (ESI) mass spectrometry (electronspray
ionization)




PAI protein abundance index
PBS phosphate buffered saline









RAJI human lymphocyte cell line derived
from Burkitt’s lymphoma
RAW264.7 mouse leukaemic monocyte
macrophage cell line
rcf relative centrifugal force
RT room temperature
s singlet
Sacc. Pier Andrea Saccardo
sat. saturated
SDS sodium dodecyl sulfate
SDS-PAGE sodium dodecyl sulfate
polyacrylamide gel electrophoresis
sp. species




















UPS ubiquitin proteasome system
VS vinyl sulfone
Z benzyloxycarbonyl
Note: The one or three letter codes for the amino
acids follow the recommendations of IUPAC. J. Biol.







Protein quality and half life are essential for the function of a cell and are controlled in
a tightly regulated fashion. Most of this work is carried out by the ubiquitin-proteasome
system (UPS), which degrades 60-90% of all proteins in the nucleus and cytoplasm of the eu-
karyotic cell.1,2 Central function in this process is proteolysis of substrates by the 26S pro-
teasome, a large multicatalytic complex, crucial for cell viability. The proteasome degrades
abnormal, damaged or misfolded proteins and is responsible for degrading short-lived reg-
ulatory proteins involved in cell differentiation, cell cycle regulation, transcriptional regu-
lation, inflammation and apoptosis. Proteasomal degradation of substrates generates pep-
tides, a fraction of which are used for MHC class I presentation. Hence, the proteasome
is involved in almost all cellular processes and its deregulation is associated with many dis-
eases. The proteasome contains catalytically active subunits with different substrate speci-
ficities and the role of these individual proteolytic activities of the proteasome in normal or
diseased state is a question that is largely unanswered. This thesis aims at developing sub-
unit specific inhibitors of the proteasome to study the individual function of proteasome
active subunits in vivo.
1.2 Ubiquitin Proteasome System
The ubiquitin proteasome system is the major proteolytic machinery in the eukaryotic
cell. Its central task is the degradation of proteins in an ATP and ubiquitin (Ub) dependent
fashion. Ubiquitin, a 9 kDa highly conserved 76 residue protein, is attached to a target
protein by an ATP-dependent cascade of E1, E2 and E3 enzymes. 3 Ubiquitin is activated
by one of the two E1 enzymes,4 which transfers ubiquitin to E2, a family of several dozen
ubiquitin-conjugating enzymes. A member of the very large family of E3 enzymes then
mediates the transfer of activated ubiquitin via its C-terminus to a lysine ǫ-amine of a pro-
1
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tein substrate or an already linked ubiquitin. 5,6 Ubiquitination is further regulated by the
action of one of the many deubiquitinating enzymes (DUB).7 If a protein contains a chain
of four or more Lys48-linked ubiquitin residues, it is recognised by the 26S proteasome as
target for destruction (Figure 1.1A).8 Ubiquitin is recycled as the ubiquitinated substrate
is transported into the catalytic chamber of the proteasome, where the peptide is cut into
small fragments. The average length of peptide products is 3-22 residues, with an average
length of 8-12 amino acids. 9 Most peptides are degraded further into single amino acids
downstream of the proteasome. About 1% escapes this fate and is trimmed N-terminally
by cytosolic aminopeptidases, transported into the endoplasmatic reticulum (ER) to be
loaded on a MHC class-I complex and presented at the cell surface. The proteasome is thus













































































Figure 1.1: (A) Schematic presentation of protein catabolism by the proteasome. (B) Schematic top view of β
ring of the constitutive proteasome. Proteolytic active subunits are depicted in dark gray (C) Proteolytic cycle of
proteasome β subunit.
1.3 Structure and function of the proteasome
The term proteasome refers to a collection of different forms of proteasome, which all con-
tain the catalytic 20S core particle. The eukaryotic 20S core particle is a 700 kDa complex
and is built up from four heptameric rings, two rings of seven distinct α subunits and two
rings of β1−7 subunits, stacked in the order αββα to form a hollow cylindrical structure
160Å by 120Å in dimension. The inside of this cylinder is partitioned into three cavities
2
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of which the central cavity, lined by β subunits, contains the proteolytic active sites. Only
β1, β2 and β5 contain proteolytic activity performed by the N-terminal threonine of these
subunits (Figure 1.1B). Via a water molecule, the N-terminal amine group activates the
γ hydroxyl of Thr1, which performs a nucleophilic attack on the target amide bond.11 A
tetrahedral intermediate is formed, which then degrades into an ester-bound peptide, releas-
ing the amine product of the substrate cleavage. The ester bond is hydrolysed by a water
molecule, regenerating the proteasome Thr1 residue and releasing the carboxylic acid prod-
uct of the substrate (Figure 1.1C).
The catalytically active β subunits differ in their substrate preference, which is induced
by differences in their substrate binding pockets. The β1 subunit (Y/δ) prefers cleaving af-
ter acidic residues (caspase-like activity), β2 (Z) prefers cleavage after basic residues (trypsin-
like activity) and the β5 (X) prefers to cleave after hydrophobic residues (chymotrypsin-like
activity). Substrate preference of the active β has been determined with fluorogenic peptides
and their activities are not as strictly defined as their names suggest and partly overlap.12
For example, next to its preference for acidic residues, β1 is able to cleave after branched
amino acids, residues also processed by β5.13
Entry of protein substrate into the channel of the 20S proteasome is hindered by α
N-termini, preventing unregulated entry of substrates in the catalytic chamber.14 To open
this gate to the proteasome, binding of a regulatory particle is required. Two 19S regula-
tory particle cap the 20S core particle to yield the 26S proteasome.15 The 19S regulatory
particle recognises and deubiquitinates ubiquitinated substrates and promotes their unfold-
ing, while the base of the particle that binds to the α-ring of 20S contains Rpt-subunits
that regulate the opening of the channel into the 20S core particle in an ATP-dependent
fashion. 3,6,16,17
In mammals, the cytokine interferon-γ induces the synthesis of three catalytic sub-
units with different substrate preference. These subunits, called β1i (LMP2), β2i (MECl1)
and β5i (LMP7) replace their constitutive counterparts in newly formed immunoprotea-
somes.18 Furthermore, interferon-γ induces the expression of a different regulatory com-
plex, the 11S or PA28 regulator, able to doubly cap the 20S core particle or form a hy-
brid proteasome (11S-20S-19S).19–21 The immunoproteasome displays substrate preferences
slightly different from the constitutive proteasome. 22,23 Peptides with an average length
of 8-10 amino acids are generated, with more basic and hydrophobic residues at their C-
terminus. These peptides are more optimal for binding to the MHC class I complex for
presentation on the cell surface.10 For a long time, the function of the immunoprotea-
some was assumed to be only to increase the pool of antigenic peptides. However, the
immunoproteasome displays increased efficiency in the degradation of oxidized proteins
and its main function appears to preserve protein homeostasis after inflammation. 24,25 In
cortical thymic epithelial cells a seventh active β subunit is expressed, which is called β5t.
Compared to β5 or β5i, the β5t substrate pocket is more hydrophilic. Subunit β5t is found
together with mainly β1i and β2i in so called thymoproteasomes. The chymotryptic activ-
ity of thymoproteasomes is decreased with respect to constitutive or immunoproteasomes
and thymoproteasomes generate low-affinity MHC class I antigens. This altered pool of
MHC class I ligands is important for the positive selection of developing thymocytes, al-




The UPS has a central role in protein degradation, which ensures its involvement in many
processes. Much knowledge about the proteolytic role of the proteasome in a cellular path-
way has been gathered with the aid of proteasome inhibitors. Over the last decades, an
increasingly large number of proteasome inhibitors has been identified, showing a broad
range of structural features and cellular activities. Nature provides a large spectrum of com-
plicated molecules able to block proteasomal function and the apparent medicinal benefits
of many of these molecules inspired organic chemists to expand the versatility of protea-
some inhibitors even more. Often, a proteasome inhibitor contains an electrophile that
is able to covalently capture the Thr1 Oγ of the proteasome and thereby blocking its cat-
alytic activity. However, many inhibitors inhibit the proteasome in a non-covalent way.
This Chapter gives an overview of classes of proteasome inhibitors.
1.5 Natural occurring proteasome inhibitors
In the search for new leads for medicine development, natural products are very often a
source of inspiration for the development of new agents directed towards therapeutic tar-
gets. Natural products are commonly extracted from plant tissues, marine organisms or
microorganism fermentation broths and screened for beneficial effects on various disease
models. The cellular target of a biologically active molecule identified in such a screen is
then sought for. In cases where natural products inhibit cell cycle progression, inflamma-
tion or microorganism growth, not rarely the proteasome is found to be inhibited. The
variety of natural occurring proteasome inhibitors is very large and this diversity provides
many lead structures for proteasome inhibitors.
1.5.1 Beta-lactones
The metabolite lactacystin (1, Figure 1.2A), produced by a Streptomyces strain, was iden-
tified as an inducer of differentiation of a mouse neuroblastoma cell line and inhibitor of
cell cycle progression due to proteasome inhibition. Lactacystin itself is inactive against the
proteasome, but upon lactonisation, the beta-lactone omuralide is formed (2, Figure 1.2A),
a potent proteasome inhibitor. 28–30 Three other families of beta-lactone natural products,
structurally related to omuralide, have been identified to date. In extracts of the marine acti-
nomycete Salinospora tropica, salinosporamides were identified as agents cytotoxic to cancer
cell lines, with salinosporamide A (3) as most potent member. 31 Highly related to sali-
nosporamides are cinnabaramides, metabolites from terrestrial streptomycete S. cinnabar-
inus with cinnabaramide A (4) depicted in Figure 1.2A. 32 Belactosin A (5), a metabolite
from Streptomyces sp. UCK14, displayes antitumour and antimicrobial activity though cell
cycle inhibition, which was later ascribed to proteasome inhibition. 33,34 Beta-lactones inac-
tivate the proteasome by nucleophilic attack of the proteasome Thr1 Oγ on the carbonyl
of the lactone, thereby forming an ester adduct with the Thr1 Oγ of the active subunits
(Figure 1.2B). In the case of salinosporamide A, as a result of beta-lactone opening, a sec-
ond reaction occurs, forming a tetrahydrofuran ring by displacement of the chloride atom.
The ester bond mediated active site inactivation by beta-lactones is reversible, although this
is a slow process because the orientation of the inhibitor-proteasome adduct is such that
4
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the entry of water into the active site is prevented, thereby preventing deacylation of the

































































Figure 1.2: Structure (A) of beta-lactones found in nature and (B) proteasome inhibition mechanism of salinospo-
ramide A.
1.5.2 Aldehydes
Leupeptin (6, Figure 1.3A) is a protease inhibitor with a broad range of enzyme families
as target due to its reactive aldehyde electrophile. This compound, isolated from various





























































hibit the β2 activity of the proteasome as well. 36,37 Fellutamides are a family of cytotoxic
peptides from marine fungus Penicillium fellutanum, and fellutamide A (7, Figure 1.3A) is a
potent proteasome inhibitor with some preference for the β5 subunit. 38,39 Another natural
occurring β5 preferring proteasome inhibitor is tyropeptin A (8, Figure 1.3A) isolated from
Kitasatospora bacteria in a search for new proteasome inhibitors.40,41 Proteasome inactiva-
tion by aldehydes occurs by attack of the proteasomal Thr1 Oγ on the aldehyde, forming a
hemiacetal bond (Figure 1.3B). The hemiacetal bond with the proteasome is reversible and
aldehydes are rapidly inactivated by oxidation to the carboxylic acid in vivo and therefore
the effect of aldehydes is not sustained.
1.5.3 α’,β’-epoxyketones
In a screen for agents with antitumor activity, natural occurring α’,β’-epoxyketone contain-
ing peptides epoxomicin (9) and eponemycin (10, Figure 1.4A) were discovered in an Actino-
mycete and Streptomycete strain, respectively.42,43 Closer analysis of fermentation broths of
species of Streptomyces identified more linear α’,β’-epoxyketone containing peptides anal-
ogous to epoxomicin or eponemycin, named TMC-86, TMC-89 and TMC-96.44,45 This
marked the discovery of truly selective proteasome inhibitors.46,47 The selectivity of these
compounds comes forth from the unique interaction of this electrophile with the protea-
some Thr1 Oγ (Figure 1.4B). First, the Thr1 Oγ performs an attack on the carbonyl of the
ketone, forming a reversible hemiacetal linkage. Next, the free amine from Thr1 opens the
epoxide ring, irreversibly forming a morpholino ring.48 Because many other common off-
targets for proteasome inhibitors, such as cysteine or serine proteases, do not possess this
N-terminal threonine functionality, these enzymes can not form the morpholino adduct

























































Figure 1.4: Structure (A) of α’-β’-epoxyketone containing inhibitors found in nature and (B) their proteasome
inhibition mechanism.
1.5.4 Syrbactins
Syrbactins are a class of structurally related proteasome inhibitors, containing syringolins,
glidobactins and the closely related cepafungins49 as subfamilies. 50 Glidobactins were iso-
lated from a Burkholderia species, in a search for antitumour and antimicrobial agents, but
6
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its cellular target was then not yet determined. 51 Later, syringolin A (11, Figure 1.5A),
secreted by plant pathogen Pseudomonas syringae pv. syringae as a virulence factor when in-
vading a plant and the earlier found structurally related glidobactin A were both identified
as potent inhibitors of the proteasome. 52–54 Syrbactins share a twelve-membered unsatu-
rated lactam core structure. The α,β-unsaturated amide in this lactam structure undergoes
Michael addition of the Thr1 Oγ of the proteasome catalytically active subunit to yield an





























































Figure 1.5: Structure (A) of syrbactins and (B) their proteasome inhibition mechanism.
1.5.5 Non-covalent natural peptoid proteasome inhibitors
The fungal plant pathogen Apiospora montagnei was found to produce complex cyclic pep-
toid molecules able to inhibit the proteasome with high selectivity.45,55 TMC95A (13, Fig-
ure 1.6), the most potent of this family, inhibits the proteasome in a non-covalent way, as
was deduced from crystallographic studies. A network of hydrogen bridges accomplishes
the formation of an anti-parallel β-sheet in the active β-sites of the proteasome, causing
potent competitive binding of this peptide-like structure. 56Another , are isolated from
myxobacteria. 57 Argyrin A (14, Figure 1.6), member of a naturally occurring cyclic peptide
family called argyrins, was found to stabilize a tumour suppressor protein through inhibi-
tion of the proteasome. 58 The exact binding mechanism remains to be determined, but an
analogue of argyrins lacking the dehydroalanine moiety lacks proteasome inhibitory capac-
ities. 59 Scytonemide A (15), a cyclic peptide-like molecule isolated from cyanobacterium
Scytonema hofmanii, potently inhibits the proteasome. Its proteasome binding mechanism
has not yet been elucidated, although covalent inactivation by the imine functionality is not
excluded.60 PR39 is an arginine and proline rich antibacterial peptide derived from porcine
bone marrow that was found to inhibit the proteasome by perturbing the 20S core particle






















































Figure 1.6: Structure of naturally occurring cyclic peptide proteasome inhibitors
1.5.6 Triterpenoids and flavonoid proteasome inhibitors
Triterpenoids form a diverse family of compounds, synthesised in plants from squalene,
a precursor or steroids. A very large variety of triterpenoids have been isolated from
plants used in traditional medicine. Subsequently, extracts of these plants were used in
screens against various disease models.62–64 A large number of triterpenoids were identified
as 20S proteasome inhibitors, however, these molecules often have multiple cellular tar-
gets. Agosterol C (16, Figure 1.7), extracted from marine sponge Acanthodendrilla reverses
multidrug resistance in tumour cell lines and has been found to inhibit the chymotryptic
activity of the proteasome, although the mechanism of inhibition is unclear.65,66 With-











































Figure 1.7: Structure of naturally occurring triterpenoid and flavonoid proteasome inhibitors.
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Cherry’ and ’Thunder of God vine’, respectively, have been investigated for their anti-
cancer properties. Withaferin A and celastrol inhibit β5 of the proteasome, and hypo-
thetically, these two compounds are able to form a covalent adduct with cellular targets
via unsaturated carbonyl moieties present in these triterpenoids.67–69 Another large fam-
ily of natural occurring compounds from which many show proteasome inhibition are
the flavonoids. Green tea polyphenol (-)-epigallocatechin-3-gallate (19, Figure 1.7) potently
inhibits the chymotryptic activity of the proteasome. 70 Docking studies suggest that the
mechanism of proteasome inhibition could be acylation of the Thr1 hydroxyl. 71 Many
other flavonoids commonly found in vegetable and fruit inhibit the chymotryptic activity
of the proteasome. 72–74 Apigenin (20, Figure 1.7), found in celery seeds, is one of the most
potent proteasome inhibitors and was found to have anticancer effects 75,76 Curcumin (21),
found in turmeric77 is also a proteasome inhibitor. Although docking studies suggest that
the unsaturated ketone in flavonoids could be susceptible to nucleophilic attack, covalent
proteasome inhibition by flavonoids has not been proven. The binding mode of these com-
pounds, however, is not clearly competitive.73 It remains unclear whether the anticancer
effects of triterpenoids and flavonoids are caused solely through proteasome inhibition.
1.6 Synthetic proteasome inhibitors
With a very large variety of natural product proteasome inhibitors as inspiration, chemists
have been synthesising proteasome inhibitors for about two decades. Natural products
inspired scaffolds were optimised for selectivity for the proteasome, increasing potency and
pharmacological benefits, and several new pharmacophores able to bind the proteasome
have been found. An overview of synthetic proteasome inhibitors follows.
1.6.1 Reversible covalent proteasome inhibitors
Simple peptide aldehydes, such as the natural occurring leupeptin and the synthetic calpain
inhibitor I and II (22, 23, Figure 1.8), were found to inhibit the proteasome, but suffered












































Figure 1.8: Structure of some synthetic aldehyde containing proteasome inhibitors.
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proteasome specific peptide aldehydes. MG132 (24) displays more selectivity for the protea-
some over other enzymes such as calpains or cathepsins and is still widely used as a model
inhibitor of the proteasome. 78–80 Compound 25 was developed later as an even more spe-
cific proteasome inhibitor. 81,82 However, the reactivity of the aldehyde electrophile enables
inhibition of targets other than the proteasome, limiting their use in vivo.
Since the discovery of peptide aldehydes, many other electrophiles have been synthe-
sised and evaluated for their capacity to selectively inhibit the proteasome in a covalent
reversible way. The boronic acid moiety yields inhibitors more potent than aldehyde coun-
terparts and suffers less from cross-reactivity with cysteine proteases, although serine pro-
teases can be modified by the boronic acid. Optimisation of the peptide sequence of a
boronic acid inhibitor yielded bortezomib, which shows selectivity for the proteasome
over most serine proteases (26, Figure 1.9A). 80 The empty orbital of boron acts as an elec-
trophile, capturing the proteasomes active site hydroxyl in a reversible way (Figure 1.9B).
Bortezomib has been approved by the FDA for the treatment of multiple myeloma. The
success of this inhibitor in the treatment of cancer resulted in a surge of second genera-










































































































Figure 1.9: (A) Structure of boronic acid containing proteasome inhibitors with medicinal benefits. (B) Protea-
some inhibition mechanism of boronic acid electrophile. (C) Structure of reversible covalent electrophiles (D)
Proteasome inhibition mechanism of α-ketoaldehyde electrophile.
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bioavailable selective proteasome inhibitor that is currently in clinical trials against multi-
ple myeloma. 83
An overview of other electrophiles able to bind the proteasome in a covalent and re-
versible way is provided in Figure 1.9C. 78,80,84–89 The mechanism of proteasome inhibition
by the α-ketoaldehyde electrophile, present in the inhibitor Cbz-Leu-Leu-Tyr-COCHO
(28), shows similarities with the epoxyketone electrophile. The catalytic Thr Oγ first
forms a reversible hemiacetal linkage with the ketone of the α-ketoaldehyde. Then, the
N-terminal amine of the proteasome reacts with the aldehyde group and reversibly forms
a 5,6-dihydro-2H -1,4-oxazine ring (Figure 1.9D). 90 This bivalent inhibition mechanism of
N-terminal threonine proteases explains the high selectivity of Cbz-Leu-Leu-Tyr-COCHO
for the proteasome over proteases with different catalytic mechanisms.
1.6.2 Non-covalent synthetic proteasome inhibitors
The reactivity of many pharmacophores to bind the proteasome in many cases leads to
side reactions of these covalent inhibitors with targets other than the proteasome. Non-
covalent proteasome inhibitors lacking a reactive electrophile were developed. A library
of 5-methoxy-1-indanones was screened for 20S proteasome inhibition, resulting in several
linear peptides able to inhibit the chymotryptic activity of the proteasome non-covalently,
with compound 29 (Figure 1.10) able to inhibit proteasome activity in cells. 91–93 The de-
manding synthesis of natural product TMC95A (13, Figure 1.6) led to the development
of simplified cyclic analogues. These compounds, such as biaryl ether 30 (Figure 1.10)
































































































Figure 1.10: Structure of some noncovalent peptide based proteasome inhibitors.
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linear analogue 31, inhibiting the chymotryptic activity of the 20S proteasome. 96,97 An-
other source of inspiration for peptoid non-covalent proteasome inhibitors was found in
HIV protease inhibitor ritonavir (32, Figure 1.10), which was found to inhibit the pro-
teasome. 98 The related benzylstatine peptide 33 was synthesised in the course of a HIV
protease project and optimisation of this motif yields a wide range of β5 selective protea-
some inhibitors. 99–101 Further optimisation of linear peptide proteasome inhibitors led to
34 (Figure 1.10), which displays better cell-permeability than the benzylstatine peptides.102
Independently, 35 was found to be a potent and cell permeable noncovalent inhibitor of
proteasome chymotryptic activity. 93,103,104
1.6.3 Peptide vinyl sulfones
Peptide vinyl sulfones, originally designed as inhibitors of cysteine proteases,105 were dis-
covered to irreversibly inhibit the proteasome when the aldehyde group in MG132 was
replaced by a vinyl sulfone to give 36 (Figure 1.11A).106 The proteasome’s active site Thr1
Oγ attacks the vinyl sulfone in a Michael addition way, forming a stable ether linkage with
the inhibitor (Figure 1.11B). The irreversibility of proteasome inhibition and ease of syn-
thesis of these vinyl sulfone compounds enables the use of these scaffolds for activity-based
































































































labelled with 125I and can be detected by autoradiography.106 This probe has most affinity
for the chymotryptic activity of the proteasome. N-terminal extension of the Leu3-VS core,
such as the adamantyl acetic acid-triaminohexanoic acid spacer in compound 38 yields an
inhibitor with increased potency, good cell permeability and about equipotent activity for
the three proteasomal subunits.107 This finding was exploited by addition of a biotin as in
compound 39 to yield an ABP that can be detected by immunoblotting. The presence of a
biotin moiety, however, hampered cell permeability of this compound. To overcome this
limitation, an azide group was introduced in the elongated inhibitor design to get a two-step
labelling ABP, 40. The azide moiety can be used to introduce a biotin after the probe bound
its target, for example introduction of a biotin by the Staudinger-Bertozzi ligation.108 This
two-step labelling strategy is used often in cases where introduction of a large tag, such as
biotin, negatively influences the biological characteristics of a probe. To be able to directly
visualise labelled proteasomes in living cells, the Ahx3-Leu3-VS scaffold was decorated with
a dansyl group to arrive at fluorescent ABP 41 (Figure 1.12).109 This fluorescent ABP was
used to study in vivo subunit specificity of anti-myeloma agent bortezomib. Substitution
of the dansyl group by the BODIPY-TMR fluorophore yielded a probe (MV151, 42) that
allows detection of labelled proteasome subunits in vivo as well as directly in SDS-PAGE
gels, greatly simplifying proteasome activity readout assays.110 Azido-BODIPY probe 43
combines direct readout by fluorescence with the presence of an azide moiety, opening up



































Figure 1.12: Structure of vinyl sulfone based fluorescent activity-based probes for the proteasome.
1.6.4 Synthetic peptide α’,β’-epoxyketones
Synthetic epoxyketones were evaluated as proteasome inhibitors first by Spaltenstein et
al. in 1996 (44, Figure 1.13).112 Later, the cellular target of potent antitumour agents epox-
omicin and eponemycin was determined to be the proteasome and the exclusive selectivity
of epoxomicin for the proteasome was illustrated by biotinylated probe 45.46,47,113 Attach-
ment of BODIPY fluorophores to the epoxomicin scaffold yielded three epoxomicin ana-
logues with different fluorescent properties. BODIPY-TMR-epoxomicin (MVB003, 49) and
azido-BODIPY-epoxomicin 50 show excellent subunit labelling in cells and have been used
13
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to study the β5t subunit.114,115 The superior proteasome selectivity inherent to this elec-
trophile lead to its widespread use in proteasome inhibitors and numerous epoxyketone
peptides with remarkable potencies and selectivities have been synthesised. Several of these
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Figure 1.13: Structure of synthetic epoxyketone inhibitors and activity based proteasome probes.
1.7 Therapeutic implications of proteasome inhibition
Controlled protein degradation by the 26S proteasome is crucial for survival of eukary-
otic cells. Among its targets are cell cycle regulators, tumour suppressors, oncogens and
regulators of apoptosis. Tumour cells are more sensitive to proteasome inhibition than
normal cells and this provides a therapeutic window for proteasome inhibitors to be used
against cancers. Cytotoxicity of proteasome inhibitors in cancer cells is the result of several
mechanisms.116 Interference with timed destruction of cell cycle regulators induces cell
cycle arrest in malignant cells. P27Ki p1 is a tumour suppressor and various malignancies
display enhanced ubiquitination of this protein, lowering its concentration due to degra-
dation by the proteasome. Proteasome inhibition rescues this protein, causing cell cycle
arrest and thus inhibits tumour cell proliferation. 58 The endoplasmatic reticulum (ER) is
responsible for the folding and maturation of proteins, and misfolded proteins are degraded
by the proteasome. Exposure to proteasome inhibitors leads to prolonged accumulation
of misfolded proteins which cause ER stress, a pro-apoptotic signal. Malignant cells are di-
viding quickly and have a high protein synthesis rate and are therefore more prone to pro-
apoptotic ER stress. Apoptosis is tightly regulated by opposing activities of pro-apoptotic
and anti-apoptotic proteins, whose levels are modulated by the proteasome. Inhibition of
the proteasome leads to higher levels of pro-apoptotic proteins such as p53, Bax and Noxa,
which are often inactivated in tumour cells.117 The proteasome is responsible for degrada-
tion of IcB, an inhibitor of NF-cB. NF-cB is a transcription factor that regulates various
immune and inflammatory responses, stimulates proliferation and suppresses apoptosis and
is upregulated in many cancer types. Bortezomib and other proteasome inhibitors prevent
14
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the degradation of IcB and thereby NF-cB is inactivated, reducing proliferation and sensi-
tizing the cells to apoptosis. Proteasome inhibitors show synergistic enhancement of cyto-
toxicity of other anticancer agents, such as melphalan and cyclophosphamide (inducers of
DNA damage), dexamethasone (anti-inflammatory agent), doxorubicin (DNA intercalator
that disrupts transcription and replication), and thalidomide.118
In 2003, bortezomib received FDA approval to be used against multiple myeloma and
later against mantle cell lymphoma. Treatment of multiple myeloma with bortezomib is
associated with many side effects, among which are peripheral neuropathy and thrombocy-
topenia, and this limits the dosage and therapeutic window of this drug.119 Upon prolonged
exposure to bortezomib, cancers can become resistant to the action of bortezomib. This is
thought to occur by a changed proteasome level and altered β subunit activity pattern.120,121
In cultured cells resistant to bortezomib, a mutation in the S1 of β5 was found which re-
duces binding of bortezomib to this subunit. Whether this mutation plays a role in clin-
ical resistance to bortezomib remains to be determined. Bortezomib displays no efficacy
against solid tumours. These limitations of bortezomib sparked the generation of second










































































Figure 1.14: Structure proteasome inhibitor bortezomib (26) used clinically against multiple myeloma and struc-
tures of proteasome inhibitors in clinical trials against various types of cancer, CEP-18770 (27), MLN-9708 (51),
salinosporamide A (marizomib, 3), carfilzomib (52), ONX-0912 (53).
Reversible covalent inhibitors 27 and 51 both can be administered orally and are in clin-
ical trials against multiple myeloma, and 51 shows better activity against solid tumours than
bortezomib. Irreversible binding epoxyketone based inhibitor carfilzomib (52) inhibits the
chymotryptic-like proteasome activity and induces cancer cell death more potently than
bortezomib, and was found to overcome resistance of tumour cells to bortezomib. Epo-
xyketone 53 displays similar subunit preference to carfilzomib and is optimised for oral
bioavailability. In cultures of malignant cells, beta-lactone salinosporamide A (clinical name
currently marizomib, 3), an inhibitor of chymotryptic and tryptic activity of the protea-
some has been shown to overcome resistance to bortezomib, which inhibits chymotryptic
and caspase-like proteasomal activity. Furthermore, salinosporamide A displays synergis-
tic interaction with bortezomib, and is dependent on the stabilisation of pro-apoptotic
proteasome substrates other than bortezomib for its anticancer efficacy.122 Compounds
salinosporamide A (3), carfilzomib (52) and ONX-0912 (53) are in clinical trials against
haematological tumours and in a number of solid tumours.117
15
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Bortezomib displays a suppressive effect on activated cells of the immune system and
its activity against proliferating cells is most likely at the basis of this effect. Bortezomib
prolongs the function of transplants in mouse models of transplantation, most likely due
to ER-stress triggered induction of apoptosis in cells producing antibodies against the trans-
plant.123 Proteasome inhibition also shows promising results in models of autoimmune
diseases.124
1.8 Subunit selective proteasome inhibitors
The proteasome is a very important part of cellular homeostasis in eukaryotic cells and
modulators of proteasome activity have demonstrated a number of medicinal benefits. In
mammals, seven distinct active β subunits are expressed and the individual role of each of
these subunits in biological processes is not well understood. The function of proteolytic
subunits of the proteasome cannot be studied individually as recombinantly expressed pro-
teins since these proteolytic subunits only work in a fully assembled proteasome. Knockout
of active β subunits is associated with defects in proteasome assembly and thereby obscures
experimental outcome.125 Subunit selective cell permeable inhibitors are useful tools to
study individual subunit activities. Inhibition of individual proteasome subunits in vitro
displayed reduction of degradation of model substrates depending on the subunit inacti-
vated. Overall protein degradation in cells was halted only if two β sites were substantially
inhibited, and cytotoxicity in most cancer cell lines could only be induced efficiently when,
next to the important β5 subunit, either β1 or β2 is inhibited as well.126–128 Whether the
different mechanisms by which bortezomib and salinosporamide A induce apoptosis in
malignant cells depends solely on their different proteasome subunit preference remains a
question to be answered.
The proteasome and immunoproteasome are essential for the generation of MHC class
I antigens but the role of each individual proteasome catalytic subunit on the generation of
certain antigens is still subject of extensive study. However, mice lacking one or more im-
munoproteasome active β subunits show decreased efficiency of MHC class I presentation
of pathogen epitopes and a lower T-cell response to these epitopes.10,129 These knockout
studies suggest that antigen presentation may be changed by altering the activity of a single
subunit. Very subunit selective and cell permeable proteasome inhibitors can be a great aid
to verify results from knockout studies and determine therapeutic potential of proteasome
inhibitor mediated shaping of the antigenic pool.
To date, an increasing number of subunit selective proteasome inhibitors has been re-
ported. Subunit selectivity for a large part has been realized by optimisation of the P1 and
P3 amino acids in oligopeptoid inhibitors, interacting with the S1 and S3 proteasome sub-
strate binding pockets, which differ the most among subunits β1, β2 and β5. This Chapter
provides a summary of subunit selective inhibitors.
1.8.1 β1 subunit
The proteasomal β1 S1 selectivity pocket is characterised by a basic side chain of Arg45
of this subunit.11 Consequently, peptides with an Asp or Glu at P1 show preference for
β1. However, the β1 subunit also has the capacity to cleave after branched amino acids
16
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and this promiscuity is demonstrated by the finding that Cbz-Gly-Pro-Phe-Leu aldehyde
(54, Figure 1.15) shows preference for β1.13 The proline at P3 is important in this motif
since it seems to prevent binding to tryptic and chymotryptic sites. Optimisation of this
motif led to YU102 (55) which is a less efficient β5 inhibitor due to lack of aromaticity
at its N-terminus.130 A scanning positional library of P1 Asp-aldehyde yielded optimised
P2-P4 sequence Ac-Ala-Pro-nLe.131 This P2-P4 motif was equipped with leucine p-phenol
vinyl sulfone to give cell permeable inhibitor 56 with some selectivity for β1i over β1, and
introduction of an N-terminal azide gave probe 57 (Figure 1.15).132 Ultimately, the vinyl
sulfone was changed for the more proteasome selective epoxyketone to arrive at NC001
(58) and azide analogue 59 as β1 selective standard inhibitors to date.127,133 Attachment of


































































Figure 1.15: Structure of β1 selective inhibitors and activity-based probes.
1.8.2 β1i subunit
The immunoproteasome more efficiently generates peptides with basic and hydrophobic
amino acids at their C-termini while its caspase-like activity is reduced and this has been
ascribed to an altered activity of β1i with respect to β1. Subunit β1i of the immunopro-
teasome has changed significantly with respect to its constitutive counterpart.11 Arg45 of
β1 is replaced for leucine which abrogates caspase-like activity and rather results in a more
chymotryptic-like activity of this subunit.134 The inhibitors presented in Figure 1.15 do
not efficiently discriminate between β1 and β1i. Among analogues of eponemycin (10) in
which bulk was introduced at the P1’ position of the inhibitor, in the form of silyl ethers,
tert-butyldimethylsilyl ether containing compound 61 (Figure 1.16) was found selective for
β1i over β1.135 In this motif, P2 substitution for Lys and attachment of a BODIPY-650 or
a fluorescein fluorophore resulted in β1i ABPs 62 and 63.136 Dipeptide aldehyde 64 has
17
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Figure 1.16: Structure of β1i selective inhibitors and activity-based probes.
1.8.3 β2 subunit
The β2 S1 pocket of the proteasome is spacious and characterised by Asp28 and Glu53
residues, explaining its preference for basic amino acid side chains.11 Leupeptin is an in-
hibitor of β2 due to its arginine aldehyde electrophile. The S3 pocket of β2 contains a
highly conserved cysteine side chain, Cys118, belonging to β3. The reactivity of this moi-
ety has been exploited for binding by the bifunctional aldehyde 65 (Figure 1.17). The alde-
hyde captures Thr1 Oγ of β2, while the N-terminal maleimide is positioned to capture
Cys118 in the S3 binding pocket, resulting in potent and selective β2 inhibition.138
The barrel shaped structure of the proteasome, in which the β subunits are in a defined
distance from each other, was exploited by bivalent aldehyde inhibitors in which the two
electrophiles are separated by a long PEG spacer. The presence of a second aldehyde at a
defined distance from the first greatly increased potency of the inhibitor with respect to its
monovalent counterpart. When the sequence Arg-Val-Arg-aldehyde was used, such as in
66, a profoundly β2 selective inhibitor results.139
The S3 pocket of β2 has an acidic character due to the presence of two aspartic acids. A
scanning positional library with asparagine vinyl sulfone at P1 stressed the importance of
the P3 residue in a proteasome inhibitor for β2 selectivity. Introduction of basicity at P3
yielded compound AcPRLN-VS (67) as selective β2 inhibitor.140 The requirement for basic
amino acid residues in peptide based inhibitors decreases the ability of these compound to
cross the cell membrane due to charged residues at physiologically pH. Ac-Arg-Leu-Arg-
EK 68 is a recently discovered very specific inhibitor for β2 in cell lysate, however, this
compound is only active in cells at high concentration. Monobasic peptides such as HMB-
Val-Ser-Arg-EK 69 and 70 display more efficient β2 inhibition in cells.128,141 Compounds

























































































Figure 1.17: Structure of β2 selective inhibitors.
1.8.4 β5 subunit
The β5 subunit prefers hydrophobic substrates, which is illustrated by a great number of
hydrophobic noncovalent proteasome inhibitors that target the β5 subunit, with examples
33, 34, 35 depicted in Figure 1.10. Epoxyketone YU101 (71, Figure 1.18), a very potent and
selective inhibitor of chymotryptic activity of constitutive and immunoproteasome, was
found by scanning the effect of introduction of large hydrophobic residues in the P2-P4
positions of a tetrapeptide epoxyketone.142 Modification of the N-terminus of this com-
pound to improve its pharmacological profile led to carfilzomib (52), currently in clinical
trials against various cancers.143,144
In a medicinal chemistry effort that led to bioavailable epoxyketone ONX-0912 (53),
multiple inhibitors have been discovered that inhibit chymotryptic activity of constitutive





























































Figure 1.18: Structure of inhibitors selective for β5/β5i.
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this study does not report on the effects of this compound on β1 or β2.145 Hydrophobic
bulky residues at the P3 position and aromaticity at the N-terminus of a proteasome in-
hibitor are factors beneficial for targeting of the chymotryptic activity of the proteasome.
This is demonstrated by P3 neopentylasparagine containing potent and selective vinyl sul-
fone 73 (Figure 1.18), discovered when optimising a motif analogous to PSI (25) by screen-
ing different P3 residues and N-terminal caps. 87
Optimisation of inhibition of chymotryptic activity of tyropeptin A (8) afforded re-
versible inhibitor 74 (Figure 1.18).146 Structural elements from compound 74 inspired the
synthesis of azide containing ABP 75 (Figure 1.19), a very selective irreversible inhibitor
of β5.127,133 Change of the naphthyl group in 75 for a BODIPY dye preserved β5 selectiv-
ity and afforded fluorescent and azide containing ABP 76.133 Incorporation of fluorinated
amino acids at P2 and P3 of a tetrapeptide epoxyketone led to the discovery of compound
77, which was found to be very selective for β5.147 This inhibitor could be transformed















































Figure 1.19: Structure of β5/β5i selective activity-based probes.
1.8.5 Discrimination between β5 and β5i subunit
The medicinal chemistry efforts that led to the discovery of ONX-0912 (53, Figure 1.14)
identified compound 79 (Figure 1.20) as an inhibitor selective for β5 over β5i.145 Interest-
ingly, β5 inhibitor 79 differs from the equipotent β5/β5i inhibitor 72 (Figure 1.18) only
in the amino acid at P1. Apparently, Phe at P1 is favourable for β5i preference while a
β5 inhibitor seems more selective carrying Leu at P1.145 Compound 80 targets β5i before
β5 and this molecule indeed contains Phe at P1 and interestingly, it bears a D-alanine at
P3.145,149,150 PR957 is another β5i selective inhibitor, carrying Phe at P1 and like 80 pos-
sesses an aromatic P2 group, which could be favourable for β5i inhibition. PR957 causes
decreased MHC class I presentation of a β5i dependent epitope.151 This finding stresses
the importance of the development of specific, cell permeable inhibitors of each of the ac-












































Figure 1.20: Structure of inhibitors able to discriminate between β5 and β5i.
1.9 Aim and outline of this Thesis
The research described in this Thesis aims at the development of novel subunit selective
inhibitors of the proteasome. In Chapter 2 three vinyl sulfone analogues of three epoxyke-
tone containing inhibitors described in literature are synthesised and characterised. Vinyl







































Figure 1.21: Structure of β5/β5i selective inhibitors 82 and 83. Structure of Michael acceptors 97 and 118.
In Chapter 3, ten Michael acceptors are coupled to three peptoid tails yielding thirty
peptide-like compounds. These compounds are assessed on their capacity to inhibit the
proteasome in cell lysate but none of the peptoid Michael acceptors are efficient proteasome
inhibitors. Using the Staudinger-Bertozzi ligation followed by affinity purification, tryptic
digestion of the isolated proteins and LC/MS2 identification, the targets of 97 and 118
(Figure 1.21) in HEK293T and RAW264.7 cells are determined.
Syringolins are potent proteasome inhibitors found in nature and contain an unusual
valine-urea-valine motif. In Chapter 4 this motif was built in peptoid epoxyketones and
vinyl sulfones yielding a 16-membered library of proteasome inhibitors. The distance be-
tween the urea and electrophile dictates subunit selectivity. Tripeptide 182 (Figure 1.22) is
the most potent and selective inhibitor of β1 in HEK cells reported to date. The longer
tetrapeptides 190 and 192 preferentially inhibit β5 and are more potent than the parent
compound, syringolin A.
In Chapter 5, three cyclooctynes are compared to the Staudinger-Bertozzi two-step
labelling strategy using azido-BODIPY labelled proteasome as test system. Although
cyclooctynes quantitatively convert azide labelled proteasomes at a lower concentration





























































Figure 1.22: Structure of β1 selective inhibitor 182, β5 selective inhibitors 190 and 192, β2 selective inhibitor 229
and fluorescent β2 probe 247.
Chapter 6 describes the synthesis and characterisation of a library of peptoid vinyl sul-
fones with basic amino acid side chains on P1 and P3. Compound 229, with a benzylamine
residue at both P1 and P3, is a potent and β2 selective proteasome inhibitor. Attachment of
a BODIPY fluorophore yielded β2 selective probe 247 (Figure 1.22). The presence of two
basic residues, however, reduced their entry into cells.
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Subunit selectivity of a proteasome
inhibitor is influenced by the
electrophile∗
2.1 Introduction
The 26S proteasome plays a crucial role in many cellular processes in eukaryotes. The
eukaryotic 20S proteasome has three proteolytic activities, namely β1 (caspase like), β2
(trypsin like) and β5 (chymotrypsin like). Upon stimulation of cells by interferon-γ, three
catalytic subunits with altered substrate preference (β5i, β2i, β1i) are expressed and built
into the immunoproteasome.152,153 These activities were assigned according to fluorogenic
substrate hydrolysis assays.12 The prokaryotic 20S proteasome has only one proteolytic
activity,154 and the evolutionary role of the quite distinct functionalities in mammals is
uncertain. Knockout studies in yeast showed that β5 is the most important catalytic ac-
tivity for viability since mutation of the active site threonine of this subunit caused the
most phenotypic defects, including significant growth retardation, while inactivation of β1
and β2 caused less severe defects.155–157 The importance of β5 for proteasome activity for
cellular growth and viability, combined with the hydrophobic nature of most β5 targeting
inhibitors, favourable for cell permeability, focused the search for proteasome inhibitors on
β5/β5i inhibiting compounds.158
Proliferating cells are more sensitive to proteasome inhibitors than non-proliferating
cells and this makes proteasome inhibition a powerful strategy in the treatment of can-
cer.158–161 The approval of proteasome inhibitor bortezomib in 2003 to be used against
multiple myeloma and mantle cell lymphoma validated proteasome inhibition as a strategy
∗M. Screen, M. Britton, S. L. Downey, M. Verdoes, M. J. Voges, A. E. M. Blom, P. P. Geurink, M. D. P.




against cancer.162,163 At the time of approval it was believed that bortezomib selectively
targets β5/β5i, however, bortezomib was later found to also target β1/β1i and β2i at clin-
ically used doses.109,126,164 This raised the question what the clinical relevance of each of
the proteasome subunit is. It was found that the effect of subunit selective proteasome in-
hibitors on proteasome substrate degradation was the largest for β5 selective inhibition,
but co-inhibition of β1 or β2 was necessary to completely stall degradation by the protea-
some.126 Next, a study on cell survival using selective proteasome inhibitors for β5 and β1
or β2 showed that cytotoxicity of proteasome inhibition, in most cell lines, correlates badly
with pure β5 inhibition and that the partial co-inhibition of β1 or β2 greatly reduced the
concentration of β5 inhibitor necessary to induce cytotoxicity.127,128
More recently, specific inhibitors of the immunoproteasome emerged.137,150,151 The spe-
cific role of the immunoproteasome in immunological processes remains to be elucidated
and small molecule inhibitors selective for the immunoproteasome are valuable assets in
these studies. Moreover, preliminary studies suggest these compounds may find applica-

























































































Figure 2.1: Two β5/β5i selective inhibitors (71, 52) and β5i selective inhibitor 81, and their vinyl sulfone ana-
logues 82, 83 and 84.
This chapter focuses on three proteasome inhibitors (52, 71, 81, Figure 2.1). YU101
was designed over a decade ago as a very potent and selective inhibitor of the chymotryp-
tic activity of both constitutive and immunoproteasome.142 PR171, also known as carfil-
zomib, differs from YU101 only in the end cap, which optimises the pharmacological pa-
rameters of this compound. PR171 is now in clinical trials for the treatment of multiple
myeloma.143,144 PR957 was identified as a specific inhibitor of the β5i subunit only.151 The
three compounds in question have the epoxyketone as electrophilic trap to target the cat-
alytically active amino acid of the preferred subunits of the proteasome. The epoxyketone is
the most selective electrophile to target the proteasome since it reacts with N-terminal thre-
onine proteases only, thereby abolishing inhibition of common side targets of other protea-
some warheads, namely cysteine proteases (vinyl sulfones)106 or serine proteases (boronic
acids),166 and it not surprising that epoxyketones are the electrophile of choice by medic-
inal chemists when designing proteasome inhibitors. However, an earlier study revealed
that changing the epoxyketone electrophile in an inhibitor with β5 preference for a vinyl
sulfone electrophile yielded an inhibitor with even more selectivity for β5, 75 (Figure 1.19,
page 20).133 In this chapter, therefore, the epoxyketone in YU101, PR171 and PR597 is re-
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placed by the vinyl sulfone, to determine if this change in electrophile results in a different
biological profile of the inhibitors.
2.2 Results and Discussion
The electrophiles necessary to synthesise the compounds shown in Figure 2.1, leucine and
phenylalanine vinyl sulfone and epoxyketone, were synthesised using protocols for leucine
vinyl sulfone (VS)106 and epoxyketone (EK).167 Compounds 71, 52 and 82, 83 contain an
identical peptide portion, which was synthesised by standard Boc-protected solution pep-
tide chemistry to arrive at 86 (Scheme 2.1). The peptide portion is block coupled to the
appropriate electrophile. Since a peptide block coupling, in which a peptide-carboxylic acid









































































Reagents and conditions: i) Boc-Leu-OH (1.2 equiv.), HCTU, (1.2 equiv.), DiPEA (3.5 equiv.), DCM, o/n,
quant. ii) DCM:TFA 1:1, 15-30 min, quant. iii) Boc-hPhe-OH (0.9 equiv.), HCTU (1.1 equiv.), DIPEA (3.5
equiv.), DMF, 2 hr., 83%. iv) hydrazine hydrate, MeOH, reflux, 3 hr., 77%. v) tBuONO (1.1 equiv.), HCl (2.8
equiv.), DMF/DCM (1:1), -30◦C, 3hr. then TFA.H-Leu-EK or TFA.H-Leu-VS (1.1 equiv.), DiPEA (5 equiv.),
DMF, -30◦C → RT, o/n, 92% (88), 78% (89). vi) Ac2O (2.2 equiv.), DiPEA (2.1 equiv.), DCM, 36% (71), 90%
(82). vii) 2-morpholinoacetic acid TFA salt (1.2 equiv.), HBTU (1.2 equiv.), DiPEA (4.5 equiv.), 2 hr., 24% (52),
69% (83).
is activated, can cause considerable racemisation at the carbon α of the carboxylic acid to be
activated, a different method is preferred. To block-couple without considerable racemisa-
tion, the azide coupling was employed.115,168 The methyl ester in 86 was transformed to the
hydrazide by treatment with hydrazine hydrate in methanol. In a one pot procedure, the
hydrazide was converted to the acyl azide with tBuONO and HCl, which was then reacted
with TFA.H-Leu-EK or TFA.H-Leu-VS to yield 88 and 89 as single diastereomers. Re-
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moval of the Boc protecting groups in 88 and 89 followed by either acetylation with acetic
anhydride or coupling to 2-morpholinoacetic acid under the influence of HBTU yielded
inhibitors 71 and 52 and potential inhibitors 82 and 83.
PR957 and vinyl sulfone analogue 84 were synthesised using a similar strategy. Boc
protected dipeptide 92 was synthesised from Boc-Ala-OH and methyl ester 91 with HBTU
as coupling reagent (Scheme 2.2). The methyl ester 92 was transformed to the hydrazide
which was then coupled to TFA.H-Phe-EK or TFA.H-Phe-VS in the two step procedure
mentioned above to yield tripeptides 94 and 95. These were, after Boc-deprotection, cou-
pled to 2-morpholinoacetic acid under the influence of HBTU to yield target compounds
81 and 84.
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Reagents and conditions: i) SOCl2 (6 equiv.), MeOH, 24 hr., quant. ii) Boc-Ala-OH (1.2 equiv.), HBTU (1.2
equiv.), DiPEA (5.25 equiv.), DCM, 99%. iii) hydrazine hydrate, MeOH, reflux, 2.5 hr., 93%. iv) tBuONO (1.1
equiv.), HCl (2.8 equiv.), DMF/DCM (1:1), -30◦C, 3 hr. then TFA.H-Phe-EK or TFA.H-Phe-VS (1.1 equiv.),
DiPEA (5 equiv.), DMF, -30◦C → RT, o/n, 72% (94), 64% (95). v) TFA:DCM (1:2), 1 hr., quant. vi) 2-
morpholinoacetic acid TFA salt (1.2 equiv.), HBTU (1.2 equiv.), DiPEA (4.5 equiv.), 2 hr., 67% (81), 81% (84).
The effect of compounds 52, 71 and 81-84 was assessed using both a fluorogenic pep-
tide hydrolysis assay and competition versus fluorescent proteasome probe MVB003. The
IC50 values were calculated from these data and the results are summarised in Table 2.1.
Consistent with what is reported in literature, in the fluorogenic peptide hydrolysis assay
(Table 2.1A) YU101 (71) and PR171 (52) are potent inhibitors of the constitutive protea-
some, with a preference for β5 and β5i . PR957 (81), identified as a β5i specific inhibitor,
indeed has a lower IC50 value against the immunoproteasome than the constitutive protea-
some. The vinyl sulfones 82 and 84 are less potent than their epoxyketone analogues 71 and
81. The most dramatic loss of potency is observed for PR957-VS (84), showing only slight
inhibition of constitutive proteasome subunits, and selectivity among immunosubunits has
decreased, in contrast to β5i selective epoxyketone 81. Vinyl sulfone 83 on the other hand
appears more potent versus β5 than epoxyketone 52. The IC50 values deduced from the
competition assays (Table 2.1B) also reflect the trend in loss of potency when changing the
26
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epoxyketone warhead to the vinyl sulfone. However, the subunit specificity improvement,
as observed in the fluorogenic peptide hydrolysis assay, is less pronounced and the IC50
values differ significantly. This discrepancy in outcome between the competition assay and
fluorogenic substrate readout can be caused by the difference between purified proteasome
and cell lysate. Next, one should be careful when comparing results from two different
analytical methods and settings.
Table 2.1: Apparent IC50 (µM) values calculated from semi log plots of residual proteasome activity against
inhibitor concentration.
Fluorogenic peptide hydrolysis assay Quantified competition assay
β5 β1 β2 β5i β1i β2i β5 β1 β2 β5/β5i β1i β2i
26S proteasome Immunoproteasome HEK293T lysate EL4 lysate
Compound IC50 (µM) A IC50 (µM) A IC50 (µM) B IC50 (µM) B
YU101 (71) ∼0.001 2.6 2.2 0.26 4.1 2.0 0.023 1.2 0.20 0.037 0.40 0.21
YU101-VS (82) ∼0.004 >100 >100 2.2 >100 >100 0.21 >50 21 2.2 2.2 12
PR171 (52) 0.069 2.7 1.5 ∼0.001 2.5 0.56 0.043 2.3 0.33 0.74 0.66 0.19
PR171-VS (83) 0.007 32 16 0.012 20 6.2 0.43 N.I. 8.8 6.9 4.7 8.9
PR957 (81) 0.27 6.1 1.2 0.012 5.7 1.0 0.61 >50 2.1 0.52 2.2 2.5
PR957-VS (84) 57 >100 82 1.4 54 47 39 N.I. 41 13 >50 N.I.
(A) Constitutive proteasomes purified from rabbit muscles or immunoproteasomes, purified from rabbit spleens,
were incubated with different concentrations of inhibitors for 30 min at 37◦C followed by measuring remaining
activity with fluorogenic peptides (Suc-LLVY-AMC, β5/β5i, Ac-LPnLD-AMC, β1/β1i, Ac-RLR-AMC, β2/β2i).
(B) Band intensities from each lane of the competition assay gels in Figure 2.2, Figure 2.3 or Figure 2.4 were
quantified and used as input. N.I. no inhibition.
Ideally, a specific inhibitor for one of the proteasomes active sites totally silences one
subunit while leaving the other subunits untouched. The IC50 value of a compound is
not a good measure for inhibitor selectivity since it gives no direct information about the
co-inhibition of other sites when one subunit is fully inhibited. Therefore it is more in-
formative to look at the effect of the inhibitor at all measured inhibitor concentrations.
YU101 (71) is a selective inhibitor of the β5 subunit of the proteasome. However, the
maximal inhibition of β5, before other subunits are influenced, is about 90% at 0.1 µM in
the fluorogenic substrate assay (Figure 2.2A) and thus this inhibitor can not fully inhibit
β5 without influencing other subunits. Compound YU101 (71) is not very selective when
it comes to immunoproteasome subunits; simultaneous reduction of activity of the three
subunits is observed from 10 nM onwards, after which a sudden drop in β5i activity is seen
for 0.1 µM onwards (Figure 2.2E). According to the fluorogenic substrate assays, YU101
(71) is able to inhibit 80% of β5 activity at 0.01 µM, a concentration at which it has no
significant influence on the immunoproteasome. This finding, however, should be verified
in a biologically more relevant setting. YU101-VS (82) is about 10-fold less potent for the
β5 subunit with respect to YU101 (71). Only slight inhibition of β1 and β2 is observed at
100 µM for YU101-VS (82) according to fluorogenic substrate assay (Figure 2.2D). YU101-
VS (82) is able to inhibit β5 almost completely (>95%) at 10 µM, at which point the β1
and β2 activities remain intact. YU101-VS (82) is also more selective within the immuno-
proteasome; about 80% reduction of β5i activity is reached before the other subunits are
inhibited significantly (10 µM, Figure 2.2H). YU101-VS (82) retains apparent β5 selectiv-



















































Figure 2.2: Fluorogenic peptide hydrolysis assay and competition assay of compounds YU101 (71) and YU101-
VS (82). Fluorogenic peptide hydrolysis assay: 26S proteasomes isolated from rabbit muscles ((A) 71, (D) 82) or
rabbit spleens ((E) 71, (H) 82) were incubated with inhibitors for 30 min. at 37◦C followed by measurements of all
three peptidase activities (circles, β5/β5i activity (Suc-LLVY-AMC), squares, β1/β1i activity (Ac-LPnLD-AMC),
triangles, β2/β2i activity (Ac-RLR-AMC). Competition assay in HEK293T lysates (15 µg) ((B) 71, (C) 82) or EL4
lysates (10 µg) ((F) 71, (G) 82) were incubated with indicated end concentrations of inhibitor for 1 hr. at 37◦C.
Residual proteasome activity was labelled by MVB003 (0.5 µM end concentration) for 1 hr. at 37◦C.
(immuno)subunits are not influenced in the fluorogenic peptide hydrolysis assay. In the
competition assay in HEK293T lysate, YU101-VS (82) leaves β1 and 2 (almost) untouched
at concentrations where β5 is inhibited (Figure 2.2C) while YU101 (71) shows considerable
co-inhibition of β1 and 2 when β5 is silenced (Figure 2.2B). The competition assay has lim-
ited use in the estimation of potency against β5i since this subunit overlaps on gel with the
constitutive β5 subunit Figure 2.2F and G). More generally, the trend that epoxyketone 71
is about tenfold more potent than vinyl sulfone 82 is again observed.
PR171 (52) shows some more potency against β5i than β5 when fluorogenic peptide
hydrolysis assay results are compared (Figure 2.3A and E); at 5 nM, 60% reduction in β5i
activity is measured while at this concentration all other subunits do not seem to be in-
fluenced. This result can once again not be verified by the competition assay (Figure 2.3B
versus F) because of β5/β5i overlap on gel. However, reduction of this combined β5/β5i
signal appears faster than the diminishing of the other subunit signals and PR171 (52) is
quite selective according to this gel-based assay. Vinyl sulfone analogue 83 starts inhibiting
28





















































Figure 2.3: Fluorogenic peptide hydrolysis assay and competition assay of compounds PR171 (52) and PR171-
VS (83). Fluorogenic peptide hydrolysis assay: 26S proteasomes isolated from rabbit muscles ((A) 52, (D) 83) or
rabbit spleens ((E) 52, (H) 83) were incubated with inhibitors for 30 min. at 37◦C followed by measurements of all
three peptidase activities (circles, β5/β5i activity (Suc-LLVY-AMC), squares, β1/β1i activity (Ac-LPnLD-AMC),
triangles, β2/β2i activity (Ac-RLR-AMC). Competition assay in HEK293T lysates (15 µg) ((B) 52, (C) 83) or EL4
lysates (10 µg) ((F) 52, (G) 83) were incubated with indicated end concentrations of inhibitor for 1 hr. at 37◦C.
Residual proteasome activity was labelled by MVB003 (0.5 µM end concentration) for 1 hr. at 37◦C.
β5 at lower concentrations than PR171 (52), according to the fluorogenic peptide hydro-
lysis assay (Figure 2.3D versus A). The β1 and β2 subunits, in the presence of increasing
concentrations of PR171-VS (83), first appear more active than the DMSO control in the
fluorogenic peptide assay (Figure 2.3D). This upregulation effect has been observed earlier
but is not understood.131 At 0.5 µM of vinyl sulfone 83, activities of β1 and β2 decrease
again with a sudden drop from 10 µM and higher concentrations. PR171-VS (83) appears
to achieve about 90% inhibition of β5 at 5 µM, before the activity of remaining subunits
becomes lower than the DMSO control. Thus, vinyl sulfone 83 is more selective than epo-
xyketone 52, since 52 is able to inhibit only 80% of β5 activity at 0.5 µM before significantly
inhibiting β1 and β2. Interestingly, the potencies of PR171-VS (83) for β5 and β5i, accord-
ing to the fluorogenic substrate assay, are roughly equivalent. In the competition assay in
HEK lysate, vinyl sulfone 83 is about tenfold less potent than epoxyketone 52, in contrast
29
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to the fluorogenic peptide hydrolysis assay. PR171-VS (83) also shows relatively lower in-
hibitory activity versus the β1 subunit (Figure 2.3B versus C) and thus also appears more
selective for β5 than epoxyketone 52. This trend is not observed in EL4 lysate (Figure 2.3F
versus G).
In the fluorogenic substrate assay graph of PR957 (81) on the constitutive proteasome
it is apparent that onset of inhibition of the three subunits occurs simultaneously (0.01
µM), albeit β5 inhibition proceeds more strongly at higher concentrations (Figure 2.4A).
PR957 (81) appears to prefer to inhibit β5i in the fluorogenic substrate assay, although
PR957 shows considerable inhibition of other subunits before β5i is silenced (Figure 2.4A
and E). Again, selectivity for β5i can not be verified with the competition assay in EL4
lysate ((Figure 2.4F). Vinyl sulfone PR957-VS (84) is a poor inhibitor for the constitutive


















































Figure 2.4: Fluorogenic peptide hydrolysis assay and competition assay of compounds PR957 (81) and PR957-
VS (84). Fluorogenic peptide hydrolysis assay: 26S proteasomes isolated from rabbit muscles ((A) 81, (D) 84) or
rabbit spleens ((E) 81, (H) 84) were incubated with inhibitors for 30 min. at 37◦C followed by measurements of all
three peptidase activities (circles, β5/β5i activity (Suc-LLVY-AMC), squares, β1/β1i activity (Ac-LPnLD-AMC),
triangles, β2/β2i activity (Ac-RLR-AMC). Competition assay in HEK293T lysates (15 µg) ((B) 81, (C) 84) or EL4
lysates (10 µg) ((F) 81, (G) 84) were incubated with indicated end concentrations of inhibitor for 1 hr. at 37◦C.
Residual proteasome activity was labelled by MVB003 (0.5 µM end concentration) for 1 hr. at 37◦C.
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Subunit selectivity of a proteasome inhibitor is influenced by the electrophile
in EL4 lysate a considerable drop in potency with respect to PR957 (81) is also observed.
The fluorogenic substrate assay shows that selectivity and potency of PR957-VS (84) for the
β5i subunit are lower than that of PR957 (Figure 2.4E and H).
2.3 Conclusion
This Chapter describes the synthesis of three epoxyketone containing potent and selective
proteasome inhibitors, their vinyl sulfone counterparts and their biological analysis by the
competition assay in HEK293T and EL4 lysates as well as fluorogenic peptide hydroly-
sis assay with purified constitutive and immunoproteasome. Compound YU101 (71), de-
signed as a selective β5 inhibitor, shows co-inhibition of β1 and β2 before β5 is completely
silenced. This compound is more active against the constitutive than the immunoprotea-
some, as assessed with fluorogenic substrate hydrolysis assay. Epoxyketone YU101 (71) is
about tenfold more potent than its vinyl sulfone analogue 82, but vinyl sulfone 82 shows
less co-inhibition of β1 and β2 and therefore is a more selective inhibitor of β5 than the par-
ent compound YU101 (71). YU101-VS (82) is selective for β5 over β5i in the fluorogenic
peptide hydrolysis and YU101-VS (82) could be a valuable tool for very selective β5 inhibi-
tion. PR171 (52), in clinical trials against multiple myeloma, shows earlier onset of β5i inhi-
bition than β5 inhibition in the fluorogenic peptide hydrolysis assay. Again, vinyl sulfone
83 is able to reduce β5 activity more before β1 and β2 are affected, and therefore is a more
selective inhibitor than epoxyketone 52. PR171-VS (83) displays about equipotent activ-
ity against immunoproteasome and constitutive proteasome chymotryptic activity. PR957
(81) shows preference for β5i, as apparent from fluorogenic peptide hydrolysis assay data,
although considerable reduction of other proteasomal subunits is observed before β5i is
silenced. Vinyl sulfone PR957-VS (84) has lost selectivity between constitutive proteasome
subunits, accompanied by a large drop in potency, with respect to epoxyketone 81. This
same observation is made for the potency and selectivity within the immunoproteasome.
Different outcomes regarding inhibitior selectivity and potency have been observed be-
tween the competition assay and fluorogenic peptide hydrolysis assay. These can be caused
by the presence of other proteasome forms in cell lysate (i.e. PA200 and PA28 activated
proteasomes) or active site specificity affecting post-translational modifications that are lost
when purifying proteasome for the fluorogenic substrate assay.
2.4 Experimental
All reagents were commercial grade and were used as received unless indicated otherwise. Dichloromethane
(DCM) and dimethyl formamide (DMF, Biosolve) were stored on 4Å molecular sieves. Reactions were moni-
tored by TLC-analysis using DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm),
spraying with 20% H2SO4 in ethanol or (NH4)6Mo7O24
.4H2O (25 g/L) and (NH4)4Ce(SO4)4
.2H2O (10 g/L)
in 10% sulfuric acid followed by charring at ∼150◦C or by spraying with an aqueous solution of KMnO4 (7%)
and KOH (2%). Column chromatography was performed on silica gel from Screening Devices (0.040 - 0.063 nm).
LC/MS analysis was performed on a LCQ Advantage Max (Thermo Finnigan) equipped with an Gemini C18
column (Phenomenex). HRMS were recorded on a LTQ Orbitrap (Thermo Finnigan). 1H- and 13C-APT-NMR
spectra were recorded on a Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory. Chem-
ical shifts are given in ppm (δ) relative to tetramethylsilane as internal standard. Coupling constants are given
in Hz. All presented 13C-APT spectra are proton decoupled. Optical rotations were measured on a Propol au-
tomatic polarimeter (sodium D line, λ = 589 nm). Boc-Leu-EK, Boc-Phe-EK, Boc-Leu-VS and Boc-Phe-VS were









Boc-Leu-Phe-OMe (85). Boc-Leu-OH.H2O (1.5 gr, 6 mmol, 1.2 equiv.) was co-
evaporated with toluene (3×), before it was dissolved in DCM. After addition of
HCTU (2.487 g, 6 mmol, 1.2 equiv.), H-Phe-OMe HCl (1.77 g, 5 mmol, 1 equiv.) and
DiPEA (2.89 ml, 17.5 mmol, 3.5 equiv.) the reaction mixture was stirred overnight.
The reaction mixture was concentrated in vacuo and the residue was dissolved in EA,
before being washed with 1 M HCl (3×), sat. aq. NaHCO3 (2×) and Brine (2×). The
organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography
(EA: PE 10 → 25%) yielded the title compound (2.0 g, 5 mmol, 100%). 1H NMR (400 MHz, CDCl3): δ ppm
7.31-7.07 (m, 5H), 6.89 (d, J = 7.15 Hz, 1H), 5.21 (d, J = 7.89 Hz, 1H), 4.91-4.77 (m, 1H), 4.22-4.13 (m, 1H), 3.67
(s, 3H), 3.17-3.01 (m, 2H), 1.74-1.52 (m, 2H), 1.46-1.41 (m, 1H), 1.43 (s, 9H), 0.90 (t, J = 6.40 Hz, 6H). 13C NMR
(100 MHz, CDCl3): δ ppm 172.21, 171.53, 155.34, 135.66, 129.07, 128.25, 126.78, 79.55, 53.03, 52.82, 51.98, 41.04,










Boc-hPhe-Leu-Phe-OMe (86). Boc-Leu-Phe-OMe 85 (0.784 g, 2 mmol, 1.1
equiv.) was dissolved in TFA/DCM 1/1 (6 ml). The reaction mixture was
stirred for 15 min., before being co-evaporated with toluene (3×). The crude
TFA salt was dissolved in DMF and a solution of Boc-hPhe-OH (0.5 g, 1.79
mmol), HCTU (0.827 g, 2 mmol, 1.1 equiv.) and DiPEA (1.04 ml, 6.27 mmol,
3.5 equiv.) in DCM (20 ml) was added. The reaction mixture was stirred for
2 hr., before it was diluted with DCM. The reaction mixture was washed with
1M HCl (3x), sat. aq. NaHCO3 (2×) and Brine (2×), before being dried over
MgSO4, filtered and concentrated in vacuo. Purification by column chroma-
tography (EA:PE 10→ 35%) yielded the title compound (0.818 g, 1.48 mmol,
83%). 1H NMR (400 MHz, CDCl3): δ ppm 7.28-7.03 (m, 10H), 7.01 (d, J = 7.72 Hz, 1H), 5.54 (d, J = 8.19 Hz,
1H), 4.81 (dd, J1 = 14.07, J2 = 6.38 Hz, 1H), 4.60-4.50 (m, 1H), 4.26-4.17 (m, 1H), 3.63 (s, 3H), 3.11-2.98 (m, 2H),
2.72-2.56 (m, 2H), 2.10-1.97 (m, 1H), 1.95-1.84 (m, 1H), 1.69-1.57 (m, 2H), 1.56-1.47 (m, 1H), 1.43 (s, 9H), 0.86
(dd, J1 = 9.70, J2 6.00 Hz, 6H).
13C NMR (100 MHz, CDCl3): δ ppm 172.01, 171.61, 171.55, 155.63, 140.88,











Boc-hPhe-Leu-Phe-NHNH2 (87). After Boc-hPhe-Leu-Phe-OMe 86 (0.819
g, 1.48 mmol) was dissolved in MeOH (50 ml), hydrazine monohydrate (2.16
ml, 44.4 mmol, 30 equiv.) was added. The reaction mixture was refluxed
for 3 hr., before being co-evaporated with toluene (3×). Purification by co-
lumn chromatography (MeOH:EA:NEt3 0:99:1→ 20:79:1) yielded the title
compound (0.632 g, 1.15 mmol, 77%). 1H NMR (400 MHz, CD3OD) ppm
7.32-7.10 (m, 10H), 4.53 (t, J = 7.42 Hz, 1H), 4.38 (dd, J1 = 9.41, J2 = 5.37
Hz, 1H), 4.04 (dd, J1 = 8.29, J2 = 4.95 Hz, 1H), 3.10 (dd, J1 = 13.80, J2 =
6.84 Hz, 1H), 2.95 (dd, J1 = 13.71, J2 = 8.12 Hz, 1H), 2.75-2.57 (m, 2H),
2.05-1.93 (m, 1H), 1.93-1.81 (m, 1H), 1.69-1.58 (m, 1H), 1.48 (s, 11H), 0.93 (d,
J = 6.52 Hz, 3H), 0.89 (d, J = 6.42 Hz, 3H).
General protocol for azide couplings
The Boc-protected warhead was dissolved in TFA:DCM (1:1, v/v) and stirred for 20 min. Coevaporation with
toluene (3×) afforded the warhead TFA-salt, which was used without further purification. The appropriate hy-
drazide was dissolved in 1:1 DMF:DCM (v/v) and cooled to -30◦C. tBuONO (1.1 equiv.) and HCl (4M sln. in
1,4-dioxane, 2.8 equiv.) were added, and the mixture was stirred for 3 hr. at -30◦C after which TLC analysis (10%
MeOH/DCM, v/v) showed complete consumption of the starting material. The warhead-TFA salt was added to
the reaction mixture as a solution in DMF with 1.1 equiv. of DiPEA. A further 3.9 equiv. of DiPEA were added
to the reaction mixture, and this mixture was allowed to warm to RT slowly overnight. The mixture was diluted
with EA and extracted with H2O (3×). The organic layer was dried over MgSO4 and purified by flash column
chromatograpy.
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Boc-hPhe-Leu-Phe-Leu-EK (88). Following the general procedure for
azide coupling the title compound was obtained from Boc-Leu-EK (0.14
g, 0.55 mmol, 1.1 equiv.) and Boc-hPhe-Leu-Phe-hydrazide 87 (0.218 g,
0.4 mmol). Purification by column chromatography (MeOH:DCM 0→
7%) yielded the title compound (0.234 g, 0.37 mmol, 92%). 1H NMR
(400 MHz, CDCl3) ppm 7.33 (s, 1H), 7.25-6.99 (m, 11H), 6.92 (s, 1H),
5.46 (s, 1H), 4.89-4.77 (m, 1H), 4.62-4.52 (m, 2H), 4.20 (s, 1H), 3.24 (d, J
= 4.71 Hz, 1H), 3.08-2.98 (m, 1H), 2.98-2.89 (m, 1H), 2.82 (d, J = 4.85
Hz, 1H), 2.70-2.53 (m, 2H), 2.08-1.86(m, 2H), 1.63-1.39 (m, 17H), 1.32-1.20 (m, 1H), 0.89-0.80 (m, 12H). 13C
NMR (100 MHz, CDCl3): δ ppm 207.86, 172.16, 171.58, 170.70, 155.92, 140.87, 136.39, 129.11, 128.41, 128.31,
126.65, 126.03, 80.01, 58.81, 54.32, 53.83, 52.22, 51.84, 49.67, 41.26, 40.00, 38.06, 34.02, 31.91, 28.32, 25.01, 24.66,














Ac-hPhe-Leu-Phe-Leu-EK (YU101) (71). Boc-hPhe-Leu-Phe-Leu-
epoxyketone 88 (34.6 mg, 50 µmol) was dissolved in TFA/DCM 1/1 (2
ml) and stirred until TLC showed complete Boc deprotection. The re-
action mixture was co-evaporated with toluene (3×) yielding the crude
hPe-Leu-Phe-Leu-EK TFA salt, which was dissolved in DCM (5 ml), put
under argon atmosphere and cooled to 0◦C. DiPEA (17 µl, 0.105 mmol,
2.1 equiv.) and Ac2O (5 µl, 0.055 mmol, 1.1 equiv.) were added and the
reaction mixture was stirred for 2 hr. More Ac2O (5 µl, 0.055 mmol,
1.1 equiv.) was added and the mixture was stirred until TLC showed
complete consumption of the starting material. The reaction mixture
was then washed with H2O (3×), dried over Na2SO4, filtered and concentrated in vacuo. Purification by column
chromatography (MeOH:DCM 0→ 3%) yielded the title compound (11.3 mg, 17.8 µmol, 36%). [α]20
D
4.5◦(c =
1, MeOH). 1H NMR (400 MHz, CDCl3/CD3OD (1/5 v/v)) ppm 7.33-7.07 (m, 10H), 4.62 (dd, J1 = 8.51, J2 =
5.70 Hz, 1H), 4.52 (dd, J1 = 10.41, J2 = 3.29Hz, 1H), 4.33 (t, J = 7.47 Hz, 1H), 4.27 (dd, J1 = 8.60, J2 = 5.52
Hz, 1H), 3.20 (d, J = 4.83 Hz, 1H), 3.14 (dd, J1 = 14.01, J2 = 5.64 Hz, 1H), 2.91 (dd, J1 = 14.03, J2 = 8.65 Hz,
1H), 2.86 (d, J = 5.01 Hz, 1H), 2.72-2.55 (m, 2H), 2.01 (s, 3H), 1.97-1.84 (m, 2H), 1.48 (s, 3H), 1.70-1.52 (m, 2H),
1.44-1.12 (m, 4H), 0.95-0.83 (m, 12H). 13C NMR (100 MHz, CDCl3/CD3OD (1/5 v/v)): δ ppm 207.51, 172.19,
172.00, 171.49, 170.94, 140.30, 136.03, 128.43, 127.64, 127.51, 125.89, 125.29, 58.22, 53.30, 52.80, 51.43, 51.33,
49.53, 48.41, 39.78, 38.58, 36.86, 32.76, 31.24, 24.27, 23.92, 22.18, 21.78, 21.11, 20.43, 20.02, 15.49. LC/MS: Rt


















2-Morpholino-acetyl-hPhe-Leu-Phe-Leu-EK (PR171) (52). Boc-
hPhe-Leu-Phe-Leu-epoxyketone 88 (0.0346 g, 0.05 mmol) was dis-
solved in TFA/DCM 1/1 (2 ml) and stirred for 25 min. The re-
action mixture was co-evaporated with toluene (3×), before being
dissolved in DCM (6.5 ml) and put under argon atmosphere. 2-
morpholinoacetic acid TFA salt (8.8 mg, 0.06 mmol, 1.2 equiv.),
HBTU (22.8 mg, 0.06 mmol, 1.2 equiv.) and DiPEA (38 µl, 0.225
mmol, 4.5 equiv.) were dissolved in DCM (5 ml) and this solution
was added to the reaction mixture. The reaction mixture was stirred
for 2 hr., before being washed with sat. aq. NaHCO3 (4×), dried
with Na2SO4, filtered and concentrated in vacuo. Purification by column chromatograhpy (MeOH:DCM 0 →
3%) yielded the title compound (8.6 mg, 11.9 µmol, 24%). [α]20
D
0◦(c = 0.17, MeOH). 1H NMR (400 MHz,
CDCl3/CD3OD (1/10 v/v)) ppm 7.32-7.08 (m, 10H), 4.61 (dd, J1 = 8.10, J2 = 5.90 Hz, 1H), 4.52 (dd, J1 = 10.46,
J2 = 3.27 Hz, 1H), 4.42 (dd, J1 = 8.27, J2 = 5.32 Hz, 1H), 4.34 (t, J = 7.44 Hz, 1H), 3.80-3.71 (m, 4H), 3.19 (d,
J = 4.99 Hz, 1H), 3.12 (dd, J1 = 13.99, J2 = 5.89 Hz, 1H), 3.02 (d, J = 2.74 Hz, 2H), 2.92 (dd, J1 = 14.05, J2 =
8.17 Hz, 1H), 2.86 (d, J = 4.99 Hz, 1H), 2.64-2.48 (m, 6H), 2.11-2.00 (m, 1H), 1.98-1.85 (m, 1H), 1.69-1.41 (m,
7H), 1.38-1.24 (m, 2H), 0.96-0.84 (m, 12H). 13C NMR (100 MHz, CDCl3/CD3OD (1/10 v/v)): δ ppm 172.42,
172.00, 171.35, 170.76, 140.84, 136.48, 129.12, 128.33, 128.25, 128.17, 126.58, 125.99, 66.75, 61.35, 53.87, 53.51,
52.43, 52.01, 51.95, 50.06, 40.55, 39.34, 37.57, 34.16, 31.81, 24.92, 24.56, 22.90, 22.47, 21.18, 20.76, 16.21. LC/MS:

















Boc-hPhe-Leu-Phe-Leu-VS (89). Following the general procedure for
azide coupling the title compound was obtained from Boc-Leu-VS 356
(0.128 g, 0.44 mmol, 1.1 equiv.) and 87 (0.218 g, 0.4 mmol). Purifi-
cation by column chromatography (MeOH:DCM 0 → 7%) yielded
the title compound (0.221 g, 0.31 mmol, 78%). 1H NMR (400 MHz,
CDCl3/CD3OD (1/10 v/v)): δ ppm 7.31-7.13 (m, 10H), 6.68 (dd, J1
= 15.06, J2 = 4.22 Hz, 1H), 6.10 (d, J = 15.17 Hz, 1H), 4.66-4.57 (m,
2H), 4.35-4.26 (m, 1H), 3.99 (dd, J1 = 8.69, J2 = 5.35 Hz, 1H), 3.21-
3.11 (m, 1H), 3.00-2.93 (m, 1H), 2.90 (s, 3H), 2.76-2.59 (m, 2H), 2.07-1.94 (m, 1H), 1.94-1.82 (m, 1H), 1.68- 1.55 (m,
2H), 1.47 (s, 11H), 1.39-1.26 (m, 1H), 0.95-0.83 (m, 12H). 13C NMR (100 MHz, CDCl3/CD3OD (1/10 v/v)): δ
ppm 178.43, 174.83, 173.89, 172.22, 148.19, 141.82, 137.62, 129.88, 129.78, 129.36, 129.23, 129.18, 127.76, 126.82,















Ac-hPhe-Leu-Phe-Leu-VS (YU101-VS) (82). Boc-hPhe-Leu-Phe-Leu-
VS 89 (35.6 mg, 50 µmol) was dissolved in TFA/DCM 1/1 (2 ml)
and stirred for 30 min. The reaction mixture was co-evaporated with
toluene(3×) yielding the crude hPe-Leu-Phe-Leu-VS TFA salt, which
was dissolved in DCM (5 ml) and cooled to 0◦C. DiPEA (17 µl, 0.105
mmol, 2.1 equiv.) and Ac2O (5 µl, 55 µmol, 1.1 equiv.) were added
and the reaction mixture was stirred for 2 hr. The reaction mix-
ture was then washed with H2O (3×), dried over Na2SO4, filtered
and concentrated in vacuo. Purification by column chromatography
(MeOH:DCM 0- → 7%) yielded the title compound (29.5 mg, 45
µmol, 90%). [α]20
D
30.5 ◦(c = 0.59, MeOH:DCM 1:1, v/v). 1H NMR (400 MHz, CDCl3/CD3OD (1/10 v/v)): δ
ppm 7.31-7.16 (m, 10H), 6.73 (dd, J1 = 15.13, J2 = 4.49 Hz, 1H), 6.17 (dd, J1 = 15.14, J2 = 1.70 Hz, 1H), 4.64-4.56
(m, 2H), 4.28-4.18 (m, 2H), 3.23-3.14 (m, 1H), 3.06-2.98 (m, 1H), 2.92 (s, 3H), 2.76-2.60 (m, 2H), 2.05 (s, 3H),
2.03-1.91 (m, 2H), 1.69-1.25 (m, 6H), 0.95-0.79 (m, 12H). 13C NMR (100 MHz, CDCl3/CD3OD (1/10 v/v)): δ
ppm 172.82, 172.50, 171.91, 170.87, 146.89, 140.16, 136.29, 128.48, 128.23, 127.91, 127.84, 127.76, 126.32, 125.53,
54.45, 53.39, 52.16, 47.32, 41.72, 41.61, 39.51, 36.62, 32.62, 31.27, 24.07, 23.93, 22.01, 21.86, 21.42, 20.68, 20.58.




















(83). Boc-hPhe-Leu-Phe-Leu-VS 89 (35.6 mg, 50 µmol) was
dissolved in TFA/DCM 1/1 (2 ml) and stirred for 25 min.
The reaction mixture was co-evaporated with toluene (3×),
before being dissolved in DCM (6.5 ml) and put under ar-
gon atmosphere. 2-morpholinoacetic acid TFA salt (8.8 mg,
60 µmol, 1.2 equiv.), HBTU (22.8 mg, 60 µmol, 1.2 equiv.)
and DiPEA (38 µl, 0.225 mmol, 4.5 equiv.) were dissolved in
DCM (5 ml) and this solution was added to the reaction mix-
ture. The reaction mixture was stirred for 2 hr., before being
washed with sat. aq. NaHCO3 (3×), dried with Na2SO4, filtered and concentrated in vacuo. Purification by co-
lumn chromatograhpy (MeOH:DCM 0→ 3%) yielded the title compound (25.7 mg, 35 µmol, 69%). [α]20
D
1.9 ◦(c
= 0.51, MeOH). 1H NMR (400 MHz, CDCl3/CD3OD (1/10 v/v)) ppm 7.34-7.16 (m, 10H), 6.67 (dd, J1 = 15.17,
J2 = 4.68 Hz, 1H), 6.06 (dd, J1 = 15.18, J2 = 1.69 Hz, 1H), 4.66-4.58 (m, 2H), 4.48-4.37 (m, 2H), 3.80-3.70 (m,
4H), 3.09 (d, J = 2.28 Hz, 2H), 3.17-3.09 (m, 1H), 3.06-2.98 (m, 1H), 2.92 (s, 3H), 2.73-2.63 (m, 2H), 2.60-2.52 (m,
4H), 2.16-1.92 (m, 2H), 1.72-1.24 (m, 6H), 0.99-0.85 (m, 12H). 13C NMR (100 MHz, CDCl3/CD3OD (1/10 v/v)):
δ ppm 174.19, 174.00, 172.76, 172.53, 148.38, 142.37, 138.13, 130.39, 129.71, 129.52, 128.11, 127.15, 67.88, 62.47,
56.33, 54.77, 54.14, 53.42, 49.09, 43.42, 42.88, 41.81, 38.65, 35.37, 33.07, 25.82, 25.62, 23.50, 23.32, 22.13, 21.83.
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O
ClH3N OMe
O H-Tyr(Me)-OMe HCl salt (91). H-Tyr(Me)-OH (0.50 g, 2.56 mmol) was dissolved in
MeOH (5.5 mL), brought under an argon atmosphere and cooled to 0◦C. To this stirred
solution SOCl2 (1.12 mL, 15.37 mmol, 6 equiv.) was added. After 24 hr. the reaction
mixture was co-evaporated with toluene (3×) to afford the title compound as a pale yellow
solid (0.63 g, 2.55 mmol, >99%). 1H NMR (400 MHz, CD3OD): δ ppm 7.17 (d, J = 8.09
Hz, 2H), 6.92 (d, J = 8.04 Hz, 2H), 4.27 (t, J = 5.73 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 3H3),
3.17 (dq, J1 = 14.55, J1 = 5.95 Hz, 2H).
13C NMR (100 MHz, CD3OD): δ ppm 170.47,








Boc-Ala-Tyr(Me)-OMe (92). Boc-Ala-OH (0.34 g, 1.8 mmol, 1.2 equiv.), HBTU
(0.74 g, 1.8 mmol, 1.2 equiv.) and 91 (0.369 g, 1.5 mmol) were dissolved in DCM
(10 mL). The reaction was initiated by addition of DiPEA (0.87 mL, 5.25 mmol, 3.5
equiv.) to the stirred solution. After 18 hr. the reaction mixture was concentrated,
the concentrate was dissolved in EA and the solution was washed with 1M aq. HCl
(3×), saturated aq. NaHCO3 (5×), Brine, dried over MgSO4 and concentrated.
This yielded 92 (0.56 g, 1.48 mmol, 99%) as a viscous light brown oil. TLC analysis (eluent: 40% EA/ 60% PE)
showed product at Rf 0.26, which was used without further purification. [α]
20
D
34.9 ◦(c = 1, CHCl3).
1H NMR
(400 MHz, CDCl3): δ ppm 7.03 (d, J = 8.56 Hz, 2H), 6.89 (d, J = 6.39 Hz, 1H), 6.80 (d, J = 8.58 Hz, 2H),
5.38 (d, J = 6.34 Hz, 1H), 4.79 (dd, J1 = 13.22, J2 = 6.08 Hz, 1H), 4.21 (s, 1H), 3.75 (s, 3H), 3.69 (s, 3H), 3.04
(dq, J1 = 13.96, J2 = 6.10 Hz, 2H), 1.43 (s, 9H), 1.31 (d, J = 7.07 Hz, 3H).
13C NMR (100 MHz, CDCl3): δ
ppm 172.32, 171.64, 158.36, 155.14, 130.03, 127.55, 113.67, 79.59, 54.87, 53.20, 52.01, 49.78, 36.75, 28.06, 18.16.
LC/MS: Rt 7.32 min (linear gradient 10 → 90% MeCN in H2O, 0.1% TFA, 15 min). HRMS: Calculated for
[C19H28N2O6Na]








Boc-Ala-Tyr(Me)-NHNH2 (93). To a solution of 92 (0.508 g, 1.34 mmol) in
MeOH (22.5 mL) was added hydrazine hydrate (1.95 mL of 64% solution, 40.05
mmol, 30 equiv.). The reaction mixture was refluxed at 70◦C. After 2.5 hr. the
reaction mixture was co-evaporated with toluene (3×) and the residue purified
with column chromatography (MeOH:EA:NEt3 0:99:1 → 20:79:1) to yield 93
(0.475 g, 1.25 mmol, 93%) as an off-white solid. 1H NMR (400 MHz, CD3OD):
δ ppm 7.12 (d, J = 8.54 Hz, 2H), 6.83 (d, J = 8.69 Hz, 2H), 4.50 (t, J = 7.18 Hz,
1H), 3.96 (q, J = 7.18 Hz, 1H), 3.75 (s, 3H), 2.97 (ddd, J1 = 21.78, J2 = 13.65, J3
= 7.12 Hz, 2H), 1.43 (s, 9H), 1.20 (d, J = 7.21 Hz, 3H). LC/MS: Rt 5.31 min (linear gradient 10→ 90% MeCN
in H2O, 0.1% TFA, 15 min). HRMS: Calculated for [C18H28N4O5H]










Boc-Ala-Tyr(Me)-Phe-EK (94). Following the general procedure for azide cou-
pling the title compound was obtained from Boc-Phe-EK (84 mg, 0.28 mmol,
1.1 equiv.) and 93 (94.7 mg, 0.25 mmol, 1 equiv.). Purification by column chro-
matography (EA:PE 0→ 60%) yielded 94 (100 mg, 0.180 mmol, 72%). [α]20
D
+25.8 ◦(c = 1, CHCl3).
1H NMR (400 MHz, CDCl3): δ ppm 7.28-7.17 (m,
3H), 7.08 (d, J = 8.57 Hz, 2H), 7.04-6.99 (m, 2H), 6.78 (d, J = 8.63 Hz, 2H),
6.74 (d, J = 7.74 Hz, 1H), 6.44 (s, 1H), 5.09 (d, J = 7.22 Hz, 1H), 4.74 (dd, J1 =
13.09, J2 = 7.41 Hz, 1H), 4.54 (dd, J1 = 13.94, J2 = 7.31 Hz, 1H), 4.12 (dd, J1
= 14.21, J2 = 7.09 Hz, 1H), 3.76 (s, 3H), 3.26-2.63 (m, 6H), 1.44 (s, 3H), 1.42 (s,
9H), 1.26 (d, J = 7.07 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ ppm 206.95,
172.36, 170.30, 158.56, 155.35, 135.45, 130.32, 129.17, 128.43, 128.19, 126.99, 113.94, 80.08, 59.04, 55.11, 54.13,
52.30, 52.26, 50.15, 37.17, 28.23, 18.28, 16.31. LC/MS: Rt 8.92 min (linear gradient 10→ 90% MeCN in H2O,
0.1% TFA, 15 min). HRMS: Calculated for [C30H39N3O7H]
















2-Morpholino-acetyl-Ala-Tyr(Me)-Phe-EK (PR957) (81). A solution of
94 (62.8 mg, 0.113 mmol) in 2 ml DCM/TFA (2/1) was stirred and coevap-
orated with toluene (3×) after 1 hr. The residue was dissolved in DCM and
2-morpholinoacetic acid TFA salt (33 mg, 0.125 mmol, 1.1 equiv.), HBTU
(52 mg, 0.125 mmol, 1.1 equiv.) and DiPEA (84 µl, 0.510 mmol, 4.5 equiv.)
were added. After 18 hr. the reaction mixture was concentrated and the
concentrate dissolved in EA. The organic solution was washed with sat.
aq. NaHCO3 (5×), brine, dried over MgSO4 and concentrated. Purifica-
tion by column chromatography (MeOH:DCM 0→ 3%) afforded the title
compound 19 (44.3 mg, 76 µmol, 67%). [α]20
D
+24.3 ◦(c = 1, CHCl3).
1H NMR (400 MHz, CDCl3): δ ppm 7.44
(d, J = 7.58 Hz, 1H), 7.29-7.20 (m, 3H), 7.08 (d, J = 8.63 Hz, 2H), 7.02 (dd, J1 = 7.62, J2 = 1.56 Hz, 2H), 6.78
(d, J = 8.65 Hz, 2H), 6.69 (d, J = 7.55 Hz, 1H), 6.31 (d, J = 7.37 Hz, 1H), 4.74 (dt, J1 = 7.87, J2 = 5.01 Hz, 1H),
4.49 (q,J = 7.00 Hz, 1H), 4.37 (p, J = 7.10 Hz, 1H), 3.77 (s, 3H), 3.69 (t, J = 4.58 Hz, 4H), 3.26 (d, J = 4.92 Hz,
1H), 3.11-2.65 (m, 7H), 2.48-2.43 (m, 4H), 1.48 (s, 3H), 1.29 (d, J = 7.04 Hz, 3H). 13C NMR (100 MHz, CDCl3):
δ ppm 206.91, 171.79, 170.26, 170.09, 158.55, 135.53, 130.33, 129.19, 128.48, 128.22, 127.06, 113.96, 66.86, 61.58,
59.14, 55.17, 54.23, 53.70, 52.56, 52.41, 48.22, 37.03, 36.73, 17.65, 16.45. LC-MS: Rt 6.72 min (linear gradient 10












Boc-Ala-Tyr(Me)-Phe-VS (95). Following the general procedure for azide cou-
pling the title compound was obtained from Boc-Phe-VS (91 mg, 0.28 mmol,
1.1 equiv.) and 93 (94.7 mg, 0.25 mmol). Purification by column chromatogra-
phy (EA:PE 50→ 80%) yielded 95 (0.186 g, 0.321 mmol, 64%) as a white solid.
[α]20
D
+29.6 ◦(c = 1, CHCl3).
1H NMR (400 MHz, CDCl3): δ ppm 7.31-7.13
(m, 5H), 7.06 (d, J = 4.2 Hz, 2H), 6.94 (d, J = 7.2 Hz, 1H), 6.80 (d, J = 8.4
Hz, 2H), 6.78-6.73 (m, 1H), 6.66 (d, J = 7.2 Hz, 1H), 6.19 (d, J = 14.8 Hz,
1H), 5.02 (m, 1H), 4.97 (m, 1H), 4.61 (q, J = 6.4 Hz, 1H), 4.03 (m, 1H), 3.76
(s, 3H), 3.14-3.10 (m, 2H), 3.00-2.89 (m, 2H), 2.80 (s, 3H), 1.37 (s, 9H), 1.31 (d,
J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ ppm 172.65, 170.40, 158.69,
156.07, 145.75, 136.03, 130.31, 130.22, 128.74, 128.47, 127.75, 127.11, 114.26, 80.87, 55.16, 54.28, 51.32, 50.40,
42.58, 40.15, 36.45, 28.25, 17.79. LC/MS: Rt 8.09 min (linear gradient 10→ 90% MeCN in H2O, 0.1% TFA, 15
min). HRMS: Calculated for [C29H39N3O7SH]















Morpholino-acetyl-Ala-Tyr(Me)Phe-VS (PR957-VS) (84). A solution
of 95 (0.106 g, 0.184 mmol, 1.0 equiv.) was dissolved in DCM/TFA
(2/1), stirred for 1.5 hr. and co-evaporated with toluene (3×). The
residue was dissolved in DCM (10 ml) and 2-morpholinoacetic acid TFA
salt (54 mg, 0.203 mmol, 1.1 equiv.), HBTU (84 mg, 0.203 mmol, 1.1
equiv.) and DiPEA (0.137 mL, 0.829 mmol, 4.5 equiv.) were added. Af-
ter 3.5 hr. the reaction mixture was concentrated and the concentrate
was dissolved in EA, washed with sat. aq. NaHCO3 (5×), brine, dried
over MgSO4 and concentrated. Purification by column chromatogra-
phy (MeOH:DCM 0 → 4%) yielded 84 (90 mg, 0.150 mmol, 81%).
[α]20
D
-19.6 ◦(c = 1, MeOH). 1H NMR (400 MHz, DMSO-d6): δ ppm 8.26 (d, J = 8.25 Hz, 1H), 8.10 (d, J =
8.21 Hz, 1H), 7.78 (d, J = 7.62 Hz, 1H), 7.32-7.15 (m, 5H), 7.10 (d, J = 8.57 Hz, 2H), 6.81 (d, J = 8.59 Hz, 2H),
6.67 (dd, J1 = 15.25 Hz, J2 = 4.86 Hz, 1H), 6.30 (dd, J1 = 15.26, J2 = 1.48 Hz, 1H), 4.74-4.65 (m, 1H), 4.44
(dd, J1 = 14.90, J2 = 8.16 Hz, 1H), 4.27 (p, J = 7.10 Hz, 1H), 3.70 (s, 3H), 3.59-3.54 (m, 4H), 3.04-2.65 (m, 9H),
2.40-2.37 (m, 4H), 1.12 (d, J = 6.96 Hz, 3H). 13C NMR (100 MHz, DMSO-d6): δ ppm 171.56, 170.25, 168.37,
157.64, 145.33, 137.27, 130.08, 129.87, 129.11, 128.10, 127.99, 126.27, 113.38, 66.04, 61.16, 54.75, 54.19, 53.07,
50.26, 47.38, 42.08, 38.73, 36.82, 18.65. LC/MS: Rt 5.92 min (linear gradient 10 → 90% MeCN in H2O, 0.1%
NH4OAc, 15 min). HRMS: Calculated for [C30H40N4O7SH]
+: 601.26905, found: 601.26838.
Competition experiments in cell lysate
HEK293T or RAJI cells were cultured on DMEM supplemented with 10% Fetal Calf Serum (FCS), 10 units/ml
penicillin and 10 µg/ml streptomycin in a 7% CO2 humidified incubator at 37
◦C. Cells were harvested, washed
2× with PBS and permeated in digitonin lysis buffer (4× pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose,
5 mM MgCl2, 5 mM DTT, 0.025% digitonin) for 15 min. on ice and centrifuged at 16.100 rcf. for 20 min. at
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4◦C. The supernatant containing the cytosolic fraction was collected and the protein content was determined
by Bradford assay (Biorad). 15 µg (HEK293T) or 10 µg (RAJI) total protein in 9 µl lysis buffer per experiment
was exposed to the inhibitors (10× solution in DMSO, 1 µl) for 1 hr. at 37◦C prior to incubation with MVB003
(500 nM end concentration) for 1 hr. at 37◦C. Reaction mixtures were boiled with Laemmli’s buffer containing
β-mercaptoethanol for 3 min. before being resolved on 12.5% SDS-PAGE. In-gel detection of fluorescently la-
belled proteins was performed in the wet gel slabs directly on the Typhoon Variable Mode Imager (Amersham
Biosciences) using the Cy3/Tamra settings (λex 532 nm, λem 560 nm)
Fluorogenic substrate hydrolysis assay
26S proteasomes were purified from rabbit muscle as described. 169 To determine inhibition of purified protea-
somes, proteasome (∼ 10ng/ml) in assay buffer (50 mM Tris-HCl pH 7.5, 40 mM KCl, 2 mM EDTA, 1 mM DTT,
100 µM ATP, 50 µg/mL BSA) was incubated with inhibitors for 30 min. at 37◦C followed by assay of activity
with 100 µM fluorogenic substrates Suc-LLVY-AMC (chymotrypsin-like site), Ac-RLR-AMC (trypsin-like site),
and Ac-nLPnLD-AMC (caspase-like site). Fluorescence of released AMC was measured (λe x 350 nm, λe m 430 nm)
continuously for 30 min at 37◦C. Residual activity was determined from the slope of the reaction progress curves









The potential of proteasome inhibitors to be used in the treatment of cancer and immuno-
logical disorders sparked many medicinal chemistry efforts to optimise peptide-based pro-
teasome inhibitors in terms of selectivity, cell permeability and subunit specificity. In the
past, much effort has been devoted to vary the peptide sequence of the recognition ele-
ment.131,140,142 The electrophilic trap, in contrast, has not been an object of such extensive
study. Well known electrophilic traps in peptide based proteasome inhibitors are the vinyl
sulfone,106 epoxyketone,48 boronic acid80 and aldehyde78 functional groups. In this work,
ten electrophilic traps, with the potential to target the proteasome, are investigated. As
recognition elements used to assess proteasome inhibition capacity the Z-Leu2 motif
106
and the AdaAhx3Leu2 motif are selected.
107 In addition, the N3PheLeu2 element yields po-
tential inhibitors in which the azide moiety can be used to determine the reactivity of the
inhibitors in cell extract using two-step labelling chemical proteomics experiments.108,170
3.2 Results and Discussion
The C-terminally modified target peptides are depicted in Figure 3.1. The first five Michael
acceptors in Figure 3.1 (compound 96-110) were derived from Boc-leucinal applying stan-
dard Horner-Wadsworth-Emmons Emmons (HWE) olefination procedures. Iodide substi-
∗W. A. van der Linden, P. P. Geurink, C. Oskam, G. A. van der Marel, B. I. Florea, H. S. Overkleeft, Org.




























































Figure 3.1: Overview of designed panel of potential proteasome inhibitors.
tution in diethyl iodomethylphosphonate by the sodium salt of 1-adamantylthiol or 1-ada-
mantylmethylthiol171 followed by peracetic acid oxidation gave 132 and 133 in 79% and
65% yield over two steps, respectively (Scheme 3.1). Reaction of aldehyde 126 with five
HWE reagents yielded 127-129, 134 and 135.
Horner-Wadsworth-Emmons olefination of 136172 using diethyl methyl phosphonoac-
etate yielded diester 137 (Scheme 3.2), which could be selectively saponified to 138 in 73%
yield. NaBH4 reduction of the 138 derived mixed anhydride afforded unsaturated fura-
nolactone 139. Cyclic vinyl ester 141, configurationally different from 139, was obtained
from chloromethylketone 140 173 in two steps. Chloride substitution in 140 by potassium
40
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Reagents and conditions: i) Diethyl cyanomethylphosphonate (1.5 equiv.), NaH (1.5 equiv.), THF, 0◦C, 30
min., then 126 (1 equiv.), o/n, 42%. ii) Tetraethyl methylenediphosphonate (1.5 equiv.), NaH (1.5 equiv.), THF,
0◦C, 30 min., then 126 (1 equiv.), 3 hr. 82%. iii) Diethyl methylphosphonate (1 equiv.), LiHMDS (2 equiv.),
THF, -78◦C, 15 min., then ClP(O)Ph2 (1 equiv.), -40
◦C, 1 hr., then 126 (1 equiv.), -40◦C, 3 hr., 5%. iv)(a) diethyl
iodomethylphosphonate (1 equiv.), THF, 0◦C, 1.5 hr. (b) 32% AcOOH in AcOH (4 equiv.), 1,4-dioxane, 0◦C, 2
hr., 79% (132), 65% (133). v) 132 or 133 (1.1 equiv.), KOtBu (1.1 equiv.), THF, 0◦C, 30 min., then 126 (1 equiv.),
62% (134), 89% (135).
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Reagents and conditions: i) methyl dimethylphosphonoacetate (1.5 equiv.), NaH (1.5 equiv.), THF, 30 min.,
0◦C, then 136 (1 equiv.), 2.5 hr., 79%. ii) LiOH (1.15 equiv.), THF, H2O, o/n, 73%. iii)(a) EtOCOCl (1.1 equiv.),
TEA (1.1 equiv.), 15 min. (b) NaBH4 (1.5 equiv.), H2O, THF, 0
◦C, 1.5 hr., 71%. iv)(a) Potassium dimethylphos-
phonoacetate (2.2 equiv.), MeCN, 50◦C, 3 hr. (b) LiCl (1.2 equiv.), NEt3 (1 equiv.), 3 hr., 52%. vi) Acetaldehyde




diethyl phosphonoacetate and subsequent intramolecular LiCl promoted HWE reaction
yielded 141 in 52% yield over two steps. HWE olefination of 142174 with acetaldehyde af-
forded vinyl ketone 143 in 86% yield, which was detritylated using dry HCl/TIS to obtain
free amine 144.
The ten potential electrophilic traps were coupled to the peptide recognition parts using
a general strategy, which is illustrated by the preparation of compounds 96-98 (Scheme 3.3).
Vinyl nitrile 127 was deprotected using TFA to give 149 in quantitative yield. BocLeu2OMe
(146) was reacted with hydrazine to yield hydrazide 148. In a one-pot procedure, hydrazide
148 was transformed into its acyl azide using tBuONO and HCl. This acyl azide was
subsequently reacted with the vinyl nitrile-TFA salt 149 under the influence of DiPEA to
yield the Boc-protected tripeptide 150 without observable epimerization during the cou-
pling. In a similar fashion, Cbz-protected tripeptide 96 was synthesised from 147. The
tripeptide 150 was deprotected with TFA and subsequently block-coupled to either azido-
phenylalanine 152175 or AdaAhx3-OH 153 to yield potential inhibitors 97 and 98, respec-
tively (Scheme 3.3).
Scheme 3.3: Preparation of compounds 96, 97 and 98 via block coupling strategy.
RHN CN
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Reagents and conditions: i) H2NNH2
.H2O (30 equiv.), MeOH, reflux, 98% (147), 75% (148). ii) 1:1 TFA:DCM,
30 min., quant. iii)(a) 147 or 148 (1 equiv.), tBuONO (1.1 equiv.), HCl (2.8 equiv.), 1:1 DMF/DCM, -30◦C, 3 hr.
(b) 149 (1.1 equiv.), DiPEA (5 equiv.), -30◦→ RT, o/n, 52% (96), 76% (150). iv) HBTU (1.1 equiv.), DiPEA (3.5
equiv.), 152 or 153 (1.1 equiv.), DMF/DCM 1/1, 5 min., then 151 (1 equiv.), 2 hr., 70% (97), 80% (98).
Next, the proteasomal inhibition capacity of the synthesised compounds was assessed.
To this end a competition assay was employed in human embryonic kidney (HEK293T)
cell lysates at a final inhibitor concentration of 0, 1, 10 and 100 µM versus fluorescent pro-
teasome inhibitor MV151 (42, final concentration 500 nM).110 Only compounds 98, 101,
104, 107, 110, 122 and 125 showed some loss of MV151 signal at 100 µM concentration,
indicating proteasome inhibition (data not shown). However, this potency is very low
compared to the known inhibitors AdaAhx3Leu3VS
107 and ZLeu3VS.
106 For the two vinyl
42
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sulfones in 105-110, the steric bulk of the adamantane group could hamper active site en-
trance and thereby lowering potency. Given the broad range of known electrophilic traps
capable of inhibiting the proteasome, such as vinyl sulfone, epoxyketones, aldehydes and
boronic acids,166 the lack of reactivity of the other inhibitors described in this chapter is
quite surprising.
To test whether these compounds target other molecules in the cell, HEK293T and
RAW264.7 cells were incubated with 50 µM of compound 97 and 118. After cell lysis,
Staudinger ligation using biotin-phosphine 154176 (Figure 5.1, page 85) introduced a bio-
tin to the azide modified proteins. Streptavidin pulldown enriched the pool of labelled
enzymes, which were then digested on-bead and analysed by mass spectrometry. The ob-
served peptides divided by the observable peptides yields the Protein Abundance Index
(PAI). The exponentially modified PAI yields the emPAI ((10PAI − 1)), which is a measure
for absolute protein quantification of the labelled enzymes.177,178 Together with the total
protein coverage by the peptides that were found back, hits were selected and depicted in
Table 3.1 and Table 3.2.
Table 3.1: Determination of cellular targets of compound 97 in HEK293T and RAW264.7 cells by affinity purifi-
cation and nano-LC/MS analysis.
HEK293T RAW267.4
Protein description Coverage (%)a emPAIb Protein description Coverage (%) emPAI
Proteasome β5 60.1 10.3 Proteasome β1i 73.0 26.8
Proteasome β2 38.3 1.1 Proteasome β1 72.0 12.1
Proteasome β1 39.3 0.5 Proteasome β5i 54.0 6.1
Cathepsin L2 21.0 0.5 Proteasome β5 72.0 11.6
Cathepsin L1 13.2 0.3 Proteasome β2 46.1 1.6
Cathepsin F 3.1 0.1 Proteasome β2i 11.0 0.2
tubulin 0.7 Cathepsin L1 44.0 2.5
Cathepsin Z 49.8 4.1
Cathepsin F 26.2 0.7
Cathepsin D 23.4 0.4
a Protein sequence coverage by peptides found back
b (10(observed peptides/observable peptides))− 1
Table 3.2: Determination of cellular targets of compound 118 in HEK293T and RAW264.7 cells by affinity
purification and nano-LC/MS analysis.
HEK293T RAW264.7
Protein description Coverage (%)a emPAIb Protein description Coverage (%) emPAI
Proteasome β5 17.5 0.3 Proteasome β1i 33.8 1.2
Proteasome β2 10.1 0.1 Proteasome β5 15.5 0.1
keratin 2.5 Proteasome β1 8.0 0.3
Cathepsin Z 12.1 0.4
Cathepsin L1 32.3 0.5
Cathepsin S 30.0 0.2
a Protein sequence coverage by peptides found back
b (10(observed peptides/observable peptides))− 1
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Surprisingly, the peptides found back with the highest emPAI and best protein coverage
belong to the active subunits of the proteasome, which means that 97 and 118 targeted the
proteasome in the HEK and RAW cells. This is remarkable since 97 and 118 do not show
proteasome inhibition in lysates at concentrations up to 100 µM in the competition as-
say in lysates versus MV151. The pull-down, tryptic digest/mass spectrometry analysis, in
which even the smallest fraction of labelled proteasome is found back, appears to be more
sensitive than the MV151 competition assay. A second class of peptides found with reason-
able coverage belong to the cathepsin family. The emPAI of most of these cathepsin hits is
low compared to the proteasome hits, which could be explained by the higher proteasome
content in mammalian cells compared to cathepsins.
3.3 Conclusion
Despite the variety of potential proteasome inhibitors synthesised in this work, no new
electrophilic trap was found which yields potent proteasome inhibitors. For future devel-
opment of proteasome inhibitors, variation in the peptide recognition part is therefore a
recommendable approach. Even though the potency of proteasome inhibition by com-
pounds 97 and 118 in a gel based competition assay is low, these compounds are able to
label the proteasome, as was confirmed with the biotin pulldown-MS2 detection method.
These results demonstrate that the biotin pulldown-MS2 assay is an attractive alternative to
the gel based competition assay, because the MS2 is very sensitive and information about
cross reactivity of an inhibitor is directly obtained. Therefore, incorporation of an azide in
potential inhibitors is a viable strategy to determine its reactivity in cell extracts.
3.4 Experimental
All reagents were commercial grade and were used as received unless indicated otherwise. Toluene (Tol.), ethyl ac-
etate (EA), and light petroleum ether (PE) were obtained from Riedel-de Haën or Biosolve and were distilled prior
to use. Dichloromethane (DCM), dimethyl formamide (DMF), and dioxane were stored on 4 Å molecular sieves.
Tetrahydrofuran (THF) was distilled from LiAlH4 prior to use. Reactions were conducted under an argon atmo-
sphere. Reactions were monitored by TLC analysis by using DC-fertigfolien (Schleicher & Schuell, F1500, LS254)
with detection by UV absorption (254 nm), spraying with 20% H2SO4 in ethanol or (NH4)6Mo7O24
.4H2O (25
g/L) and (NH4)4Ce(SO4)4
.2H2O (10 g/L) in 10% sulfuric acid followed by charring at ∼150
◦C or by spraying
with an aqueous solution of KMnO4 (7%) and KOH (2%). Column chromatography was performed on silica gel
from Screening Devices (0.040-0.063 nm). LC/MS analysis was performed on a LCQ Advantage Max (Thermo
Finnigan) equipped with an Gemini C18 column (Phenomenex). HRMS were recorded on a LTQ Orbitrap
(Thermo Finnigan). 1H- and 13C-APT-NMR spectra were recorded on a Jeol JNM-FX-200 (200/50), Bruker
DPX-300 (300/75 MHz), Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory. Chemi-
cal shifts are given in ppm (δ) relative to tetramethylsilane as an internal standard. Coupling constants are given in
Hz. All presented 13C-APT spectra are proton decoupled. Optical rotations were measured on a Propol automatic
polarimeter (sodium D line, λ = 589 nm).
BocHN
O
Boc-Leucinal (126). Boc-leucine Weinreb amide (1.7 g 6.2 mmol) was dissolved in Et2O
(30 mL) at 0◦C. LiAlH4 (0.24 g, 6.2 mmol, 1 equiv.). was added, and the mixture was
stirred for 30 min. The reaction mixture was quenched by slow addition of 1M HCl. The
water layer was extracted with Et2O (3×). The combined organic layers were washed with
brine and dried over Na2SO4, yielding the title compound, which was used without further
purification.
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BocHN CN
(S,E)-4-Boc-amino-6-methylhept-2-enenitrile (127). Diethyl cyanomethylphosphonate
(1.39 g, 7.88 mmol, 1.5 equiv.) was dissolved in THF (30 mL) at 0◦C. NaH (60% disp.
in mineral oil, 0.315 g, 7.88 mmol, 1.5 equiv.) was added and the mixture was stirred for 30
minutes. Boc-leucinal 126 (1.11 g, 5.16 mmol, 1 equiv.) in THF was added, and the mix-
ture was stirred o/n. EA was added, and the mixture was washed with 1M HCl (2×) and
brine. The organic layer was dried with MgSO4 and concentrated. Column chromatography (EA:PE (10→ 25%))
yielded the title compound (0.52 g, 2.18 mmol, 42%). 1H NMR (200 MHz, CDCl3): δ ppm 6.61 (dd, J1 = 16.3
Hz, J2 = 5.1 Hz, 1H), 5.49 (dd, J1 = 16.1 Hz, J2 = 1.5 Hz, 1H), 4.45-4.20 (m, 2H), 1.80-1.35 (m, 12H), 0.94 (d,






Boc-leucine vinyl diethylphosphonate (128). Tetraethyl methylenediphosphonate (0.9
g, 3.12 mmol, 1.5 equiv.) was dissolved in THF (10 mL) at 0◦C. NaH (60% disp in mineral
oil, 125 mg, 3.12 mmol, 1.5 equiv.) was added, and the mixture was stirred for 30 minutes
at 0◦C. Boc-leucinal 126 (448 mg, 2.08 mmol, 1 equiv.) in THF was added and the resulting
mixture was stirred for 3 hr. 1M HCl and EA were added, and the layers were separated.
The organic layer was washed with 1M HCl and brine and was dried with MgSO4 and
concentrated. Column chromatography yielded the title compound (596 mg, 1.71 mmol,
82%). [α]20
D
-14.5◦(c = 1, CHCl3).
1H NMR (200 MHz, CDCl3): δ ppm 6.66 (ddd, J1 = 21.9 Hz, J2 = 17.2 Hz,
J3 = 4.8 Hz, 1H), 5.77 (ddd, J1 = 17.2 Hz, J2 = 3.7 Hz, J3 = 1.5 Hz, 1H), 4.45-4.15 (m, 2H), 4.17-4.02 (m, 4H),
1.78-1.50 (m, 1H), 1.44 (s, 9H), 1.40-1.25 (m, 8H), 0.93 (d, J = 6.6 Hz, 6H). 13C NMR (50.1 MHz, CDCl3): δ ppm
154.70, 153.08, 152.99, 116.85, 113.13, 78.13, 77.64, 77.00, 76.35, 60.88, 60.77, 50.63, 50.22, 42.53, 27.61, 23.97,






methylphosphonate (0.96 g, 6.32 mmol, 1 equiv.) was dissolved in THF and cooled to -
78◦C. LiHMDS (12.64 mL 1M sln. in THF/EtPh, 2 equiv.) was added and the solution was
stirred for 15 min. Chlorodiphenylphosphinoxide (1.5 g, 6.32 mmol, 1 equiv.) was added
and the solution was stirred for 1h at -40◦C. Boc-leucinal 126 (1.48 g, 6.3 mmol, 1 equiv.)
in THF was added dropwise, and the mixture was stirred for 3h at -40◦C. The reaction was
quenched with H2O, and the resulting mixture was extracted with EA (3×). The combined
organic layers were dried with Na2SO4 and concentrated. Flash column chromatography (EA:PE 40 → 80%,
2×)) yielded the title compound (184 mg, 0.29 mmol, 5% isolated yield). 1H NMR (400 MHz, CDCl3): δ ppm
7.78-7.36 (m, 10H), 6.79-6.51 (m, 1H), 6.45-6.32 (m, 1H), 4.98-4.71 (m, 1H), 4.42-4.20 (m, 1H), 1.88-1.13 (m, 12H),
0.98-0.83 (m, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 155.08, 152.01, 133.35, 133.11, 132.30, 132.08, 131.60,







Diethyl 1-adamantylsulfonylmethylphosphonate (132). 1-adamantylthiol (1.77 g, 10
mmol, 1 equiv.) was dissolved in THF (50 mL) at 0◦C. NaH (60% disp. in min. oil, 0.42
g, 10.5 mmol, 1.05 equiv.) was added, and the mixture was stirred for 1 hr. Diethyl iodo-
methylphosphonate (2.78 g, 10 mmol, 1 equiv.) in THF was added, and the mixture was
stirred for 1.5 hr. The reaction was quenched with 1M HCl, and the mixture was extracted
with DCM (2×). The organic layer was dried with MgSO4 and concentrated. The residue
was dissolved in 1,4-dioxane and cooled to 0◦C. AcOOH (8.4 mL 32% in AcOH (w/w), 40
mmol, 4 equiv.) was added and the mixture was stirred for 2 hr. Sat. aq. NaHCO3 was
added, and the mixture was extracted with EA (2×). The organic layer was dried with MgSO4 and concentrated.
The residue was recrystallised from EA:PE to yield the title compound (2.79 g, 7.95 mmol, 79%). 1H NMR (400
MHz, CDCl3): δ ppm 4.31-4.23 (m, 4H), 3.48 (d, J = 18.7 Hz, 2H), 2.21 (s, 3H), 2.04 (d, J = 2.3 Hz, 6H), 1.80-1.66








Diethyl 1-adamantylmethylsulfonylmethylphosphonate (133). 1-adamantyl-
methylthiol 171(1.82 g, 10 mmol) was dissolved in THF (50 mL) at 0◦C. NaH (60%
disp. in mineral oil, 0.42 g, 10.5 mmol, 1.05 equiv.) was added and the solution was
stirred for 1 hr. Diethyl iodomethylphosphonate (2.78 g, 10 mmol, 1 equiv.) was
added, and the mixture was stirred for 2 hr. The reaction was quenched by the addition of 1M HCl. The water
layer was extracted with DCM (3×) and the combined organic layers were dried with MgSO4 and evaporated.
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The residue was dissolved in dioxane at 0◦C and AcOOH (6.8 mL 39% sln in AcOH (w/w), 40 mmol, 4 equiv.)
was added. The reaction was allowed to warm to RT and stirred for 1 hr. Sat. aq. NaHCO3 was added, and this
mixture was extracted with EA (3×). The combined organic layers were dried over MgSO4 and evaporated. The
residue was recrystallised from EA:PE, yielding two crops of the title compound (total 2.38 g, 6.54 mmol, 65%).
1H NMR (400 MHz, CDCl3): δ ppm 4.28-4.18 (m, 4H), 3.52 (d, J = 16.5 Hz, 1H), 3.21 (s, 2H), 2.04-1.97 (m, 3H),
1.90-1.87 (m, 6H), 1.78-1.60 (m, 6H), 1.37 (t, J = 7.1 Hz, 1H).
BocHN S
O O
Boc-leucinyl vinyl-1-adamantylsulfone (134). Diethyl 1-adamantylsulfonylmethyl-
phosphonate 133 (1.9 g, 5.4 mmol, 1.1 equiv.) was dissolved in 50 mL THF at 0◦C.
KOtBu (607 mg, 5.4 mmol, 1.1 equiv.) was added and the mixture was stirred for
30 min. Boc-leucinal 126 (1.06 g, 4.92 mmol, 1 equiv.) in THF was added and the
mixture was stirred at 0◦C for 1 hr. Sat. aq. NH4Cl was added and the mixture was
extracted with EA (2×). The organic layer was dired with MgSO4 and concentrated.
Column chromatography (EA:PE (5 → 30%)) and recrystallisation from DCM:PE
yielded the title compound (1.22 g, 3.06 mmol, 62%). 1H NMR (400 MHz, CDCl3): δ ppm 6.69 (dd, J = 15.0,
5.33 Hz, 1H), 6.33 (d, J = 15.1 Hz, 1H), 5.17 (d, J = 7.6 Hz, 1H), 4.40-4.29 (m, 1H), 2.14 (s, 3H), 2.01-1.90 (m, 6H),
1.80-1.62 (m, 7H), 1.47-1.41 (m, 11H), 0.96-0.91 (m, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 154.77, 150.76,




ethyl 1-adamantylmethylsulfonylmethylphosphonate 133 (2.12 g, 5.83 mmol, 1.1
equiv.) was dissolved in THF (50 mL) and cooled to 0◦C. KOtBu (0.65 g, 5.83
mmol, 1.1 equiv.) was added and the mixture was stirred for 30 min. Boc-leucinal
126 (1.14 g, 5.3 mmol, 1 equiv.) in THF (30 mL) was slowly added and the mixture
was stirred for 90 min. The reaction was quenched with sat. aq. NH4Cl. More
sat. aq. NH4Cl was added, and the resulting mixture was extracted with EA. The
organic phase was washed with brine, dried over MgSO4 and evaporated. Column
chromatography (EA:PE (0→ 12%)) yielded the title compound (2.0 g, 4.7 mmol,
89%). 1H NMR (400 MHz, CDCl3): δ ppm 6.74 (dd, J1 = 15.0, J2 = 5.2 Hz, 1H), 6.46 (dd, J1 = 15.1, J2 1.2 Hz,
1H), 5.12 (d, J = 8.3 Hz, 1H), 4.44-4.33 (m, 1H), 2.81 (s, 1H), 2.02-1.97 (m, 3H), 1.87-1.79 (m, 6H), 1.75-1.63 (m,
7H), 1.47-1.41 (m, 11H), 0.94 (d, J = 6.7 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 154.82, 147.16, 130.30,






(S)-dimethyl-2-(1-Boc-amino-3-methylbutyl)maleate (137). 40 mL THF was cooled to
0◦C. NaH (60% disp. in oil, 156 mg, 3.9 mmol, 1.5 equiv.) was added, followed by methyl
dimethylphosphonoacetate (580 µL, 3.9 mmol, 1.5 equiv.) and the mixture was stirred for
30 min. at 0◦C. (S)-3-(Boc-amino)-5-methyl-2-oxohexanoic acid methyl ester (136) 172 (708
mg, 2.6 mmol, 1 equiv.) in THF was added and the mixture was stirred for 2.5 hr. Sat. aq.
NH4Cl was added, and the mixture was extracted with EA. The organic layer was washed
with sat. aq. NaHCO3, brine, dried with MgSO4 and concentrated. Column chromato-
graphy (EA:PE (5 → 25%)) yielded the title compound (674 mg, 2.04 mmol, 79%). [α]20
D
-31.1◦(c = 1, CHCl3).
1H NMR (400 MHz, CDCl3): δ ppm 6.03 (s, 1H), 5.31 (d, J = 8.3
Hz, 1H), 4.49-4.40 (m, 1H), 3.81 (s, 3H), 3.72 (s, 3H), 1.84-1.62 (m, 1H), 1.60-1.33 (m, 11H), 0.96-0.89 (m, 6H).
13C NMR (100 MHz, CDCl3): δ ppm 167.15, 164.78, 154.55, 149.93, 119.54, 79.02, 51.78, 51.42, 51.32, 41.82,






(S,Z)-4-Boc-amino-3-(methylxycarbonyl)-6-methylhept-2-enoic acid (138). (S)-
dimethyl-2-(1-Boc-amino-3-methylbutyl)-maleate 137 (674 mg, 2.04 mmol) was dissolved
in THF (8 mL) at 0◦C. LiOH (2.04 mL 1M aq sln, 2.04 mmol, 1 equiv.) was added and
the solution was stirred for 2.5 hr. LiOH (306 µL 1M aq sln, 306 µmol, 0.15 equiv.) was
added and the solution was allowed to warm to RT and stirred o/n. 1M aq. HCl was
added, and the mixture was extraced with EA (2×). The combined organic layers were
washed with brine, dried with MgSO4 and concentrated. Column chromatography (EA:PE (30→ 70%)) yielded
the title compound (467 mg, 1.48 mmol, 73%). [α]20
D
-23.3◦(c= 1, CHCl3).
1H NMR (400 MHz, CDCl3, mixture
of rotamers): δ ppm 10.55 (s, 1H), 6.57 (d, J = 7.1 Hz, 1H), 6.03 (s, 1H), 5.94 (s, 1H), 5.06 (d, J = 8.5 Hz, 1H),
4.50-4.41 (m, 1H), 4.28-4.19 (m, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 1.81-1.63 (m, 2H), 1.53-1.40 (m, 22H), 0.97-0.87 (m,
12H). 13C NMR (100 MHz, CDCl3, mixture of rotamers): δ ppm 168.30, 167.59, 167.19, 156.93, 154.88, 152.01,
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carbonyl)-6-methylhept-2-enoic acid 138 (312 mg, 0.99 mmol) was dissolved in 20 mL THF
at 0◦C. NEt3 (153 µL, 1.1 mmol, 1.1 equiv.) and EtOCOCl (110 µL, 1.1 mmol, 1.1 equiv.)
were added and the mixture was stirred for 15 min. The mixture was filtered into a solution
of NaBH4 (60 mg, 1.5 mmol, 1.5 equiv.) in 20 mL H2O at 0
◦C. The mixture was allowed to
warm to RT and stirred for 1.5 hr. 1M HCl was added and the mixture was extracted with EA.
The organic layer was washed with 1M HCl, sat. aq. NaHCO3 and brine. After drying with
MgSO4 and concentration, the residue was purified with column chromatography (EA:PE (10→ 50%)), yielding
the title compound (190 mg, 0.70 mmol, 71%). 1H NMR (400 MHz, CDCl3): δ ppm 7.28 (s, 1H), 5.31 (d, J = 8.7
Hz, 1H), 4.82 (s, 2H), 4.66-4.55 (m, 1H), 1.66-1.53 (m, 3H), 1.43 (s, 9H), 0.99-0.89 (m, 6H). 13C NMR (100 MHz,









amino)-5-methylhexane 140 173 (0.79 g, 3 mmol) was coevaporated with toluene and dis-
solved in dry MeCN. Potassium dimethylphosphonoacetate (1.36 g, 6.6 mmol, 2.2 equiv.)
was coevaporated with toluene and added to the reaction mixture, followed by stirring at
50◦C for 3 hr. EA and 20% aq. NaH2PO4 were added, layers separated, and the water
layer was extracted with EA (2×). The combined organic layers were dried over MgSO4
and concentrated. The residue was dissolved in dry MeCN (50 mL) and LiCl (153 mg, 3.6
mmol, 1.2 equiv.) and NEt3 (0.42 mL, 3 mmol, 1 equiv.). After 3 hr., the reaction mixture
was poured into 1M HCl, followed by extraction with EA. The organic layer was dried over MgSO4 and concen-
trated. Flash column chromatography (EA:toluene (0→ 15%)) yielded the title compound (418 mg, 1.55 mmol,
52%). 1H NMR (200 MHz, CDCl3): δ = 5.91 (q, J = 1.5 Hz, 1H), 5.44 (d, J = 8.0 Hz, 1H), 4.95-4.75 (m, 2H),
4.74-4.60 (m, 1H), 1.85-1.57 (m, 3H), 1.44 (s, 9H), 0.99-0.89 (m, 6H). 13C NMR (50.1 MHz, CDCl3): δ ppm 173.4,
172.2, 155.2, 114.7, 79.6, 71.3, 47.2, 42.0, 28.0, 24.3, 22.7, 21.1. [α]20
D
-73.2◦(c = 1, MeOH). HRMS: calcd for
[C14H23NO4Na]




5-methylhexane 142 174 (12 g, 23.64 mmol) was dissolved in EtOH (100 mL) and acetaldehyde
(11 mL, 190 mmol, 8 equiv.) was added. K2CO3 (3.5 g, 25 mmol, 1.06 equiv.) was added in
portions, and the reaction was stirred o/n. The reaction mixture was filtered and concentrated.
The residue was dissolved in EA and extracted with sat. aq. NaHCO3 and brine. The organic
layer was dried with MgSO4 and concentrated. Column chromatography (EA:PE (1→ 5%))
yielded the title compound (8.06 g, 20.27 mmol, 86%). 1H NMR (400 MHz, CDCl3): δ ppm
7.53-7.02 (m, 15H), 6.45-6.24 (m, 1H), 5.69 (dd, J1 = 15.6, J2 = 1.6 Hz, 1H), 3.59 (t, J = 6.6 Hz, 1H), 3.15-3.01 (m,
1H), 1.75-1.64 (m, 1H), 1.57 (dd, J1 = 6.9, J2 = 1.36 Hz, 3H), 1.44 (t, J = 6.8 Hz, 2H), 0.86 (d, J = 6.6 Hz, 3H),
0.84 (d, J = 6.6 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ ppm 202.53, 146.29, 140.79, 128.76, 127.43, 125.98,
70.96, 58.07, 45.00, 24.33, 23.28, 22.51, 17.58.
ClH3N
O
(S,E)-5-amino-7-methyloct-2-en-4-one HCl (144). (S,E)-5-amino-7-methyloct-2-en-4-one 143
(440 mg, 1.1 mmol) was dissolved in 6 mL Et2O. HCl (550 µL 4M sln in dioxane, 2 equiv.)
and TIS (341 µL, 1.65 mmol, 1.5 equiv.) were added and the mixture was stirred for 1 hr.
The reaction mixture was filtered and the residue washed with Et2O (4x). The residue was
recrystallised from DCM/Et2O (3×), yielding the title compound (134 mg, 0.7 mmol, 63%).
1H NMR (400 MHz, CD3OD): δ ppm 8.60 (s, 3H), 7.07 (dq, J1 = 13.9, J2 = 6.9 Hz, 1H),
6.24 (dd, J1 = 15.5, J2 = 1.1 Hz, 1H), 4.53-4.43 (m, 1H), 2.14-2.00 (m, 1H), 1.97-1.92 (m, 3H),
1.92-1.86 (m, 1H), 1.71-1.60 (m, 1H), 1.04 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 6.5 Hz, 3H). 13C NMR (100 MHz,








O ZLeu2NHNH2 (147). ZLeu2OMe 145 (6.67 g, 17 mmol) was dissolved in 50 mL
MeOH. H2NNH2 ·H2O (10 mL, 200 mmol, 30 equiv.) was added, and the mixture
was refluxed o/n. The mixture was coevaporated with toluene (3×) and subjected to
flash column chromatography (MeOH:EA:NEt3 (0:99:1→ 20:79:1)) to yield the title
compound (6.53 g, 16.6 mmol, 98%). 1H NMR (400 MHz, CD3OD): δ ppm 7.42-7.28
(m, 5H), 5.12 (s, 2H), 4.62 (s, 2H), 4.40 (dd, J1 = 9.4, J2 = 5.4 Hz, 1H), 4.17 (t, J = 7.6











(148). BocLeu2OMe 146 (1.62 g, 4.52 mmol) was dissolved in 50
mL MeOH. H2NNH2 ·H2O (6.57 mL, 136 mmol, 30 equiv.) was added and the
mixture was refluxed for 2 hr. Concentration and column chromatography yielded
the title compound (1.21 g, 3.38 mmol, 75%). 1H NMR (400 MHz, CD3OD): δ ppm
4.46-4.39 (m, 1H), 4.11 (t, J = 7.5 Hz, 1H), 1.76-1.46 (m, 6H), 1.43 (s, 9H), 0.95-0.87
(m, 12H).
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Reagents and conditions: i) HCl H-Ahx-OMe (1 equiv.), Ada-AcOH (1.1 equiv.), HCTU (1.15 equiv.), DiPEA
(3.25 equiv.), DCM, 3 hr., quant. ii) LiOH (1M aq. sln., 1.1 equiv.), THF, 0◦C, 12 hr., 99% (156), 95% 153). iii)(a)
Boc-Ahx2-OMe, TFA/DCM 1/1, 30 min., quant. (b) 156 (1 equiv.), HCTU (1.15 equiv.), DiPEA (3.3 equiv.),






AdaAhxOMe (155). To a solution of methyl 6-aminohexanoate HCl salt (0.78
g, 4.30 mmol) and 1-adamantaneacetic acid (0.94 g, 4.73 mmol, 1.1 equiv.) in
DCM (25 mL) were added HCTU (2.0 g, 4.94 mmol, 1.15 equiv.) and DiPEA
(2.31 mL, 14 mmol, 3.25 equiv.). The mixture was stirred for 3 hr., after which
EA (100 mL) was added followed by washing of the mixture with 1M HCl (2×),
sat. aq. NaHCO3 (2×) and brine. Drying over MgSO4 and concentration of
the mixture resulted in crude product, which was further purified by column
chromatography (EA:PE (10→ 100%)). The product (yield: 1.38 g, 4.30 mmol,
quant.) was obtained as a colorless solid. LC/MS: linear gradient 10% → 90% MeCN/(0.1% TFA/H2O): Rt
(min): 8.71 (ESI-MS (m/z): 322.20 (M+H+)). 1H NMR (400 MHz, CDCl3): δ ppm 5.60-5.53 (m, 1H), 3.67 (s,
3H), 3.24 (dd, J1 = 13.2, J2 = 6.9 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 1.99-1.94 (m, 3H), 1.91 (s, 2H), 1.73-1.59 (m,
15H), 1.56-1.48 (m, 2H), 1.41-1.31 (m, 2H). 13C NMR (100 MHz, CDCl3): δ ppm 173.95, 170.81, 51.78, 51.42,






AdaAhxOH (156). Methyl ester 155 (2.79 g, 8.68 mmol) was dissolved in
THF (35 mL) and cooled to 0◦C. An aqueous solution of LiOH (1M, 9.54
mmol, 9.54 mL, 1.1 eq.) was added and the reaction was stirred at 0◦C for
12 hr. after which TLC analysis indicated complete consumption of starting
material. Water (50 mL) was added and the mixture was extracted twice with
EA. Next, the aqueous layer was acidified with concentrated HCl to pH 1
and extracted again with EA (2×). The latter two combined organic layers were dried (MgSO4) and concentrated
under reduced pressure, which yielded the title compound (yield: 2.63 g, 8.57 mmol, 99%) as a colorless solid.
LC/MS: linear gradient 10%→ 90% MeCN/(0.1% TFA/H2O): Rt (min): 7.49 (ESI-MS (m/z): 308.13 (M+H
+)).
1H NMR (400 MHz, CDCl3): δ ppm 10.87 (s, 1H), 5.95 (t, J = 5.6 Hz, 1H), 3.24 (dd, J1 = 13.2, J1 = 6.81 Hz, 2H),
2.34 (t, J = 7.3 Hz, 2H), 1.99-1.92 (m, 5H), 1.73-1.58 (m, 14H), 1.53 (dt, J1 = 14.7, J2 = 7.4 Hz, 2H), 1.43-1.33 (m,
2H). 13C NMR (100 MHz, CDCl3): δ ppm 177.96, 171.55, 51.49, 42.48, 39.15, 36.62, 33.86, 32.63, 29.11, 28.51,
26.24, 24.20.
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OMe (157). Methyl 6-(6-(tert-butoxycarbonylamino)hexanami-
do)hexanoate 179 (3.37 g, 9.39 mmol, 1.1 equiv.) was dissolved in DCM/TFA
(1/1, v/v) and stirred for 30 mintues before being coevoparated with toluene
(3×). AdaAhxOH 156 (2.63 g, 8.57 mmol, 1 equiv.) was dissolved in DMF.
HCTU (4.08 g, 9.86 mmol, 1.15 eq) and DiPEA (5.12 mL, 31 mmol, 3.3 equiv.)
were added and the mixture was stirred for 10 min. Methyl 6-hexanamido hex-
anoate TFA salt in DMF was added, and the mixture was stirred for 2 hr. The
mixture was concentrated, dissolved in DCM, washed with 1M HCl (2×), sat. aq. NaHCO3 (4x) and brine.
The organic layer was dried with MgSO4 and concentrated. The title compound was obtained as a colorless solid
(yield: 4.10 g, 7.49 mmol, 87%) after column purification (EA 0 → 15% MeOH:EA). LC/MS: linear gradient
10%→ 90% MeCN/(0.1% TFA/H2O): Rt (min): 7.93 (ESI-MS (m/z): 548.33 (M+H
+)). 1H NMR (400 MHz,
CDCl3): δ ppm 6.42 (t, J = 5.7 Hz, 1H), 6.38 (t, J = 5.6 Hz, 1H), 6.13 (t, J = 5.6 Hz, 1H), 3.66 (s, 3H), 3.25-3.18
(m, 6H), 2.31 (t, J = 7.4 Hz, 2H), 2.18 (t, J = 7.4 Hz, 4H), 1.98-1.94 (m, 3H), 1.92 (s, 2H), 1.73-1.58 (m, 18H),
1.56-1.47 (m, 6H), 1.39-1.29 (m, 6H). 13C NMR (100 MHz, CDCl3): δ ppm 173.95, 172.97, 172.92, 171.02, 51.54,









OH (153). Methyl ester 157 (4.10 g, 7.49 mmol) was dissolved in
THF/MeOH 5:1 (35 mL) and cooled to 0◦C. An aqueous solution of LiOH
(1M, 8.24 mmol, 8.24 mL, 1.1 eq.) was added and the reaction was stirred at RT
for 12 hr. after which TLC analysis indicated complete consumption of starting
material. Water (50 mL) was added and the mixture was extracted twice with
EA. Next, the aqueous layer was acidified with concentrated HCl to pH 1 and
extracted with DCM (3×). The combined DCM layers were dried (MgSO4)
and concentrated under reduced pressure, which yielded the title compound
(3.79 g, 7.12 mmol, 95%) as a colorless solid. LC/MS: linear gradient 10%→ 90% MeCN/(0.1% TFA/H2O): Rt
(min): 7.21 (ESI-MS (m/z): 534.33 (M+H+)). 1H NMR (400 MHz, CD3OD): δ ppm 7.96-7.90 (m, 2H), 7.86-7.79
(m, 1H), 3.19-3.11 (m, 6H), 2.29 (t, J = 7.4 Hz, 2H), 2.17 (t, J = 7.4 Hz, 4H), 1.97-1.93 (m, 3H), 1.91 (s, 2H), 1.74
(d, J = 12.3 Hz, 3H), 1.69-1.57 (m, 15H), 1.55-1.46 (m, 6H), 1.40-1.28 (m, 6H) . 13C NMR (100 MHz, CD3OD):
177.40, 175.97, 173.74, 51.91, 43.79, 40.21, 37.95, 37.02, 34.83, 33.81, 30.24, 30.19, 30.14, 27.68, 27.58, 27.53, 26.74,
25.75 .
General protocol for azide couplings The Boc-protected warhead was dissolved in TFA:DCM (1:1, v/v) and
stirred for 20 min. Coevaporation with toluene (3×) afforded the warhead TFA-salt, which was used without
further purification. The appropriate hydrazide (147 or 148) was dissolved in 1:1 DMF:DCM (v/v) and cooled
to -30◦C. tBuONO (1.1 equiv.) and HCl (4M sln. in 1,4-dioxane, 2.8 equiv.) were added, and the mixture was
stirred for 3 hr. at -30◦C after which TLC analysis (10% MeOH/DCM, v/v) showed complete consumption of
the starting material. The warhead-TFA salt was added to the reaction mixture as a solution in DMF with 1.1
equivalent of DiPEA. A further 3.9 equivalents of DiPEA were added to the reaction mixture, and this mixture
was allowed to warm to RT slowly overnight. The mixture was diluted with EA and washed with H2O (3×). The
organic layer was dried over MgSO4 and purified by flash column chromatograpy.
General protocol for block couplings The Boc-protected tripeptide was dissolved in TFA:DCM (1:1, v/v) and
stirred for 20 min. Coevaporation with toluene (3×) afforded the tripeptide TFA-salt, which was used without
further purification. The carboxylic acid (152 or 153, 1 equiv.) was dissolved in DCM:DMF (1/1, v/v). HBTU
(1.1 equiv.), DiPEA (3.5 equiv.) were added and the mixture was stirred for 5 min. A solution of the tripeptide
TFA salt in DMF was added and the mixture was stirred for 2 hr. before being concentrated. The residue was
taken up in DCM, washed with 1M HCl (2×), sat. aq. NaHCO3 (4x), brine, and dried with Na2SO4. The residue









(S,E)-4-Cbz-Leu2-amino-6-methylhept-2-enenitrile (96). Following the gen-
eral procedure for azide coupling the title compound was obtained from (S,E)-
4-Boc-amino-6-methylhept-2-enenitrile 127 (141 mg, 0.59 mmol, 1.1 equiv.)
and CbzLeu2NHNH2 147 (210 mg, 0.534 mmol, 1 equiv.). Purification by
flash chromatography (EA:PE (0 → 40%)) gave the title compound (138 mg,
0.277 mmol, 52%). 1H NMR (500 MHz, CD3OD): δ ppm 7.35-7.29 (m, 6H),
6.74 (dd, J1 = 16.3, J1 = 5.0 Hz), 5.59-5.55 (m, 1H), 5.13-5.05 (m, 2H), 4.56-4.55 (m, 1H), 4.38-4.35 (m, 1H),
4.12-4.09 (m, 1H), 1.70-1.34 (m, 9H), 0.96-0.97 (m, 18H). 13C NMR (125 MHz, CD3OD): δ ppm 175.11, 175.03,
49
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173.93, 173.85, 158.24, 156.50, 137.78, 129.34, 129.27, 128.87, 118.16, 99.83, 67.50, 54.90, 53.13, 50.20, 42.94,











(S,E)-4- Boc-Leu2-amino-6-methylhept-2-enenitrile (150). Following the
general procedure for azide coupling the title compound was obtained
from (S,E)-4-Boc-amino-6-methylhept-2-enenitrile 127 (49 mg, 0.21 mmol, 1.1
equiv.) and BocLeu2NHNH2 148 (67 mg, 0.187 mmol, 1 equiv.). Purification
by flash chromatography (EA:PE (0→ 30%)) gave the title compound (66 mg,
0.14 mmol, 76%). 1H NMR (400 MHz, CDCl3): δ ppm 7.00-6.90 (m, 1H),
6.62 (dd, J1 = 16.4 Hz, J2 = 4.9 Hz, 2H), 5.56 (d, J = 16.4 Hz, 1H), 5.12-
5.00 (m, 1H), 4.67-4.58 (m, 1H), 4.41-4.35 (m, 1H), 4.08-4.00 (m, 1H), 1.82-1.25
(m, 18H), 1.10-0.85 (m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm 172.89,
171.45, 156.17, 154.54, 117.31, 99.64, 80.81, 53.92, 52.23, 48.92, 42.69, 40.57, 40.09, 28.23, 24.88, 24.82, 24.69,













lowing the general procedure for block coupling, the title compound
was obtained from (S,E)-4-Boc-Leu2-amino-6-methylhept-2-enenitrile
150 (66 mg, 0.14 mmol, 1 equiv.) and azido-phenylalanine 152 175 (29
mg, 0.154 mmol, 1.1 equiv.). Flash column chromatography (EA:tol
(0 → 30%)) yielded the title compound (53 mg, 99 µmol, 70%). 1H
NMR (400 MHz, CDCl3): δ ppm 7.35-7.20 (m, 5H), 7.06-6.98 (m,
1H), 6.96-6.86 (m, 1H), 6.59 (dd, J1 = 16.3 Hz, J2 = 5.5 Hz, 1H), 5.44
(d, J = 16.3 Hz, 1H), 4.57-4.42 (m, 3H), 4.24 (dd, J1 = 7.8 Hz, J2 = 4.1
Hz, 1H), 3.21 (dd, J1 = 14.2 Hz, J2 = 3.6 Hz, 1H), 3.05 (dd, J1 = 14.2 Hz, J2 = 7.9 Hz, 1H), 1.82-1.22 (m, 9H),
1.04-0.73 (m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm 171.78, 171.43, 169.05, 154.39, 135.61, 129.37, 128.69,
127.35, 117.05, 99.73, 64.75, 51.95, 51.87, 49.17, 42.42, 41.10, 40.36, 38.00, 24.92, 24.67, 24.59, 22.80, 22.69, 22.61,
22.20, 21.77. HRMS: calcd. for [C29H44N7O3]
















trile (98). Following the general procedure for block
coupling, the title compound was obtained from (S,E)-
4-Boc-Leu2-amino-6-methylhept-2-enenitrile 150 (64 mg,
138 µmol) and AdaAhx3OH 153 (81 mg, 152 µmol, 1.1
equiv.). Flash column chromatography (MeOH:DCM (2
→ 8%)) yielded 98 (108 mg, 123 µmol, 80%). 1H NMR
(400 MHz, CD3OD): δ ppm 8.12-8.04 (m, 2H), 8.00 (d,
J = 8.2 Hz, 1H), 7.95 (t, J = 5.1 Hz, 2H), 7.87-7.82 (m,
1H), 6.73 (dd, J1 = 16.4, J2 = 5.0 Hz, 1H), 5.55 (d, J = 16.4 Hz, 1H), 4.60-4.49 (m, 1H), 4.39-4.25 (m, 2H), 3.13
(dd, J1 = 12.1, J2 = 6.0 Hz, 6H), 2.23 (t, J = 7.3 Hz, 2H), 2.15 (t, J = 7.4 Hz, 4H), 1.95-1.87 (m, 5H), 1.76-1.24 (m,
38H), 0.96-0.84 (m, 18H). 13C NMR (100 MHz, CD3OD): δ ppm 176.45, 175.95, 175.17, 174.37, 173.73, 156.76,
118.25, 99.86, 53.71, 53.45, 51.93, 50.40, 43.74, 43.12, 41.67, 41.51, 40.31, 40.26, 40.18, 37.90, 37.04, 36.66, 33.77,
30.22, 30.15, 30.12, 27.65, 27.59, 27.56, 26.73, 26.56, 25.94, 25.89, 25.78, 23.47, 23.42, 22.12, 21.93, 21.88. HRMS
calcd. for [C50H86N7O6]












Cbz-Leu2-leucinyl vinyl diethylphosphonate (99). Following the gen-
eral procedure for azide coupling the title compound was obtained from
Boc-leucinyl vinyl diethylphosphonate 128 (98 mg, 280 µmol, 1.1 equiv.)
and CbzLeu2NHNH2 147 (100 mg, 254 µmol, 1 equiv.). Purification by
flash chromatography (MeOH:DCM (0 → 3%)) gave the title compound
99 (71 mg, 117 µmol, 46%). [α]20
D
-50.6◦(c = 1, CHCl3). IR (film) 3269,
2955, 2870, 1699, 1645, 1539, 1468, 1387, 1367, 1232, 1024, 962 cm−1. 1H
NMR (400 MHz, CDCl3): δ ppm 7.85-7.70 (m, 1H), 7.36-7.22 (m, 5H),
6.78-6.62 (m, 2H), 5.85-5.72 (m, 1H), 5.14-4.97 (m, 2H), 4.70-4.54 (m, 2H),
4.45-4.35 (m, 1H), 4.08-3.93 (m, 4H), 1.83-1.68 (m, 1H), 1.66-1.31 (m, 8H), 1.32-1.20 (m, 6H), 0.94-0.77 (m, 18H).
13C NMR (100 MHz, CDCl3) δ ppm 172.36, 171.29, 156.21, 153.02, 152.99, 136.31, 128.17, 127.69, 127.50, 116.21,
114.35, 66.43, 61.65, 61.58, 61.52, 53.24, 51.77, 49.28, 49.06, 42.64, 41.37, 40.74, 24.62, 24.53, 24.41, 24.36, 22.82,
50
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Boc-Leu2-leucinyl vinyl diethylphosphonate (158). Following the gen-
eral procedure for azide coupling the title compound was obtained from
Boc-leucinyl vinyl diethylphosphonate 128 (86 mg, 0.246 mmol, 1.1 equiv.)
and BocLeu2NHNH2 148 (80 mg, 0.224 mmol, 1 equiv.). Purification by
flash chromatography EA:tol (50 → 100%) gave the title compound (118
mg, 0.205 mmol, 92%). 1H NMR (400 MHz, CDCl3): δ ppm 7.48-7.40
(m, 1H), 6.72 (ddd, J1 = 22.2 Hz, J2 = 17.2 Hz, J3 = 5.2 Hz, 1H), 5.81 (t,
J = 18.5 Hz, 2H), 5.56-5.50 (m, 1H), 4.72-4.63 (m, 1H), 4.55-4.48 (m, 1H),
4.12-4.00 (m, 5H), 1.75-1.20 (m, 25H), 0.95-0.86 (m, 18H). 13C NMR (100
MHz, CDCl3): δ ppm 172.68, 171.22, 155.84, 152.60, 152.56, 116.90, 115.05, 80.00, 61.77, 61.72, 61.67, 53.26,















Azido-Phe-Leu2-leucinyl vinyl diethylphosphonate (100). Fol-
lowing the general procedure for block coupling, the title
compound was obtained from Boc-Leu2-leucinyl vinyl diethyl-
phosphonate 158 (118 mg, 205 µmol, 1 equiv.) and azido-
phenylalanine 152 (44 mg, 230 µmol, 1.1 equiv.). Flash column
chromatography (EA:tol (50 → 100%)) yielded 100 (68 mg, 100
µmol, 50%). [α]20
D
-36.8◦(c = 1, CHCl3). IR (film) 3277, 2957,
2926, 2112, 1641, 1541, 1468, 1387, 1367, 1226, 1163, 1053, 1024,
964 cm−1. 1H NMR (400 MHz, CDCl3): δ ppm 7.33-7.19 (m,
5H), 7.08-6.99 (m, 1H), 6.68 (ddd, J1 = 22.2, J2 = 17.2, J3 = 5.3 Hz, 1H), 5.77 (t, J = 17.2 Hz, 1H), 4.70-4.60 (m,
1H), 4.55-4.45 (m, 2H), 4.25 (dd, J1 = 8.3, J2 = 4.2 Hz, 1H), 4.12-3.96 (m, 4H), 3.22 (dd, J1 = 14.1, J2 = 3.7 Hz,
1H), 3.04 (dd, J1 = 14.1, J2 = 8.3 Hz, 1H), 1.77-1.16 (m, 15H), 1.00-0.78 (m, 18H).
13C NMR (100 MHz, CD3OD):
δ ppm 171.56, 171.05, 168.88, 152.42, 135.94, 129.37, 128.55, 127.14, 117.06, 115.20, 64.64, 61.89, 61.83, 61.76,
51.89, 51.62, 49.56, 49.34, 43.18, 41.03, 40.91, 38.00, 29.64, 24.81, 24.72, 24.48, 22.78, 22.74, 22.54, 22.50, 22.07,
21.99, 16.32, 16.29, 16.26, 16.23. HRMS: calcd. for [C32H54N6O6P]



















nate (101). Following the general procedure for
block coupling, the title compound was obtained
from Boc-Leu2-leucinyl vinyl diethylphosphonate
158 (122 mg, 212 µmol, 1 equiv.) and AdaAhx3OH
153 (124 mg, 233 µmol, 1.1 equiv.). Flash column
chromatography (MeOH:DCM (2→ 10%)) yielded
101 (149 mg, 150 µmol, 71%). [α]20
D
-38.2◦(c = 1,
MeOH). IR (film) 3277, 3072, 2928, 2905, 2868,
1638, 1545, 1452, 1367, 1234, 1053, 1028, 968 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 8.14-8.03 (m, 3H), 7.96
(t, J = 5.1 Hz, 2H), 7.89-7.84 (m, 1H), 6.67 (ddd, J1 = 22.1, J2 = 17.2, J3 = 4.8 Hz, 1H), 5.86-5.74 (m, 1H), 4.64-
4.54 (m, 1H), 4.45-4.30 (m, 2H), 4.05 (p, J = 7.3, 4H), 3.18-3.11 (m, 6H), 2.25 (t, J = 7.3, 2H), 2.17 (t, J = 7.4 Hz,
4H), 1.97-1.89 (m, 5H), 1.80-1.25 (m, 45H), 0.98-0.87 (m, 18H). 13C NMR (100 MHz, CD3OD): δ ppm 176.23,
175.88, 174.85, 174.15, 173.66, 154.79, 154.74, 117.24, 115.37, 63.43, 63.37, 53.50, 53.29, 51.91, 51.05, 50.83, 43.73,
43.49, 41.82, 41.72, 40.29, 40.24, 37.90, 37.02, 36.66, 33.75, 30.21, 30.14, 30.10, 27.64, 27.58, 27.55, 26.71, 26.57,














Boc-Leu2-leucinyl vinyl diphenylphosphinoxide (159). Following the
general procedure for azide coupling the title compound was obtained
from Boc-leucinyl-vinyl diphenylphosphinoxide 129 (380 mg, 0.92 mmol,
1.1 equiv.) and BocLeu2NHNH2 148 (300 mg, 0.84 mmol, 1 equiv.). Pu-
rification by flash chromatography EA:tol (30 → 70%, 3×) gave the title
compound (221 mg, 0.345 mmol, 41%). 1H NMR (400 MHz, CDCl3): δ
ppm 7.87-7.33 (m, 10H), 6.81 (d, J = 7.1 Hz, 1H), 6.73-6.42 (m, 2H), 5.47 (d, J = 5.5 Hz, 1H), 4.83-4.69 (m, 1H),
4.56-4.48 (m, 1H), 4.08-3.98 (m, 1H), 1.83-1.15 (m, 15H), 1.03-0.77 (m, 18H). 13C NMR (100 MHz, CDCl3): δ
51
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ppm 172.49, 171.33, 155.89, 151.63, 133.49, 133.01, 132.44, 131.96, 131.60, 131.24, 131.15, 128.49, 128.42, 128.30,













Cbz-Leu2-leucinyl vinyl diphenylphosphinoxide (102). Following the
general procedure for azide coupling the title compound was obtained
from Boc-leucinyl-vinyl diphenylphosphinoxide 129 (179 mg, 280 µmol,
1.1 equiv.) and CbzLeu2NHNH2 147 (100 mg, 254 µmol, 1 equiv.). Pu-
rification by flash chromatography (MeOH:DCM (0→ 3%)) gave the title
compound 102 (79 mg, 117 µmol, 46%). [α]20
D
-56.8◦(c = 1, CHCl3). IR
(film) 3271, 3059, 2955, 1701, 1645, 1539, 1437, 1387, 1367, 1263, 1236,
1171, 1121, 1105, 1043, 1028, 972 cm−1. 1H NMR (400 MHz, CDCl3): δ
ppm 7.75 (d, J = 8.6 Hz, 1H), 7.71-7.60 (m, 4H), 7.54-7.24 (m, 11H), 6.90
(d, J = 7.9 Hz, 1H), 6.67-6.40 (m, 2H), 6.05 (d, J = 7.4 Hz, 1H), 5.12-4.95 (m, 2H), 4.78-4.68 (m, 1H), 4.59-4.51 (m,

















Azido-Phe-Leu2-leucinyl vinyl diphenylphosphinoxide (103).
Following the general procedure for block coupling, the title
compound was obtained from Boc-Leu2-leucinyl vinyl diphenyl-
phosphinoxide 159 (75 mg, 117 µmol, 1.1 equiv.) and azido-
phenylalanine 152 (22 mg, 120 µmol, 1.1 equiv.). Flash column
chromatography (EA:tol (50 → 100%), 2×) yielded 103 (71 mg,
100 µmol, 85%). [α]20
D
-43.6◦(c = 1, CHCl3). IR 3281, 3059,
2955, 2928, 2870, 2112, 1641, 1541, 1437, 1387, 1367, 1173, 1121,
1105, 1028, 997 cm−1. 1H NMR (400 MHz, CDCl3): δ ppm 7.86-
7.34 (m, 10H), 7.28-7.13 (m, 5H), 7.05 (d, J = 8.0 Hz, 1H), 6.60-6.37 (m, 2H), 4.82-4.70 (m, 1H), 4.63-4.54 (m,
1H), 4.49-4.41 (m, 1H), 4.28-4.22 (m, 1H), 3.19-3.10 (m, 1H), 3.04-2.95 (m, 1H), 1.81-1.16 (m, 9H), 0.94-0.71
(m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm 171.39, 171.09, 169.23, 151.88, 136.08, 133.01, 132.38, 131.92,
131.37, 131.27, 131.18, 131.08, 129.29, 128.66, 128.61, 128.54, 128.49, 127.00, 121.51, 120.50, 64.30, 51.95, 51.74,
49.79, 49.62, 43.16, 41.17, 40.59, 37.94, 24.85, 24.80, 24.46, 22.76, 22.70, 22.22, 22.00, 21.91. HRMS: calcd. for
[C40H54N6O4P]



















oxide (104). Following the general procedure for
block coupling, the title compound was obtained
from Boc-Leu2-leucinyl vinyl diphenylphosphinox-
ide 159 (72 mg, 113 µmol, 1.1 equiv.) and Ada-
Ahx3OH 153 (60 mg, 124 µmol, 1.1 equiv.). Flash
column chromatography (MeOH:DCM (5→ 11%))
yielded 104 (101 mg, 96 µmol, 85%). [α]20
D
-41.0◦(c
= 1, MeOH). IR 3277, 2928, 2904, 2849, 1638, 1545,
1437, 1367, 1277, 1171, 1121, 1105 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 8.14 (d, J = 8.3 Hz, 1H), 8.08
(d, J = 6.5 Hz, 1H), 8.04 (d, J = 7.4 Hz, 1H), 7.99-7.91 (m, 2H), 7.89-7.82 (m, 1H), 7.74-7.47 (m, 10H), 6.73-6.46
(m, 2H), 4.73-4.63 (m, 1H), 4.43-4.35 (m, 1H), 4.34-4.26 (m, 1H), 3.20-3.08 (m, 6H), 2.25 (t, J = 7.3 Hz, 1H), 2.16
(t, J = 7.2 Hz, 1H), 1.96-1.89 (m, 5H), 1.79-1.25 (m, 39H), 0.98-0.82 (m, 18H). 13C NMR (100 MHz, CD3OD): δ
ppm 176.41, 175.94, 174.98, 174.31, 173.73, 153.55, 133.90, 133.49, 132.84, 132.72, 132.35, 132.28, 132.25, 132.18,
130.02, 130.00, 129.90, 129.88, 121.76, 120.75, 53.75, 53.46, 51.93, 51.51, 51.34, 43.74, 43.43, 41.75, 41.62, 40.30,
40.25, 37.90, 37.03, 36.65, 33.76, 30.22, 30.12, 27.64, 27.60, 27.55, 26.71, 26.54, 25.98, 25.94, 25.89, 23.45, 23.40,
23.30, 22.14, 22.08, 21.98. HRMS: calcd. for [C61H96N6O7P]










Boc- Leu2-leucinyl vinyl 1-adamantylsulfone (160). Following the
general procedure for azide coupling the title compound was obtained
from Boc-leucinyl vinyl 1-adamantylsulfone 134 (410 mg, 1 mmol, 1.1
equiv.) and BocLeu2NHNH2 148 (330 mg, 0.91 mmol, 1 equiv.). Pu-
rification by flash chromatography EA:tol (0 → 40%) gave the title
compound (383 mg, 0.6 mmol, 66%). 1H NMR (400 MHz, CDCl3):
52
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δ ppm 7.36-7.22 (m, 1H), 6.77 (dd, J1 = 15.2, J2 = 4.9 Hz, 1H), 6.73-6.71 (m, 1H), 6.42 (d, J = 15.1 Hz, 1H),
5.40 (d, J = 4.7 Hz, 1H), 4.81-4.71 (m, 1H), 4.47 (dd, J1 = 14.5, J2 = 7.9 Hz, 1H), 4.09-4.00 (m, 1H), 2.14 (s, 3H),
2.01-1.91 (m, 6H), 1.78-1.46 (m, 15H), 1.44 (s, 9H), 0.96-0.87 (m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm
172.61, 171.23, 156.05, 150.22, 123.19, 80.19, 59.62, 53.61, 51.97, 48.14, 42.85, 40.75, 40.42, 35.71, 34.44, 28.23,










Cbz-Leu2-leucinyl vinyl 1-adamantylsulfone (105). Following the
general procedure for azide coupling the title compound was obtained
from Boc-leucinyl vinyl 1-adamantylsulfone 134 (206 mg, 0.5 mmol,
1.1 equiv.) and CbzLeu2NHNH2 147 ( 177 mg, 0.45 mmol, 1 equiv.).
Purification by flash chromatography (EA:tol (0→ 25%)) gave the title
compound (271 mg, 400 µmol, 89%). [α]20
D
-44.4◦(c = 1, CHCl3). IR
(film) 3287, 2957, 2914, 1699, 1645, 1539, 1454, 1263, 1134, 1047, 1028,
976 cm−1. 1H NMR (400 MHz, CDCl3): δ ppm 7.44-7.28 (m, 5H),
6.88 (d, J = 6.7 Hz, 1H), 6.76 (dd, J1 = 15.1, J2 = 5.1 Hz, 1H), 6.37 (d,
J = 15.1 Hz, 1H), 5.94 (d, J = 6.6 Hz, 1H), 5.14-5.01 (m, 2H), 4.79-4.69 (m, 1H), 4.51 (q, J = 7.6 Hz, 1H), 4.19 (dd,
J1 = 13.6, J2 = 6.9 Hz, 1H), 2.11 (s, 3H), 1.99-1.87 (m, 6H), 1.84-1.33 (m, 15H), 0.93-0.82 (m, 18H).
13C NMR
(100 MHz, CDCl3): δ ppm 172.41, 171.28, 156.69, 150.59, 136.25, 128.68, 128.35, 128.01, 123.19, 67.17, 59.86,
54.01, 52.08, 48.37, 42.94, 40.95, 35.89, 34.66, 28.20, 25.15, 24.89, 24.78, 22.97, 22.90, 22.68, 22.44, 22.19, 22.04.
HRMS Calcd. for [C37H58N3O6S]













Azido-Phe-Leu2-leucinyl vinyl 1-adamantylsulfone (106).
Following the general procedure for block coupling, the ti-
tle compound was obtained from Boc- Leu2-leucinyl vinyl
1-adamantylsulfone 160 (140 mg, 220 µmol, 1 equiv.) and
azido-phenylalanine 152 (46 mg, 242 µmol, 1.1 equiv.). Flash
column chromatography (EA:tol (20→ 40%)) yielded the ti-
tle compound (81 mg, 112 µmol, 52%). [α]20
D
-35.0◦(c = 1,
CHCl3). IR (film) 3287, 2955, 2912, 2112, 1643, 1541, 1456,
1304, 1283, 1259, 1136 cm−1. 1H NMR (400 MHz, CDCl3):
δ ppm 7.49 (d, J = 8.2 Hz, 1H), 7.38-7.11 (m, 5H), 6.77 (dd, J1 = 15.1, J2 = 5.3 Hz, 1H), 6.38 (d, J = 15.1 Hz, 1H),
4.82-4.69 (m, 1H), 4.62-4.52 (m, 2H), 4.22 (dd, J1 = 8.3, J2 = 4.0 Hz, 1H), 3.19 (dd, J1 = 14.2, J2 = 3.8 Hz, 1H),
3.04 (dd, J1 = 14.1, J2 = 8.5 Hz, 1H), 2.13 (s, 3H), 1.99-1.88 (m, 6H), 1.84-1.32 (m, 15H), 0.94-0.81 (m, 18H).
13C
NMR (100 MHz, CDCl3): δ ppm 171.65, 171.13, 169.03, 150.21, 135.95, 129.29, 128.58, 127.16, 123.33, 64.57,
59.72, 51.92, 51.68, 48.26, 42.87, 41.09, 41.06, 37.89, 35.71, 34.55, 28.04, 24.99, 24.73, 24.53, 22.72, 22.69, 22.24,
22.16, 22.04. HRMS calcd. for [C38H59N6O5S]















fone (107). Following the general procedure
for block coupling, the title compound was ob-
tained from Boc-Leu2-leucinyl vinyl 1-adamantyl-
sulfone 160 (140 mg, 220 µmol, 1 equiv.) and
AdaAhx3OH 153 (252 mg, 242 µmol, 1.1 equiv.).
Flash column chromatography (EA:MeOH (0→
7%)) yielded 107 (158 mg, 152 µmol, 69%). [α]20
D
-34.0◦(c = 1, MeOH). IR (film) 3285, 2910, 2851,
1639, 1541, 1454, 1279, 1134 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 8.08-7.98 (m, 1H), 7.96-7.87 (m, 2H),
7.84-7.78 (m, 1H), 6.69 (dd, J1 = 15.1, J2 = 4.9 Hz, 1H), 6.41 (d, J = 15.1 Hz, 1H), 4.67-4.60 (m, 1H), 4.34 (t, J =
7.3 Hz, 1H), 4.24 (dd, J1 = 8.5, J2 = 6.4 Hz, 1H), 3.19-3.04 (m, 6H), 2.27-2.18 (m, 2H), 2.18-2.04 (m, 7H), 2.00-
1.82 (m, 12H), 1.84-1.38 (m, 29H), 1.37-1.22 (m, 6H), 0.97-0.82 (m, 18H). 13C NMR (100 MHz, CD3OD): δ ppm
176.40, 175.89, 175.81, 175.00, 174.18, 173.68, 152.03, 124.26, 60.82, 53.92, 53.32, 51.93, 51.88, 49.64, 43.74, 43.15,
41.56, 40.31, 40.26, 40.18, 40.13, 37.91, 37.04, 36.99, 36.83, 36.58, 35.64, 33.76, 30.22, 30.13, 29.59, 27.65, 27.62,














Boc-Leu2-leucinyl vinyl 1-adamantylmethylsulfone (161). Fol-
lowing the general procedure for azide coupling the title compound
was obtained from Boc-leucinyl vinyl 1-adamantylmethylsulfone
135 (800 mg, 1.88 mmol, 1.1 equiv.) and BocLeu2NHNH2 148 (610
mg, 1.71 mmol, 1 equiv.). Purification by flash chromatography
EA:tol (0 → 20%) gave the title compound 33 (1.01 g, 1.55 mmol,
91%). 1H NMR (400 MHz, CDCl3): δ ppm 7.38 (d, J = 8.3 Hz,
1H), 7.08 (d, J = 5.8 Hz, 1H), 6.78 (dd, J1 = 15.1, J2 = 5.2 Hz, 1H), 6.52 (d, J = 15.0 Hz, 1H), 5.55 (d, J = 5.5 Hz,
1H), 4.78-4.69 (m, 1H), 4.52-4.44 (m, 1H), 4.21-4.07 (m, 1H), 2.80 (s, 2H), 2.02-1.97 (m, 3H), 1.84-1.81 (m, 6H),
1.76-1.48 (m, 18H), 1.44 (s, 9H), 0.96-0.86 (m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm 172.76, 171.37, 155.83,











Cbz-Leu2-leucinyl vinyl 1-adamantylmethylsulfone (108). Fol-
lowing the general procedure for azide coupling the title compound
was obtained from Boc-leucinyl vinyl 1-adamantylmethylsulfone
135 (309 mg, 0.73 mmol, 1.1 equiv.) and CbzLeu2NHNH2 147
(260 mg, 0.66 mmol, 1 equiv.). Purification by flash chromatography
(EA:tol (0→ 25%)) gave the title compound 108 (365 mg, 530 µmol,
73%). [α]20
D
-50.6◦(c = 1, CHCl3). IR (film) 3290, 2959, 2907, 1699,
1645, 1539, 1456, 1263, 1240, 1132, 1139, 1028 cm−1. 1H NMR (400
MHz, CDCl3): δ ppm 7.75-7.49 (m, 2H), 7.36-7.25 (m, 5H), 6.76
(dd, J1 = 15.0, J2 = 5.2 Hz, 1H), 6.47 (d, J = 15.0 Hz, 1H), 6.43-6.29 (m, 1H), 5.14-4.97 (m, 2H), 4.76-4.65 (m,
1H), 4.61-4.52 (m, 1H), 4.41-4.31 (m, 1H), 2.75 (s, 2H), 2.00-1.95 (m, 3H), 1.85-1.22 (m, 21H), 0.94-0.78 (m, 18H).
13C NMR (100 MHz, CDCl3): δ ppm 172.44, 171.37, 156.33, 146.66, 136.24, 130.61, 128.36, 127.94, 127.60, 66.92,
66.71, 53.47, 51.89, 47.62, 42.62, 41.96, 41.32, 40.64, 36.29, 34.20, 28.22, 24.82, 24.53, 22.78, 22.62, 22.56, 22.34,
21.76. HRMS calcd. for [C38H60N3O6S]














fone (109). Following the general procedure for block
coupling, the title compound was obtained from Boc-Leu2-
leucinyl vinyl 1-adamantylmethylsulfone 161 (232 mg, 357
µmol, 1.1 equiv.) and azido-phenylalanine 152 (62 mg, 320
µmol, 1 equiv.). Flash column chromatography (EA:tol
(0 → 50%)) yielded 109 (144 mg, 200 µmol, 62%). [α]20
D
-35.0◦(c = 1, CHCl3). IR (film) 3277, 2957, 2907, 2851,
2110, 1638, 1541, 1454, 1387, 1313, 1265, 1132, 1119, 968
cm−1. 1H NMR (400 MHz, CDCl3): δ ppm 7.69 (d, J = 6.4 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.48 (d, J = 8.1
Hz, 1H), 7.33-7.13 (m, 5H), 6.75 (dd, J1 = 15.1, J2 = 5.7 Hz, 1H), 6.44 (d, J = 15.0 Hz, 1H), 4.73-4.63 (m, 2H),
4.62-4.54 (m, 1H), 4.24 (dd, J1 = 8.6, J2 = 4.2 Hz, 1H), 3.15 (dd, J1 = 14.2, J2 = 3.7 Hz, 1H), 3.04 (dd, J1 = 14.2,
J2 = 8.7 Hz, 1H), 2.77 (s, 2H), 2.02-1.95 (m, 3H), 1.85-1.32 (m, 21H), 0.97-0.80 (m, 18H).
13C NMR (100 MHz,
CDCl3): δ ppm 171.72, 171.42, 168.96, 146.10, 135.97, 131.02, 129.23, 128.57, 127.14, 66.88, 64.41, 51.95, 51.54,
47.83, 42.75, 42.02, 41.42, 40.87, 37.84, 36.32, 34.29, 28.26, 24.90, 24.64, 24.55, 22.67, 22.65, 22.46, 22.37, 21.98.
HRMS calcd. for [C39H61N6O5S]















methylsulfone (110). Following the general
procedure for block coupling, the title com-
pound was obtained from Boc- Leu2-leucinyl
vinyl 1-adamantylmethylsulfone 161 (227 mg,
348 µmol, 1.1 equiv.) and AdaAhx3OH 153
(170 mg, 320 µmol, 1 equiv.). Flash column
chromatography (MeOH:DCM (0 → 7%))
yielded 110 (313 mg, 290 µmol, 92%). [α]20
D
-
33.2◦(c= 1, MeOH). IR (film) 3277, 3080, 2903,
2849, 1636, 1541, 1452, 1367, 1343, 1281, 1117, 1034 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 8.06 (t, J = 7.3
Hz, 2H), 7.91 (t, J = 5.0 Hz, 2H), 7.81 (t, J = 4.9 Hz, 1H), 6.72 (dd, J1 = 15.1, J2 = 5.0 Hz, 1H), 6.56 (d, J = 15.1
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Hz, 1H), 4.70-4.61 (m, 1H), 4.43-4.29 (m, 2H), 3.21-3.09 (m, 6H), 2.90 (s, 2H), 2.32-2.21 (m, 2H), 2.17 (t, J = 7.3
Hz, 4H), 2.01-1.23 (m, 61H), 0.99-0.85 (m, 18H). 13C NMR (100 MHz, CD3OD): δ ppm 176.18, 176.10, 175.74,
175.65, 174.88, 174.80, 174.09, 174.01, 173.52, 147.66, 132.22, 67.65, 53.60, 53.21, 51.87, 49.15, 49.06, 43.66, 43.16,
43.01, 41.56, 41.47, 40.24, 40.19, 37.86, 37.52, 36.99, 36.57, 35.12, 33.69, 30.15, 30.10, 30.03, 29.75, 27.58, 27.54,











Boc-Leu2-(R)-5-amino-5,6-dihydro-pyran-2-one (163). Following the general
procedure for azide coupling the title compound was obtained from (R)-5-(Boc-
amino)-5,6-dihydro-pyran-2-one 162 180 (103 mg, 484 µmol, 1.1 equiv.) and
BocLeu2NHNH2 148 (158 mg, 440 µmol, 1 equiv.). Purification by flash chro-
matography (EA:tol (30 → 60%)) gave the title compound (129 mg, 290 µmol,
67%). 1H NMR (400 MHz, CDCl3): δ ppm 7.68-7.51 (m, 1H), 6.92-6.84 (m,
2H), 6.08 (d, J = 9.7 Hz, 1H), 5.32-5.22 (m, 1H), 4.83-4.71 (m, 1H), 4.51-4.43 (m,
2H), 4.33-4.24 (m, 1H), 4.13-4.03 (m, 1H), 1.78-1.48 (m, 6H), 1.43 (s, 9H), 0.99-
0.86 (m, 12H). 13C NMR (100 MHz, CDCl3): δ ppm 172.87, 172.39, 162.76,









Cbz-Leu2-(R)-5-amino-5,6-dihydro-pyran-2-one (111). Following the general
procedure for azide coupling the title compound was obtained from (R)-5-
(Boc-amino)-5,6-dihydro-pyran-2-one 162 180 (36 mg, 160 µmol, 1.1 equiv.) and
CbzLeu2NHNH2 147 (59 mg, 150 µmol, 1 equiv.). Purification by flash chro-
matography (EA:tol (20→ 50%)) gave the title compound 111. [α]20
D
-106.8◦(c
= 1, CHCl3). IR (film) 3288, 2957, 2930, 1717, 1699, 1645, 1533, 1456, 1387,
1261, 1231, 1092, 1040 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 7.40-7.26
(m, 5H), 6.93 (dd, J1 = 9.7, J2 = 4.5 Hz, 1H), 6.10 (dd, J1 = 9.8, J2 = 1.1 Hz,
1H), 5.09 (s, 2H), 4.72-4.65 (m, 1H), 4.48 (dd, J1 = 11.6, J2 = 4.4 Hz, 1H), 4.38
(dd, J1 = 9.7, J2 = 5.0 Hz, 1H), 4.27 (dd, J1 = 11.5, J2 = 5.0 Hz, 1H), 4.11 (t, J = 7.5 Hz, 1H), 1.77-1.26 (m, 6H),
0.99-0.85 (m, 12H). 13C NMR (100 MHz, CDCl3): δ ppm 172.47, 172.20, 162.88, 156.69, 144.16, 135.91, 130.85,
128.55, 128.28, 127.91, 122.85, 69.91, 68.14, 67.31, 54.28, 51.83, 41.57, 40.88, 40.45, 24.88, 24.76, 22.87, 21.73,
21.68. HRMS calcd. for [C25H36N3O6]













lowing the general procedure for block coupling, the title com-
pound was obtained from Boc-Leu2-(R)-5-amino-5,6-dihydro-pyran-
2-one 163 (44 mg, 100 µmol, 1 equiv.) and azido-phenylalanine
152 (21 mg, 110 µmol, 1.1 equiv.). Flash column chromatography
(EA:PE (20→ 70%)) yielded 112 (19 mg, 37 µmol, 37%). IR (film)
3279, 2957, 2926, 2112, 1734, 1645, 1541, 1456, 1229, 1094 cm−1. 1H
NMR (400 MHz, CD3OD): δ ppm 7.34-7.19 (m, 5H), 6.94 (dd, J1
= 9.8, J2 = 4.6 Hz, 1H), 6.11 (d, J = 4.6 Hz, 1H), 4.72-4.64 (m, 1H),
4.50 (dd, J1 = 11.5, J2 = 4.4 Hz, 1H), 4.41-4.34 (m, 2H), 4.30 (dd, J1 = 11.6, J2 = 4.8 Hz, 1H), 3.19 (dd, J1 =
14.0, J2 = 4.9 Hz, 1H), 2.98 (dd, J1 = 14.0, J2 = 8.48 Hz, 1H), 1.79-1.48 (m, 6H), 1.02-0.83 (m, 12H).
13C NMR
(100 MHz, CD3OD): δ ppm 174.91, 174.33, 171.74, 146.37, 137.87, 130.47, 129.59, 128.04, 123.34, 71.12, 65.51,

















(113). Following the general procedure for block cou-
pling, the title compound was obtained from Boc-Leu2-(R)-
5-amino-5,6-dihydro-pyran-2-one 163 (44 mg, 100 µmol,
1 equiv.) and AdaAhx3OH 153 (57 mg, 110 µmol, 1.1
equiv.). Flash column chromatography (EA:MeOH (0 →
15%)) yielded 113 (76 mg, 89 µmol, 89%). [α]20
D
-54.0◦(c =
1, MeOH). IR (film) 3285, 2905, 2851, 1732, 1641, 1545,
1439, 1202, 1175, 1134, 1094 cm−1. 1H NMR (400 MHz,
CD3OD): δ ppm 8.49 (d, J = 7.3 Hz, 1H), 8.11 (d, J = 6.7
55
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Hz, 1H), 8.07 (d, J = 7.3 Hz, 1H), 8.00-7.92 (m, 2H), 7.90-7.83 (m, 1H), 6.97-6.90 (m, 1H), 6.09 (d, J = 9.7 Hz,
1H), 4.74-4.63 (m, 1H), 4.54-4.45 (m, 1H), 4.43-4.24 (m, 3H), 3.22-3.06 (m, 6H), 2.25 (t, J = 7.1 Hz, 2H), 2.18 (t,
J = 7.0 Hz, 4H), 1.01-0.86 (m, 12H), 1.99-1.89 (m, 5H), 1.81-1.20 (m, 36H). 13C NMR (100 MHz, CD3OD): δ
ppm 176.46, 176.02, 175.93, 175.08, 174.84, 174.75, 173.80, 146.64, 123.18, 71.00, 55.82, 53.55, 53.15, 51.96, 43.77,
43.33, 43.24, 41.84, 41.63, 40.32, 40.27, 40.19, 40.14, 37.93, 37.06, 37.01, 36.68, 33.79, 30.23, 30.17, 30.12, 27.66,












ing the general procedure for azide coupling the title compound was obtained
from (5R,6R)-5-(Boc-amino)-6-methyl-5,6-dihydropyran-2-one 164 181 (112 mg,
495 µmol, 1.1 equiv.) and BocLeu2NHNH2 148 (161 m g, 450 µmol, 1 equiv.).
Purification by flash chromatography (EA:tol (30→ 60%)) gave the title com-
pound 37 (168 mg, 370 µmol, 82%). 1H NMR (400 MHz, CDCl3): δ ppm 7.52
(d, J = 5.6 Hz, 1H), 7.12-7.00 (m, 1H), 6.85 (dd, J1 = 9.6, J2 = 5.77 Hz, 1H),
6.12 (d, J = 9.6 Hz, 1H), 5.28 (d, J = 6.3 Hz, 1H), 4.72-4.64 (m, 2H), 4.50-4.42
(m, 1H), 4.13-4.02 (m, 1H), 1.71-1.44 (m, 6H), 1.43 (s, 9H), 1.31 (d, J = 6.3 Hz,
3H), 0.97-0.87 (m, 12H). 13C NMR (100 MHz, CDCl3): δ ppm 172.87, 172.71, 164.00, 155.84, 143.31, 122.73,










ing the general procedure for azide coupling the title compound was obtained
from (5R,6R)-5-(Boc-amino)-6-methyl-5,6-dihydropyran-2-one 164 181 (36 mg,
160 µmol, 1.1 equiv.) and CbzLeu2NHNH2 147 (59 mg, 150 µmol, 1 equiv.).
Purification by flash chromatography (EA:tol (25 → 60%)) gave the title com-
pound 357 (13 mg, 27 µmol, 18%). [α]20
D
-278.8◦(c = 1, CHCl3). IR (film) 2957,
1734, 1717, 1699, 1684, 1668, 1639, 1558, 1541, 1506, 1456, 1387, 1250, 1067
cm−1. 1H NMR (400 MHz, CDCl3): δ ppm 7.42-7.29 (m, 5H), 7.04 (d, J = 8.5
Hz, 1H), 6.83 (dd, J1 = 9.5, J2 = 6.0 Hz, 1H), 6.38 (d, J = 6.8 Hz, 1H), 6.15
(d, J = 9.5 Hz, 1H), 5.22 (d, J = 4.0 Hz, 1H), 5.19-5.03 (m, 2H), 4.71-4.60 (m, 2H), 4.48-4.38 (m, 1H), 4.11-4.03
(m, 1H), 1.83-1.39 (m, 6H), 1.28 (d, J = 6.3 Hz, 3H), 0.99-0.84 (m, 12H). 13C NMR (100 MHz, CDCl3): δ ppm
172.37, 143.02, 128.57, 128.34, 128.19, 123.17, 78.36, 75.97, 70.12, 67.59, 54.38, 52.23, 43.75, 40.73, 40.67, 31.42,
24.99, 24.83, 23.00, 22.88, 21.74, 21.51, 16.23. HRMS calcd. for [C26H38N3O6]













one (115). Following the general procedure for block coupling,
the title compound was obtained from Boc-Leu2-(5R,6R)-5-amino-
6-methyl-5,6-dihydropyran-2-one 165 (32 mg, 70 µmol, 1 equiv.) and
azido-phenylalanine 152 (15 mg, 77 µmol, 1.1 equiv.). Flash column
chromatography (EA:PE (20 → 65%)) yielded 115 (22 mg, 42 µmol,
60%). IR (film) 3281, 2955, 2926, 2870, 2112, 1736, 1639, 1533, 1456,
1387, 1251, 1069 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 7.35-
7.20 (m, 5H), 6.92 (dd, J1 = 9.6, J2 = 6.1 Hz, 1H), 6.15 (d, J = 9.6
Hz, 1H), 4.78-4.68 (m, 1H), 4.63 (dd, J1 = 5.9, J2 = 3.3 Hz, 1H), 4.44-4.35 (m, 2H), 4.16 (dd, J1 = 8.4, J2 = 4.96
Hz, 1H), 3.19 (dd, J1 = 14.02, J2 = 4.93 Hz, 1H), 2.98 (dd, J1 = 13.98, J2 = 8.46 Hz, 1H), 1.74-1.22 (m, 9H),
1.00-0.83 (m, 12H). 13C NMR (100 MHz, CD3OD): δ ppm 174.19, 144.85, 133.33, 130.49, 129.58, 128.03, 123.70,
77.58, 65.55, 53.25, 45.21, 41.91, 41.78, 38.70, 25.94, 25.82, 23.42, 23.35, 22.13, 22.04, 16.73. HRMS calcd. for
[C27H39N6O5]















pyran-2-one (116). Following the general procedure for
block coupling, the title compound was obtained from
Boc-Leu2-(5R,6R)-5-amino-6-methyl-5,6-dihydropyran-2-
one 165 (41 mg, 90 µmol, 1 equiv.) and AdaAhx3OH 153
(51 mg, 100 µmol, 1.1 equiv.). Flash column chromatogra-
phy (EA:MeOH (0→ 15%)) yielded 116 (31 mg, 35 µmol,
40%). [α]20
D
-100.0◦(c = 1, MeOH). IR (film) 3285, 2905,
56
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2851, 1734, 1639, 1541, 1456, 1369, 1257, 1204, 1069 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 8.42 (d, J =
8.3 Hz, 1H), 8.10 (d, J = 6.6 Hz, 1H), 8.06 (d, J = 6.4 Hz, 1H), 7.99-7.91 (m, 2H), 7.89-7.83 (m, 1H), 6.95-6.87
(m, 1H), 6.14 (d, J = 9.4 Hz, 1H), 4.77-4.67 (m, 1H), 4.67-4.59 (m, 1H), 4.45-4.31 (m, 2H), 4.15-4.05 (m, 1H),
3.21-3.10 (m, 6H), 2.29-2.12 (m, 6H), 1.99-1.89 (m, 5H), 1.80-1.18 (m, 41H), 0.98-0.87 (m, 12H). 13C NMR (100
MHz, CD3OD): δ ppm 176.28, 176.04, 175.08, 174.93, 174.85, 173.83, 144.87, 123.67, 77.55, 53.28, 53.19, 51.97,
45.20, 43.79, 41.87, 41.79, 40.34, 40.29, 37.94, 37.07, 36.72, 33.81, 30.25, 30.19, 30.13, 27.67, 27.59, 26.74, 26.63,
25.93, 23.46, 23.39, 22.11, 22.01, 16.73. HRMS calcd. for [C48H81N6O8]








Boc-Leu2-3-leucinylfuran-2(5H)-one (166). Following the general pro-
cedure for azide coupling the title compound was obtained from Boc-
3-leucinylfuran-2(5H )-one 139 (71 mg, 264 µmol, 1.1 equiv.) and
BocLeu2NHNH2 148 (86 mg, 240 µmol, 1 equiv.). Purification by flash
chromatography (EA:tol (30→ 70%)) gave the title compound (47 mg, 95
µmol, 40%). 1H NMR (400 MHz, CDCl3) δ ppm 7.38-7.35 (m, 1H), 7.01
(d, J = 8.3 Hz, 1H), 6.65 (d, J = 7.3 Hz, 1H), 5.11-5.02 (m, 1H), 4.94-4.82
(m, 1H), 4.82-4.75 (m, 2H), 4.43-4.34 (m, 1H), 4.11-4.02 (m, 1H), 1.75-
1.40 (m, 18H), 1.02-0.80 (m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm









Cbz-Leu2-3-leucinylfuran-2(5H)-one (117). Following the general pro-
cedure for azide coupling the title compound was obtained from Boc-
3-leucinylfuran-2(5H )-one 139 (56 mg, 208 µmol, 1.1 equiv.) and
CbzLeu2NHNH2 147 ( 79 mg, 200 µmol, 1 equiv.). Purification by flash
chromatography (EA:tol (20→ 50%)) gave the title compound (91 mg, 172
µmol, 86%). [α]20
D
-76.8◦(c = 1, CHCl3). IR (film) 3346, 3329, 2957, 2870,
1738, 1697, 1672, 1647, 1541, 1506, 1456, 1387, 1367, 1269, 1209, 1070,
1040 cm−1. 1H NMR (400 MHz, CDCl3/CD3OD, 1/1): δ ppm 7.72 (d,
J = 8.3 Hz, 1H), 7.43-7.28 (m, 6H) , 5.11 (q, J = 12.3 Hz, 2H), 4.45-4.41
(m, 3H), 4.40-4.35 (m, 1H), 4.15 (dd, J1 = 8.2, J2 = 6.7 Hz, 1H), 1.75-1.43 (m, 9H), 1.02-0.82 (m, 18H).
13C NMR
(100 MHz, CDCl3/CD3OD, 1/1): δ ppm 173.37, 172.96, 171.98, 156.70, 146.27, 135.73, 134.03, 128.08, 127.75,
127.32, 70.26, 66.56, 53.65, 51.68, 44.31, 41.23, 40.55, 39.76, 24.38, 24.26, 22.41, 22.32, 22.28, 21.05, 20.96, 20.82.
HRMS calcd for [C29H44N3O6]











Azido-Phe-Leu2-3-leucinylfuran-2(5H)-one (118). Following the
general procedure for block coupling, the title compound was ob-
tained from Boc-Leu2-3-leucinylfuran-2(5H )-one 166 (24.6 mg, 50
µmol, 1 equiv.) and azido-phenylalanine 152 (12 mg, 64 µmol, 1.3
equiv.). Flash column chromatography (MeOH:DCM (0→ 2.5%))
yielded 118 (14 mg, 25 µmol, 50%). IR (film) 3277, 2957, 2932, 2110,
1749, 1639, 1541, 1457, 1387, 1340, 1287, 1207, 1067, 1049 cm−1. 1H
NMR (400 MHz, CDCl3): δ ppm 7.36-7.21 (m, 5H), 6.98 (d, J = 8.6
Hz, 1H), 6.80 (d, J = 7.6 Hz, 1H), 6.58 (d, J = 7.9 Hz, 1H), 4.90 (dd,
J1 = 15.6, J2 = 8.1 Hz, 1H), 4.82-4.77 (m, 2H), 4.47-4.32 (m, 2H), 4.27 (dd, J1 = 7.7, J2 = 4.1 Hz, 1H), 3.29 (dd,
J1 = 14.1, J2 = 3.9 Hz, 1H), 3.1 (dd, J1 = 14.1, J2 = 7.8 Hz, 1H), 1.80-1.20 (m, 9H), 0.95-0.81 (m, 18H). HRMS
calcd for [C30H45N6O5]
















lowing the general procedure for block coupling, the title
compound was obtained from Boc-Leu2-3-leucinylfuran-
2(5H )-one 166 (23 mg, 46 µmol, 1 equiv.) and
AdaAhx3OH 153 (27 mg, 51 µmol, 1.1 equiv.). Flash co-
lumn chromatography (MeOH:DCM (3→ 8%)) yielded
119 (40 mg, 44 µmol, 95%). [α]20
D
-35.2◦(c = 1, MeOH.
IR (film) 3275, 2905, 1747, 1636, 1541, 1456, 1340, 1205,
1067, 1045 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm
8.23-8.07 (m, 4H), 7.97 (t, J = 4.8 Hz, 1H), 7.50-7.47 (m, 1H), 4.87-4.82 (m, 2H), 4.80-4.70 (m, 1H), 4.41-4.26 (m,
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2H), 3.22-3.09 (m, 6H), 2.28 (t, J = 7.4 Hz, 2H), 2.20 (t, J = 7.3 Hz, 4H), 1.98-1.88 (m, 5H), 1.79-1.23 (m,
39H), 0.99-0.84 (m, 18H). 13C NMR (100 MHz, CD3OD): δ ppm 176.67, 176.18, 176.15, 176.09, 175.25, 174.99,
174.27, 173.87, 149.49, 148.79, 135.42, 72.18, 53.92, 53.50, 51.94, 51.88, 49.86, 45.53, 43.71, 42.92, 41.60, 41.42,
40.32, 40.19, 40.13, 40.00, 37.86, 37.01, 36.70, 36.65, 33.79, 30.11, 30.01, 29.97, 27.51, 27.47, 27.32, 26.58, 26.51,












Boc-Leu2-4-leucinyl-furan-2(5H)-one (167). Following the general pro-
cedure for azide coupling the title compound was obtained from Boc-
4-leucinyl-furan-2(5H )-one 141 (124 mg, 0.46 mmol, 1.1 equiv.) and
BocLeu2NHNH2 148 (149 mg, 0.42 mmol, 1 equiv.). Purification by flash
chromatography EA:tol (20→ 50%) gave the title compound (118 mg, 0.24
mmol, 57%). 1H NMR (400 MHz, CDCl3): δ ppm 6.62-6.58 (m, 1H), 5.92











Cbz-Leu2-4-leucinyl-furan-2(5H)-one (120). Following the general pro-
cedure for azide coupling the title compound was obtained from Boc-
4-leucinyl-furan-2(5H )-one 141 (77 mg, 286 µmol, 1.1 equiv.) and
CbzLeu2NHNH2 147 ( 102 mg, 260 µmol, 1 equiv.). Purification by flash
chromatography (EA:tol (30 → 70%)) gave the title compound (112 mg,
211 µmol, 81%). [α]20
D
-80.2◦(c = 1, CHCl3. IR (film) 3269, 2957, 2934,
2870, 1782, 1751, 1699, 1668, 1641, 1539, 1471, 1456, 1387, 1369, 1261, 1238, 1153, 1120, 1030 cm−1. 1H NMR
(400 MHz, CDCl3 δ ppm 7.41 (d, J = 8.2 Hz, 1H), 7.36-7.24 (m, 5H), 6.13 (d, J = 4.8 Hz, 1H), 5.92-5.89 (m, 1H),
5.15-4.97 (m, 2H), 4.88-4.66 (m, 3H), 4.43 (dd, J1 = 14.2, J2 = 7.3 Hz, 1H), 4.25-4.17 (m, 1H), 1.86-1.31 (m, 9H),
0.95-0.81 (m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm 173.74, 172.69, 172.05, 171.63, 156.78, 135.81, 128.53,
128.25, 127.59, 115.17, 71.61, 66.96, 54.24, 52.22, 45.81, 41.82, 41.07, 40.06, 24.92, 24.67, 24.44, 23.19, 22.69, 22.57,
21.96, 21.86, 21.16. HRMS calcd. for [C29H44N3O6]













Azido-Phe-Leu2-4-leucinyl-furan-2(5H)-one (121). Following the
general procedure for block coupling, the title compound was ob-
tained from Boc-Leu2-4-leucinyl-furan-2(5H )-one 167 (59 mg, 120
µmol, 1 equiv.) and azido-phenylalanine 152 (26 mg, 130 µmol, 1.1
equiv.). Flash column chromatography (EA:tol (30→ 60%) yielded
121 (31 mg, 55 µmol, 45%). [α]20
D
-61.6◦(c = 1, CHCl3. IR (film)
3273, 2957, 2932, 2872, 2110, 1782, 1753, 1638, 1541, 1465, 1437,
1387, 1369, 1248, 1223, 1153, 1032 cm−1. 1H NMR (400 MHz,
CDCl3): δ ppm 7.36-7.20 (m, 5H), 7.06-7.02 (m, 1H), 6.82-6.78 (m,
1H), 6.75-6.71 (m, 1H), 5.94-5.92 (m, 1H), 4.88-4.73 (m, 3H), 4.42-4.35 (m, 1H), 4.33-4.25 (m, 2H), 3.27 (dd, J1 =
14.1 Hz, J2 = 4.2 Hz, 1H), 3.08 (dd, J1 = 14.1 Hz, J2 = 7.5 Hz, 1H), 1.80-1.30 (m, 9H), 0.98-0.80 (m, 18H).
13C
NMR (100 MHz, CDCl3): δ ppm 171.77, 171.66, 171.11, 169.34, 135.41, 129.39, 128.71, 127.40, 115.44, 71.59,
64.91, 52.34, 52.07, 45.94, 42.02, 40.60, 39.97, 38.05, 24.95, 24.64, 24.59, 23.16, 22.76, 22.72, 21.90, 21.87, 21.34.
HRMS: calcd. for [C30H45N6O5]
















lowing the general procedure for block coupling,
the title compound was obtained from Boc-Leu2-4-
leucinyl-furan-2(5H )-one 167 (59 mg, 120 µmol) and
AdaAhx3OH 153 (69 mg, 130 µmol, 1.1 equiv.).
Flash column chromatography (MeOH:DCM (0→ 7%)
yielded 122 (87 mg, 96 µmol, 80%). [α]20
D
-54.0◦(c = 1,
MeOH. IR (film) 3285, 2928, 2903, 2870, 1780, 1747,
1638, 1541, 1439, 1367, 1277, 1242, 1155, 1032 cm−1.1H
NMR (400 MHz, CD3OD): δ ppm 7.85 (t, J = 5.2 Hz, 1H), 7.95 (t, J = 5.4 Hz, 2H), 5.95 (d, J = 1.5 Hz, 1H),
4.91-4.84 (m, 3H), 4.38-4.27 (m, 2H), 3.18-3.11 (m, 6H), 2.28-2.22 (m, 2H), 2.17 (t, J = 7.5 Hz, 4H), 1.96-1.92
(m, 3H), 1.92-1.90 (m, 2H), 1.83-1.44 (m, 33H), 1.39-1.29 (m, 6H), 0.98-0.88 (m, 18H). 13C NMR (100 MHz,
CD3OD): δ ppm 176.41, 175.95, 175.86, 175.06, 174.52, 174.27, 173.73, 115.72, 73.25, 53.65, 53.35, 51.94, 47.29,
43.75, 42.60, 41.62, 41.40, 40.31, 40.26, 40.18, 37.91, 37.04, 36.99, 36.62, 33.77, 30.22, 30.14, 27.65, 27.60, 27.56,
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Boc-Leu2-(S,E)-5-amino-7-methyloct-2-en-4-one (168). Following the
general procedure for azide coupling the title compound was obtained
from (E,S)-1-isobutyl-2-oxo-pent-3-enyl-amine HCl salt 144 (100 mg, 520
µmol, 1.1 equiv.) and BocLeu2NHNH2 148 (170 mg, 470 µmol, 1 equiv.).
Purification by flash chromatography (EA:tol (0 → 25%)) gave the title
compound (119 mg, 250 µmol, 48%). 1H NMR (400 MHz, CDCl3): δ
ppm 7.02 (dq, J1 = 15.5, J2 = 6.9 Hz, 1H), 6.85 (d, J = 7.4 Hz, 1H), 6.68
(d, J = 7.9 Hz, 1H), 6.21 (dd, J1 = 15.6, J2 = 1.7 Hz, 1H), 5.07 (d, J = 6.6
Hz, 1H), 4.89-4.82 (m, 1H), 4.54-4.45 (m, 1H), 4.17-4.07 (m, 1H), 1.93 (dd,
J1 = 6.9, J2 = 1.6 Hz, 3H), 1.73-1.34 (m, 18H), 0.99-0.85 (m, 18H).
13C NMR (100 MHz, CDCl3): δ ppm 197.79,









Cbz-Leu2-(S,E)-5-amino-7-methyloct-2-en-4-one (123). Following the
general procedure for azide coupling the title compound was obtained
from (E,S)-1-isobutyl-2-oxo-pent-3-enyl-amine HCl salt 144 (38 mg, 200
µmol, 1.1 equiv.) and CbzLeu2NHNH2 147 (71 mg, 180 µmol, 1 equiv.).
Purification by flash chromatography (EA:tol (0 → 25%)) gave the title
compound (62 mg, 120 µmol, 67%). [α]20
D
-45.5◦(c = 1, CHCl3. IR
(film) 3263, 2955, 2936, 2870, 1699, 1663, 1641, 1539, 1466, 1437, 1387,
1367, 1286, 1261, 1234, 1121, 1045, 1028, 970 cm−1. 1H NMR (400 MHz,
CDCl3): δ ppm 7.35-7.25 (m, 5H), 7.21 (d, J = 8.3 Hz, 1H), 6.20 (dd, J1 =
15.7, J2 = 1.6 Hz, 1H), 5.82 (d, J = 1.6 Hz, 1H), 5.16-5.01 (m, 2H), 4.88 (dt, J1 = 9.3, J2 = 4.1 Hz, 1H), 4.59 (dd,
J1 = 15.2, J2 = 7.5 Hz, 1H), 4.35-4.26 (m, 1H), 1.90 (dd, J1 = 6.9, J2 = 1.5 Hz, 3H), 1.76-1.35 (m, 9H), 0.94-0.82
(m, 18H), 7.06-6.95 (m, 1H). 13C NMR (100 MHz, CDCl3): δ ppm 197.92, 172.09, 171.48, 156.19, 144.83, 136.34,
128.67, 128.40, 127.98, 127.84, 66.81, 54.21, 53.36, 51.66, 41.59, 41.19, 40.84, 24.78, 24.66, 24.57, 23.25, 22.72,
22.45, 22.19, 21.82, 18.41. HRMS calcd. for [C29H46N3O5]












Following the general procedure for block coupling, the title com-
pound was obtained from Boc-Leu2-(S,E)-5-amino-7-methyloct-2-
en-4-one 168 (40 mg, 83 µmol, 1 equiv.) and azido-phenylalanine
152 (23 mg, 120 µmol, 1.45 equiv.). Flash column chromatography
(MeOH:DCM (0→ 4%)) yielded 124 (36 mg, 66 µmol, 79%). [α]20
D
-31.5◦(c = 1, CHCl3). IR (film) 3273, 2955, 2930, 2870, 2110, 1638,
1541, 1456, 1437, 1387, 1367, 1255, 1221, 1152, 970 cm−1. 1H NMR
(400 MHz, CD3OD): δ ppm 7.33-7.18 (m, 5H), 7.00 (dq, J1 = 20.7,
J2 = 6.9 Hz, 1H), 6.28 (dd, J1 = 15.6, J2 = 1.7 Hz, 1H), 4.70 (dd, J1 = 9.1, J2 = 5.42 Hz, 1H), 4.47-4.41 (m, 1H),
4.14 (dd, J1 = 8.5, J2 = 5.0 Hz, 1H), 3.18 (dd, J1 = 14.0, J2 = 5.0 Hz, 1H), 2.97 (dd, J1 = 14.0, J2 = 8.5 Hz, 1H),
1.91 (dd, J1 = 6.9, J2 = 1.6 Hz, 3H), 1.74-1.45 (m, 9H), 1.00-0.85 (m, 18H).
13C NMR NMR (100 MHz, CD3OD):
δ ppm 199.71, 174.31, 174.06, 145.97, 137.86, 130.44, 129.59, 129.37, 128.04, 65.49, 56.27, 53.10, 52.99, 42.06,


















(125).Following the general procedure for block cou-
pling, the title compound was obtained from Boc-
Leu2-(S,E)-5-amino-7-methyloct-2-en-4-one 168 (59 mg,
122 µmol, 1 equiv.) and AdaAhx3OH 153 (72 mg,
135 µmol, 1.1 equiv.). Flash column chromatography
(MeOH:DCM (2→ 8%)) yielded the title compound (88
mg, 98 µmol, 80%). [α]20
D
-44.0◦(c = 1, CD3OD). IR
(film) 3281, 2928, 2905, 2868, 1636, 1545, 1439, 1367,
1276, 1171, 1067, 972 cm−1. 1H NMR (400 MHz, CD3OD): δ ppm 8.22 (d, J = 7.9 Hz, 1H), 8.08 (t, J = 6.7, 6.69
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Hz, 2H), 7.95 (t, J = 5.0 Hz, 2H), 7.88-7.82 (m, 1H), 7.04-6.94 (m, 1H), 6.32-6.26 (m, 1H), 4.68 (dd, J1 = 14.3, J2 =
8.1 Hz, 2H), 4.49-4.34 (m, 2H), 3.19-3.09 (m, 6H), 2.23 (t, J = 7.4 Hz, 2H), 2.17 (t, J = 7.4 Hz, 1H), 1.98-1.88 (m,
5H), 1.78-1.43 (m, 36H), 1.39-1.27 (m, 6H), 0.97-0.87 (m, 18H). 13C NMR (100 MHz, CD3OD): δ ppm 199.63,
176.09, 175.95, 174.78, 174.46, 173.74, 145.86, 129.25, 56.38, 53.17, 52.99, 51.93, 43.74, 41.92, 41.85, 40.85, 40.31,
40.25, 37.90, 37.03, 36.98, 36.68, 33.76, 30.21, 30.13, 27.64, 27.56, 26.71, 26.61, 25.91, 25.78, 23.69, 23.45, 23.40,
22.22, 22.06, 21.90, 18.56. HRMS calcd. for [C51H89N6O7]
+ 897.67873, found 897.67942.
Competition experiments in vitro
HEK293T cells were cultured on DMEM supplemented with 10% Fetal Calf Serum (FCS), 10 units/ml penicillin
and 10 µg/ml streptomycin in a 7% CO2 humidified incubator at 37
◦C. Cells were harvested, washed with PBS
(2×) and permeated in digitonin lysis buffer (4× pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose, 5 mM
MgCl2, 5 mM DTT, 0.025% digitonin) for 15 min. on ice followed by centrifugin at 16.100 rcf. for 20 min at 4
◦C.
The supernatant containing the cytosolic fraction was collected and the protein content was determined by Brad-
ford assay (Biorad). 10 µg total protein per experiment was exposed to the inhibitors (10× solution in DMSO) for
1 hr. at 37◦C prior to incubation with MV151 (500 nM) for 1 hr. at 37◦C. Reaction mixtures were boiled with
Laemmli’s buffer containing β-mercaptoethanol for 3 min. before being resolved on 12.5% SDS-PAGE. In-gel de-
tection of fluorescently labelled proteins was performed in the wet gel slabs directly on the Typhoon Variable
Mode Imager (Amersham Biosciences) using the Cy3/Tamra settings (λex 532, λem 560). Competition experi-
ments were repeated twice.
Cell treatment
HEK293T or RAW264.7 cells (2× 15 cm dishes) were incubated with 50 µM 97 of 118 or DMSO for 3hr at
37◦C in culture medium (DMEM (PAA), 10% FCS (Hyclone), 10 U/ml penicillin and 10 mg/ml streptomycin
(PAA)). Cells were washed and harvested in PBS, snap frozen in N2(l) and kept at -80
◦C until analysis. Cell pellets
were resuspended in 800 µl lysis buffer (50 mM Tris pH7.5, 250 mM sucrose, 1 mM MgCl2, 1 mM DTT, 0.025%
digitonin) for 15 min. on ice, lysed by sonication with 2 pulses of 30 sec, and centrifuged at 16.100 rcf. for 20 min.
at 4◦C. The supernatant containing the cytosolic fraction was collected and the protein content was determined
by Bradford assay. (BioRad).
Affinity purification
Some 2 mg of protein in 200 µl was precleared with 50 µl Streptavidin agarose beads (Pierce) under vigorous
shaking for 1 hr. at RT to remove endogenously biotinylated proteins. Bead-free lysate (200 µl) was reacted with
300 µM biotin phosphin 154 176 (1.5 µl from a DMF stock) for 2hr. at 37◦C, denatured by boiling for 5 min.
with 1% SDS and precipitated with chloroform/ methanol (C/M). The protein pellet was rehydrated in 180 µl
8M urea/100 mM NH4HCO3, reduced with 10 µl 90mM DTT for 30 min. at 37
◦C, alkylated with 15 µl 200 mM
iodoacetamide at room temp (RT) in the dark for 30 min., cleared by centrifugation at 13,000 g and desalted by
C/M. The pellet was dispersed in 25 µl PD buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl) with 2% SDS in a
heated (37◦C) sonic bath. Stepwise (3× 25 µl, 4× 100 µl and 1× 500 µl) addition of PD buffer afforded a clear
solution that was incubated with 50 µl MyOne T1 Streptavidin grafted beads (Invitrogen) at RT with vigorous
shaking for 2 hr. The beads were stringently washed with 2 x 300 µl PD buffer with 0.1% SDS, 2× 300 µl PD
buffer, 2× 300 µl wash buffer I (4M urea/50 mM NH4HCO3), 2× 300 µl wash buffer II (50 mM Tris HCl pH 7.5,
10 mM NaCl) and 2× 300 µl water. Beads were taken up in 100 µl digest buffer (100 mM Tris HCl pH 7.8, 100 mM
NaCl, 1mM CaCl2, 2% MeCN) and digested with 500 ng trypsin o.n. at 37
◦C. Supernatant containing peptides
was acidified with 5 µl formic acid (FA) to pH<4, desalted on Stage tips and dissolved in 50 µl H2O/MeCN/FA
(97/3/0.1%).
LC/MS analysis
Tryptic peptides were analysed on a Surveyor nanoLC system (Thermo) hyphenated with a LTQ-Orbitrap
mass spectrometer (Thermo). Gold and carbon coated emitters (OD/ID=360/25 µm tip ID=5 µm), trap
(OD/ID=360/100 µm packed with 25 mm robust Poros 10R2/ 15 mm BioSphere C18 5 µm 120Å) and ana-
lytical columns (OD/ID=360/75 µm packed with 20 cm BioSphere C18 5 µm 120Å) were from Nanoseparations
(Nieuwkoop, The Netherlands). The mobile phases (A: 0.1% FA/H2O, B: 0.1% FA/MeCN) were made with
ULC/MS grade solvents (Biosolve). The emitter tip was coupled end-to-end with the analytical column via a 15
mm long TFE teflon tubing sleeve (OD/ID 0.3x1.58 mm, Supelco, USA) and installed in a stainless steel holder
mounted in a nano-source base (Upchurch scientific, Idex, USA). General mass spectrometric conditions were:
an electrospray voltage of 1.8 kV was applied to the emitter, no sheath and auxiliary gas flow, ion transfer tube
temperature 150◦C, capillary voltage 41V, tube lens voltage 150V. Internal mass calibration was performed with
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air-borne protonated polydimethylcyclosiloxane (m/z = 445.12002) and the plasticizer protonated dioctyl phtha-
late ions (m/z = 391.28429) as lock mass. 182 For shotgun proteomics analysis, 10 µl of the samples was pressure
loaded on the trap column with a 10 µl/min flow for 5 min followed by peptide separation with a gradient of
35 min 5-30% B, 15 min. 30-60% B, 5 min. A at a flow of 300 µl/min split to 250 nl/min. by the LTQ divert
valve. For each data dependent cycle, one full MS scan (300-2000 m/z) acquired at high mass resolution (60,000
at 400 m/z, AGC target 1×106, maximum injection time 1,000 ms) in the Orbitrap was followed by 3 MS/MS
fragmentations in the LTQ linear ion trap (AGC target 5 × 103, max inj. time 120 ms) from the three most
abundant ions. 183 MS2 settings were: collision gas pressure 1.3 mT, normalized collision energy 35%, ion selec-
tion threshold of 500 counts, activation q = 0.25 and activation time of 30 ms. Fragmented precursor ions that










































Figure 4.1: Structure of syringolin A
and B
Syringolins form a class of small molecule natural
products that are secreted by strains of the plant
pathogen Pseudomonas syringae pv. syringae (Pss)
when these are invading a plant. 52 Syringolin A
and B (Figure 4.1) are of particular interest as these
molecules act upon the plant proteasome to com-
promise plant defence mechanisms against invad-
ing pathogens.184,185 The eukaryotic 20S proteasome
contains three catalytically active β subunits, β1, β2
and β5, which display caspase-like, trypsin-like and
chymotrypsin-like activity, respectively.12 The plant
20S proteasome is homologous to the mammalian
proteasome and syringolins are potent and selective
inhibitors of the human 20S proteasome as well. 54
Small molecule proteasome inhibitors show promis-
ing antitumour activity and bortezomib is used in
the clinic against multiple myeloma, whereas several other proteasome inhibitors are in
clinical trials.144,145,186–188 Biological evaluation of syringolins on tumour cells has shown
inhibition of cell proliferation and induction of apoptosis.189,190 This sparked the interest
∗W. A. van der Linden, L. I. Willems, T. B. Shabaneh, N. Li, M. Ruben, B. I. Florea, G. A. van der Marel, M.
Kaiser, A. F. Kisselev, H. S. Overkleeft, Org. Biomol. Chem. 2011, in press.
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of several organic chemists and lately, the total syntheses of several syringolins have been
published.191–194
With the total syntheses of syringolin A and B completed, the opportunity opened up
to perform structure-activity relationship studies of syringolins and their analogues. Sy-
ringolins contain a 12-membered lactam core structure the nature of which differs among
the members of this family of compounds. Syringolin A (SylA) has two (E)-configured
double bonds resulting in a strained system, and syringolin B has only one ring unsatura-
tion. The α,β-unsaturated amide in the ring system is responsible for covalently and irre-
versibly inactivating the catalytic Thr1 Oγ of the 20S proteasome β subunits via Michael
addition. 54 SylA and SylB inhibit β2 and β5 potently and β1 at higher concentration.195
The electrophilic lactam is quite rigid in structure and probably determines to a large ex-
tent the proteasome specificity. Attached to the lactam core structure is a peptoid fragment,
which differs among the syringolins. SylA and SylB contain a valine-urea-valine moiety at
their pseudo N-terminus. An ureido linkage induces chain reversal in a peptide, and for
this reason has been installed in protease inhibitors.196–198 It is also found in several natu-
ral peptide-based compounds with antibiotic activity.199–201 However, the syringolins are
the only examples of proteasome inhibitors that contain this moiety. Some research has
already been conducted on the exocyclic part of syringolins, including a D-amino acid scan
of the two valines (174, 175 and 176, Figure 4.2), revealing that the naturally occurring
configuration yields the most potent compounds.194 Addition of aliphatic (173)193 or hy-
drophilic (170, 171)194 tails yielded inhibitors with increased potency with respect to SylA.
Addition of a fluorophore was tolerated, yielding proteasome probe 169. 202 Hybrids be-
tween SylA and a structurally related naturally occurring proteasome inhibitor glidobactin





























































































Figure 4.2: Literature SylA modifications
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The proteasome subunit selectivity pattern of an inhibitor is important for its antitu-
mour activity. Inhibition of β5 is essential, but co-inhibition of β1 or β2 is usually needed
for the compound to be cytotoxic in cell lines derived from various cancers.127,128,169 The
structural elements in syringolins that are responsible for proteasome subunit selectivity
are therefore useful in the design of new proteasome inhibitors. To determine the effect
of the valine-urea-valine motif in the biological profile of syringolins this moiety is incor-
porated in a more conventional linear peptide based proteasome inhibitor design. In this
design, the unsaturated lactam Michael acceptor is replaced with leucine vinyl sulfone (VS),
another Michael acceptor commonly used to arrive at potent proteasome inhibitors. A
leucine epoxyketone (EK) is used as well since this warhead often yields more potent and
selective inhibitors than the vinyl sulfone. 204
4.2 Results and Discussion
The first set of target compounds subject of the here presented study are displayed in Fig-
ure 4.3. Direct attachment of the leucine derived electrophilic trap to the valine-urea-valine
moiety yields two tripeptide compounds (179 and 183). The carboxylic acid functionality
is masked as a tert-butyl ester as its synthetic precursor (178 and 182). A benzylamide cap
is also used (180 and 184), since aromaticity at the N-terminus of a short proteasome in-
hibitor could be beneficial for its potency.142,205 The decyl chain, improving syringolin A
activity,193 is also used in this library (181 and 185). When the tripeptide structure is com-
pared to SylA, the distance between the electrophile of the inhibitor and the urea group



























































































































Figure 4.3: Panel of synthesised potential proteasome inhibitors.
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between the urea and electrophile, yielding tetrapeptide inhibitors (186-193, Figure 4.3).
The synthesis of the tripeptide vinyl sulfones commenced with coupling of TFA.H-
LeuVS106 to Boc-Val-OH to yield Boc-protected dipeptide 194 from which the Boc pro-
tecting group was removed to yield dipeptide 195 (Scheme 4.1). This dipeptide was reacted
with valine tert-butyl ester isocyanate, valine benzylamide isocyanate or decyl isocyanate
to yield three inhibitors 178, 180 and 181. Peptide 178 was deprotected with TFA to yield
179.
In an attempt to react dipeptide epoxyketone TFA.H-Val-Leu-EK with valine tert-butyl
ester isocyanate, no formation of compound 182 was detected. Rather, dipeptide TFA.H-
Val-Leu-EK cyclizes in this basic reaction medium. As an alternative approach to obtain












































































































































Reagents and conditions: i) Boc-Val-OH (1.1 equiv.), HBTU (1.2 equiv.), DiPEA (3.5 equiv.), EA, 4 hr., quant. ii)
TFA:DCM 1:1, 30 min., quant. iii) 3 isocyanates (1 equiv.), DiPEA (2.2 equiv.), DCM, 1 hr.-o/n, 80% (178), 36%
(180), 67% (181). iv) TFA, 45 min, quant. v) hydrazine hydrate (30 equiv.), MeOH, reflux, o/n. vi) tBuONO (1.1
equiv.), HCl (2.8 equiv.), DMF:EA 3:1, -30◦C, 3 hr. then TFA.H-Leu-EK (1.1 equiv.), DiPEA (5 equiv.), DMF,
-30◦C → RT o/n, 47% (182), 20% (184), 35% (185). vii) valine benzylamide isocyanate (0.83 equiv.) or decyl
isocyanate (1.05 equiv.), DiPEA (1.2 equiv.), DCM, 1-2 hr., 53% (198), 60% (200). viii) 4M HCl/dioxane, 1 hr.
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compound 182, the methyl ester in compound 196193 was transformed to the hydrazide
(197) which was then in situ transformed to the acyl azide and coupled to TFA.H-Leu-
EK to arrive at 182, which was subsequently deprotected to gain 183 (Scheme 4.1). Com-
pounds 184 and 185 were synthesised by a modified approach. Reacting 202206 with valine
benzylamide isocyanate or decyl isocyanate yielded 198 and 200, which were then Boc-
deprotected to yield hydrazides 199 and 201 which were transformed to the acyl azide in
situ and coupled to TFA.H-Leu-EK to obtain 184 and 185.
The synthesis of tetrapeptide vinyl sulfones and epoxyketones followed a general strat-
egy (Scheme 4.2). Methyl ester 203 207 was transformed to the corresponding hydrazide
204 by hydrazine hydrate in methanol. This compound was in situ transformed to its acyl
azide and then coupled to TFA.H-Leu-VS or TFA.H-Leu-EK to arrive at 205 and 207. Car-
bamate 205 was deprotected with TFA in DCM to give 206, which in the next step was
reacted with the three isocyanates mentioned in the section above to yield tetrapeptides




















































































R = tBu 
R = H






















































Reagents and conditions: i) hydrazine hydrate (20 equiv.), MeOH, reflux, 2 hr. ii) tBuONO (1.1 equiv.), HCl
(2.8 equiv.), DMF:EA 3:1, -30◦C, 3 hr. then TFA.H-Leu-VS (1.1 equiv.) TFA.H-Leu-EK (1.1 equiv.), DiPEA (5
equiv.), DMF, -30◦C→RT o/n, 72% (205), 90% (207). iii) TFA:DCM 1:1, 30 min., quant. iv) valine tert-butylester
isocyanate, valine benzylamide isocyanate or decyl isocyanate, DiPEA, DCM, 70% (186), 23% (188), 43% (189).
v) valine tert-butylester isocyanate, valine benzylamide isocyanate or decyl isocyanate, DiPEA, DCM, 28% (190),
40% (192), 29% (193). vi) TFA, 1 hr., quant.
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186, 188 and 189. Compound 186 was deprotected with TFA to yield 187. The same
strategy, employing 207, led to 190-193.
In a first assessment of inhibitory potency the sixteen compounds were subjected to
a competition assay versus BODIPY-TMR-epoxomicin (MVB003, 49).114 Extracts from
HEK293T or EL4 cells were incubated with a broad concentration range of inhibitor for
one hour, after which remaining proteasome activity was labelled with MVB003. After
SDS-PAGE separation of the proteome, the wet gel slabs were scanned on a Typhoon fluo-
rescence scanner. Results are displayed in Figure 4.4. Proteasome subunits were assigned


























































































Figure 4.4: Competition assay in cell lysate versus MVB003. (A) HEK293T (15 µg) or (B) EL4 lysate (10 µg)
was incubated with indicated end concentrations of inhibitor for 1 hr. at 37◦C. Residual proteasome activity was
labelled by MVB003 (0.5 µM end concentration) for 1 hr. at 37◦C.
One first obvious conclusion from this broad concentration scan is that the syringolin
A inspired ureido peptide moiety, coupled to leucine epoxyketone or vinyl sulfone, yields
active proteasome inhibitors (Figure 4.4). Generally, the inhibitors containing a vinyl sul-
fone are less potent than their epoxyketone counterparts, which is in agreement with pre-
vious observations.169,204
A second obvious trend is that tripeptide inhibitors show some selectivity for β1. The
most distinct selectivity for β1 is displayed by 182 in HEK lysate (Figure 4.4). In EL4
lysate, tripeptide vinyl sulfones 178, 179, 180 appear to silence β1i before β1 is targeted
(Figure 4.4). Their epoxyketone counterparts, however, target β1 and β1i more simultane-
ously. The tetrapeptide inhibitors appear to preferentially target β5. Compounds contain-
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ing the long aliphatic tail (181, 185, 189, 193) are far less potent than their counterparts
lacking this moiety. This is in sharp contrast to lipophilic SylA analog 173, which is much
more potent than parent compound SylA.193
To gain better insight in the subunit selectivity of the most potent inhibitors, the com-
petition assay was repeated with a more detailed concentration series (Figure 4.5). Tri-
peptide vinyl sulfones 178-181 as well as 185 and 189 were omitted because the inhibitory
effect of these compounds falls mostly outside the more diluted concentration range. There
is a difference in the outcome of the competition assay in HEK lysate and EL4 lysate (Fig-
ure 4.5A and B). The potency of tetrapeptide vinyl sulfones in HEK lysate does not seem to
be matched in EL4 lysate. For example, 186 and 188 seem much less potent in EL4 lysate
than in HEK lysate (Figure 4.5A and B). This could be explained by the overlap of β5 sub-
units of the constitutive and immunoproteasome on gel. Inhibition of one of these signals


































































































































































Figure 4.5: Competition assay in cell lysate versus MVB003. (A) HEK293T (15 µg) or (B) EL4 lysate (10 µg)
was incubated with indicated end concentrations of inhibitor for 1 hr. at 37◦C. Residual proteasome activity was
labelled by MVB003 (0.5 µM end concentration) for 1 hr. at 37◦C.
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In HEK lysate (Figure 4.5A), several library members indeed are subunit selective; 186
inhibits β5 by more than 90% at about 1 µM, at which concentration β1 and β2 appear
untouched. Compound 190 fully inhibits β5 at 100 nM, before inhibiting β1 and β2. Com-
pound 182 is very selective for the β1 subunit. Compared to NC001 (58, Table 4.1), a
very selective tetrapeptide epoxyketone, compound 182 is only slightly less potent in HEK
lysate.127,133 The benzyl amides in this library are generally less selective than their tert-
butyl counterparts; 188 co-inhibits β2 before complete β5 inhibition is reached while 186
shows more selectivity. Benzyl amide 184 co-inhibits β5 much earlier than the selective
tert-butyl ester 182. The difference in selectivity between 190 and 192, however, is less
pronounced. The parent compound, SylA, inhibits β5 and β2 in the low micromolar range
and only inhibits β1 at higher concentration (Figure 4.5). In this respect, the activities of
the tetrapeptide inhibitors of this library in general more resemble that of SylA than the ac-
tivities of the tripeptides do. Interestingly, there are several compounds in this library that
display more potent proteasome inhibition than the parent compound, SylA. Compounds
190 and 192 are the most potent inhibitors in this study; compared to SylA in HEK lysate
(Figure 4.5A), these two compounds inhibit β5 at about 100-fold lower concentration.
The most potent and selective compounds were also analysed for their inhibitory ca-
pacities against purified proteasomes isolated from rabbit muscles (constitutive 26S protea-
some) or rabbit spleens (immunoproteasome) with subunit specific fluorogenic peptides
(Table 4.1A and B). To better compare these results with the competition assay gels from
Figure 4.5, the gel bands were quantified and plotted against inhibitor concentrations. From
these plots, the IC50 values were calculated and the results are summarised in Table 4.1C
and D.
Table 4.1: Apparent IC50 (µM) values calculated from semi log plots of residual proteasome activity against
inhibitor concentration.
Fluorogenic peptide hydrolysis assay Quantified competition assay
β5 β1 β2 β5i β1i β2i β5 β1 β2 β5/β5i β1i β2i
26S proteasome Immunoproteasome HEK293T lysate EL4 lysate
Compound IC50 (µM) A IC50 (µM) B IC50 (µM) C IC50 (µM) D
182 >30 1.7 >30 >100 24 N.I. 50 0.46 >100 N.I. 0.079 N.I.
183 50 1.4 >100 16 0.4 42
184 >10 1.2 >100 ∼20 1.0 N.I. 2.9 0.52 >100 24 0.67 N.I.
186 1.0 >30 >30 0.13 N.I. N.I. 0.23 100 100 3.3 5.9 46
187 4.2 50 >100 13 2.3 32
188 0.64 18 10 0.077 >3 >3 0.17 100 2.1 4.4 32 22
190 ∼0.3 >0.3 >0.3 0.007 ∼1 ∼1 0.016 1.3 0.69 0.32 13 2.0
191 0.48 2.8 5.9 7.2 5.0 3.1
192 0.013 0.24 0.3 0.005 1.0 0.28 0.008 2.4 0.28 0.69 23 1.6
193 0.5 100 100 19 28 39
SylA 1.3 25 6.6 1.2 1.7 2.8
NC001 (58) >50 0.31 N.I.
Constitutive proteasomes purified from rabbit muscles (A) or immunoproteasomes, purified from rabbit spleens
(B), were incubated with different concentrations of inhibitors for 30 min at 37◦C followed by measurement
of remaining activity with fluorogenic peptides (Suc-LLVY-AMC, β5/β5i, Ac-LPnLD-AMC, β1/β1i, Ac-RLR-
AMC, β2/β2i). Band intensities from competiton assay gels in HEK293T lysate (C) or EL4 lysate (D) in Figure 4.4
and Figure 4.5 were used as input. N.I. no inhibition.
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The IC50 values found with the fluorogenic peptide hydrolysis assay are in most cases
higher than those found in the competition assay, but one should be careful when com-
paring IC50 values obtained with two very different experimental setups. The subunit
selectivity trends found with the fluorogenic peptide assay, however, in most cases agree
with the results from the competition assay. In both settings, 182 is a selective β1 pro-
teasome inhibitor, while 192 is a selective β5 inhibitor. In the fluorogenic substrate assay,
compound 190 shows onset of inhibition of the constitutive β1 and β2 sites when β5 is
targeted, while in the competition assay in HEK293T lysate this compound appears more
selective. Tetrapeptide vinyl sulfones 186 and 188 appear more potent towards β5i than
β5 in the fluorogenic substrate assay (Table 4.1A and B). The differences in potency and
selectivity between competition assay in cell lysate and fluorogenic substrate hydrolysis by
purified proteasome can be caused by the presence of other proteasome forms in cell lysate
(i.e. PA200 and PA28 activated proteasomes) or post-translational modifications that affect
active site specificity and that are either species or tissue specific and may be lost during
preparation of proteasomes from muscle or spleen.
Compounds 182, 190 and 192 were evaluated on their proteasomal inhibition capaci-
ties in living HEK cells to assess cell permeability of these compounds. Subunit selective
proteasome inhibitors NC001 (58) and NC005-VS were used for comparison.127,133 Living
HEK cells were incubated with the inhibitors for 4 hr. after which remaining proteasomal
activity was labelled by cell permeable probe MVB003 (Figure 4.6). The results are sum-
marised in Table 4.2. Interestingly, 182 shows fivefold higher potency in living HEK cells














































































Figure 4.6: Competition assay in living HEK cells.
Cells (1.106) were incubated with indicated end concen-
trations of inhibitor (100× stock in DMSO) for 4 hr. at
37◦C. Residual proteasome activity was labelled with
MVB003 (5 µM end concentration, 100×DMSO stock)
for 2 hr. at 37◦C.
Quantified competition assay gels
β5 β1 β2
Compound IC50 (µM)
182 6.7 0.065 >10
NC001 >10 0.34 >10
190 <0.05a 0.31 0.23
192 <0.05a 0.16 0.063
NC005-VS 0.058 N.I. N.I.
Table 4.2: Apparent IC50 (µM) values calculated from
semi log plots of residual proteasome activity against in-
hibitor concentration. Band intensities from each lane
of competition assay gels in living cells (Figure 4.6) were
quantified and used as input. N.I. no inhibition. a about
80% inhibition of activity observed at 50 nM.
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This difference can be ascribed to better cell permeability of 182, possibly due to its smaller
size than NC001. Compound 182 is the most potent and selective β1 inhibitor to date.
Compounds 190 and 192 do inhibit the proteasome in living HEK cells and therefore are
cell permeable, but their β5 selectivity is much lower than observed in HEK extracts and
NC005-VS is much more β5 selective in cells than 190 and 192.
Having evaluated a small library of proteasome inhibitors containing tri- and tetrapep-
tides with the valine-urea-valine motif, a dramatic shift in selectivity from β1 to β5 is ob-
served when the ureido linkage is moved one place in the molecule. A tetrapeptide vinyl
sulfone scaffold was selected in which the ureido-linkage is ’shifted’ through the molecule
to arrive at two more potential proteasome inhibitors with the urea after the first or second
amino acid in the peptide instead of the third (Scheme 4.3). The Fmoc group in 209 208
and 211 was removed by DBU. 209 Dipeptide 212 was coupled to Fmoc-Val-OH and again
deprotected with DBU to arrive at tripeptide 214. TFA.H-Leu-VS was converted to its
isocyanate by phosgene and DiPEA in DCM193 and subsequently reacted with amine 214
which resulted in tetrapeptide 215. Amine 210 was converted to the isocyanate by phos-
gene and sat. aq. NaHCO3
210 and reacted with amine 195 which resulted in tetrapeptide
216.



















R = Fmoc, n = 0
R = H, n = 0 
R = Fmoc, n = 1 




















































Reagents and conditions: i) EtSH (10 equiv.), DBU (0.1 equiv.), THF, 1.5-2hr., 97% (210), 93% (212), 91% (214).
ii) Fmoc-Val-OH (1.05 equiv.), HBTU (1.15 equiv.), DiPEA (2.25 equiv.), DCM, 1.5 hr., 95%. iii) phosgene (1.1
equiv.), DiPEA (2.2 equiv.), DCM, 10 min, then 214 (1.1 equiv.), DiPEA (2.2 equiv.), 2 hr., 83%. iv) phosgene (1.2
equiv.), DCM/sat. aq. NaHCO3, 0
◦C, 10 min. then 195 (1 equiv.), (2.2 equiv.), 54%.
Compounds 215 and 216 were subjected to the competition assay in HEK and EL4
lysate versus MVB003 (Figure 4.7). In HEK lysate, only at high concentrations (100 µM),
proteasome inhibition is observed. In EL4 lysate, on the other hand, compound 216 ap-
pears to inhibit β1i selectively from 5 µM and higher concentrations, when β1 remains
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mostly untouched. However, the window of β1i specific inhibition is small. The activity
of 216 resembles the activities of tripeptide vinyl sulfones 178, 179 and 180, where the ure-
ido linkage is at the same distance from the warhead. Compound 215 only shows some
inhibition of β1 at 50 µM in EL4 lysate. Apparently, the place of the ureido-linkage in
the peptide inhibitor determines its activity and selectivity for proteasome subunits. The
relatively low activity of 215 could be the result of ’inversed’ amino acid side chain config-
uration caused by chain reversal due to the ureido linkage. Substitution for D-amino acids
at P2-4 for 215 might restore activity of this scaffold. Usage of D-amino acids at P3 and P4
for 216 might improve its activity as well.
1 10 100 00.1
A
216













































Figure 4.7: Competition assay in (A) HEK lysate (15 µg protein) or (B) EL4 lysate (10 µg protein). Lysates
were incubated with indicated end concentrations of inhibitor for 1 hr. at 37◦C. Residual proteasome activity was
labelled by MVB003 (0.5 µM end concentration) for 1 hr. at 37◦C.
4.3 Conclusion
Incorporation of the exocyclic valine-urea-valine motif, which is found in syringolin A,
into a vinyl sulfone or epoxyketone oligopeptide results in a new set of potent proteasome
inhibitors. In general, epoxyketone containing inhibitors are more potent than their vinyl
sulfone counterparts, but this increase in potency is often accompanied by a decrease in sub-
unit selectivity.133,169,204 The position of the ureido linkage with respect to the electrophilic
trap has a profound effect on proteasome subunit selectivity. A short distance, as in com-
pounds 182-184 and 178-180 results in preference for the β1 subunit of the proteasome. In
compounds 178-181 and 216, a slight preference for β1i is observed in EL4 lysate. When
an extra amino acid is incorporated in between the ureido linkage and the warhead, as in
inhibitors 186-189 and 190-193, a preference for the β5 subunit is observed, with tetrapep-
tide epoxyketones 190 and 192 being quite selective inhibitors of the β5 site. When the
ureido linkage is incorporated after P1 in the peptide, as for compound 215 proteasomal
inhibition is mostly lost.
Tripeptide epoxyketone 182 is a potent and very selective inhibitor of the β1 subunit.
In living cells, this compound is fivefold more potent than NC001 and is the most potent
β1 selective compound known to date. Further optimisation of this compound, for ex-
ample by changing the P2 valine for a norleucine residue or changing the tert-butyl for a
smaller methyl group, might make this molecule even more selective for β1. Tetrapeptide
epoxyketones 190 and 192 are the most potent compounds in this library, more potent
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than the parent compound SylA. The subunit selectivity pattern of 192 shows similarities
to that of SylA, but displays higher potency, indicating that the antitumour activity of this
compound should be assessed.
Translating the findings of this study back to the case of syringolin A meets difficul-
ties. One can envisage that the molecular basis of selectivity of 182, 190 and 192 can be
unravelled with the crystal structures of these compounds in complex with 20S protea-
somes. 35,54,211
4.4 Experimental
All reagents were commercial grade and were used as received unless indicated otherwise. Toluene (Tol.) (pu-
rum), ethyl acetate (EA) (puriss.), and light petroleum ether (PE) (puriss.) were obtained from Riedel-de Haën
or Biosolve and were distilled prior to use. Dichloromethane (DCM), dimethyl formamide (DMF), and dioxane
were stored on 4 Å molecular sieves. Tetrahydrofuran (THF) was distilled from LiAlH4 prior to use. Reactions
were conducted under an argon atmosphere. Reactions were monitored by TLC analysis by using DC-fertigfolien
(Schleicher & Schuell, F1500, LS254) with detection by UV absorption (254 nm), spraying with 20% H2SO4 in
ethanol or (NH4)6Mo7O24
.4H2O (25 g/L) and (NH4)4Ce(SO4)4
.2H2O (10 g/L) in 10% sulfuric acid followed by
charring at ∼150◦C or by spraying with an aqueous solution of KMnO4 (7%) and KOH (2%). Column chroma-
tography was performed on silica gel from Screening devices (0.040-0.063 nm). LC/MS analysis was performed
on a LCQ Advantage Max (Thermo Finnigan) equipped with an Gemini C18 column (Phenomenex). HRMS
was recorded on a LTQ Orbitrap (Thermo Finnigan). 1H- and 13C-APT-NMR spectra were recorded on a Bruker
DPX-300 (300/75 MHz) or Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory. Chem-
ical shifts are given in ppm (δ) relative to tetramethylsilane as an internal standard. Coupling constants are given
in Hz. All presented 13C-APT spectra are proton decoupled. TFA.H-Leu-EK 184 and TFA.H-Leu-VS 106 were
obtained by literature procedures. NC001 (58), NC005-mvs and SylA were obtained as described. 127,133,193
General procedure for the formation of isocyanates A 193
Amine or amine HCl salt (1 equiv.) was dissolved in DCM and DiPEA (2.2 equiv.) was added. This solution was
slowly added to a solution of triphosgene (0.35 equiv) or phosgene (1.1 equiv, 20 wt-% sln in Tol.) and the mixture
was stirred for an additional 10 minutes after addition and used in the next step without any purification.
General procedure for the formation of isocyanates B 210
HCl.H-ValNHBn 212 or H-Val-Leu-OtBu was dissolved in 1:1 DCM:sat.aq. NaHCO3 at 0
◦ C. The layers were
allowed to separate and phosgene (1.2 equiv., 20 wt-% in Tol.) was added to the DCM layer and stirring was con-
tinued for 10 minutes after which the mixture was extracted with DCM (3×). The organic layers were combined
and dried over Na2SO4 and concentrated. The resulting crude isocyanate was used without further purification.
General procedure for azide coupling
Hydrazide or hydrazide HCl (1 equiv.) was dissolved in DMF:EA 3:1 and cooled to -30◦ C. tBuONO (1.1 equiv.)
and HCl (4M in dioxane, 2.8 equiv.) were added and the resulting mixture stirred for 3 hr. TFA.H-Leu-EK or
TFA.H-Leu-VS (1.1 equiv.) in DMF was added followed by DiPEA (5 equiv.) and the mixture was allowed to
warm to RT overnight. The mixture was diluted with EA and washed with H2O (3×). The organic layer was






Boc-Val-Leu-VS (194). Boc-Val-OH (359 mg, 1.65 mmol, 1.1 equiv.) was dissolved in
EA. HBTU (683 mg, 1.8 mmol, 1.2 equiv.), DiPEA 0.87 mL, 5.25 mmol, 3.5 equiv.)
and TFA.LeuVS (1.5 mmol, 1 equiv.) were added and the mixture stirred for 4 hr. The
mixture was washed with 1M HCl (3×), sat. aq. NaHCO3 (3×) and brine before being
dried over Na2SO4. The residue was purified by column chromatography (30% EA:PE
→ 60% EA:PE) to yield the title compound (587 mg, 1.5 mmol, quant.). 1H NMR (400
MHz, CDCl3): δ 6.88 (d, J = 6.6 Hz, 1H), 6.79 (dd, J1 = 15.1, J2 = 5.3 Hz, 1H), 6.52
(d, J = 15.1 Hz, 1H), 5.33 (d, J = 7.5 Hz, 1H), 4.87-4.62 (m, 1H), 3.86 (dd, J1 = 8.3, J2 = 7.1 Hz, 1H), 2.89 (s, 3H),
2.15-2.00 (m, 1H), 1.70-1.56 (m, 1H), 1.40 (s, 9H), 0.96-0.81 (m, 12H). 13C NMR (100 MHz, CDCl3): δ 171.63,
155.89, 147.63, 129.16, 79.80, 60.25, 47.65, 42.62, 42.48, 30.17, 28.15, 24.50, 22.63, 21.65, 19.27, 17.85.
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TFA.H-Val-Leu-VS (195). Boc-Val-Leu-VS (194) was stirred in 1:1 DCM:TFA for 30 minutes before coevapo-













tBuO-Val-urea-Val-Leu-VS (178). A solution of TFA.H-Val-Leu-VS (195),
305 µmol, 1 equiv.) and DiPEA (111 µl, 671 µmol, 2.2 equiv.) in DCM was
added to the isocyanate of valine tert-butyl ester (obtained from HCl.H-
Val-OtBu (64 mg, 305 µmol, 1 equiv.) employing general procedure A).
The remaining solution was stirred for 1 hr and concentrated. The residue
was dissolved in EA and washed with 1M HCl (2×), sat. aq. NaHCO3 and
brine before being dried over Na2SO4. Column chromatography (40%
EA:PE → 70% EA:PE) yielded the title compound (119 mg, 243 µmol, 80%). LC/MS: Rt 10.28 min (linear
gradient 10→ 90% MeCN+ 0.1%TFA, 15 min). 1H NMR (400 MHz, CDCl3): δ ppm 7.42 (d, J = 7.98 Hz, 1H),
6.80 (dd, J1 = 15.06, J2 = 5.76 Hz, 1H), 6.70 (d, J = 15.16 Hz, 1H), 6.34 (d, J = 7.99 Hz, 1H), 6.00 (d, J = 8.97
Hz, 1H), 4.76-4.67 (m, 1H), 4.24 (dd, J1 = 8.82, J2 = 5.29 Hz, 1H), 4.03 (t, J = 8.40, 1H), 2.93 (s, 3H), 2.13-1.94
(m, 2H), 1.73-1.58 (m, 1H), 1.47 (s, 9H), 1.46-1.38 (m, 2H), 0.97-0.84 (m, 18H). 13C NMR (100 MHz, CDCl3):
δ ppm 219.35, 172.97, 172.34, 158.28, 147.04, 129.88, 81.59, 60.16, 58.69, 48.02, 42.66, 42.53, 31.37, 30.76, 28.04,
24.60, 22.56, 22.08, 19.47, 18.99, 18.56, 17.98. HRMS calcd. for [C23H44N3O6S1]












HO-Val-urea-Val-Leu-VS (179). t-Bu ester 178 was stirred in 1 ml TFA for 45
min before being coevaporated with toluene (3×) to yield the title compound
in quantitative yield. LC/MS: Rt 6.19 min (linear gradient 10→ 90% MeCN
+ 0.1%TFA, 15 min). 1H NMR (400 MHz, CD3OD): δ ppm 6.78 (dd, J1
= 15.17, J2 = 5.29 Hz, 1H), 6.63 (dd, J1 = 15.18, J2 1.34 Hz, 1H), 4.73-4.64
(m, 1H), 4.19 (d, J = 4.72 Hz, 1H), 3.99 (d, J = 6.60 Hz, 1H), 2.95 (s, 3H),
2.21-2.09 (m, 1H), 2.08-1.99 (m, 1H), 1.78-1.62 (m, 1H), 1.60-1.50 (m, 1H),
1.49-1.38 (m, 1H), 1.03-0.84 (m, 18H). 13C NMR (100 MHz, CD3OD): δ ppm 176.02, 174.72, 160.55, 148.57,
130.92, 60.94, 59.47, 49.14, 43.35, 42.83, 32.18, 32.05, 25.86, 23.37, 21.94, 19.96, 19.75, 18.30, 17.94. HRMS calcd.
for [C19H36N3O6S1]












Benzylamide-Val-urea-Val-Leu-VS (180). Vinyl sulfone 195 (225 µM, 1
equiv.) and DiPEA (41 µl, 241 µmol, 1.1 equiv.) were dissolved in DCM
and this mixture was added to the isocyanate of valine benzylamide (ob-
tained from HCl.H-Val-NHBn 212 (104 mg, 338 µmol, 1.5 equiv.) employ-
ing general procedure B). The remaining solution was stirred overnight and
concentrated. The residue was dissolved in DCM and washed with H2O
(2×) and dried over Na2SO4. Column chromatography (DCM → 10%
MeOH:DCM) yielded the title compound (43 mg, 81 µmol, 36%). LC/MS: Rt 7.53 min (linear gradient 10
→ 90% MeCN+ 0.1%TFA, 15 min). 1H NMR (400 MHz, CDCl3/CD3OD 1/1): δ ppm 7.36-7.21 (m, 5H), 6.81
(dd, J1 = 15.13, J2 = 5.17 Hz, 1H), 6.59 (dd, J1 = 15.12, J2 = 1.49 Hz, 1H), 4.75-4.65 (m, 1H), 4.41 (q, J = 14.94,
2H), 4.02 (d, J = 6.69 Hz, 1H), 3.96 (d, J = 6.64 Hz, 1H), 2.96 (s, 3H), 2.06 (m, 2H), 1.74-1.61 (m, 1H), 1.59-1.37
(m, 2H), 1.02-0.84 (m, 18H). ). 13C NMR (100 MHz, CDCl3/CD3OD): δ ppm 172.64, 147.33, 128.73, 128.00,
127.02, 126.78, 59.24, 58.95, 47.35, 42.71, 41.92, 41.84, 30.66, 30.25, 24.22, 22.08, 20.90, 18.70, 18.60, 17.14, 17.09.
HRMS calcd. for [C26H43N4O5S1]











Decyl-urea-Val-Leu-VS (181). Vinyl sulfone 195 (266 µM, 1 equiv.) and DiPEA
(100 µl, 585 µmol, 2.2 equiv.) were dissolved in DCM and this solution was added
to 1-isocyanatodecane (obtained from decyl amine (58 µl, 293 µmol, 1.1 equiv.)
employing general procedure A). The remaining solution was stirred for 1 hr
and washed with 1M HCl (3×) and sat. aq. NaHCO3 and the solution was dried
over Na2SO4. Column chromatography (40% EA:PE → 80% EA:PE) yielded
the title compound (85 mg, 179 µmol, 67%). 1H NMR (400 MHz, CDCl3): δ
ppm 8.28 (d, J = 7.54 Hz, 1H), 6.88 (dd, J1 = 15.10, J2 = 6.04 Hz, 1H), 6.68 (d, J = 14.98 Hz, 1H), 6.55-6.43 (m,
1H), 5.91-5.83 (m, 1H), 4.77-4.64 (m, 1H), 4.12-4.04 (m, 1H), 3.24-3.09 (m, 1H), 3.05-2.95 (m, 1H), 2.93 (s, 1H),
2.02-1.85 (m, 1H), 1.72-1.58 (m, 1H), 1.54-1.35 (m, 5H), 1.33-1.21 (m, 16H), 1.02-0.81 (m, 12H). 13C NMR (100
MHz, CDCl3): δ ppm 173.49, 158.70, 147.46, 129.73, 60.05, 47.94, 42.73, 42.69, 40.42, 31.87, 31.35, 30.47, 29.64,
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tBuO-Val-urea-Val-NHNH2 (197). Methyl ester 196
193 (234 mg, 708 µmol, 1
equiv.) was dissolved in MeOH. Hydrazine hydrate (1 ml, 21 mmol, 30 equiv.)
was added and the mixture refluxed overnight. Coevaporation with toluene (4×)
yielded the title compound which was used without further purification. 1H NMR
(400 MHz, CD3OD): δ 6.41 (dd, J1 = 12.3, J2 = 9.1 Hz, 1H), 4.17-4.00 (m, 1H),
3.99-3.84 (m, 1H), 2.06 (dt, J1 = 12.1, J2 = 6.8 Hz, 1H), 2.02-1.89 (m, 1H), 1.46 (s,
9H), 1.01-0.85 (m, 12H). 13C NMR (100 MHz, CD3OD): δ 173.87, 173.48, 160.37, 82.45, 60.25, 60.18, 59.27,













tBuO-Val-urea-Val-Leu-EK2 (182). Prepared by the general procedure for
azide coupling employing 197 (33 mg, 100 µmol, 1 equiv.) and TFA.H-Leu-
EK (31 mg, 110 µmol, 1.1 equiv.). Purification by column chromatogra-
phy (DCM → 1% MeOH:DCM, 2×) yielded the title compound (22 mg,
47 µmol, 47%). LC/MS: Rt 8.93 min (linear gradient 10→ 90% MeCN +
0.1%TFA, 15 min). 1H NMR (400 MHz, CDCl3): δ ppm 6.49 (d, J = 7.55
Hz, 1H), 5.51 (d, J = 8.52 Hz, 1H), 5.39 (d, J = 8.82 Hz, 1H), 4.60 (ddd, J1
= 10.60, J2 = 7.72, J3 = 3.23 Hz, 1H), 4.26 (dd, J1 = 8.78, J2 = 4.62 Hz, 1H), 4.08 (dd, J1 = 8.56, J2 = 7.07 Hz,
1H), 3.36 (d, J = 4.98 Hz, 1H), 2.88 (d, J = 4.97 Hz, 1H), 2.15-1.93 (m, 2H), 1.76-1.59 (m, 2H), 1.46 (s, 9H), 1.51 (s,
3H), 1.58-1.51 (m, 1H), 0.95-0.82 (m, 18H). 13C NMR (100 MHz, CDCl3): δ ppm 208.44, 172.72, 172.24, 157.72,
81.63, 59.27, 59.11, 58.47, 52.48, 50.41, 39.97, 31.49, 31.18, 29.71, 28.08, 25.13, 23.36, 21.33, 19.27, 18.98, 18.10,
17.65, 16.78. HRMS calcd. for [C24H44N3O6]













HO-Val-urea-Val-Leu-EK (183). t-Bu ester 182 (13 mg, 28 µmol) was stirred
with 2 mL TFA for 1 hr before being coevaporated with toluene (3×) to yield
the title compound quantitatively. LC/MS: Rt 9.05 min (linear gradient 10→
90% MeCN+ 0.1%TFA, 15 min). 1H NMR (400 MHz, CD3OD): δ 4.56 (dd,
J1 = 10.6, J2 = 3.0 Hz, 1H), 4.20 (d, J = 4.8 Hz, 1H), 4.06 (d, J = 6.6 Hz, 1H),
3.29 (d, J = 5.1 Hz, 1H), 2.95 (d, J = 5.1 Hz, 1H), 2.16 (dq, J1 = 13.6, J2 = 6.8
Hz, 1H), 2.11-1.90 (m, 1H), 1.84-1.22 (m, 3H), 1.48 (s, 3H), 1.16-0.78 (m, 18H).
13C NMR (100 MHz, CD3OD): δ 209.58, 176.05, 174.89, 160.41, 60.09, 59.98, 59.39, 53.06, 51.79, 40.25, 32.45,














Benzylamide-Val-urea-Val-NHNHBoc (198). A solution of H-Val-
NHNHBoc 206 (260 mg, 1.12 mmol, 1.2 equiv.) and DiPEA (203 µl, 1.23
mmol, 1.2 equiv.) in DCM was added to a solution of valine benzylamide
isocyanate (prepared from HCl.H-Val-NHBn (229 mg, 943 µmol, 1 equiv.) us-
ing general procedure B) in DCM. The resulting mixture was stirred for 2 hr.
The mixture was washed with 1M HCl (2×) and brine and dried over MgSO4.
Column chromatography (DCM → 5% MeOH:DCM) yielded the title compound (230 mg, 496 µmol, 53%).
LC/MS: Rt 7.08 min (linear gradient 10→ 90% MeCN + 0.1%TFA, 15 min), (ESI-MS (m/z): 464.00 (M+H)
+).
1H NMR (400 MHz, CD3OD, CDCl3): δ 7.89 (t, J = 5.7 Hz, 1H), 7.37-7.18 (m, 5H), 4.43-4.29 (m, 2H), 4.02 (d, J
= 6.5 Hz, 1H), 3.96 (d, J = 6.7 Hz, 1H), 2.19-1.91 (m, 2H), 1.44 (s, 9H), 1.00-0.83 (m, 12H). 13C NMR (100 MHz,













Benzylamide-Val-urea-Val-NHNH3Cl (199). 198 (250 mg, 600 µmol) was
stirred with 4 ml 4M HCl in dioxane for 1 hr before coevaporation with toluene
(3×), yielding the title compound which was used without purification. LC/MS:
Rt 4.87 min (linear gradient 10 → 90% MeCN + 0.1%TFA, 15 min), (ESI-MS
(m/z): 364.00 (M−Cl−)+). 1H NMR (400 MHz, DMSO): δ 9.26 (t, J = 5.9 Hz,
1H), 8.31-7.77 (m, 5H), 7.31 (d, J = 8.2 Hz, 1H), 7.18 (d, J = 9.1 Hz, 1H), 5.11
(t, J = 6.3 Hz, 1H), 4.98-4.74 (m, 1H), 2.90-2.54 (m, 2H), 1.98-1.45 (m, 12H).
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Benzylamide-Val-urea-Val-Leu-EK (184). Prepared by the general proce-
dure for azide coupling employing 199 (39 mg, 100 µmol, 1 equiv.) and
TFA.H-Leu-EK (31 mg, 110 µmol, 1.1 equiv.). Purification by column chro-
matography (DCM→ 3% MeOH:DCM) yielded the title compound (10 mg,
20 µmol, 20%). LC/MS: Rt 8.41 min (linear gradient 10 → 90% MeCN +
0.1%TFA, 15 min). 1H NMR (400 MHz, CDCl3:CD3OD): δ 7.43-7.18 (m,
5H), 4.54 (dd, J1 = 10.6, J2 = 3.1 Hz, 1H), 4.37 (dd, J1 = 36.1, J2 = 14.9 Hz, 2H), 4.04 (dd, J1 = 6.7, J2 = 4.9 Hz,
2H), 3.29 (d, J = 5.0 Hz, 1H), 2.91 (d, J = 5.1 Hz, 1H), 2.09-1.93 (m, 2H), 1.80-1.64 (m, 1H), 1.48 (s, 3H), 1.57-1.21
(m, 1H), 0.99-0.85 (m, 18H). 13C NMR (100 MHz, CDCl3:CD3OD): δ 208.39, 173.42, 173.29, 158.71, 138.24,
128.21, 127.28, 126.93, 59.28, 58.85, 58.71, 51.96, 50.41, 42.84, 39.06, 31.08, 31.05, 24.94, 22.69, 20.49, 18.74, 18.71,
17.30, 16.05. HRMS calcd. for [C27H43N4O5]









Decyl-urea-Val-NHNHBoc (200). A solution of H-Val-NHNHBoc 206 (237 mg,
1.02 mmol, 1 equiv.) and DiPEA (185 µl, 1.12 mmol, 1.1 equiv.) in DCM was added
to a solution of decyl isocyanate (prepared from decylamine (213 µl, 1.07 mmol, 1.05
equiv.) using general procedure A) in DCM. The resulting mixture was stirred for 1
hr. The mixture was washed with 1M HCl (2×) and brine and dried over MgSO4.
Column chromatography (PE→ 40% acetone:PE) yielded the title compound (250
mg, 600 µmol, 60%). LC/MS: Rt 10.23 min (linear gradient 10 → 90% MeCN + 0.1%TFA, 15 min), (ESI-MS
(m/z): 415.00 (M+H)+). 1H NMR (400 MHz, CD3OD:CDCl3): δ 6.03 (d, J = 8.8 Hz, 1H), 5.98 (t, J = 5.2 Hz,
1H), 5.56 (t, J = 5.1 Hz, 1H), 4.07 (s, 1H), 3.22-2.99 (m, 2H), 2.09-2.00 (m, 1H), 1.47 (s, 9H), 1.34-1.20 (m, 16H),
0.98 (dd, J1 = 14.5, J2 = 6.8 Hz, 6H), 0.88 (t, J = 6.8 Hz, 3H).
13C NMR (100 MHz, CD3OD, CDCl3): δ 172.75,









Decyl-urea-Val-NHNH3Cl (201). 200 (250 mg, 600 µmol) was stirred with 4 ml
4M HCl in dioxane for 1 hr before coevaporation with toluene (3×) yielded the title
compound which was used without purification. LC/MS: Rt 7.39 min (linear gradi-
ent 10→ 90% MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z): 315.00 (M−Cl−)+). 1H
NMR (400 MHz, CD3OD:CDCl3): δ 4.06 (d, J = 6.2 Hz, 1H), 3.28-3.01 (m, 2H),
2.17-2.05 (m, 1H), 1.56-1.44 (m, 2H), 1.41-1.14 (m, 14H), 0.99 (t, J = 7.1 Hz, 6H),










Decyl-urea-Val-Leu-EK (185). Prepared by the general procedure for azide cou-
pling employing 201 (53 mg, 151 µmol, 1 equiv.) and TFA.H-Leu-EK (47 mg,
166 µmol, 1.1 equiv.). Purification by column chromatography (DCM → 3%
MeOH:DCM and 10% EA:Tol.→ 30% EA:Tol.) yielded the title compound (24
mg, 53 µmol, 35%). LC/MS: Rt 11.18 min (linear gradient 10→ 90% MeCN +
0.1% TFA, 15 min). 1H NMR (400 MHz, CDCl3): δ 6.84 (d, J = 7.4 Hz, 1H),
5.56 (d, J = 8.5 Hz, 1H), 5.03 (t, J = 5.6 Hz, 1H), 4.71-4.43 (m, 1H), 4.10 (t, J
= 7.8 Hz, 1H), 3.35 (d, J = 5.0 Hz, 1H), 3.25-3.00 (m, 2H), 2.89 (d, J = 5.0 Hz, 1H), 2.10-1.85 (m, 1H), 1.52 (s,
3H), 1.73-1.36 (m, 3H), 1.40-1.16 (m, 16H), 0.97-0.80 (m, 15H). 13C NMR (100 MHz, CDCl3): δ 208.37, 173.26,
158.22, 59.27, 59.15, 52.41, 50.56, 40.75, 40.57, 39.63, 31.88, 31.40, 30.28, 30.20, 29.68, 29.57, 29.40, 29.34, 29.31,








O Boc-Val-Leu-NHNH2 (204). Methyl ester 203
207 was dissolved in 50 ml MeOH and
hydrazine hydrate (9.7 ml, 200 mmol, 20 equiv.) was added and the mixture refluxed
for 2 hr. The reaction mixture was coevaporated with toluene. (5×) and the residue
used without further purification. 1H NMR (400 MHz, CD3OD): δ 4.43 (dd, J =
9.4, 5.6 Hz, 1H), 3.86 (d, J = 7.0 Hz, 1H), 2.03 (dq, J = 13.6, 6.7 Hz, 1H), 1.91-1.49










Boc-Val-Leu2-VS (205). Prepared from 204 (344 mg, 1 mmol, 1 equiv.) and
TFA.H-Leu-VS (336 mg, 1.1 mmol, 1.1 equiv.) using the general procedure for
azide coupling. Column chromatography (Tol. → 80% EA:Tol.) yielded the
title compound (362 mg, 719 µmol, 72%). 1H NMR (400 MHz, CDCl3): δ
7.39-7.22 (m, 1H), 6.97 (d, J = 6.8 Hz, 1H), 6.85 (dd, J1 = 15.1, J2 = 5.3 Hz,
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1H), 6.61 (d, J = 15.1 Hz, 1H), 5.45 (d, J = 6.6 Hz, 1H), 4.85-4.69 (m, 1H), 4.57-4.42 (m, 1H), 3.92 (t, J = 6.7 Hz,
1H), 2.94 (s, 3H), 2.14 (dq, J1 = 13.5, J2 = 6.8 Hz, 1H), 1.76-1.39 (m, 6H), 1.45 (s, 9H), 0.97-0.91 (m, 18H).
13C
NMR (100 MHz, CDCl3): δ 172.02, 171.57, 156.30, 147.44, 129.36, 80.22, 60.69, 52.16, 47.72, 42.76, 42.71, 40.41,










Boc-Val-Leu2-EK (207). Prepared from 204 (344 mg, 1 mmol, 1 equiv.) and
TFA.H-Leu-EK (314 mg, 1.1 mmol, 1.1 equiv.) using the general procedure
for azide coupling. Column chromatography (20% EA:Tol. → 60% EA:Tol.)
yielded the title compound (437 mg, 903 µmol, 90%). 1H NMR (400 MHz,
CDCl3): δ 7.59 (d, J = 7.1 Hz, 1H), 7.44 (d, J = 6.9 Hz, 1H), 5.95 (d, J = 9.0
Hz, 1H), 4.70-4.45 (m, 2H), 4.05 (t, J = 8.5 Hz, 1H), 3.45 (d, J = 4.2 Hz, 1H),
2.87 (d, J = 5.0 Hz, 1H), 2.09-1.94 (m, 1H), 1.75-1.30 (m, 6H), 1.51 (s, 3H), 1.45
(s, 9H), 0.98-0.82 (m, 18H). 13C NMR (100 MHz, CDCl3): δ 208.57, 172.02,
















tBuO-Val-urea-Val-Leu2-VS (186). 205 (50 mg, 100 µmol, 1 equiv.)
was treated with 1:1 TFA:DCM for 30 minutes, coevaporated with
toluene (3×). The residue was dissolved in DCM and DiPEA (40
µmol, 244 µmol, 2.4 equiv.) was added and this mixture was added
to a solution of valine tert-butyl ester isocyanate (prepared from
HCl.H-Val-OtBu (23 mg, 110 µmol, 1.1 equiv.) using general pro-
cedure A). The resulting mixture was stirred for 30 minutes before
being washed with 1M HCl and sat. aq. NaHCO3 and dried over
MgSO4. Column chromatography (DCM → 1% MeOH:DCM) afforded the title compound (42 mg, 70 µmol,
70%). LC/MS: Rt 8.80 min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min).
1H NMR (400 MHz,
CDCl3/CD3OD 1/1): δ ppm 6.81 (dd, J1 = 15.13, J2 = 4.91 Hz, 1H), 6.62 (dd, J1 = 15.14, J2 = 1.36 Hz, 1H),
4.74-4.63 (m, 1H), 4.39 (t, J = 7.37, 1H), 4.04 (d, J = 5.13 Hz, 1H), 3.95 (d, J = 5.78 Hz, 1H), 2.97 (s, 3H), 2.16-
2.03 (m, 2H), 1.73-1.57 (m, 6H), 1.47 (s, 1H), 1.04-0.88 (m, 24H). 13C NMR (100 MHz, CDCl3/CD3OD): δ ppm
173.00, 172.27, 171.43, 158.72, 146.50, 128.55, 80.62, 59.40, 58.16, 51.38, 47.07, 41.18, 41.06, 39.34, 29.89, 29.78,

















HO-Val-urea-Val-Leu2-VS (187). t-Bu ester 186 (21 mg, 35 µmol) was
stirred with 2 ml TFA for 1 hr before being coevaporated with toluene
(3×) to yield the title compound quantitatively. 1H NMR (400 MHz,
CD3OD:CDCl3): δ ppm 7.94 (d, J = 8.3 Hz, 1H), 7.41 (d, J = 7.5 Hz,
1H), 6.82 (dd, J1 = 15.1, J2 = 4.8 Hz, 1H), 6.59 (dd, J1 = 15.1, J2 =
1.5 Hz, 1H), 4.78-4.64 (m, 1H), 4.45-4.31 (m, 1H), 4.22 (d, J = 4.9 Hz,
1H), 3.91 (d, J = 5.6 Hz, 1H), 2.98 (s, 3H), 2.29-2.02 (m, 2H), 1.76-
1.36 (m, 6H), 1.10-0.80 (m, 24H). 13C NMR (100 MHz, CD3OD): δ
175.91, 175.12, 174.46, 160.92, 148.35, 130.84, 61.26, 59.51, 53.42, 49.16, 43.26, 42.83, 41.44, 32.06, 31.83, 25.96,

















Benzylamide-Val-urea-Val-Leu2-VS (188). 205 (51 mg, 101 µmol,
1 equiv.) was treated with 1:1 TFA:DCM for 30 minutes, coevap-
orated with toluene (3×). The residue was dissolved in DCM and
DiPEA (37 µl, 222 µmol, 2.2 equiv.) was added and this mixture
was added to a solution of valine benzylamide isocyanate (prepared
from HCl.H-Val-NHBn (35 mg, 144 µmol, 1.4 equiv.) using general
procedure B). The resulting mixture was stirred overnight. Upon
quenching with H2O the title compound precipitated as a white
solid (15 mg, 23 µmol, 23%). LC/MS: Rt 7.88 min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min).
1H NMR (400 MHz, CDCl3:CD3OD): δ 7.37-7.15 (m, 5H), 6.83 (dd, J1 = 15.1, J2 = 5.3 Hz, 6H), 6.59 (dd, J1
= 15.1, J2 = 1.2 Hz, 6H), 4.58-4.24 (m, 4H), 4.08 (dd, J1 = 15.4, J2 = 7.1 Hz, 2H), 2.93 (s, 3H), 2.20-1.88 (m,
2H), 1.80-1.53 (m, 4H), 1.54-1.13 (m, 2H), 1.19-0.59 (m, 24H). 13C NMR (100 MHz, CDCl3:CD3OD): δ 173.14,
172.46, 172.09, 158.43, 147.20, 137.61, 128.53, 127.92, 126.89, 126.84, 126.65, 59.16, 58.76, 51.60, 47.28, 42.51,
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41.78, 41.68, 39.81, 30.97, 30.57, 24.29, 24.06, 22.07, 21.97, 21.01, 20.83, 18.53, 18.47, 17.40, 17.32. HRMS calcd.
for [C32H54N5O6S]














Decyl-urea-Val-Leu2-VS (189). 205 (50 mg, 100 µmol, 1 equiv.) was
treated with 1:1 TFA:DCM for 30 minutes, coevaporated with toluene
(3×). The residue was dissolved in DCM and DiPEA (36 µmol, 220
µmol, 2.2 equiv.) was added and this mixture was added to a solution
of decyl isocyanate (prepared from decylamine (24 mg, 160 µmol, 1.6
equiv.) using general procedure A). The resulting mixture was stirred
for 3 hr before being washed with 1M HCl (3×) and H2O (3×) and dried
over Na2SO4. Column chromatography (DCM → 2% MeOH:DCM)
afforded the title compound (25 mg, 43 µmol, 43%). LC/MS: Rt 10.91 min (linear gradient 10→ 90% MeCN +
0.1% TFA, 15 min).1H NMR (400 MHz, CD3OD): δ ppm 6.82 (dd, J1 = 15.2, J2 = 4.9 Hz, 1H), 6.66 (dd, J1 =
15.2, J2 = 1.5 Hz, 1H), 4.74-4.66 (m, 1H), 4.42 (dd, J1 = 9.6, J2 = 5.3 Hz, 1H), 3.97 (d, J = 5.8 Hz, 1H), 3.23-3.06
(m, 2H), 3.00 (s, 3H), 2.16-2.02 (m, 1H), 1.80-1.57 (m, 5H), 1.54-1.43 (m, 3H), 1.39-1.27 (m, 14H), 1.08-0.87 (m,
21H). 13C NMR (100 MHz, CD3OD): δ 175.43, 174.52, 161.13, 148.39, 130.83, 61.47, 53.45, 43.22, 42.81, 41.27,
41.06, 33.07, 31.87, 31.30, 30.76, 30.70, 30.52, 30.46, 28.02, 26.01, 25.86, 23.74, 23.47, 23.42, 21.90, 21.69, 19.85,
18.30, 14.45. HRMS calcd. for [C30H59N4O5S]
















tBuO-Val-urea-Val-Leu2-EK (190). 207 (41 mg, 85 µmol, 1 equiv.)
was treated with 1:1 TFA:DCM for 30 minutes, coevaporated with
toluene (3×). The residue was dissolved in DCM and DiPEA (31 µl,
187 µmol, 2.2 equiv.) was added and this mixture was added to a solu-
tion of valine tert-butyl ester isocyanate (prepared from HCl.H-Val-
OtBu (27 mg, 128 µmol, 1.6 equiv.) using general procedure A). The
resulting mixture was stirred overnight. The reaction mixture was
washed with 1M HCl (3×), H2O (3×) and dried over Na2SO4. Co-
lumn chromatography (DCM→ 2% MeOH:DCM) yielded the title compound (14 mg, 24 µmol, 28%). LC/MS:
Rt 9.84 min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min).
1H NMR (400 MHz, CDCl3): δ ppm
8.02 (s, 1H) 6.49 (d, J = 7.5 Hz, 1H), 6.19 (s, 1H), 4.74-4.60 (m, 1H), 4.53 (dd, J1 = 14.7, J2 = 7.4 Hz, 1H), 4.38
(dd, J1 = 9.2, J2 = 4.9 Hz, 1H), 4.25 (t, J = 8.3 Hz, 1H), 3.41 (d, J = 4.8 Hz, 1H), 2.87 (d, J = 4.8 Hz, 1H),
2.09-1.95 (m, 1H), 1.90-1.30 (m, 7H), 1.52 (s, 3H), 1.49 (s, 1H), 1.01-0.74 (m, 24H). 13C NMR (100 MHz, CDCl3):
δ ppm 173.37, 172.83, 171.92, 157.73, 81.41, 59.13, 58.85, 58.11, 52.56, 52.01, 50.32, 40.96, 39.12, 32.42, 31.96,


















HO-Val-urea-Val-Leu2-EK (191). t-Bu ester 190 (11 mg, 19 µmol) was
stirred with 1 ml TFA for 1 hr and coevaporated with toluene (3×) to
yield the title compound quantitatively. 1H NMR (400 MHz, CD3OD):
δ 4.54 (dd, J1 = 10.7, J2 = 3.0 Hz, 1H), 4.47 (dd, J1 = 8.7, J2 = 6.3 Hz,
1H), 4.20 (d, J = 4.6 Hz, 1H), 4.05 (d, J = 6.4 Hz, 1H), 3.27 (d, J = 5.1
Hz, 1H), 2.94 (d, J = 5.1 Hz, 1H), 2.24-2.12 (m, 1H), 2.10-1.97 (m, 1H),
1.82-1.26 (m, 6H), 1.48 (s, 3H), 1.18-0.58 (m, 24H). 13C NMR (100 MHz, CD3OD): δ 171.60, 61.96, 57.29, 56.33,
50.10, 49.65, 48.90, 39.10, 37.12, 29.42, 29.06, 23.26, 22.75, 20.82, 20.41, 19.27, 18.45, 16.90, 16.77, 15.26, 14.91,
14.10. HRMS calcd. for [C26H47N4O7]
















Benzylamide-Val-urea-Val-Leu2-EK (192). 207 (50 mg, 101 µmol, 1
equiv.) was treated with 1:1 TFA:DCM for 30 minutes, coevaporated
with toluene (3×). The residue was dissolved in DCM and DiPEA (37
µl, 222 µmol, 2.2 equiv.) was added and this mixture was added to
a solution of valine benzylamide isocyanate (prepared from HCl.H-
Val-NHBn (34 mg, 144 µmol, 1.4 equiv.) using general procedure B).
The resulting mixture was stirred for 3 hr. The reaction mixture was
washed with H2O (3×) and dried over Na2SO4. Column chromato-
graphy (DCM→ 4% MeOH:DCM) followed by crystallisation (DCM:PE) yielded the title compound (25 mg, 40
µmol, 40%). LC/MS: Rt 8.51 min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15 min).
1H NMR (400 MHz,
CD3OD): δ 7.35-7.18 (m, 5H), 6.57 (dd, J1 = 8.9, J2 = 6.1 Hz, 1H), 4.58-4.49 (m, 2H), 4.44 (d, J = 15.0 Hz, 1H),
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4.33 (d, J = 14.9 Hz, 1H), 4.18-4.04 (m, 2H), 3.25 (d, J = 5.0 Hz, 1H), 2.89 (d, J = 5.0 Hz, 1H), 2.05-1.88 (m, 2H),
1.77-1.24 (m, 6H), 1.48 (s, 3H), 0.99-0.83 (m, 24H). 13C NMR (100 MHz, CD3OD, CDCl3): δ 207.71, 172.54,
172.42, 172.22, 157.96, 137.61, 127.50, 126.59, 126.20, 58.39, 58.15, 58.08, 51.24, 50.56, 49.71, 42.09, 39.95, 38.11,

















Decyl-urea-Val-Leu2-EK (193). 207 (49 mg, 101 µmol, 1 equiv.) was
treated with 1:1 TFA:DCM for 30 minutes, coevaporated with toluene
(3×). The residue was dissolved in DCM and DiPEA (37 µl, 222 µmol,
2.2 equiv.) was added and this mixture was added to a solution of decyl
isocyanate (prepared from decylamine (24 µl, 121 µmol, 1.2 equiv.) using
general procedure A). The resulting mixture was stirred overnight. The re-
action mixture was washed with 1M HCl (3×), H2O (3×) and dried over
Na2SO4. Column chromatography (DCM → 2% MeOH:DCM) yielded
the title compound (16 mg, 29 µmol, 29%). LC/MS: Rt 11.30 min (linear gradient 10→ 90% MeCN+ 0.1% TFA,
15 min). 1H NMR (400 MHz, CD3OD, CDCl3): δ ppm 4.55-4.51 (m, 1H), 4.43 (dd, J1 = 8.9, J2 = 5.5 Hz, 1H),
4.03 (d, J = 6.5 Hz, 1H), 3.29 (d, J = 5.0 Hz, 1H), 3.20-2.99 (m, 2H), 2.90 (d, J = 5.0 Hz, 1H), 2.11-1.92 (m, 1H),
1.77-1.32 (m, 6H), 1.49 (s, 3H), 1.39-1.10 (m, 16H), 1.05-0.78 (m, 21H). 13C NMR (100 MHz, CDCl3:CD3OD):
δ 208.04, 172.86, 172.33, 158.66, 58.57, 58.53, 51.76, 50.85, 49.99, 40.15, 39.50, 38.69, 31.34, 30.60, 29.65, 29.60,
29.04, 29.00, 28.84, 28.75, 26.34, 24.55, 24.04, 22.54, 22.07, 22.00, 21.11, 20.28, 18.50, 17.02, 15.97, 13.25. HRMS
calcd. for [C25H47N4O7S]






H-Val-Leu-OtBu (210). Fmoc-Val-Leu-OtBu 208 (956 mg, 1.88 mmol, 1 equiv.) was dis-
solved in THF and treated with EtSH (1.4 ml, 18.8 mmol, 10 equiv.) and DBU (28 µl,
188 µmol, 0.1 equiv.) for 2 hr and coevaporated with toluene. Column chromatography
(EA:PE:MeOH 50:50:0 → 100:0:0 → 95:0:5) yielded the title compound (524 mg, 1.83
mmol, 97%). 1H NMR (400 MHz, CDCl3): δ 7.71 (d, J = 8.5 Hz, 1H), 4.57-4.42 (m,
1H), 3.27 (d, J = 4.0 Hz, 1H), 2.35-2.19 (m, 1H), 2.05 (s, 2H), 1.80-1.49 (m, 3H), 1.46 (s,
9H), 0.99 (d, J = 7.0 Hz, 3H), 0.97-0.89 (m, 6H), 0.85 (d, J = 6.9 Hz, 3H). 13C NMR (100







Fmoc-Leu2-OtBu (211). Leucine tert-butyl ester (382 mg, 2.04 mmol, 1 equiv.) was
dissolved in DCM and Fmoc-Leu-OH (757 mg, 2.14 mmol, 1.05 equiv.), HBTU (890
mg, 2.35 mmol, 1.15 equiv.) and DiPEA (759 µl, 4.59 mmol, 2.25 equiv.) were added
and the mixture was stirred for 2 hr before being concentrated. The residue was taken
up in EA and washed with 1M HCl (2×), sat. aq. NaHCO3 (4×) and brine before
drying over MgSO4. Column chromatography (Tol. → 16% EA:Tol.) afforded the
title compound (1.09 gr, 2.04 mmol, quant.). 1H NMR (400 MHz, CDCl3): δ 7.70 (d,
J = 7.5 Hz, 2H), 7.56 (t, J = 7.0 Hz, 2H), 7.40-7.29 (m, 2H), 7.23 (t, J = 7.0 Hz, 2H),
7.13 (d, J = 7.6 Hz, 1H), 7.02 (d, J = 7.9 Hz, 1H), 5.99 (d, J = 8.7 Hz, 1H), 4.49 (dd, J1 = 13.8, J2 = 7.9 Hz, 1H),
4.43-4.33 (m, 2H), 4.32-4.24 (m, 1H), 4.20-4.13 (m, 1H), 1.80-1.46 (m, 6H), 1.43 (s, 9H), 0.98-0.83 (m, 12H). 13C
NMR (100 MHz, CDCl3): δ 172.11, 171.62, 156.05, 143.65, 143.50, 140.97, 127.38, 126.79, 124.89, 119.64, 81.33,






H-Leu2-OtBu (212). Fmoc-Leu2-OtBu 211 (1.09 gr, 2.04 mmol, 1 equiv.) was dissolved in
THF and EtSH (1.5 ml, 20 mmol, 10 equiv.) and DBU (30 µL, 200 µmol, 0.1 equiv.) were
added and the mixture was stirred for 1.5 hr. before being coevaporated with toluene.
Column chromatography (EA:PE:MeOH 50:50:0 → 100:0:0 → 95:0:5) yielded the title
compound (586 mg, 1.95 mmol, 93%). 1H NMR (400 MHz, CDCl3): δ 7.71 (d, J = 8.6
Hz, 1H), 4.46 (dt, J1 = 8.7, J2 = 5.2 Hz, 1H), 3.42 (dd, J1 = 9.6, J2 = 4.2 Hz, 1H), 1.87 (s,
2H), 1.81-1.29 (m, 6H), 1.46 (s, 9H), 1.07-0.81 (m, 12H). 13C NMR (100 MHz, CDCl3):
δ 175.06, 171.77, 80.92, 53.03, 50.39, 43.69, 41.17, 27.46, 24.42, 24.28, 22.93, 22.39, 21.53,
20.95.
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Fmoc-Val-Leu2-OtBu (213). H-Leu-Leu-OtBu (212), 586 mg, 1.95 mmol,
93%), Fmoc-Val-OH (695 mg, 2.05 mmol, 1.05 equiv.), HBTU (850 mg, 2.24
mmol, 1.15 equiv.) and DiPEA (725 µl, 4.39 mmol, 2.25 equiv.) were dissolved
in DCM and stirred for 1.5 hr. before being washed with 1M HCl (2×), sat. aq.
NaHCO3 (4×) and dried over MgSO4. Column chromatography (EA:Tol. 0
→ 30%) yielded the title compound (1.15 gr, 1.85 mmol, 95%). 1H NMR (400
MHz, CDCl3): δ 7.73 (d, J = 7.5 Hz, 2H), 7.64-7.52 (m, 2H), 7.37 (dd, J1 =
9.5, J2 = 5.1 Hz, 2H), 7.30-7.22 (m, 2H), 7.15 (d, J = 8.0 Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 6.11 (d, J = 9.1 Hz,
1H), 4.66 (dd, J1 = 15.1, J2 = 7.5 Hz, 1H), 4.53 (dd, J1 = 13.5, J2 = 8.5 Hz, 1H), 4.44 (dd, J1 = 10.1, J2 = 7.3 Hz,
1H), 4.30-4.22 (m, 1H), 4.19 (t, J = 7.2 Hz, 1H), 4.12 (t, J = 8.2 Hz, 1H), 2.15-1.99 (m, 1H), 1.77-1.46 (m, 6H),
1.43 (s, 9H), 0.94 (t, J = 6.4 Hz, 6H), 0.86 (dd, J1 = 10.1, J2 = 6.2 Hz, 12H).
13C NMR (100 MHz, CDCl3): δ
171.88, 171.45, 171.35, 156.47, 143.82, 141.20, 127.60, 126.99, 125.21, 125.13, 119.86, 81.70, 67.07, 60.31, 51.58,










H-Val-Leu2-OtBu (214). Fmoc-Val-Leu-Leu-OtBu 213 (1.15 gr, 1.85 mmol, 1
equiv.) was dissolved in THF and treated with EtSH (1.37 ml, 18.5 mmol, 1 equiv.)
and DBU (28 µl, 185 µmol, 0.1 equiv.) for 1.5 hr before being concentrated and pu-
rified on column chromatography (EA:PE:MeOH 50:50:0→ 100:0:0→ 95:0:5) to
yield the title compound (672 mg, 1.68 mmol, 91%) 1H NMR (400 MHz, CDCl3):
δ 7.85 (d, J = 8.8 Hz, 3H), 7.40 (d, J = 7.7 Hz, 3H), 4.74-4.58 (m, 3H), 4.40 (dd, J
= 13.9, 7.9 Hz, 3H), 3.23 (d, J = 4.1 Hz, 3H), 2.36-2.18 (m, 3H), 1.74-1.49 (m, 6H),
1.46 (s, 9H), 0.98 (d, J = 6.9 Hz, 3H), 0.95-0.87 (m, 12H), 0.84 (d, J = 6.9 Hz, 3H).
13C NMR (100 MHz, CDCl3): δ 174.15, 171.75, 171.41, 80.93, 59.87, 51.25, 50.67, 41.00, 40.87, 30.63, 27.60,
















tBuO-Leu-Val-urea-Val-Leu-VS (216). BocValLeuVS 194 (64 mg,
164 µmol, 1 equiv.) was stirred in 1:1 TFA:DCM for 30 min. before
being coevaporated with toluene (3×). The residue was dissolved in
DCM and treated with the isocyanate of Val-Leu-OtBu (obtained
from H-Val-Leu-OtBu 210 (54 mg, 188 µmol, 1.15 equiv.) employ-
ing general procedure B) and DiPEA (60 µl, 361 µmol, 2.2 equiv.).
The mixture was stirred for 2 hr before being washed with 1M HCl
(2×) and dried over MgSO4. Column chromatography (1% MeOH:DCM 1→ 3% MeOH:DCM) yielded the title
compound (54 mg, 90 µmol, 54%). LC/MS: Rt 9.02 min (linear gradient 10→ 90% MeCN+ 0.1% TFA, 15 min).
1H NMR (400 MHz, CD3OD): δ 6.81 (dd, J1 = 15.2, J2 = 5.4 Hz, 1H), 6.68 (d, J = 15.2 Hz, 1H), 6.57-6.39 (m,
1H), 4.83-4.66 (m, 1H), 4.36 (t, J = 7.5 Hz, 1H), 4.15 (t, J = 6.5 Hz, 1H), 4.05 (t, J = 6.4 Hz, 1H), 2.98 (s, 3H),
2.04 (dq, J = 13.0, 6.5 Hz, 2H), 1.71 (td, J1 = 13.3, J2 = 6.6 Hz, 2H), 1.67-1.53 (m, 4H), 1.47 (s, 9H), 1.15-0.82 (m,
24H). 13C NMR (100 MHz, CD3OD): δ 174.66, 174.59, 173.20, 148.49, 130.97, 82.56, 60.91, 60.84, 60.00, 52.90,
49.12, 43.34, 42.84, 41.66, 32.63, 32.30, 28.27, 25.91, 25.83, 23.37, 23.29, 22.10, 22.06, 20.00, 18.54, 18.49. HRMS:
calcd. for [C29H55N4O7S]

















.H-Leu-VS (220 µmol, 1
equiv.) was transformed to its isocyanate employing general pro-
cedure A. H-Val-Leu-Leu-OtBu 214 (97 mg, 242 µmol, 1.1 equiv.)
and DiPEA (80 µl, 484 µmol, 2.2 equiv.) were dissolved in DCM
and added to the isocyanate solution and the resulting mixture was
stirred for 2 hr, washed with 1M HCl (2×) and dried over MgSO4.
Column chromatography (DCM 0→ 3% MeOH:DCM) yielded the
title compound (113 mg, 183 µmol, 83%). LC/MS: Rt 9.40 min (lin-
ear gradient 10→ 90% MeCN + 0.1% TFA, 15 min). 1H NMR (400 MHz, CDCl3 CD3OD): δ 7.93 (t, J = 7.9
Hz, 2H), 6.84 (dd, J1 = 15.1, J2 = 5.1 Hz, 1H), 6.53 (d, J = 15.1 Hz, 1H), 6.31 (d, J = 8.0 Hz, 1H), 6.02 (d, J =
8.8 Hz, 1H), 4.55-4.42 (m, 2H), 4.35 (dd, J1 = 14.5, J2 = 8.1 Hz, 1H), 4.13-4.03 (m, 1H), 2.98 (s, 3H), 2.09-1.95
(m, 1H), 1.85-1.50 (m, 9H), 1.47 (s, 9H), 1.10-0.77 (m, 24H). 13C NMR (100 MHz, CDCl3 CD3OD): δ 172.55,
172.15, 171.43, 157.68, 148.96, 127.92, 81.13, 51.14, 50.99, 48.16, 42.58, 41.69, 40.28, 40.11, 30.76, 26.96, 24.12,
23.96, 21.90, 20.96, 20.74, 18.39, 16.92. HRMS: calcd. for [C30H57N4O7S]
+ 617.39425, found 617.39466.
Competition experiments in cell lysate
HEK293T and EL4 cells were cultured on DMEM supplemented with 10% Fetal Calf Serum (FCS), 10 units/ml
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penicillin and 10 µg/ml streptomycin in a 7% CO2 humidified incubator at 37
◦C. Cells were harvested, washed
2× with PBS and permeated in digitonin lysis buffer (4× pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose,
5 mM MgCl2, 5 mM DTT, 0.025% digitonin) for 15 min. on ice and centrifuged at 16.100 rcf. for 20 min at
4◦C. The supernatant containing the cytosolic fraction was collected and the protein content was determined by
Bradford assay (Biorad). 15 µg (HEK293T) total protein per experiment in 9 µl lysis buffer was exposed to the
inhibitors (10× solution in DMSO, 1 µl) for 1 hr. at 37◦C prior to incubation with MVB003 (500 nM) for 1 hr.
at 37◦C. Reaction mixtures were boiled with Laemmli’s buffer containing β-mercaptoethanol for 3 min. before
being resolved on 12.5% SDS-PAGE. In-gel detection of fluorescently labelled proteins was performed in the wet
gel slabs directly on the Typhoon Variable Mode Imager (Amersham Biosciences) using the Cy3/Tamra settings
(λex 532 nm, λem 560 nm).
Competition experiments in living cells
1×106 HEK cells were seeded and grown overnight. 100× stock solution of inhibitor was added to 1 ml medium
and the cells were incubated for 4 hr. at 37◦C. MVB003 (100× stock solution in DMSO, 5 µM end concentration)
was added and incubated for 2 hr. at 37◦C. Cells were harvested, washed 2× with PBS and permeated in digitonin
lysis buffer (4× pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl2, 5 mM DTT, 0.025% digitonin)
for 15 min. on ice and centrifuged at 16.100 rcf. for 20 min at 4◦C. The supernatant containing the cytosolic
fraction was collected and the protein content was determined by Bradford assay (Biorad). 10 µg protein (dilution
with lysis buffer) was boiled in Laemmli’s sample buffer and resolved as described above. Coomassie Brilliant Blue
staining of the gel verified protein loading.
Fluorogenic substrate assay
26S proteasomes were purified from rabbit muscle as described. 169 To determine inhibition of purified protea-
somes, proteasome (∼ 10ng/ml) in assay buffer (50 mM Tris-HCl pH 7.5, 40 mM KCl, 2 mM EDTA, 1 mM DTT,
100 µM ATP, 50 µg/mL BSA) was incubated with inhibitors for 30 min at 37◦C followed by assay of activity
with 100 µM fluorogenic substrates Suc-LLVY-AMC (chymotrypsin-like site), Ac-RLR-AMC (trypsin-like site),
and Ac-nLPnLD-AMC (caspase-like site). Fluorescence of released AMC was measured (λe x 350 nm, λe m 430





proteasome profiling using copper-free
click reagents: a comparative study∗
5.1 Introduction
Activity-based protein profiling (ABPP) has emerged in recent years as a powerful strat-
egy to map enzyme activity in complex biological samples. Generally, an activity-based
probe (ABP) consists of an electrophilic trap that reacts covalently and irreversibly with an
enzyme active site residue, an enzyme (family) recognition element and a reporter group
(biotin, epitope tag and/or fluorophore) to assist in visualisation and/or identification of
the modified enzyme(s). 213–215 ABPP has met with considerable success in the profiling of
esterases 216,217 and proteases 218–220 and the numerous literature reports that have appeared
over the years include examples in which photo-activatable groups are used to target en-
zymes (for instance, matrix metalloproteases)148,221 that do not employ an amino acid side
chain functionality as the nucleophile in the hydrolysis of their substrates. In recent years
other enzyme families (glycosidases, 222–224 kinases) 225–227 were successfully modified using
ABPP protocols, pointing towards the general applicability of this strategy. Next to visual-
isation and identification of enzyme activities, ABPP has proven its merit in the assessment
of potency and specificity of enzyme inhibitors in cell extracts and living cells. 204,228 In
these studies, cells or cell extract has first been treated with a prospective inhibitor, for
instance designed to act against a specific member of an enzyme family, after which a
broad-spectrum (ABP) aimed at the enzyme family at large has been added to the sam-
ple to visualise remaining enzyme activities. 229 A specific class of ABPs and subject of this
Chapter are those that employ bioorthogonal chemistry as a means to introduce the visu-
∗W. A. van der Linden, N. Li, S. Hoogendoorn, M. Ruben, M. Verdoes, J. Guo, G.-J. Boons, G. A. van der
Marel, B. I. Florea, H. S. Overkleeft, Bioorg. Med. Chem. 2011, in press.
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alisation/identification tag. Inspired by the cell-surface glycoprotein engineering work of
Bertozzi and co-workers, who employed a Staudinger ligation handle to tag azide-modified
sialic acid residues,176 a protocol was developed in which the three proteasome catalytic
activities have first been modified with a pan-reactive, cell permeable inhibitor. Next, the
cells were lysed, the azides modified with a Staudinger-Bertozzi reagent and the proteins
resolved by SDS-PAGE. In this fashion proteasome active sites could be modified with
high efficiency and with relatively little background labelling.108 In a later study it was
revealed that Staudinger-Bertozzi ligation could be achieved with complete conversion of
all azides, but that a large excess of the Staudinger-Bertozzi reagent is needed.111 Cravatt
and co-workers, in a study on esterase ABPP, demonstrated that essentially the same ob-
jective could be reached by making use of copper(I)-catalyzed azide-alkyne cycloaddition
’click’ ligation. 230 Two-step ABPP is now recognized as an attractive alternative for direct
ABPP especially in cases where the tag interferes with enzyme recognition (such as where
the enzyme/enzyme family at hand is rather specific with respect to the nature of its sub-
strate/substrate analogue) or hampers bioavailability of the probe. In part for this reason
several research groups worldwide are involved in the development and application of new,
more efficient bioorthogonal ligation strategies. Two main developments in the field are
the evaluation of the Diels-Alder ligation, 231,232 with major advances especially in the use
of inverse-electron-demand Diels-Alder reactions, 233–235 and in the application of cyclooc-
tynes in copper-free, strain-promoted click ligations. 236–242 In this chapter the efficiency and
selectivity of three recently reported cyclooctyne derivatives are compared in the two-step
bioorthogonal ABPP of proteasome activities in cell extracts and in living cells, set against
Staudinger-Bertozzi ligation as the benchmark.
5.2 Results and Discussion
The panel of reagents employed in this study is depicted in Figure 5.1. The strategy is based
on previous work111 in which an azide-modified BODIPY containing proteasome probe
was employed, effectively a direct ABPP and two-step ABPP in one. After proteasome la-
belling, modification of the azide with a bioorthogonal tag can be monitored in two ways,
either by fluorescence read-out and looking for a mobility-shift of the modified proteasome
active sites or by biotin-streptavidin blotting if the bioorthogonal tag is equipped with a bio-
tin. This experimental setup allowed the observation that Staudinger-Bertozzi phosphane
154 can be used to quantitatively tag all azide-modified proteasome active sites.111 As a pos-
itive control in these studies biotin-BODIPY modified proteasome probe was employed.
For the purpose of this study azido-BODIPY-epoxomicin 50, biotin-BODIPY-epoxomicin
217,114 biotin-cyclooctyne derivatives 218 (DIBO), 242 219 (BCN) 243 and 220 (MFCO) 244
were used. Cyclooctyne derivatives 218-220 were selected for the two reasons, namely: a)
they have proven their merit in extracellular bioorthogonal ligation and b) their synthesis
has been well described.
As the first research objective (Figure 5.2) the labelling efficiency of the three strain-
induced click reagents was determined to label azide modified proteasome active sites in
cell extracts. To this end, lysates derived from human embryonic kidney (HEK293T) cells
that express the constitutive proteasome as the single proteasome particle, were treated with
azido-BODIPY-epoxomicin (50) at 5 µM final concentration. As can be seen (for instance,
Figure 5.2A lane 2) three bands are apparent after SDS-PAGE separation of the proteome
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Figure 5.1: Structures of the compounds used in this study.
content followed by fluorescence read-out obtained by scanning the wet gel slabs using a
Typhoon fluorescence scanner. Based on previous work the three bands were assigned to
the constitutive proteasome active sites, β1, β2 and β5, as indicated in Figure 5.2A.110,111
Biotin-cyclooctynes 218 (Figure 5.2A), 219 (Figure 5.2B) and 220 (Figure 5.2C) were added
to the cell extracts to final concentrations ranging from 0.5 to 100 µM and incubated at
37◦C for 1 hr. Proteasome active subunits labelled with 50 appear at a different position
on the SDS-PAGE gel than subunits in which the azide of 50 has reacted with a two-step
labelling reagent. This gel mobility shift indicates that all azides are (almost) quantitatively
modified within the mentioned concentration range for all three cyclooctyne derivatives.
The fully and bioorthogonally modified proteasome active sites now appear at a position
approximating that of proteasome active sites labelled with the dual ABPP 217 (compare





























































































































Figure 5.2: Determination of two-step label concentration for full conversion of labelled proteasome in cell lysate.
HEK293T lysates labelled with fluorescent proteasome probe 50 were incubated with indicated concentrations of
two-step labelling reagents ((A) DIBO (218), (B) BCN (219), (C) MFCO (220) and (D) Staudinger-Bertozzi (154))
for 1 hr. followed by SDS-PAGE separations of proteins and fluorescence readout of the wet gel slabs.
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In contrast, labelling with Staudinger-Bertozzi reagent 154 (Figure 5.2D) is nearing com-
pletion only at 200 µM final concentration (a value corresponding to what is observed in
previous work)111 and from this experiment it is apparent that strain-induced click ligation
is the more efficient approach at least where it concerns amounts of reagent used. Closer
perusal of the experiments involving the three click reagents reveals a marked difference
in efficiency, with ligation to dibenzylcyclooctyne derivative 218 complete at 5 µM final
concentration and ligation to the two other reagents 219 and 220 complete between 50 and
100 µM final concentration. However, streptavidin readout of the Western blot indicated
that the expected proteasome signals were overshadowed by tremendous background (Fig-
ure 5.5, page 89). This background increased proportionally with the amount of cyclooc-
tyne added. Therefore, some preliminary optimization attempts were performed, none
of which could significantly improve the signal to noise ratio of the cyclooctyne two-step
labelling (Figure 5.6, page 90).
In the next experiment the time and temperature dependency and labelling efficiency
of the panel of bioorthogonal ligation reagents was determined. In these experiments fi-
nal concentrations for all compounds were applied that are below those identified in the
first experiment as needed for full conversion (218 (0.5 µM final concentration), 219 (5
µM), 220 (5 µM) and 154 (50 µM)). As expected, labelling at 0◦C proceeded much slower
than labelling at 37◦C for all reagents (Figure 5.3). From the experiments at 37◦C it is ap-
parent that DIBO 218 is the most reactive of the series, with significant labelling after 30
minutes. Maximal labelling with compounds 219 was achieved after two hours, while com-
pounds 220 and 154 show increase in labelling up to four hours of reaction time. These
results roughly correspond to the reported reaction rates of the cyclooctynes in literature
in which DIBO and BCN have a similar reaction rate, 242,243,245 followed by MFCO244 with
the lowest reaction rate in this series. Here, it should be noted that one has to be careful in










































































































































































































































































































Figure 5.3: Time and temperature dependence of two-step labelling reaction in 50 labelled HEK293T cell lysates.
Lysates (25 µg) were incubated with two-step reagents ((A) DIBO (218), B BCN (219), C MFCO (220) and D
Staudinger-Bertozzi (154)) for indicated time and temperature followed by C/M precipitation. Proteins were
resolved by SDS-PAGE and fluorescence detected in the wet gel slabs.
In a final experiment it was established whether both activity-based probe and bioor-
thogonal tag could be applied in living cells (Figure 5.4). Surprisingly, all three the click
reagents, and indeed also the Staudinger-Bertozzi reagent, proved cell-permeable and in
all four experiments significant bioorthogonal proteasome tagging was observed. This is
apparent from the multiple bands that appear on gel as visualised by in-gel fluorescence
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detection, and in most cases also after biotin-streptavidin blotting. With respect to this
latter analysis some important differences were observed. As expected based on previous
































































Figure 5.4: Cell permeability of two-step labelling reagents 218, 219, 220 and 154. HeLa cells are incubated with
50 (5 µM) for 2 hr. followed, after washing, by 218-154 for 4 hr. After washing, cells were lysed and proteins
resolved by SDS-PAGE followed by western blotting. A. fluorescence readout and B. streptavidin blot of labelled
cell lysates. BM = biotinylated molecular weight marker. DC = dual colour molecular weight marker.
Compound 219 and to a lesser extend also compound 220 delivered proteasome bands
based on probing for a biotin moiety. The background labelling, albeit much lower than in
experiments in lysates, is much more prominent for 219 and 220 compared to Staudinger-
Bertozzi 154. Rather surprisingly, and as yet not understood, is the almost complete ab-
sence (vague bands are visible) in the experiment employing biotin-cyclooctyne 218. This
result is at odds with the clear positive bioorthogonal labelling of proteasome subunits as
visualised by fluorescence read-out.
5.3 Conclusion
In conclusion, the results in this chapter underscore previous reports on the versatility
of strain-promoted cyclooctynes in bioorthogonal chemistry, in particular with respect to
two-step activity-based protein profiling. The three reagents tested, and in particular cy-
clooctyne 218, outperform Staudinger-Bertozzi ligation reagent 154 where it comes to re-
activity and stoichiometry. At the same time, it is equally clear that neither of the reagents
is truly bioorthogonal in the sense that they modify the desired target, and nothing else.
Background labelling as observed with the cyclooctynes in general is extensive, rather more
so than observed by Staudinger-Bertozzi ligation, even though lower final concentrations
of the cyclooctynes are needed. Apparently reactions between these highly strained sys-
tems and functional groups inherent to biological samples are more prominent, whereas
the intrinsic sensitivity of the biotinylated phosphane towards oxidation, 236,246 is the main
causative for the need of large excesses of this reagent. Interestingly, all ligation reagents
proved cell permeable and a general trend observed is that bioorthogonal ligation in living
cells is much cleaner with respect to background labelling than performing this step in cell
extracts. Future research involving pull-down followed by proteomics analysis is needed to
unearth the nature of the proteins modified by the cyclooctyne reagents at functionalities
other than an azide, and possibly also the nature of these functionalities. In addition, the
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stability of the cyclooctyne reagents under physiological conditions should be studied. Re-
cently, a report came out that describes the thiol-yne reaction, a free radical addition of two
thiols to an alkyne under the influence of ultraviolet light and radical initiator. 247 Whether
this process plays a role in the background formation observed in this Chapter remains to
be determined. In a more general sense, these results also underscore the need for the devel-
opment of fast reacting, more selective bioorthogonal ligation reagents that can be used at
low concentrations, especially for application in cell extracts.
5.4 Experimental
All reagents were of commercial grade and were used as received unless indicated otherwise. Dichloromethane
(DCM) and dimethyl formamide (DMF, Biosolve) were stored on 4Åmolecular sieves. Reactions were monitored
by TLC-analysis using DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm), spray-
ing with 20% H2SO4 in ethanol or (NH4)6Mo7O24
.4H2O (25 g/L) and (NH4)4Ce(SO4)4
.2H2O (10 g/L) in 10%
sulfuric acid followed by charring at ∼150◦C or by spraying with an aqueous solution of KMnO4 (7%) and KOH
(2%). Column chromatography was performed on silica gel from Screening Devices (0.040 - 0.063 nm). HRMS
were recorded on a LTQ Orbitrap (Thermo Finnigan). 1H- and 13C-APT-NMR spectra were recorded on a Bruker
AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory. Chemical shifts are given in ppm (δ) rela-
tive to tetramethylsilane as internal standard. Coupling constants are given in Hz. All presented 13C-APT spectra
are proton decoupled. DIBO 218, 242 BCN 219, 243 Staudinger-Bertozzi reagent 154 111 and compound 217 and












O MFCO (220). 1-fluorocyclooct-2-ynecarboxylic acid (21.2
mg, 126 µmol) was coupled to biotinylated diaminotri-
ethyleneglycol 111 (60 mg, 160 µmol) by literature proce-
dure 244 to yield MFCO 220 (27 mg, 51 µmol, 41% over 2
steps). 1H NMR (400 MHz, CD3OD, mixture of diastere-
omers): δ ppm 4.52 (dd, J1 = 7.7, J2 = 4.9 Hz, 1H), 4.33 (dd, J1 = 7.8,J2 = 4.4 Hz, 1H), 3.73 - 3.54 (m, 8H), 3.47 -
3.35 (m, 4H), 3.29 - 3.15 (m, 1H), 2.95 (dd, J1 = 12.7, J2 = 4.9 Hz, 1H), 2.73 (d, J = 12.7 Hz, 1H), 2.40 - 2.21 (m,
6H), 2.18 - 1.56 (m, 9H), 1.54 - 1.41 (m, 3H). 13C NMR (100 MHz, CD3OD, mixture of diastereomers): δ ppm
176.22, 176.13, 171.03 (J = 24.9 Hz), 166.07, 110.14 (d, J = 10.3 Hz), 95.2 (J = 185.4 Hz), 88.28 (J = 31.5 Hz),
71.27, 70.61, 70.20, 63.35, 61.60, 57.02, 47.69 (J = 24.8 Hz), 41.06, 40.42, 40.30, 36.73, 35.00, 30.12, 29.78, 29.50,
26.86, 26.76, 21.07, 21.05. HRMS Calcd. for [C25H40F1N4O5S1]
+ 527.26980, found 527.26986.
Two-step labelling of fluorescently labelled proteasomes in lysate
HEK293T cells were cultured on DMEM supplemented with fetal calf serum (FCS, 10%), penicillin (10 units
mL−1), and streptomycin (10 mg mL−1) in a CO2 (5%) humidified incubator at 37
◦C. Some 15×106 HEK293T
cells were seeded on a 15 cm Petri dish and cultured overnight. 50 (5 µM final concentration, 100x DMSO stock)
or DMSO was added in 10 mL fresh medium and incubated for 2 hr. at 37◦C. The medium was removed and
the cells were harvested in cold PBS and washed (3 ×) with cold PBS before the pellet was flash frozen (N2 (l)).
The pellet was resuspended in 400 µl digitonin lysis buffer [Tris pH 7.5 (50 mM), sucrose (250 mM), MgCl2 (5
mM), dithiothreitol (DTT; 1 mM), digitonin (0.025 %)] and incubated on ice for 10 min. before spinning down
at 16100 relative centrifugal force (rcf) at 0◦C. The supernatant was collected and the protein concentration was
determined by the Bradford assay. 25 µg protein in 9 µl lysis buffer was treated with 1 µl 10× stock of two-step
labelling reagent (in DMSO for 218, 219, 220, in DMF for 154; no solubility issues were observed when dissolving
the compounds in DMSO (20 µM) or adding the DMSO stocks to lysate) or 217 and incubated for 1 hr. at 37◦C
before the reaction was stopped by chloroform/methanol precipitation. 248 The pellet was redissolved in 10 µl
2× Laemli’s sample buffer. The proteins were resolved on 12.5% SDS-PAGE gel and the fluorescently labelled
proteasome subunits visualised by scanning the wet gel slab on a Typhoon variable mode imager (Amersham
Biosciences, using the Cy3/TAMRA setting (λex 532 nm, λem 560 nm)). Proteins were electrotransferred to
polyvinylidene (PVDF) membranes. The blots were blocked with BSA (1%) in TBS-Tween 20 (0.1% Tween 20)
for 30 min. at RT, hybridized for 30 min. with streptavidin/HRP (1:10 000) in blocking buffer, washed, and
visualised with the aid of an ECL+ kit (Amersham Biosciences).
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Two-step labelling of fluorescently labelled proteasomes in living cells
HeLa cells (75.104) were seeded and grown overnight on 2 mL medium as mentioned above. The medium was
removed and replaced with 1 mL fresh medium containing 10 µl of a 100× DMSO stock of 50 or 217 (5 µM end
concentration) followed by 2 hr. incubation. The medium was removed and the cells were washed with PBS. 1 mL
fresh medium containing 10 µl of a 100× stock solution of the click reagent (in DMSO for 218, 219, 220, in DMF
for 154) was added and incubated for 4 hr., after which the cells were scrutinized under visual light microscope.
The cells were washed with PBS, harvested and washed with 3× with PBS before being lysed as described above.












































































































Figure 5.5: Western blots from the gels depicted in Figure 5.2, readout with Streptavidin-HRP and ECL+. (A)






















































































Figure 5.6: Attempt at optimization of the bioortogonality of the cyclooctyne reagents 218, 219, 220 in lysates
(25 µg protein) of 50 incubated HEK cells. (A) Fluorescence and (B) Streptavidin readout of 218 (10 µM), (C)
Fluorescence and (D) Streptavidin readout of 219 (100 µM), (E) Fluorescence and (F) Streptavidin readout of 220
(100 µM). General procedure: Lysate (25 µg in 9 µl lysis buffer) was treated with 1 µl 10× octyne in DMSO
followed by incubation for 1 hr. and chloroform/methanol precipitation (C/M). The proteins were redissolved in
10 µl 2× Laemli’s sample buffer and boiled for 3 min. before loading on SDS-PAGE gel. (G) General procedure.
(H) Incubation at 0◦C. (I) Denature lysate + sample buffer at 55◦C 15 min., load on gel. (J) No C/M (K) Lysate
+ 4× sample buffer, 100◦C 3 min. then cyclooctyne, 37◦C 1 hr., load on gel (L) DTT/iodacetamide capping.
Lysate C/M, proteins taken up in 20 µl 8M urea + 100 mM NH4HCO3, 15 min. RT, DTT (5 mM) 30 min. 37
◦C,
iodacetamide (13 mM) 30 min. RT in the dark followed by C/M, take up in 90 µl 0.1% SDS/ 50 mM Tris pH 7.4,
add cyclooctyne, 37◦C 1 hr., C/M, dissolve in 10 µl 2× SB, boil 3 min., load on gel. (M) DTT/DNTB capping. 9
µl lysate was incubated with 80 µl 9M urea for 15 min. at RT. Incubate with 0.5 µl 1M DTT for 30 min. at 55◦C.
Add 4.7 µl 1M 5,5’-dithiobis-(2-nitrobenzoic acid) in DMSO, 2 hr. RT, C/M, take up in 90 µl 0.1% SDS/ 50 mM




Basicity at P1 and P3 induces β2
selectivity in proteasome inhibitors
6.1 Introduction
The 26S proteasome is the central protein degrading machinery in the eukaryotic cell. In
eukaryotes, seven distinct proteolytic active subunits are present in the 20S proteasome.
The constitutive subunits are β1 (cleaving after acidic amino acids), β2 (cleaving after basic
amino acids) and β5 (cleaving after hydrophobic amino acids). Three immuno-subunits can
replace the constitutive catalytic subuntis and are named β1i, β2i, β5i. In cortical thymic
epithelial cells, β5t replaces β5i in so-called thymoproteasomes. 26 Amino acid preference at
the cleavage site of these subunits has been determined using fluorogenic substrate cleavage
assays.12 Selective inhibitors of the proteasome, and subunit selective proteasome inhibitors
in particular, are useful tools to determine the involvement of the proteasome in cellular
processes. A number of selective inhibitors and probes of the β1/β1i or β5/β5i which dis-
play cell permeability has been reported in literature (See Chapter 1).127,130,132,133,147 For the
β2 subunit, several selective inhibitors have been described (Figure 6.1). Using a scanning
positional library, Nazif et al. have demonstrated that the character of the P3 amino acid
side chain in an inhibitor dramatically influences specificity for the β2 subunit. Incorpo-
ration of arginine at P3 induced β2 preference and gave structures 67 and 221 (Figure 6.1)
as leads.140 In this scanning positional library, the P1 position was fixed at asparagine, but
substitution of this residue with leucine abrogated β2 selectivity of the scaffolds. The pref-
erence of the β2 subunit for basic substrates dictates the use of basic amino acid residues
in the peptide fragment of a peptide based inhibitor, which, in most cases, renders the re-
sulting inhibitor not able to cross cell membrane. Inhibitors 67 and 221 indeed suffer from






















































































Figure 6.1: Literature β2 selective inhibitors.
More recently, the synthesis of β2 selective compound 222, based on the leupeptin scaf-
fold (Ac-Leu-Leu-Arg-aldehyde), has been described.128 Overnight treatment of cells with
this inhibitor indeed reduces β2 activity in these cells. Incorporation of an azide gave ac-
tivity based probe 223 which does not significantly bind cellular targets other than β2 or
β2i. Substitution of the P3 leucine in 222 for arginine gave 68, which was indeed a more
potent and selective inhibitor for β2 than 222 in cell lysate. Inhibitor 68, however, displays
very limited cell permeability. Compound 69 shows more preference for β2 than 222 and
at the same time shows cell permeability. This inhibitor was used in cellular assays to block
the tryptic activity of the proteasome to sensitize multiple myeloma cells to antimyeloma
agents such as bortezomib and carfilzomib.128 However, compounds 222 and 69 contain
the arginine epoxyketone, which is difficult to synthesise. These difficulties might be ex-
plained by the possibility of the P1 arginine side chain to cyclise onto the epoxyketone
electrophile.
Potential cyclisation problems could be overcome by the use of phenylalanine deriva-
tives at P1 since a para-substituted phenyl side chain prevents cyclisation of the basic moiety
onto the electrophile. Basicity of the side chains could be varied, resulting in compounds
70, 224 and 225 (Figure 6.2).141 The compound with the benzyl amine side chain at P1, 70,
displays selectivity for β2. However, the concentration range in which β2 is silenced by
70 and the other subunits unaffected is rather small. Lowering the pKa of the side chains
at P1, namely by using an aniline or pyridine moiety (compound 224 and 225, respec-
tively) resulted in equipotent inhibition of β2 and β5 for 224 or even a slight preference
for β5 for 225.141 This Chapter describes the synthesis and biological evaluation of a li-
brary of proteasome inhibitors with varying basicity at both the P1 and P3 position of the
inhibitor to determine the influence on the proteasome subunit selectivity. The library
consists of analogues of 70, 224 and 225, in which the P3 position is functionalised with a
4-aminomethylphenylalanine, 4-aminophenylalanine or 4-pyridylalanine side chain and at
P1 either leucine or 4-aminomethylphenylalanine is incorporated (Figure 6.2).
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Figure 6.2: Structure of the compounds used in this study.
6.2 Results and Discussion
Retrosynthetically, compounds 226 and 229 could be made by coupling N3-Phe(4-CH2-
NHBoc)-Leu-NHNH2 to H-Leu-VS or H-Phe(4-CH2NHBoc)-VS using the azide coupling.
In a similar fashion, 227 and 230 or 228 and 231 could be prepared from N3-Phe(4-NHBoc)-
Leu-NHNH2 or N3-Ala(4-pyridine)-Leu-NHNH2, respectively. The synthesis of peptide
hydrazides 236, 241 and 245 is depicted in Scheme 6.1. Carboxylic acid 232141 was coupled
to leucine methyl ester and subsequently the Cbz protected N-terminus in 233 liberated by
hydrogenation to yield 234. Coupling to N3-Phe-OH and subsequent reaction with hy-
drazine hydrate yielded hydrazide 236. Fmoc protected amino acid 237 was coupled to
HCl.H-Leu-OMe after which the Fmoc group was removed in solution using EtSH and
DBU. 209 The resulting amine 239 was coupled to N3-Phe-OH to yield 240, which was then
treated with hydrazine hydrate to obtain 241. Hydrazide 245 was prepared from hydrazine
hydrate and methyl ester 244, the latter of which was synthesised from commercially avail-
able 242 using standard Boc protected solution phase chemistry (Scheme 6.1).
Hydrazide 236 was coupled to H-Phe(4-CH2NHBoc)-VS
141 in the azide coupling reac-
tion to yield Boc-protected inhibitor 246, which was subsequently deprotected with TFA to
yield compound 229 (Scheme 6.2). In a similar way, the five other inhibitors were prepared
using the appropriate amines and hydrazides.
Compounds 70 and 224-231 were evaluated on their proteasome inhibition capacities
in a competition assay versus MVB003 (49) in cell lysates from HEK293T and RAJI cells.
HEK cells only expresses constitutive proteasome while RAJI, a lymphoblast cell line de-
rived from Burkitt’s lymphoma, displays both constitutive and immunoproteasome (Fig-
ure 6.3). The pKa of the side chain of the amino acid at the P1 position of compounds 70
and 224-231 determines proteasome subunit selectivity. In HEK lysate, the benzylamine
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Reagents and conditions: i) HBTU (1.2 equiv.), HCl.H-Leu-OMe (1.1 equiv.), DiPEA (3.5 equiv.), DCM, 2
hr., quant. (233), 70% (238), 83% (243). ii) TFA (1.2 equiv.), MeOH, Pd/C (10 mol-%), H2, 3 hr. then sat. aq.
NaHCO3, quant. iii) N3-Phe-OH (1.2 equiv.), HBTU (1.3 equiv.), DiPEA (2.5 equiv.), DCM, 1.5-2 hr., 74% (235),
94% (240) iv) Hydrazine hydrate (60 equiv.), MeOH, o/n., quant. v) EtSH (10 equiv.), DBU (0.1 equiv.), THF, 30
min., quant. vi) (a) TFA:DCM 1:1, 30 min, quant. (b) N3-Phe-OH (1.1 equiv.), HBTU (1.1 equiv.), DiPEA (4.5
equiv.), DCM, 1.5 hr., 76%.






























Reagents and conditions: i) tBuONO (1.1 equiv.), HCl (2.8 equiv.), DMF:DCM 3:1, -30◦C, 3hr. then H-Phe(4-
CH2NHBoc)-VS, DiPEA (5 equiv.), DMF, -30
◦C→ RT o/n, 30% ii) DCM:TFA 1:1, 30 min.
residue at P1 yields β2 selective inhibitor 70 (Figure 6.3A). Inhibitors with aniline or pyri-
dine as P1 substituent, compound 224 and 225, respectively, are roughly equipotent against
β2 and β5. At physiological pH, the benzylamine side chain is presumably the only moi-
ety of the three selected side chains that is charged. These results correspond to what was
reported by Geurink.141 Basicity at the P3 position adds to β2 preference, albeit not as ab-
solute as P1 basicity, and P3 basicity in itself did not yield a β2 selective inhibitor in this
study. This result corresponds to what is observed by Nazif et al., who installed leucine
at P1 in β2 selective vinyl sulfone 67 (Figure 6.1) to yield Ac-Pro-Arg-Leu-Leu-VS, which
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displayed restored activity against β5. In this study, compound 226, with the benzylamine
at P3, displays almost equipotent β2/β5 inhibition, while 227 and 228 show about 30-fold
more potency against β5 than β2 (Figure 6.3A). Compounds 229-231 are selective β2 in-
hibitors. Double benzylamine 229 is the most potent and β2 selective compound found in
this Chapter, more selective than 70. Compounds with aniline or pyridine at P3 do show


































































































































Figure 6.3: Competition assay of compounds 70 and224-231 in cell lysate. (A) HEK293T lysate (15 µg) and
(B) RAJI lysate (10 µg) was treated with 10× DMSO stock of indicated inhibitor for 1 hr. at 37◦C. Residual
proteasome activity was labelled with MVB003 (0.5 µM end concentration) for 1 hr. at 37◦C.
The selectivity of compounds 70 and 224-231 in RAJI lysate corresponds to what is
observed in HEK lysate (Figure 6.3B versus Figure 6.3A). However, the effect of inhibitors
on β5/β5i can not be determined directly since these subunits, in this experimental setup,
appear to overlap with β1i (Figure 6.3B). In all competition experiments in cell lysate for
compounds 70 and 224-231, the activity of β1, as was measured by MVB003 labelling,
increased when activity of β2 or β5 decreased, sometimes to values up to 300% of the
DMSO treated control. This effect has been observed earlier and is not well understood
but could be a result of allosteric regulation within the proteasome.131 An upregulation
effect on β1i, similar to β1 upregulation, is likely. This potential upregulation effect on
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β1i overshadows a decrease of the β5/β5i subunit signal. In RAJI lysate, the inhibitors
with benzylamine at P1 appear to have limited preference for β2 over β2i. On the other
hand, compounds 227 and 228, with leucine at P1, show some more potency against β2i
than for β2 and this suggests that peptide sequence optimisation could yield inhibitors that
can discriminate between tryptic activities of constitutive and immunoproteasome. An
overview of quantified competition experiments is provided in Table 6.1.
Table 6.1: Apparent IC50 (µM) values calculated from semi log plots of residual proteasome activity, quantified
from gel lanes from competition assays (Figure 6.3, Figure 6.4, Figure 6.5) against inhibitor concentration. β1 is
not inhibited in lysate and not significantly inhibited in cells and therefore it was omitted in this table.
HEK lysate HEK cells RAJI lysate RAJI cells
Compound β5 β2 β5 β2 β5, β5i,
β1i
β2i β2 β5, β5i,
β1i
β2i β2
IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM)
70 5.8 0.084 >50 2.7 19 0.15 0.029 37 ∼0.5 <0.5
224 1.1 1.5 <0.5 ∼0.5 9.2 0.98 0.63 <0.5 <0.5 <0.5
225 1.5 2.5 0.98 1.8 7.3 5.5 2.0 2.0 1.9 1.2
226 0.48 0.19 5.8 17 17 0.49 0.32 10 0.56 0.46
227 0.093 2.7 <0.5 1.9 1.3 0.91 2.4 0.74 0.60 2.4
228 0.16 5.6 0.66 6.7 4.7 4.1 8.9 1.2 2.0 3.3
229 21 0.022 >50 50 ∼50 0.080 0.012 >50 18 4.4
230 2.8 0.047 >50 10 40 0.32 0.053 >50 2.2 0.69
231 5.5 0.051 >50 27 33 0.75 0.038 >50 6.4 0.80
Next, the ability of compounds 70 and 224-231 to cross cell membrane was assessed. In-
hibitors were incubated with living HEK or RAJI cells for four hours, after which remain-
ing proteasome activity was labelled with cell permeable MVB003 (Figure 6.4, Figure 6.5).
Compound 70 inhibits β2 with some selectivity, although it is not able to silence β2 at a
concentration where β5 is unaffected (Figure 6.4). Inhibitor 229, superior to 70 in selec-
tivity and potency against β2, in HEK cells inhibits only about 50% of tryptic activity at
50 µM, while 70 reaches this level already at 5 µM. Apparently, the presence of the ben-
zylamine moiety in an inhibitor reduces its capability to inhibit proteasomes inside HEK
cells (Figure 6.4). Compounds 230 and 231 also appear to have difficulties crossing the cell
membrane. Compounds 224, 225, 227 and 228, on the other hand, inhibit their target
subunits at a lower concentration than the more basic benzylamine containing compounds
(Figure 6.4). It is therefore remarkable that 70 is able to enter cells, given the large negative
effect the benzylamine moiety has on cell permeability.
Selectivity trends from the competition assay in RAJI cells (Figure 6.5) in general agree
with the selectivity trends found in the competition assay in HEK cells. One exception is
that 226 targets β2 more potently than β5 in RAJI cells, while in HEK cells this preference
is reversed. An explanation for this discrepancy can not be given. An important difference
in potency trends between RAJI and HEK cell assays is that in RAJI cells, the benzylamine
functionality hampers inhibitors less in the entrance to cells. At 0.5 µM, 70 inhibits more
than 50% of both β2 and β2i, while in HEK cells, this level is only reached at 5 µM. In
RAJI cells, 229-231 are also more active than in HEK cells. Compound 229, while not able
to fully inhibit β2 in HEK cells at 50 µM, silenced β2 in RAJI cells at 50 µM, and left about
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Figure 6.4: Competition assay in HEK293T cells. Cells (1.106) were exposed to indicated concentration of in-
hibitor for 4 hr. at 37◦C and remaining active proteasome was labelled with MVB003 (5 µM end concentration)
for 2 hr. at 37◦C. Competition assay gels were quantified, corrected for gel loading and mean remaining activity





















































































































Figure 6.5: Competition assay in RAJI cells. Cells (1.106) were exposed to indicated concentration of inhibitor
for 4 hr. at 37◦C and remaining active proteasome was labelled with MVB003 (5 µM end concentration) for 2
hr. at 37◦C. Competition assay gels were quantified, corrected for gel loading and mean remaining activity values
plotted against concentration.
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20% of β2i activity untouched. More importantly, 229 left β5 activity almost intact at this
concentration in RAJI cells. However, the combination of the signals for β5, β5i and β1i
in this experimental setup hampers the analysis of chymotryptic activity and selectivity of
this compound should be analysed using different methods.
A fluorescent activity-based probe selective for the β2 subunit has not been reported
to date. Previously, attachment of a BODIPY dye to 70 afforded a molecule that targeted
β2 and β5 simultaneously.141 Attachment of a BODIPY dye to the selective inhibitor 229
might yield a β2 selective probe. Compound 229 was reacted with a green fluorescent
BODIPY-alkyne115 in a copper(I) catalysed click reaction. For this reaction, the in situ
generation of copper(I) from CuSO4 and sodium ascorbate was avoided since this cop-
per/ascorbic acid dyad is able to oxidise benzylic amines as present in 229.141,249 Rather,
direct addition of copper(I) by the use of Cu(MeCN)4PF6 is preferred.
250 This copper(I)
catalysed ’click’ reaction afforded target molecule 247 in 36% yield after HPLC purifica-
tion (Scheme 6.3).




























Reagents and conditions: i) BODIPY-alkyne (1.5 equiv.), TBTA (1 equiv.), Cu(MeCN)4PF6 (1 equiv.), 1:1:1
H2O:tBuOH:MeCN, o/n, then EDTA (5 equiv.), 36%.
First, 247 was incubated with HEK293T or RAJI lysate for 1 hr. after which the remain-
ing proteasome activities were labelled with MVB003. Dual wavelength readout afforded si-
multaneous analysis of competition and labelling (Figure 6.6A-D). In the competition assay
in HEK lysate, at 1 µM, activity of β2 is almost completely competed away (Figure 6.6A).
From 5 µM concentration and higher, inhibition of β5 becomes visible by reduction of
MVB003 signal. Labelling of β2 becomes visible at 10 nM (Figure 6.6B) and labelling of β5
starts to become visible already at 0.5 µM. Probe 247 thus does display some selectivity for
β2 over β5 but compared to 229, this probe clearly lost specificity due to the attachment of
the BODIPY dye. Probe 247 is not able to fully label β2 before β5 is targeted. Note that in
Figure 6.6B, in the lane where no 247 is added, faint bands are visible and this is presumably
due to background fluorescence of MVB003 at this wavelength. The above trends are also
seen in RAJI lysate (Figure 6.6C). In living HEK cells, 247 reduces MVB003 labelled β2
slightly at 10 and 50 µM. This is in contrast with the effect of this compound in cell lysate,
where at 0.5 µM the β2 activity is silenced. Probe 247 thus suffers from poor cell perme-
ability. In the direct readout of the probe (Figure 6.6F), again faint bands are observed in the
lane where no 247 was added and this is again most likely background fluorescence from
MVB003. At 10 µM, labelling of β2 is observed with only faint binding to the β5 subunit
(Figure 6.6F). Interestingly, at 50 µM, β2 labelling signal from 247 is decreased with respect
to 10 µM. On the gel, a higher running fluorescent signal in the channel for compound
247 is observed (not shown). The nature of this background signal and whether this accu-
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mulation of signal is the cause for the reduction in proteasome labelling both remain to be
determined.
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00.005 0.01 0.05 0.50.1 1 5 10 50







































Figure 6.6: Analysis in cell lysate and living cells of 247. Competition in HEK293T (A) and RAJI (C) lysate.
Lysates (15 µg for HEK, 10 µg for RAJI) were incubated with indicated concentration of 247 for 1 hr. at 37◦C
followed by labelling of remaining proteasome activities by MVB003. (E) Competition assay in living HEK cells.
Cells (1.106) were incubated with 247 for 4 hr. at 37◦C followed by MVB003 for 2 hr. at 37◦C. (A, C, E) MVB003
readout, λe x 532 nm, λe m 560 nm. (B, D, F) 247 readout, λe x 488 nm, λe m 520 nm. * = background fluorescence
of MVB003.
6.3 Conclusion
The biological effect of incorporation of basicity, in the form of benzylamine, aniline and
pyridine moieties, at the P1 and P3 position of a proteasome inhibitor was studied. A
residue that is charged at physiologically pH at the P1 position of the inhibitor is most
important to get to β2 selectivity. This was illustrated by compounds 70, 224, 225, from
which only 70 displays selectivity for β2.141 Basicity at only P3 does not lead to a selec-
tive inhibitor for β2. A combination of basicity at both P1 and P3 gives inhibitors with
good selectivity for β2, illustrated by the potent and selective inhibitor 229. In RAJI lysate
it appears that compounds with benzylamine on P1 prefer β2 more than β2i and this in-
dicates that amino acid sequence optimisation of the benzylamine inhibitors may yield
compounds able to discriminate between tryptic activity of constitutive and immunopro-
teasome. The presence of charged residues in a proteasome inhibitor hampers its entry into
cells. In HEK293T cells, inhibitors 224, 225 and 227, 228 are more efficient at inhibit-
ing the proteasome than benzylamine containing compounds. Compound 229, superior
in selectivity and potency in cell lysate, poorly enters HEK cells. RAJI cells, however, are
entered more efficiently by benzylamine containing inhibitors than HEK cells. The better
cell permeability in RAJI cells could be exploited for the treatment of Burkitt’s lymphoma.
Inhibition of proteasomes in untransformed cells by a proteasome inhibitor drug leads to
side effects of this drug, and the better entry of inhibitors 229, 230, 231 in malignant cells
can reduce severity of side effects. BODIPY containing compound 247 is the first example
of a fluorescent probe that targets β2 with reasonable selectivity. However, its main usage
would be in cell lysate since this probe displays poor cell permeability.
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6.4 Experimental
All reagents were commercial grade and were used as received unless indicated otherwise. Toluene (Tol.), ethyl ac-
etate (EA), and light petroleum ether (PE) were obtained from Riedel-de Haën or Biosolve and were distilled prior
to use. Dichloromethane (DCM), dimethyl formamide (DMF), and dioxane were stored on 4 Å molecular sieves.
Tetrahydrofuran (THF) was distilled from LiAlH4 prior to use. Reactions were conducted under an argon atmo-
sphere. Reactions were monitored by TLC analysis by using DC-fertigfolien (Schleicher & Schuell, F1500, LS254)
with detection by UV absorption (254 nm), spraying with 20% H2SO4 in ethanol or (NH4)6Mo7O24
.4H2O (25
g/L) and (NH4)4Ce(SO4)4
.2H2O (10 g/L) in 10% sulfuric acid followed by charring at ∼150
◦C or by spraying
with an aqueous solution of KMnO4 (7%) and KOH (2%). Column chromatography was performed on silica gel
from Screening Devices (0.040-0.063 nm). LC/MS analysis was performed on a LCQ Advantage Max (Thermo
Finnigan) equipped with an Gemini C18 column (Phenomenex). HRMS were recorded on a LTQ Orbitrap
(Thermo Finnigan). 1H- and 13C-APT-NMR spectra were recorded on a Bruker DPX-300 (300/75 MHz) or
Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory or a Bruker DMX 600 (600/150
MHz) with cryoprobe. Chemical shifts are given in ppm (δ) relative to tetramethylsilane as an internal standard.
Coupling constants are given in Hz. All presented 13C-APT spectra are proton decoupled.
General protocol for azide couplings
The appropriate hydrazide was dissolved in 1:1 DMF:DCM (v/v) and cooled to -30◦C. tBuONO (1.1 equiv.) and
HCl (4M sln. in 1,4-dioxane, 2.8 equiv.) were added, and the mixture was stirred for 3hr. at -30◦C after which TLC
analysis (10% MeOH/DCM, v/v) showed complete consumption of the starting material. The warhead as a free
amine was added to the reaction mixture as a solution in DMF. DiPEA (5 equivalents) was added to the reaction
mixture, and this mixture was allowed to warm to RT slowly overnight. The mixture was diluted with EA and








Cbz-Phe(4-CH2NHBoc)-Leu-OMe (233). Cbz-Phe(4-CH2NHBoc)-OH 232 (214
mg, 0.5 mmol, 1 equiv.) was dissolved in DCM. HBTU (228 mg, 0.6 mmol, 1.2
equiv.), HCl.H-Leu-OMe (100 mg, 0.55 mmol, 1.1 equiv.) and DiPEA (0.29 ml, 1.75
mmol, 3.5 equiv.) were added and the mixture was stirred for 2 hr before being
concentrated. The residue was dissolved in EA and washed with 1M HCl (2×), sat
aq NaHCO3 (4×), brine and dried over MgSO4. Column chromatography (tol→ 30
EA:tol) yielded the title compound (282 mg, 508 µmol, quant.). 1H NMR (400 MHz,
CDCl3): δ ppm 7.35-7.22 (m, 5H), 7.19 - 7.04 (m, 4H), 6.81 (d, J = 6.7 Hz, 1H), 5.76
(d, J = 8.4 Hz, 1H), 5.16 - 4.94 (m, 2H), 4.69 - 4.45 (m, 2H), 4.26 - 4.11 (m, 2H), 3.67
(s, 3H), 3.13 - 2.88 (m, 2H), 1.64 - 1.47 (m, 3H), 1.44 (s, 9H), 0.94 - 0.81 (m, 6H). 13C NMR (101 MHz, CDCl3):
δ ppm 172.83, 170.76, 155.81, 137.23, 136.04, 135.30, 129.37, 128.28, 127.92, 127.70, 127.57, 79.13, 66.70, 55.73,








H-Phe(4-CH2NHBoc)-Leu-OMe (234). Cbz-Phe(4-CH2NHBoc)-Leu-OMe 233 (282
mg, 508 µmol) was dissolved in MeOH. TFA (45 µl, 607 µmol, 1.2 equiv.) was added
and the mixture was bubbled through with Ar for 20 min. 10% Pd/C was added (50
mg) and the flask was filled with an H2 atmosphere for 3 hr. The mixture was filtered
over celite and concentrated. The residue was dissolved in DCM and sat. aq. NaHCO3
and the aqueous layer was extracted with DCM (3×). The organic layers were dried
over Na2SO4 and concentrated to yield the title compound (221 mg, quant.), which was
used without further purification. 1H NMR (400 MHz, CDCl3): δ ppm 7.67 (d, J =
8.6 Hz, 1H), 7.22 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 5.11 (s, 1H), 4.61 (td, J
= 8.9, 5.0 Hz, 1H), 4.28 (d, J = 5.6 Hz, 2H), 3.72 (s, 3H), 3.61 (dd, J = 9.0, 4.0 Hz, 1H), 3.19 (dd, J = 13.7, 3.9 Hz,
1H), 2.72 (dd, J = 13.7, 9.0 Hz, 1H), 1.70 - 1.48 (m, 3H), 1.45 (s, 9H), 1.03 - 0.89 (m, 6H). 13C NMR (101 MHz,
CDCl3): δ ppm 173.91, 173.25, 155.77, 137.47, 136.49, 129.35, 127.56, 79.21, 56.06, 52.03, 50.13, 44.07, 41.22,














OMe 234 (68 mg, 161 µmol, 1 equiv.) was dissolved in DCM (5 ml) and N3-
Phe-OH (37 mg, 193 µmol, 1.2 equiv.), HBTU (79 mg, 209 µmol, 1.3 equiv.)
and DiPEA (67 µl, 403 µmol, 2.5 equiv.) were added and the mixture was
stirred for 90 min. before being washed with 1M HCl (2×), sat aq. NaHCO3
(3 ×) and dried over Na2SO4. Column chromatography (10 EA:tol → 35
EA:tol) yielded the title compound (71 mg, 119 µmol, 74%). 1H NMR (400
MHz, CDCl3): δ ppm 7.40 - 7.20 (m, 5H), 7.17 (d, J = 7.8 Hz, 2H), 7.04 (d, J = 7.9 Hz, 2H), 6.97 (d, J = 8.1 Hz,
1H), 6.34 (d, J = 7.5 Hz, 1H), 4.93 (s, 1H), 4.67 (dd, J = 14.3, 7.1 Hz, 1H), 4.51 (td, J = 8.2, 5.4 Hz, 1H), 4.26
(d, J = 5.2 Hz, 2H), 4.16 (dd, J = 8.2, 4.2 Hz, 1H), 3.70 (s, 3H), 3.24 (dd, J = 14.1, 4.1 Hz, 1H), 3.08 - 2.82 (m,
3H), 1.62 - 1.46 (m, 3H), 1.45 (s, 9H), 0.88 (d, J = 6.1 Hz, 6H). 13C NMR (101 MHz, CDCl3): δ ppm 172.71,
169.82, 168.38, 155.80, 137.63, 135.83, 135.00, 129.51, 129.42, 128.60, 127.81, 127.24, 79.36, 65.13, 54.03, 52.25,













N3-Phe-Phe(4-CH2NHBoc)-Leu-NHNH2 (236). Methyl ester 235 (71 mg,
119 µmol) was dissolved in MeOH (5 ml). Hydrazine hydrate (350 µl, 7.1
mmol, 60 equiv.) was added and the mixture was stirred o/n before being
coevaporated with tol (3×). The residue was used without further purifica-
tion. LC/MS: Rt 7.52 min (linear gradient 10→ 90% MeCN + 0.1% TFA,
15 min), (ESI-MS (m/z): 595.00 (M+H)+). 1H NMR (400 MHz, CD3OD):
δ ppm 7.26 (ddd, J = 19.9, 13.4, 7.9 Hz, 7H), 7.15 (d, J = 8.0 Hz, 2H), 4.63
(t, J = 7.2 Hz, 1H), 4.36 (dd, J = 9.0, 6.0 Hz, 1H), 4.21 (s, 2H), 4.10 (dd, J =
8.7, 5.1 Hz, 1H), 3.13 (dd, J = 13.9, 5.1 Hz, 1H), 3.06 (dd, J = 13.7, 6.5 Hz,








Fmoc-Phe(4-NHBoc)-Leu-OMe (238). Fmoc-Phe(4-NHBoc)-OH (210 mg, 418
µmol, 1 equiv.) was dissolved in DCM and HCl.H-Leu-OMe (77 mg, 460 µmol, 1.1
equiv.), HBTU (190 mg, 502 µmol, 1.2 equiv.) and DiPEA (242 µl, 1.46 mmol, 3.5
equiv.) were added and the mixture stirred for 1 hr. after which it was washed with
1M HCl (2 ×), sat. aq. NaHCO3 (4 ×) and brine and dried over MgSO4. Column
chromatography (10% acetone:PE → 20% acetone:PE) yielded the title compound
(206 mg, 294 µmol, 70%). 1H NMR (400 MHz, CDCl3): δ ppm 7.76 (d, J = 7.5 Hz,
2H), 7.54 (t, J = 6.9 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.35 - 7.20 (m, 4H), 7.11 (d, J
= 7.1 Hz, 2H), 6.54 (s, 1H), 6.29 (d, J = 6.6 Hz, 1H), 5.44 (d, J = 7.2 Hz, 1H), 4.55
(td, J = 8.4, 5.4 Hz, 1H), 4.41 (dd, J = 10.3, 7.2 Hz, 1H), 4.32 (s, 1H), 4.18 (t, J = 6.9 Hz, 1H), 3.68 (s, 3H), 3.15 -
2.94 (m, 2H), 1.65 - 1.39 (m, 3H), 1.51 (s, 9H), 0.97 - 0.78 (m, 6H). 13C NMR (101 MHz, CDCl3): δ ppm 172.74,
170.69, 155.89, 152.64, 143.67, 143.60, 141.16, 137.31, 130.58, 129.83, 127.64, 127.01, 124.98, 119.88, 118.55, 80.41,








H-Phe(4-NHBoc)-Leu-OMe (239). Fmoc-Phe(4-NHBoc)-Leu-OMe (181 mg, 294 µmol,
1 equiv.) was dissolved in THF and EtSH (220 µl, 2.94 mmol, 10 equiv.) and DBU
(one drop) were added and the mixture stirred for 30 min. After concentration, column
chromatography (50% EA:PE→ EA→ 10% MeOH:EA) yielded the title compound (120
mg, 294 µmol, quant). 1H NMR (400 MHz, CDCl3 CD3OD): δ ppm 7.35 (d, J = 7.8
Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 4.48 (t, J = 5.3 Hz, 1H), 3.71 (s, 3H), 3.68 - 3.61 (m,
1H), 3.04 (dd, J = 13.6, 4.8 Hz, 1H), 2.77 (dd, J = 13.6, 7.9 Hz, 1H), 1.66 - 1.56 (m, 3H),
1.52 (s, 9H), 1.08 - 0.81 (m, 6H). 13C NMR (101 MHz, CDCl3 CD3OD): δ ppm 173.84,
172.56, 153.26, 137.23, 130.17, 128.88, 118.11, 81.21, 55.02, 51.11, 49.95, 39.73, 39.23,










NHBoc N3-Phe-Phe(4-NHBoc)-Leu-OMe (240). H-Phe(4-NHBoc)-Leu-OMe
(120 mg, 294 µmol, 1 equiv.) was dissolved in DCM. N3-Phe-OH (82
mg, 430 µmol, 1.5 equiv.), HBTU (163 mg, 430 µmol, 1.5 equiv.) and
DiPEA (161 µl, 975 µmol, 3.3 equiv.) were added and the mixture stirred
for 2 hr. before being washed with 1M HCl (2×), sat. aq. NaHCO3 (4×)
and brine and dried over MgSO4. Column chromatography (10% EA:tol
→ 40% EA:tol) yielded the title compound (160 mg, 276 µmol, 94%). 1H
102
Basicity at P1 and P3 induces β2 selectivity in proteasome inhibitors
NMR (400 MHz, CDCl3): δ ppm 7.55 - 7.20 (m, 7H), 7.01 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.0 Hz, 1H), 6.60 (s,
1H), 6.26 (d, J = 7.9 Hz, 1H), 4.62 (dd, J = 14.3, 7.2 Hz, 1H), 4.50 (td, J = 8.3, 5.5 Hz, 1H), 4.18 (dd, J = 8.2, 4.1
Hz, 1H), 3.70 (s, 3H), 3.25 (dd, J = 14.1, 4.1 Hz, 1H), 3.02 - 2.75 (m, 3H), 1.68 - 1.37 (m, 3H), 1.51 (s, 9H), 0.88
(d, J = 6.1 Hz, 6H). 13C NMR (101 MHz, CDCl3): δ ppm 172.67, 170.14, 168.53, 152.70, 137.36, 135.86, 130.22,















OMe (160 mg, 276 µmol) was dissolved in MeOH and hydrazine hydrate (800
µl, 16.6 mmol, 60 equiv.) was added and the mixture was stirred overnight.
Coevaporation with toluene (3×) yielded the title compound which was used
without further purification. LC/MS: Rt 7.54 min (linear gradient 10→ 90%
MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z): 581.13. 1H NMR (400 MHz,
CD3OD): δ ppm 7.40 - 7.17 (m, 7H), 7.02 (d, J = 8.5 Hz, 2H), 4.61 (t, J =
7.0 Hz, 1H), 4.35 (t, J = 7.3 Hz, 1H), 4.13 (dd, J = 8.6, 4.8 Hz, 1H), 3.15 (dd,
J = 14.0, 4.7 Hz, 1H), 3.00 - 2.81 (m, 3H), 1.60 - 1.45 (m, 3H), 1.51 (s, 9H),








Boc-Ala(4-pyridine)-Leu-OMe (243). Boc-Ala(4-pyridine)-OH (133 mg, 500 µmol, 1
equiv.) was dissolved in DMF and HCl.H-Leu-OMe (92 mg, 550 µmol, 1.1 equiv.),
HBTU (228 mg, 600 µmol, 1.2 equiv.) and DiPEA (290 µl, 1.75 mmol, 3.5 equiv.) were
added and the mixture stirred for 2 hr. The mixture was diluted with EA and washed
with sat. aq. NaHCO3. The aqueous layer was extracted with DCM and the combined
organic fractions were dried over Na2SO4 and concentrated. Column chromatography
(1:1 tol:ea→ 1:2→ 4:1) yielded the title compound (164 mg, 417 µmol, 83%). 1H NMR
(400 MHz, CDCl3 CD3OD): δ ppm 8.43 (d, J = 4.4 Hz, 2H), 8.14 (d, J = 7.7 Hz, 1H),
7.29 (d, J = 5.1 Hz, 2H), 6.37 (d, J = 8.7 Hz, 1H), 4.57 - 4.49 (m, 1H), 4.49 - 4.41 (m,
1H), 3.72 (s, 3H), 3.18 (dd, J = 13.8, 5.5 Hz, 1H), 2.90 (dd, J = 13.8, 8.7 Hz, 1H), 1.77 - 1.57 (m, 3H), 1.38 (s, 9H),
0.94 (dd, J = 9.7, 6.0 Hz, 6H). 13C NMR (101 MHz, CDCl3 CD3OD): δ ppm 172.70, 171.29, 155.41, 148.08,












N3-Phe-Ala(4-pyridine)-Leu-OMe (244). Boc-Ala-(4-pyridine)-Leu-OMe (164
mg, 417 µmol) was dissolved in 1:1 DCM:TFA and stirred for 30 minutes before
being coevaporated with toluene (3 ×). In a separate flask, N3-Phe-OH (88 mg,
459 µmol, 1.1 equiv.) was dissolved in DCM and HBTU (174 mg, 459 µmol,
1.1 equiv.), DiPEA (310 µl, 1.88 mmol, 4.5 equiv.) were added. After 5 min.
of stirring, this mixture was added to the flask containing TFA salt of H- Ala(4-
pyridine)-Leu-OMe and this mixture was stirred for 1 hr. before being washed
with H2O (2 ×). Column chromatography (DCM→ 2% MeOH:DCM) yielded the title compound (148 mg, 317
µmol, 76%). 1H NMR (400 MHz, CDCl3): δ ppm 8.44 (d, J = 5.4 Hz, 2H), 7.39 - 7.10 (m, 7H), 7.00 (d, J = 5.7
Hz, 2H), 4.82 (dd, J = 14.7, 6.7 Hz, 1H), 4.62 - 4.47 (m, 1H), 4.18 (dd, J = 8.1, 4.3 Hz, 1H), 3.71 (s, 3H), 3.23 (dd,
J = 14.0, 4.2 Hz, 1H), 3.08 - 2.87 (m, 3H), 1.75 - 1.37 (m, 3H), 0.89 (d, J = 6.1 Hz, 6H). 13C NMR (101 MHz,
CDCl3): δ ppm 172.70, 169.52, 168.56, 149.45, 145.23, 135.63, 129.36, 128.56, 127.26, 124.71, 64.85, 52.85, 52.25,













N3-Phe-Ala(4-pyridine)-Leu-NHNH2 (245). Methyl ester 244 (113 mg, 242
µmol) was dissolved in MeOH and hydrazine hydrate (700 µl, 14.5 mmol,
60 equiv.) was added and the mixture was stirred o/n. Coevaporation with
toluene (3 ×) yielded the title compound which was used without further
purification. LC/MS: Rt 4.86 min (linear gradient 10→ 90% MeCN + 0.1%
TFA, 15 min), (ESI-MS (m/z): 467.20. 1H NMR (400 MHz, CD3OD): δ
ppm 8.40 (d, J = 5.7 Hz, 2H), 7.35 - 7.17 (m, 5H), 7.14 (d, J = 5.9 Hz, 2H),
4.75 (dd, J = 8.3, 5.6 Hz, 1H), 4.40 - 4.29 (m, 1H), 4.10 (dd, J = 8.3, 4.9 Hz,
1H), 3.22 - 3.05 (m, 2H), 2.92 (ddd, J = 14.0, 10.7, 8.5 Hz, 2H), 1.67 - 1.51 (m,
















N3-Phe-Phe(4-CH2NHBoc)-Leu-Leu-VS (358). Prepared follow-
ing the general procedure for azide coupling using N3-Phe-Phe(4-
CH2NHBoc)-Leu-NHNH2 (27 mg, 45 µmol) and TFA
.H-Leu-VS (50
µmol). Column chromatography (DCM→ 4% MeOH:DCM) yielded
the title compound (19 mg, 25 µmol, 56%). LC/MS: Rt 9.76 min (lin-
ear gradient 10→ 90% MeCN + 0.1% TFA, 15 min). 1H NMR (400
MHz, CD3OD): δ ppm 7.38 - 7.16 (m, 7H), 7.09 (d, J = 8.0 Hz, 2H),
6.81 (dd, J = 15.1, 5.2 Hz, 1H), 6.54 (d, J = 15.1 Hz, 1H), 4.66 (dd, J
= 9.1, 4.8 Hz, 1H), 4.62 - 4.59 (m, 1H), 4.35 (t, J = 7.2 Hz, 1H), 4.23
(s, 2H), 4.10 (dd, J = 8.8, 4.5 Hz, 1H), 3.22 - 3.11 (m, 1H), 3.05 (dd, J = 14.0, 5.6 Hz, 1H), 2.99 (s, 3H), 2.89 (ddd, J
= 27.2, 13.9, 8.4 Hz, 2H), 1.79 - 1.46 (m, 6H), 1.45 (s, 9H), 1.12 - 0.72 (m, 12H). 13C NMR (101 MHz, CD3OD):
δ ppm 172.02, 170.99, 169.39, 147.06, 137.40, 135.64, 134.44, 128.83, 128.75, 128.10, 127.03, 126.65, 64.29, 53.85,
51.71, 47.46, 43.44, 41.83, 41.73, 40.04, 37.57, 36.77, 27.61, 24.23, 24.20, 22.14, 22.06, 21.02, 20.83. HRMS calcd
for [C38H56N7O7S]
















CH2NHBoc)-Leu-Leu-VS was dissolved in 1:1 TFA:DCM and stirred
for 30 min before coevaporation with toluene (3 ×). 1H NMR (400
MHz, CD3OD): δ ppm 7.49 - 7.09 (m, 9H), 6.82 (dd, J = 15.2, 5.2 Hz,
1H), 6.63 (dd, J = 15.2, 1.5 Hz, 1H), 4.99 - 4.61 (m, 2H), 4.38 (dd, J
= 9.5, 5.4 Hz, 1H), 4.09 (s, 2H), 4.05 (dd, J = 9.1, 4.9 Hz, 1H), 3.23
- 3.08 (m, 2H), 3.00 (s, 3H), 2.98 - 2.81 (m, 2H), 1.82 - 1.43 (m, 6H),
1.13 - 0.77 (m, 12H). 13C NMR (101 MHz, CD3OD): δ ppm 172.92,
171.56, 170.18, 147.05, 138.08, 136.45, 131.50, 129.81, 129.49, 128.94,
128.68, 128.24, 126.70, 64.07, 54.24, 52.21, 47.90, 42.64, 41.83, 41.39,
40.45, 37.43, 37.13, 24.55, 24.47, 22.00, 20.61. HRMS calcd for [C33H48N7O5S]














N3-Phe-Phe(4-NHBoc)-Leu-Leu-VS (359). Prepared following the
general procedure for azide coupling using N3-Phe-Phe(4-NHBoc)-
Leu-NHNH2 241 (28 mg, 48 µmol) and TFA
.H-Leu-VS (53 µmol).
Column chromatography (DCM→ 2% MeOH:DCM) yielded the ti-
tle compound (18 mg, 24 µmol, 51%). LC/MS: Rt 9.86 min (linear
gradient 10 → 90% MeCN + 0.1% TFA, 15 min). 1H NMR (400
MHz, CDCl3/CD3OD): δ ppm 7.39 - 7.16 (m, 7H), 7.03 (d, J = 8.4
Hz, 2H), 6.77 (dd, J = 15.1, 5.1 Hz, 1H), 6.52 (dd, J = 15.1, 1.3 Hz,
1H), 4.66 - 4.60 (m, 1H), 4.57 - 4.52 (m, 1H), 4.31 (dd, J = 9.3, 5.0 Hz,
1H), 4.10 (dd, J = 8.7, 4.5 Hz, 1H), 3.14 (dd, J = 13.4, 3.7 Hz, 1H), 3.04 - 2.93 (m, 1H), 2.98 (s, 3H), 2.86 (dd, J =
14.1, 9.0 Hz, 2H), 1.71 - 1.37 (m, 6H), 1.50 (s, 9H), 1.13 - 0.74 (m, 12H). 13C NMR (101 MHz, CDCl3 CD3OD): δ
ppm 172.02, 171.17, 169.50, 153.25, 147.01, 137.51, 135.61, 129.54, 129.01, 128.73, 128.67, 128.07, 126.64, 118.27,
64.23, 54.02, 51.82, 47.46, 41.80, 41.60, 39.94, 37.58, 36.36, 27.55, 24.24, 24.16, 22.12, 21.99, 20.94, 20.73. HRMS
calcd for [C37H54N7O7S]
















NHBoc)-Leu-Leu-VS 359 was stirred with 1:1 TFA:DCM for 30 min.
and coevaporated with toluene (3×). 1H NMR (400 MHz, CD3OD):
δ ppm 7.38 (d, J = 8.4 Hz, 2H), 7.35 - 7.18 (m, 7H), 6.82 (dd, J = 15.2,
5.2 Hz, 1H), 6.63 (dd, J = 15.2, 1.5 Hz, 1H), 4.78 - 4.61 (m, 2H), 4.38
(dd, J = 9.6, 5.4 Hz, 1H), 4.06 (dd, J = 8.9, 5.0 Hz, 1H), 3.22 (dd, J
= 14.0, 4.9 Hz, 1H), 3.11 (dd, J = 14.0, 5.0 Hz, 1H), 3.00 (s, 3H), 2.99
- 2.91 (m, 1H), 2.85 (dd, J = 13.9, 8.9 Hz, 1H), 1.90 - 1.44 (m, 6H),
1.15 - 0.79 (m, 12H). 13C NMR (101 MHz, CD3OD): δ ppm 172.96,
171.37, 170.11, 147.08, 137.83, 136.41, 130.86, 130.80, 129.79, 129.47, 128.96, 128.23, 126.70, 122.37, 64.09, 53.98,


















N3-Phe-Phe(4-pyridine)-Leu-Leu-VS (228). Prepared following the
general procedure for azide coupling using N3-Phe-Phe(4-pyridine)-
Leu-NHNH2 245 (41 mg, 88 µmol) and TFA
.H-Leu-VS (97 µmol).
Column chromatography (DCM→ 4% MeOH:DCM+ 0.1% AcOH)
yielded the title compound (29 mg, 46 µmol, 53%). LC/MS: Rt 6.48
min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min). 1H
NMR (400 MHz, CD3OD): δ ppm 8.42 (d, J = 6.0 Hz, 2H), 7.39 -
7.16 (m, 7H), 6.81 (dd, J = 15.2, 5.4 Hz, 1H), 6.63 (dd, J = 15.2, 1.3
Hz, 1H), 4.78 (dd, J = 9.3, 5.0 Hz, 1H), 4.72 - 4.65 (m, 1H), 4.38 (dd, J = 9.4, 5.5 Hz, 1H), 4.09 (dd, J = 8.5, 5.3
Hz, 1H), 3.25 - 3.18 (m, 1H), 3.12 (dd, J = 14.0, 5.3 Hz, 1H), 3.00 (s, 3H), 2.98 - 2.82 (m, 2H), 1.80 - 1.42 (m,
6H), 1.07 - 0.90 (m, 12H). 13C NMR (101 MHz, CD3OD): δ ppm 174.21, 172.33, 171.52, 149.93, 148.87, 148.40,
137.73, 130.95, 130.36, 129.60, 128.09, 126.39, 65.41, 54.48, 53.60, 49.26, 43.29, 42.80, 41.93, 38.68, 38.02, 25.94,
25.85, 23.38, 23.35, 22.05. HRMS calcd for [C31H44N7O5S]















(246). Obtained by the general protocol for azide coupling
from N3-Phe-Phe(4-CH2NHBoc)-Leu-NHNH2 (45 mg, 76
µmol) and H-Phe(4-CH2NHBoc)-VS (30 mg, 84 µmol, 1.1
equiv.). Column chromatography (10% acetone:tol → 25%
acetone:tol) yielded the title compound (21 mg, 23 µmol, 30%.
LC/MS: Rt 10.04 min (linear gradient 10 → 90% MeCN +
0.1% TFA, 15 min). 1H NMR (400 MHz, CDCl3/CD3OD):
δ ppm 7.38 - 7.06 (m, 13H), 6.83 (dd, J = 15.4, 5.2 Hz, 1H),
6.60 - 6.45 (m, 2H), 4.90 - 4.77 (m, 1H), 4.62 - 4.53 (m, 1H), 4.35
- 4.26 (m, 1H), 4.26 - 4.14 (m, 4H), 4.09 (dd, J = 8.7, 4.6 Hz, 1H), 3.13 (dd, J = 14.1, 4.6 Hz, 1H), 3.05 - 2.80
(m, 7H), 1.59 - 1.49 (m, 3H), 1.45 (s, 9H), 0.93 (d, J = 6.0 Hz, 6H), 0.91 - 0.87 (m, 1H). 13C NMR (101 MHz,
CD3OD CDCl3): δ ppm 171.81, 156.29, 145.77, 137.60, 134.82, 129.75, 129.08, 129.03, 128.35, 127.39, 126.95,
79.32, 64.57, 53.86, 51.86, 50.54, 43.78, 42.17, 40.13, 38.99, 37.86, 29.35, 27.96, 24.34, 22.40, 21.19. HRMS calcd
for [C47H65N8O9S]















Boc/protected compound 246 was stirred in 1:1 TFA:DCM
for 30 minutes before being coevaporated with toluene (3× to
yield the title compound quantitatively. LC/MS: Rt 5.35 min
(linear gradient 10→ 90% MeCN + 0.1% TFA, 15 min). 1H
NMR (400 MHz, CD3OD): δ ppm 7.53 - 7.20 (m, 13H), 6.84
(dd, J = 15.2, 5.3 Hz, 1H), 6.60 (dd, J = 15.2, 1.4 Hz, 1H),
4.66 (dd, J = 9.6, 4.9 Hz, 1H), 4.33 (dd, J = 9.7, 5.0 Hz, 1H),
4.18 - 4.02 (m, 4H), 3.24 - 3.08 (m, 2H), 3.05 (d, J = 7.6 Hz,
1H), 2.96 (s, 3H), 2.98 - 2.80 (m, 3H), 1.67 - 1.55 (m, 2H), 1.54
- 1.44 (m, 1H), 1.04 - 0.85 (m, 6H). 13C NMR (101 MHz, CD3OD): δ ppm 174.26, 173.08, 171.72, 146.65, 139.57,
139.45, 137.83, 133.01, 132.95, 131.90, 131.28, 131.14, 130.33, 130.24, 130.11, 129.63, 128.09, 65.50, 65.43, 55.94,

















Prepared following the general procedure for azide coupling
using N3-Phe-Phe(4-NHBoc)-Leu-NHNH2 241 (50 mg, 86
µmol) and H-Phe(4-CH2NHBoc)-VS (95 µmol). Column
chromatography (DCM → 1.5% MeOH:DCM) yielded the
title compound (10 mg, 11 µmol, 13%). LC/MS: Rt 10.15 min
(linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min). 1H
NMR (400 MHz, CD3OD): δ ppm 7.48 - 7.17 (m, 11H), 7.11
(d, J = 8.5 Hz, 2H), 6.83 (dd, J = 15.2, 5.2 Hz, 1H), 6.55 (d, J
= 15.0 Hz, 1H), 4.85 - 4.78 (m, 1H), 4.60 (dd, J = 8.2, 6.1 Hz,
1H), 4.28 (dd, J = 8.7, 5.6 Hz, 1H), 4.18 (s, 2H), 4.13 (dd, J = 8.7, 5.0 Hz, 1H), 3.14 (dd, J = 14.0, 4.9 Hz, 1H),
3.02 (dd, J = 14.0, 6.0 Hz, 2H), 2.94 (s, 3H), 2.89 (dd, J = 14.0, 8.8 Hz, 3H), 1.51 (d, J = 4.4 Hz, 9H), 1.55 - 1.47
(m, 3H), 1.46 (s, 9H), 0.94 (d, J = 6.3 Hz, 3H), 0.89 (d, J = 6.3 Hz, 3H). 13C NMR (101 MHz, CD3OD): δ
105
Chapter 6.
ppm 174.04, 173.26, 171.66, 155.20, 146.97, 139.57, 139.53, 137.80, 136.90, 131.79, 131.70, 130.71, 130.51, 130.38,
129.61, 128.47, 128.07, 119.84, 80.79, 80.16, 65.56, 55.95, 53.72, 52.54, 44.74, 42.83, 41.68, 40.01, 38.89, 37.98,
28.79, 28.71, 25.76, 23.38, 21.99. HRMS calcd for [C46H63N8O9S]


















was stirred with 1:1 TFA:DCM for 30 min. and coevaporated
with toluene (3×). 1H NMR (400 MHz, CD3OD): δ ppm 7.51
- 7.08 (m, 13H), 6.83 (dd, J = 15.2, 5.4 Hz, 1H), 6.59 (dd, J =
15.2, 1.3 Hz, 1H), 4.88 - 4.79 (m, 1H), 4.69 (dd, J = 9.9, 4.8 Hz,
1H), 4.33 (dd, J = 9.8, 5.0 Hz, 1H), 4.09 (s, 2H), 4.08 - 3.96 (m,
1H), 3.23 (dd, J = 14.1, 4.8 Hz, 1H), 3.11 (dd, J = 14.0, 5.0 Hz,
1H), 3.05 (dd, J = 10.3, 3.0 Hz, 2H), 3.02 - 2.91 (m, 1H), 2.96 (s,
3H), 2.83 (dd, J = 14.0, 9.0 Hz, 1H), 1.72 - 1.40 (m, 3H), 0.98 (d,
J = 6.3 Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H). 13C NMR (101 MHz, CD3OD): δ ppm 174.30, 172.89, 171.64, 146.60,
139.62, 139.53, 137.81, 133.03, 132.17, 131.92, 131.31, 130.91, 130.34, 130.24, 129.64, 128.11, 123.96, 65.52, 55.62,

















Prepared following the general procedure for azide coupling
using N3-Phe-Ala(4-pyridine)-Leu-NHNH2 245 (27 mg, 58
µmol) and H-Phe(4-CH2NHBoc)-VS (64 µmol). Column
chromatography (DCM→ 6% MeOH:DCM) partially purified
the title compound (7 mg, 9 µmol, 15%, purity about 85%).
LC/MS: Rt 7.15 min (linear gradient 10→ 90% MeCN + 0.1%
TFA, 15 min). 1H NMR (400 MHz, CD3OD): δ ppm 8.40 (d, J
= 6.1 Hz, 2H), 7.47 - 7.19 (m, 11H), 6.85 (dd, J = 15.3, 5.5 Hz,
1H), 6.56 (d, J = 15.3 Hz, 1H), 4.81 (s, 1H), 4.74 (dd, J = 9.2, 5.2 Hz, 1H), 4.42 - 4.28 (m, 1H), 4.19 (s, 2H), 4.09
(dd, J = 8.4, 5.4 Hz, 1H), 3.24 - 3.05 (m, 3H), 2.94 (s, 3H), 3.02 - 2.84 (m, 3H), 1.71 - 1.47 (m, 3H), 1.45 (s, 9H),
0.97 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CD3OD): δ ppm 172.69, 170.90, 170.13,
148.54, 147.45, 145.58, 136.32, 135.57, 130.35, 129.17, 128.97, 128.21, 127.08, 126.69, 125.02, 63.99, 53.12, 52.18,



















was stirred with 1:1 TFA:DCM for 30 min. and coevaporated
with toluene (3 ×). 1H NMR (400 MHz, CD3OD): δ ppm 8.67
(d, J = 6.0 Hz, 2H), 7.79 (d, J = 6.3 Hz, 2H), 7.48 - 7.34 (m,
4H), 7.32 - 7.09 (m, 5H), 6.82 (dd, J = 15.2, 5.5 Hz, 1H), 6.58
(dd, J = 15.2, 1.4 Hz, 1H), 4.85 - 4.65 (m, 2H), 4.30 (dd, J = 9.9,
5.1 Hz, 1H), 4.19 - 4.05 (m, 1H), 4.10 (s, 2H), 3.43 (dd, J = 14.0,
5.4 Hz, 1H), 3.23 - 3.00 (m, 4H), 2.95 (s, 3H), 3.00 - 2.88 (m,
1H), 1.73 - 1.32 (m, 3H), 0.98 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CD3OD): δ
ppm 174.27, 171.64, 146.56, 143.83, 139.70, 137.62, 134.54, 133.05, 131.97, 131.34, 130.42, 130.25, 129.62, 128.82,
128.15, 65.27, 54.15, 53.76, 52.76, 44.01, 42.76, 41.87, 40.02, 38.88, 38.52, 25.88, 23.39, 21.86. HRMS calcd for
[C35H45N8O5S]
+ 689.32281, found 689.32267.
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.TFA)-VS (247). Azide 229 (3.94 mg, 4.17 µmol)
was dissolved in 1:1:1 tBuOH:H2O:MeCN (0.5 ml) and the
solution was degassed with Ar. BODIPY-alkyne 115 (2 mg, 6.3
µmol, 1.5 equiv.) and TBTA (2.2 mg, 4.17 µmol, 1 equiv.)
were added, followed by Cu(MeCN)4PF6 (1.56 mg, 4.17 µmol,
1 equiv.). The mixture was stirred overnight under an argon
atmosphere. EDTA (8.7 mg, 21 µmol, 5 equiv.) in H2O (300
µl) was added and this mixture was directly subjected to HPLC
purification (38-48% MeCN in H2O +0.1 % TFA) to afford
the product (1.85 mg, 1.49 µmol, 36%). LC/MS: Rt 6.48 min
(linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min). 1H
NMR (600 MHz, CD3OD): δ ppm 7.44-7.30 (m, 4H), 7.28-7.14
(m, 4H), 7.01 (d, J = 13.3 Hz, 7H), 6.78 (dd, J = 15.1, 5.4 Hz,
1H), 6.55 (d, J = 15.1 Hz, 1H), 6.11 (s, 2H), 5.47 (d, J = 16.2 Hz, 1H), 4.60 (d, J = 5.3 Hz, 1H), 4.34-4.28 (m, 1H),
4.11-3.96 (m, 4H), 3.28-2.84 (m, 6H), 2.92 (s, 3H), 2.79-2.67 (m, 2H), 2.44 (s, 6H), 2.40-2.31 (m, 8H), 1.86 (s, 2H),
1.64-1.28 (m, 7H), 0.99-0.85 (m, 6H). HRMS calcd for [C56H72BF2N10O5S]
+ 1045.54635, found 1045.54639.
Competition experiments in cell lysate
HEK293T or RAJI cells were cultured on DMEM supplemented with 10% Fetal Calf Serum (FCS), 10 units/ml
penicillin and 10 µg/ml streptomycin in a 7% CO2 humidified incubator at 37
◦C. Cells were harvested, washed
2× with PBS and permeated in digitonin lysis buffer (4× pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose, 5
mM MgCl2, 5 mM DTT, 0.025% digitonin) for 15 min. on ice and centrifuged at 16.100 rcf. for 20 min at 4
◦C. The
supernatant containing the cytosolic fraction was collected and the protein content was determined by Bradford
assay (Biorad). 15 µg (HEK293T) or 10 µg (RAJI) total protein per experiment was exposed to the inhibitors (10×
solution in DMSO) for 1 hr. at 37◦C prior to incubation with MVB003 (500 nM) for 1 hr. at 37◦C. Reaction
mixtures were boiled with Laemmli’s buffer containing β-mercaptoethanol for 3 min. before being resolved on
12.5% SDS-PAGE. In-gel detection of fluorescently labelled proteins was performed in the wet gel slabs directly
on the Typhoon Variable Mode Imager (Amersham Biosciences) using the Cy3/Tamra settings (λex 532 nm, λem
560 nm) for MVB003 or Cy2 settings (λex 488 nm, λem 520 nm) for 247.
Competition experiments in living cells
1×106 HEK293T or RAJI cells were seeded and grown overnight. 100× stock solution of inhibitor was added
to 1 ml medium and the cells were incubated for 4 hr. at 37◦C. MVB003 (100× stock solution in DMSO, 5 µM
end concentration) was added and incubated for 2 hr. at 37◦C. Cells were harvested, washed 2× with PBS and
permeated in digitonin lysis buffer (4× pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl2, 5
mM DTT, 0.025% digitonin) for 15 min. on ice and centrifuged at 16.100 rcf. for 20 min at 4◦C. The supernatant
containing the cytosolic fraction was collected and the protein content was determined by Bradford assay (Biorad).
10 µg protein (dilution with lysis buffer) was boiled in Laemmli’s sample buffer and resolved as described above.





Summary and Future Prospects
This thesis aims at finding proteasome inhibitors with unique characteristics and focuses
on subunit selectivity. In Chapter 1, an overview of proteasome inhibitors has been
provided, detailing both those found in nature and several originating from synthetic ef-
forts. While proteasome-selective inhibition can be achieved with the natural product epox-
omicin, among others, a full panel of subunit selective and cell-permeable inhibitors is not
yet available. In particular, the discrimination of an inhibitor between a constitutive sub-
unit and its immune-counterpart is a remaining challenge. Subunit selective inhibitors can
greatly aid the determination of the role of a specific subunit in a biological process, for ex-
ample the generation of peptides that are presented on the MHC class-I receptor. Subunit
selective inhibitors can also help in determining the ideal proteasome inhibition profile for
clinically used proteasome inhibitors targeted against various cancers. This is illustrated by
the finding that while β5 inhibition is essential for cytotoxicity against various cancer cell
lines, pure β5 inhibition is very often not enough to bring about the cytotoxic effect and
partial co-inhibition of β1 or β2 is also necessary.127,128
As has been described in Chapter 2, the nature of the electrophilic trap in three in-
hibitors selective for β5/β5i influences the potency and proteasome subunit selectivity
pattern. Epoxyketone YU101 (71) shows preference for β5/β5i but this compound can
also target β1 and β2 at concentrations were full β5 inhibition was reached. Vinyl sulfone
analogue YU101-VS (82) displays more selective β5 inhibition than epoxyketone 71. Carfil-
zomib (52) preferentially targets the β5/β5i subunits and displays a slight bias against β5i.
The vinyl sulfone analogue of carfilzomib, PR171-VS (83), in contrast, is equipotent against
β5 and β5i. Vinyl sulfone 83 is also more selective for β5/β5i over the other active subunits
than carfilzomib (52). Epoxyketone PR957 (81) is selective for β5i over the other subunits,




In an attempt to discover more electrophiles able to target the proteasome, ten Michael
acceptors have been synthesised as described in Chapter 3. However, these electrophilic
traps, when coupled to appropriate peptide fragments, do not potently bind the protea-
some. This is remarkable, considering the breadth of range of electrophiles able to potently
bind the proteasome. Two azide containing peptide Michael acceptors from this library
were incubated in HEK293T and RAW264.7 cells. The cellular targets of these compounds
were determined by introduction of a biotin with the Staudinger-Bertozzi ligation, pull-
down of biotin-containing protein and analysis by LC/MS. Surprisingly, catalytically ac-
tive proteasomal subunits were pulled out, indicating these two compounds do inhibit the
proteasome, although with low potency. Along with the proteasomal subunits, several
cathepsins were also identified and this encourages further screening of the compounds
described in Chapter 3 for their ability to inhibit cysteine protease family members.
Chapter 4 describes the effect of incorporation of the valine-urea-valine motif, present
in syringolin A, into peptoid vinyl sulfone and epoxyketone inhibitors. A dramatic dif-
ference in subunit preference was found when the distance between ureido linkage and
electrophile was changed. Tripeptide 182 (Figure 7.1) might well be the most potent β1
inhibitor in living cells reported to date. Tetrapeptides 190 and 192, on the other hand,
prefer β5 more. Compound 190 and 192 also potently inhibit the proteasome in cells, and































































Figure 7.1: Ureido linkage containing proteasome inhibitors. Urea moiety after P2 (A) yields β1 selective com-
pounds 182 and 216. Urea moiety after P3 (B) yields β5 preferring inhibitors 190 and 192.
An immunoproteasome specific inhibitor is a great asset to the biological community
since it can be used to determine the role of the immunoproteasome in various processes.
The immunoproteasome may be a tumour marker and a immunoproteasome selective fluo-
rescent imaging probe can be very valuable as a tool for cancer screening.136 Compounds
182 and 216 show some preference for β1i over β1. In an attempt to obtain β1i selective
activity based probes, the tBu ester in 216 and 182 was replaced by a para-azidomethylene
benzylamide to lead to compounds 254 and 255, respectively (Scheme 7.1). The epoxyke-
tone version of 254, compound 256, was also synthesised.
Coupling 4-(azidomethyl)-benzylamine251 to Boc-Val-OH and Boc-Leu-OH yielded
amides 248 and 249 (Scheme 7.1). Boc protected compound 249 was deprotected with
HCl and coupled to Boc-Val-OH to yield dipeptide 250. The Boc group in 250 and dipep-
tide vinyl sulfone Boc-Val-Leu-VS (194) were removed with HCl. The amine group from
HCl.H-Val-Leu-VS was transformed to its isocyanate and reacted with dipeptide 251 to
110
Summary and Future Prospects












































































































Reagents and conditions: i) Boc-Leu-OH or Boc-Val-OH (1.1 equiv.), HBTU (1.2 equiv.), DiPEA (2.5 equiv.),
DCM, 59% (248), 48% (249). ii) 4 M HCl/dioxane, 1 hr. quant. iii) (a) TFA:DCM 1:1, 30 min, quant. (b) Boc-
Val-OH (1.1 equiv.), HBTU (1.15 equiv.), DiPEA (3.5 equiv.), DMF, 1 hr., 70%. iv) Phosgene (2 equiv.), DCM:sat.
aq. NaHCO3, 10 min., 0
◦C, then H-Val-NHNHBoc (1.1 equiv.), DCM, 57% (252), 76% (253). v) First HCl.H-
Val-Leu-VS (1.28 equiv.), phosgene (2 equiv.), DCM:sat. aq. NaHCO3, 10 min., 0
◦C, then 251 (1 equiv.), DiPEA
(2 equiv.), DCM, 30% vi) tBuONO (1.1 equiv.), HCl (1.8 equiv.), DMF:EA 3:1, -30◦C, 3hr. then H-Leu-EK (1.1
equiv.), DiPEA (5 equiv.), DMF, -30◦C→ RT o/n, 41% (255), 53% (256).
yield 254. Compound 248 was treated with HCl and transformed to its isocyanate counter-
part before reaction with H-Val-NHNHBoc (202) to yield protected hydrazide 252. Pro-
tected hydrazide 253 was synthesised from the isocyanate of 251 and H-Val-NHNHBoc
(202). Boc-hydrazides 252 and 253 were deprotected and coupled to leucine epoxyketone
to yield tripeptide 255 and tetrapeptide 256 in the azide coupling reaction.
To assess the subunit selectivity of probes 254, 255 and 256, these compounds were used
in a fluorogenic substrate hydrolysis assay with purified proteasome. Next, 3T3 cells were
incubated with or without interferon-γ for 48 hours to induce the immunoproteasome,
after which the cells were incubated with the three probes for 2 hr. The cells were harvested,
lysed and remaining proteasome activities labelled with MVB003 (49, 0.5 µM). The results
are summarised in Table 7.1A and B.
The fluorogenic peptide assay showed that 254 is not active against constitutive or im-
munoproteasome (Table 7.1A). This is in contrast to the competition assay, where 254
appears to inhibit β1i and β2i, although not potently (Table 7.1B). A big difference be-
tween MVB003 competition and fluorogenic substrate assay was also observed for 255.
This compound has almost the same potency for β1 and for β1i and its selectivity over
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Table 7.1: Apparent IC50 (µM) values calculated from semi log plots of residual proteasome activity against
inhibitor concentration. (A) Fluorogenic substrate assay and (B) Competition assay in 3T3 cells versus MVB003.
Fluorogenic peptide assay Quantified competition assay
β1 β2 β5 β1i β2i β5i β1 β2 β5 β1i β2i β5/β5i
26S proteasome Immunoproteasome - INF-γ + INF-γ
Cmp IC50 (µM) A IC50 (µM) A IC50 (µM) B IC50 (µM) B
254 N.I. N.I. N.I. >500 N.I. >500 N.I. N.I. N.I. 11 22 >50
255 0.48 2.7 37 0.40 31 5.7 0.95 N.I. 9.5 0.10 N.I. >10
256 135 N.I. >500 104 >500 300 >10 N.I. N.I. 0.27 ≫10 N.I.
(A) Constitutive proteasomes purified from rabbit muscles or immunoproteasomes, purified from rabbit spleens,
were incubated with different concentrations of inhibitors for 30 min. at 37◦C followed by measuring remaining
activity with fluorogenic peptides (Suc-LLVY-AMC, β5(i), Ac-LPnLD-AMC, β1(i), Ac-RLR-AMC β2(i)) or (B)
3T3 cells were grown for 48 hr. with or without 100 units interferon-γ and then incubated 2 hr. with inhibitor (254
0.05-50 µM, 255 0.005-5 µM, 256 0.01-10 µM). After cell harvest and lysis, residual proteasome activity readout
with MVB003 (0.5 µM). band intensities from each lane of competition assay gels (not shown) were quantified and
used as input. N.I. no inhibition.
β2/β2i and β5/β5i is only about five fold in the fluorogenic substrate assay (Table 7.1A).
In the competition assay this compound has almost tenfold preference for β1i over β1. Te-
trapeptide epoxyketone 256 shows low potency and subunit preference in the fluorogenic
peptide assay, whereas the competition assay identified β1i as the only target inhibited with
submicromolar potency. In a preliminary study to more directly analyze the specificity of
compounds 254, 255 and 256, cell extracts from the inhibitor treated interferon-γ induced
and uninduced 3T3 cells were labelled with biotin by means of the Staudinger-Bertozzi liga-
tion (200 µM 154 for 1 hr.). Streptavidin-HRP readout of the Western blots revealed probe
254 labels β1 and β1i at a concentration of 5 µM and higher, 255 labels both β1 and β1i
from 10 nM and higher and bands for β1 and β1i appeared at 0.5 µM and higher concen-
trations for 256. Thus, none of the three inhibitors are selective for β1i over β1 (data not
shown).
The selectivity and potency of epoxyketone probes 255 and 256 for β1i may be im-
proved by application of previous optimisation efforts from literature.13,130,131,135 First, the
bulky silyl ether at P1’ as found in β1i preferring inhibitor 61 (Figure 1.16, page 18) can
be introduced to have more discrimination between β1 and β1i (Figure 7.2A).135 Next, ac-
tivity towards β5 may be reduced by using smaller residues at the pseudo-N-terminus of
the molecule, for example the use of glycine at P4 instead of leucine or an alkyl chain in-
stead of the bulky aromatic group.131 Introduction of norleucine at P2 and proline at P3
may reduce β5 inhibition even more.13,131 The ureido linkage induces chain reversal in a
peptide and thus the orientation of amino acid residues at P3 and P4 may be unfavourable.
Although a D-amino acid scan for the two amino acids flanking the ureido linkage in sy-
ringolin A showed that the L-configuration yields the most active syringolin,194 D-amino
acids at P3 or P4 of peptoid epoxyketone analogues may give different results because of
the sutructural differences between syringolin A and linear peptoid inhibitors.
Amino acid sequence alignment and modelling studies of the constitutive proteasome
and immunoproteasome indicated that the β1i S1 pocket is more hydrophobic and con-
stricted than β1 S1 pocket. 5,11,252 Commonly, Leu or Asp has been used as P1 residue in
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inhibitors selective for β1. Use of a large acidic P1 residue could abrogate β1i inhibition
while leaving β1 inhibition unhampered. Candidate P1 residues for β1 selectivity are glu-













































Figure 7.2: (A) Potential optimisation of β1i immunoproteasome probes. (B) Potential probes with selectivity
for β1 over β1i.
The preference for existing β5 selective inhibitors may be increased further by integrat-
ing the ureido linkage in their design. Hybridizing fluorinated peptide 77147 and tetrapep-
tide epoxyketones 190 and 192 (Figure 7.1B) yields potential β5 selective compounds 257
or 258 (Figure 7.3). The incorporation of the ureido linkage in NC005 (259, Figure 7.3)
can be accomplished by transforming commercially available 2-naphthylmethyleneamine
into its isocyanate and reaction with H-Phe-Tyr-Leu-EK, an intermediate in the synthesis
of NC005,133 to yield 260. Then, the use of pentafluorophenylalanine at P2 yields the

































































Figure 7.3: Combining structural elements favourable for β5 selective inhibition.
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Previously, N3-Phe-Leu2-Phe(4-CH2NH2)-VS (70) was synthesised, which appears to be
a cell permeable compound with reasonable selectivity for β2.141 Chapter 6 has described
the synthesis of a focused library of peptide vinyl sulfones with a basic residue at P1 and/or
P3. Depending on the pKa of the P1 residue and to a lesser extent the P3 residue, selectivity














Figure 7.4: Structure of 229.
Compound 229, with both at P1 and
P3 the alanine-4-benzylamine residue (Fig-
ure 7.4), is a much more β2 selective in-
hibitor than 70 in cell lysate. However, its
entry into cells is much less efficient than
70, probably due to the presence of a sec-
ond benzyl amine. Interestingly, in RAJI
cells, β2 was much more inhibited by 229
than in HEK293T cells. Recently, other compounds with β2 selectivity have been pub-
lished which are based on arginine epoxyketone. Of these inhibitors, 69 (Figure 7.5) showed
β2 selectivity and cell permeability,128 and this is in agreement with what is found for 262






























Figure 7.5: Improved β2 selective proteasome inhibitors from literature.
β2 inhibition. A powerful strategy for amino acid sequence optimisation of an inhibitor is
the synthesis of positional scanning libraries containing both natural and unnatural amino
acids. A requirement of this strategy is solid phase peptide synthesis of the library, and this
can be achieved by attaching the benzylamine side chain to a resin. To facilitate the attach-
ment of the alanine-4-benzylamine vinyl sulfone on resin, amine 263 was protected with
FmocCl to yield 264, which was deprotected with HCl to yield 265 (Scheme 7.2). Wang
resin was activated with p-nitrophenyl chloroformate to give resin 266. 253 This resin was
allowed to react with 265 in the presence of base to yield carbamate resin 267. Resin loading
was about 50% of theoretical maximum loading. Next, standard Fmoc-based solid phase
peptide chemistry led to the formation of resin-bound peptide 268. Unfortunately, during
the SPPS, accumulation of side products on the resin occurred, mainly due to esterification
of activated amino acids with Wang-hydroxyls. Before the final product (269) was liberated
from resin, saponification of the ester side products was attempted. However, many side
products were released when the resin was subjected to strong acidic cleavage. Thus, before
this strategy can be applied for the synthesis of libraries of β2 selective candidates, resin
loading should be optimised and subsequently, unreacted immobilized hydroxyl functions
should be capped.
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R1 = H, R2 = Boc
R1 = Fmoc, R2 = Boc

































Reagents and conditions: i) Fmoc-Cl (1.1 equiv.), DiPEA (1.5 equiv.), EA:DMF 20:1, 0◦C, 63%. ii) 4M HCl/-
dioxane, 1 hr., quant. iii) p-nitrophenylchloroformate (2 equiv.), N-methylmorpholine (2 equiv.), DCM, 0◦→ RT
o/n. iv) 265 (2 equiv.), HOBt (3 equiv.), DiPEA (6 equiv.), DMF, RT, 24 hr., 50% theoretical loading. v) SPPS vi)
(a) sat. LiOH in 1:1 THF:H2O, 2 hr. (b) 95% TFA/H2O, 1.5 hr.




























































Compound 229 displays very selective β2 inhibition but a lack of cell permeability ren-
ders this compound unsuitable for in vivo studies. Transiently protecting the benzyl amines
on 229 may improve cell permeability characteristics. This can be done by protecting the
amines in 229 in the form of a self-immolative disulfide carbamate (272, Scheme 7.3). 254–256
The cytosol of a cell contains high concentrations of glutathione and these free thiols are
able to reduce the disulfide bridges in 272, releasing the active inhibitor 229. One very
important requirement is that prodrug 272, or the form in which one of the two protecting
groups has been released, does not inhibit any proteasomal activities. Therefore, the large
adamantyl group is chosen, since the bulky adamantyl group may increase cell-permeability
and hamper proteasomal recognition due to steric hindrance. The disulfide linker can be
synthesised by reacting 1-adamantyl disulfide (270) 257 with β-mercaptoethanol, followed
by conversion of the alcohol to activated carbonate 271, 255 which can be used to install the
carbamate onto 229 to give bisprotected 272 (Scheme 7.3).
Loidl. et al. have demonstrated that a bivalent inhibitor, which contains two tripeptide
aldehydes separated by a PEG-spacer, displays a 100-fold increase in potency with respect to
its mono-aldehyde counterpart.139 Depending on the amino acids in the tripeptide(s), these
molecules potently inhibit the β2, β5 or both β2 and β5 subunits of the proteasome. The
synergy of proteasome inhibition displayed by two appropriately spaced electrophiles can
be applied to yield proteasome inhibitors with unique subunit selectivity. The subunits of
the 20S proteasome have characteristic intersubunit distances (Figure 7.6A) and a bivalent
inhibitor of appropriate length can inhibit only a limited number of subunits with this
synergy and thus potency.11,139 Furthermore, the profound increase in potency may only
be induced by the unique shape of the proteasome. This may lower the concentration of
inhibitor necessary to reach the desired inhibitory effect on the proteasome and this lower
inhibitor concentration should attenuate the inhibition of off-targets.
Bivalent inhibitors of the proteasome can in theory be mimicked by two single protea-
some inhibitors which show affinity for each other. A single agent should not be a very
A
C
Å  β1  β2  β5  
β1  29 27 63 
β2  49 65 63 

























































Figure 7.6: (A) Intersubunit distance of the proteasome. In grey are intersubunit distances within one β-ring (B)
Supramolecular binding pair. (C) Potential supramolecular proteasome inhibitors and supramolecular spacer.
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potent proteasome inhibitor, until a second, complementary proteasome inhibitor is intro-
duced, which allows spatial arrangement in the proteasome to induce synergy in inhibition
analogous to the work of Loidl et al.139 In supramolecular polymer chemistry, quadruple
hydrogen bonding templates are used that form dimers with each other with great affin-
ity (Figure 7.6B). 258,259 In this work, a chosen pair of hydrogen bonding templates was
modified to allow attachment to proteasome inhibitors at their N-termini. A spacer of
different lengths was incorporated between electrophile and N-terminal cap (Figure 7.6C).
This should tune the length of the inhibitor pair and determine in between which pro-
teasome subunits this inhibitor system may work synergistically (Figure 7.6A). A pair of
inhibitors both containing a spacer of five aminohexanoic acid moieties should be able to
span about the same distance as the PEG-bisaldehydes from Loidl et al.139 A reversible
covalent warhead was used to allow the molecule to arrange itself in the most optimal spa-
tial configuration in the proteasome. The synthetically convenient ketofuran warhead was
chosen, which yields inhibitors of low potency. 88 The desired synergistic enhancement of
proteasome inhibition by hydrogen bonding may also be induced by a system in which
the distance between the electrophiles of two proteasome inhibitors, containing a hydro-
gen bonding template, is managed by a separate entity that contains the complementary
hydrogen bonding template separated by a spacer (Figure 7.6C). The decorated spacer, in
itself potentially biologically inert, could enhance the potency of its complementary pro-
teasome inhibitor. This concept should have significant pharmacological benefits since the
concentration of inhibitor necessary to reach a certain degree of proteasome inhibition can
be lowered by addition of an inert molecule.
Scheme 7.4: Synthesis of quadruple hydrogen binding templates and PEG-dimer 283.








































































Reagents and conditions: i) tert-butyl 6-amino-6-oxohexanoate (1.2 equiv.),Cs2CO3 (1.4 equiv.), Xantphos (8
mol-%) and Pd2dba3 (4 mol-%), dioxane, microwave 150
◦C, 20 min., 70%. ii) TFA, 1 hr., quant. iii) HBTU
(1.1 equiv.), DIPEA (2.2 or 3.3 equiv.), propargylamine (2 equiv.), DMF or DCM, 1 hr., 99% (277), 54% (282).
iv) HCl, MeOH, reflux, o/n, then sat. aq. NaHCO3, 84%. v) pyridine-2-carbonyl azide (1.3 equiv.), toluene,
100◦C, 2 hr. then 279, 100◦C, o/n, 92%. vi) NaOH (1 equiv.), THF/H2O 1:1, 2 hr., 71%. vii) 282 ( 2.2 equiv.),
tetraethyleneglycol diazide (1 equiv.), NaAsc (2.2 equiv.), CuSO4 (0.44 equiv.), tBuOH:MeCN:H2O, o/n, 46%
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The synthesis of naphthyridine template commenced with a Pd-catalyzed amidation260
using chloride 273 259 and tert-butyl 6-amino-6-oxohexanoate 274 to yield 275 in 70% yield
(Scheme 7.4). The tert-butyl protecting group in 275 was removed by TFA to yield 276
quantitatively as a mono-TFA salt. The complementary template synthesis commenced
with esterification of 6-aminopicolinic acid in acidic MeOH, followed by neutralization, to
yield methyl ester 279 in 84% yield. The ureido-linkage was introduced by Curtius rear-
rangement of pyridine-2-carbonyl azide, 261 followed by addition of 279 and additional heat-
ing to yield urea 280 in 92% yield. Saponification yielded 281, which was coupled to propar-
gylamine and subsequently used in a CuI-catalyzed click reaction with tetraethyleneglycol
diazide262 to obtain 283. In a similar way, 276 was coupled to propargylamine to yield
alkyne 277, which was attached to tetraethyleneglycol diazide to yield 284. Ketofuran elec-
trophile 285 was prepared by reaction of 2-lithiumfuran with Boc-leucine Weinreb amide in
82% yield (Scheme 7.5). 88 After deprotection with TFA this molecule was used in an azide
coupling with BocLeu2NHNH2 to yield tripeptide 286. Standard Boc-protected solution
peptide chemistry (Scheme 7.5) using Boc-Ahx3-OH or Boc-Ahx5-OH and subsequently
276 or 281 afforded hydrogen bonding template containing inhibitors 294-299 shown in
Scheme 7.5.




















































































Reagents and conditions: i) Furan (2.5 equiv.), n-BuLi (1.6 M in pentanes, 2.6 equiv.), 0◦C, 90 min. then Boc-
Leu-weinreb amide (1 equiv.), THF, -78◦C, 3 hr., 82%. ii) TFA:DCM 1:1, 30 min, quant. iii) Boc-Leu2NHNH2 (
1 equiv.), tBuONO (1.1 equiv.), HCl (1.8 equiv.), DMF:EA 3:1, -30◦C, 3 hr. then TFA.H-Leu-2-furan (1.1 equiv.),
DiPEA (5 equiv.), DMF, -30◦C→ RT o/n, 88% iv) Boc-Ahx3,5-OH, HBTU, DiPEA, 79% (292, 92% (293). v) 276
or 281, HBTU, DiPEA, DMF, 27-86%
Proteasome inhibition by the six inhibitors shown in Scheme 7.5 was assessed with a
competition assay in HEK293T lysate versus MV151 (42). The results are summarised in
Table 7.2. The potency of the inhibitors lies in the high micromolar range, as was antici-
pated by the choice for the ketofuran electrophile. The compounds show preference for β5,
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but this preference diminishes when the inhibitors were elongated. When naphthyridine
294, 295 or 296 was coincubated with complementary urea 297, 298 or 299, no significant
increase in proteasome inhibition was observed other than the addition of the effects of the
two single inhibitors. Coincubation of spacer-templates 283 or 284 with their complemen-
tary inhibitor did not lead to increased proteasome inhibition (data not shown).
Table 7.2: Apparent IC50 (µM) values cal-
culated from semi log plots of residual
proteasome activity against inhibitor con-
centration. Band intensities from each
lane of a competition assay (not shown)
in HEK293T lysate (15 µg protein) versus
MV151 (0.5 µM end concentration) were






294 17 ∼100 ∼100
297 >100 ≫100 ≫100
295 34 N.I. >100
298 5.4 70 17
296 12 40 25
299 14 ∼100 41
Explanations for the lack of synergy can be
found in the choice of either the spacer or the
hydrogen bonding templates. The bivalent in-
hibitors of Loidl et al. contain a long PEG spacer,
which is not able to form any secondary struc-
ture.139 Incorporation of a shorter PEG spacer
instead of the aminohexanoic acid spacer may
improve characteristics of the inhibitors. Most
of the hydrogen bonding templates from liter-
ature have been designed for and tested in hy-
drophobic media. In an aqueous environment,
their recognition and binding strength may be
lessened. A possible solution can be the use of
other templates that are able to form more hy-
drogen bonds and thus show more affinity for
each other, or templates specifically designed for
use in aqueous media. 263 The use of short non-
self complementary peptide nucleic acid (PNA)
sequences 264,265 at the N-terminus of elongated
reversible inhibitors could yield the desired supramolecular synergistic proteasome in-
hibitors.
Chapter 5 showed the efficiency of two-step labelling of three cyclooctynes compared
to the Staudinger-Bertozzi ligation. A very high concentration of phosphane reagent was
needed to completely convert the target azide with the Staudinger-Bertozzi ligation, which
is in contrast with the much lower concentration of cyclooctynes necessary to quanti-
tatively convert the azido-BODIPY-epoxomicin decorated proteasomes. However, back-
ground labelling of the cyclooctynes is high and their use in two-step activity based protein
profiling is questionable since extensive background deteriorates the sensitivity and accu-
racy of two-step labelling. A possible explanation for this reactivity in cells or cell extracts
can be a side reaction of the alkyne with free thiols, known as the thiol-yne reaction. 247
Two-step activity-based protease profiling is a valuable tool for the chemical biology re-
search field to determine the targets of their tag containing covalently reacting probes. An
example in this work is in Chapter 3, where the the Staudinger-Bertozzi ligation was used
to determine cellular targets of two azide containing compounds inactive towards the pro-
teasome. An alternative for the Staudinger-Bertozzi reaction in activity-based protease pro-
filing may be the inverse-electron-demand Diels-Alder ligation. In this ligation, a tetrazine
reacts with either a functionalised trans-cyclooctene (Figure 7.7A) 233 or a functionalised
norbornene (Figure 7.7B), 234 and these reactions occur with high efficiency and selectivity.
A disadvantage of this strategy is that compared to the azide, the cyclooctene, norbornene







































































Figure 7.7: (A) Example of trans-cyclooctyn inverse demand Diels-Alder reaction with tetrazine derivative. (B)
Example of norbornene inverse demand Diels-Alder reaction with tetrazine derivative. (C) Synthesis of a fluores-
cent norbornene epoxomicin potential proteasome inhibitor.
may influence its biological characteristics unfavourably. Nevertheless, the efficiency and
bioorthogonality of the inverse-electron-demand Diels-Alder reaction should be studied. A
possible test system may be the instalment of norbornene onto azido-BODIPY-epoxomicin
302 using copper catalysed click reaction (Figure 7.7C). This inhibitor can then be used to
label proteasomes, after which the concentration of tetrazine-biotin 303 necessary to quan-
titatively convert norbornene labelled proteasome and background labelling can be deter-
mined simultaneously, analogous to what was done for three cyclooctynes in Chapter 5.
7.1 Experimental
All reagents were commercial grade and were used as received unless indicated otherwise. Toluene (Tol.), ethyl ac-
etate (EA), and light petroleum ether (PE) were obtained from Riedel-de Haën or Biosolve and were distilled prior
to use. Dichloromethane (DCM), dimethyl formamide (DMF), and dioxane were stored on 4 Å molecular sieves.
Tetrahydrofuran (THF) was distilled from LiAlH4 prior to use. Reactions were conducted under an argon atmo-
sphere. Reactions were monitored by TLC analysis by using DC-fertigfolien (Schleicher & Schuell, F1500, LS254)
with detection by UV absorption (254 nm), spraying with 20% H2SO4 in ethanol or (NH4)6Mo7O24
.4H2O (25
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g/L) and (NH4)4Ce(SO4)4
.2H2O (10 g/L) in 10% sulfuric acid followed by charring at ∼150
◦C or by spray-
ing with an aqueous solution of KMnO4 (7%) and KOH (2%). Column chromatography was performed on
silica gel from Screening Devices (0.040-0.063 nm). LC/MS analysis was performed on a LCQ Advantage Max
(Thermo Finnigan) equipped with an Gemini C18 column (Phenomenex). HRMS were recorded on a LTQ Or-
bitrap (Thermo Finnigan). 1H- and 13C-APT-NMR spectra were recorded on a Bruker DPX-300 (300/75 MHz)
or Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory. Chemical shifts are given in
ppm (δ) relative to tetramethylsilane as an internal standard. Coupling constants are given in Hz. All presented
13C-APT spectra are proton decoupled. Microwave reactions were performed on an Emrys Optimizer (Biotage






Boc-Val-(4-methyleneazide)-benzylamide (248). Boc-Val-OH (191 mg, 881 µmol,
1.1 equiv.) was dissolved in DCM. HBTU (304 mg, 961 µmol, 1.2 equiv.), 4-
(azidomethyl)-benzylamine 251 (130 mg, 801 µmol, 1 equiv.), DiPEA (331 µl, 2
mmol, 2.5 equiv.) were added and the mixture stirred for 1 hr. before being con-
centrated. The residue was dissolved in EA and washed with 1M HCl (2×), sat. aq.
NaHCO3 (3×), brine and dried with MgSO4. Column chromatography (tol. →
30% EA:tol.) afforded the title compound (170 mg, 470 µmol, 59%) 1H NMR (400 MHz, CDCl3) δ ppm 7.27 -
7.21 (m, 4H), 7.08 (s, 1H), 5.36 (d, J = 8.9 Hz, 1H), 4.39 (ddd, J = 47.0, 15.2, 5.9 Hz, 2H), 4.28 (s, 2H), 4.00 (t, J
= 7.8 Hz, 1H), 2.09 (dt, J = 16.6, 8.3 Hz, 1H), 1.39 (s, 9H), 0.93 (dd, J = 9.6, 7.0 Hz, 6H). 13C NMR (101 MHz,






Boc-Leu-(4-methyleneazide)-benzylamide (249). Boc-leucine hydrate (213 mg,
855 µmol, 1.1 equiv.) was coevaporated with toluene (3×) and dissolved in DCM.
HBTU (354 mg, 932 µmol, 1.2 equiv.), 4-(azidomethyl)-benzylamine 251 (126 mg,
777 µmol, 1 equiv.), DiPEA (321 µl, 1.94 mmol, 2.5 equiv.) were added and the
mixture stirred for 1 hr. before being concentrated. The residue was dissolved in
EA and washed with 1M HCl (2×), sat. aq. NaHCO3 (3×), brine and dried with
MgSO4. Column chromatography (tol. → 30% EA:tol.) afforded the title com-
pound (141 mg, 378 µmol, 48%). 1H NMR (400 MHz, CDCl3) δ ppm 7.34 - 7.14 (m, 4H), 5.35 (d, J = 7.8 Hz,
1H), 4.48 - 4.31 (m, 2H), 4.27 (s, 2H), 4.24 (d, J = 4.5 Hz, 1H), 1.77 - 1.46 (m, 3H), 1.38 (s, 9H), 0.91 (t, J = 6.5
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ ppm 172.88, 155.79, 138.39, 134.16, 128.29, 127.71, 79.75, 54.26, 52.96,








Boc-Val-Leu-(4-methyleneazide)-benzylamide (250). Carbamate 249
(141 mg, 376 µmol) was dissolved in TFA:DCM 1:1 for 30 min and co-
evaporated with toluene (3×). To this residue was added a solution of Boc-
Val-OH (90 mg, 414 µmol, 1.1 equiv.), HBTU (164 mg, 432 µmol, 1.15
equiv.) and DiPEA (218 µl, 1.32 mmol, 3.5 equiv.) in DMF and the mix-
ture stirred for 1 hr. The solution was diluted with EA, washed with 1M
HCl (3×), sat. aq. NaHCO3 (3×), brine and dried with MgSO4. Column
chromatography (tol. → 40% EA:tol.) afforded the title compound (125 mg, 263 µmol, 70%). 1H NMR (400
MHz, CDCl3) δ ppm 7.75 (s, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.26 - 7.12 (m, 4H), 5.66 (d, J = 8.8 Hz, 1H), 4.69 -
4.55 (m, 1H), 4.41 - 4.21 (m, 2H), 4.26 (s, 2H), 4.06 (t, J = 8.1 Hz, 1H), 1.99 (dt, J = 14.0, 7.0 Hz, 1H), 1.83 - 1.56
(m, 3H), 1.38 (s, 9H), 1.06 - 0.59 (m, 12H). 13C NMR (101 MHz, CDCl3) δ ppm 172.20, 172.06, 155.86, 138.55,















Carbamate 248 (170 mg, 470 µmol, 1 equiv.) was dissolved in 4M
HCl/dioxane and stirred for 1 hr. before coevaporation with toluene
(3×). The residue was dissolved in 1:1 DCM:sat.aq. NaHCO3 at 0
◦3.
Phosgene (495 µl 20 w-% in toluene, 940 µmol, 2 equiv.) was added
to the DCM layer and the mixture stirred vigorously for 10 min.
The water layer was then extracted with DCM (3×), the organic layers dried with Na2SO4 and concentrated.
The residue was dissolved in DCM and H-Val-NHNHBoc (202, 120 mg, 517 µmol, 1.1 equiv.) was added and the
mixture stirred o/n. Addition of H2O and evaporation of DCM caused precipitation of the title compound (138
mg, 266 µmol, 57%). LCMS: Rt 7.59 min (linear gradient 10→ 90% MeCN+ 0.1% TFA, 15 min), ESI-MS (m/z):
518.93 (M+H)+). 1H NMR (400 MHz, CD3OD) δ ppm 7.30 (q, J = 8.3 Hz, 4H), 4.41 (q, J = 15.1 Hz, 2H),
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4.32 (s, 2H), 4.07 (d, J = 5.9 Hz, 1H), 4.00 (d, J = 6.6 Hz, 1H), 2.04 (dq, J = 13.4, 6.7 Hz, 2H), 1.46 (s, 9H), 1.11 -
0.79 (m, 12H). 13C NMR (101 MHz, CD3OD) δ ppm 172.77, 158.08, 137.88, 133.85, 127.74, 127.18, 80.17, 58.86,


















NHBoc (253). Carbamate 250 (170 mg, 470 µmol, 1 equiv.)
was dissolved in 4M HCl/dioxane and stirred for 1 hr. before
coevaporation with toluene (3×). The residue was dissolved
in 1:1 DCM:sat.aq. NaHCO3 at 0
◦3. Phosgene (180 µl 20
w-% in toluene, 340 µmol, 2 equiv.) was added to the DCM
layer and the mixture stirred vigorously for 10 min. The
water layer was then extracted with DCM (3×), the organic layers dried with Na2SO4 and concentrated. The
residue was dissolved in DCM and H-Val-NHNHBoc (202, 43 mg, 187 µmol, 1.1 equiv.) was added and the
mixture stirred o/n and concentrated. Column chromatography (DCM→ 5% MeOH:DCM) afforded the title
compound (79 mg, 124 µmol, 76%). 1H NMR (400 MHz, CD3OD) δ ppm 7.32 - 7.22 (m, 4H), 4.51 (t, J = 7.2
Hz, 1H), 4.36 (s, 2H), 4.31 (s, 2H), 4.15 - 4.09 (m, 1H), 4.05 (d, J = 6.9 Hz, 1H), 1.98 (ddd, J = 20.8, 13.0, 7.4 Hz,
2H), 1.67 - 1.60 (m, 3H), 1.45 (s, 9H), 1.03 - 0.82 (m, 18H). 13C NMR (101 MHz, CD3OD) δ ppm 172.81, 172.34,
158.19, 155.35, 137.91, 133.77, 127.72, 127.10, 80.20, 58.83, 56.68, 53.58, 51.18, 41.98, 39.92, 30.96, 30.40, 27.09,



















Leu-VS (254). Carbamate 250 (46 mg, 97 µmol, 1
equiv.) was dissolved in 4M HCl/dioxane and stirred
for 1 hr. before coevaporation with toluene (3×) to
yield HCl.H-Val-Leu-(4-methyleneazide)-benzylamide.
Boc-Val-Leu-VS (194, 49 mg, 125 µM, 1.28 equiv.) was
dissolved in 4M HCl/dioxane and stirred for 1 hr. before
coevaporation with toluene (3×). The residue was dissolved in 1:1 DCM:sat.aq. NaHCO3 at 0
◦3. Phosgene (132
µl 20 w-% in toluene, 250 µmol, 2 equiv.) was added to the DCM layer and the mixture stirred vigorously for 10
min. The water layer was then extracted with DCM (3×), the organic layers dried with Na2SO4 and concentrated.
The residue was dissolved in DCM and a solution of HCl.H-Val-Leu-(4-methyleneazide)-benzylamide and DiPEA
(33 µl, 200 µmol, 2 equiv.) in DCM was added and the resulting mixture stirred o/n before being concentrated.
Column chromatography (DCM → 4% MeOH:DCM) afforded the title compound (20 mg, 29 µmol, 30%).
LCMS: Rt 8.60 min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min).
1H NMR (400 MHz, CD3OD,
CHCl3) δ ppm 7.30 - 7.21 (m, 4H), 6.81 (dd, J = 15.1, 5.5 Hz, 1H), 6.66 - 6.58 (m, 1H), 4.72 - 4.63 (m, 1H), 4.61 -
4.51 (m, 1H), 4.35 (d, J = 5.4 Hz, 2H), 4.30 (s, 2H), 4.17 (d, J = 7.1 Hz, 1H), 4.02 (d, J = 7.6 Hz, 1H), 2.94 (s, 3H),
2.19 - 1.85 (m, 2H), 1.76 - 1.56 (m, 4H), 1.53 - 1.34 (m, 2H), 1.07 - 0.75 (m, 24H). 13C NMR (101 MHz, CD3OD,
CHCl3) δ ppm 172.73, 172.51, 172.26, 158.16, 147.00, 137.94, 133.76, 128.68, 127.74, 126.99, 58.93, 58.52, 53.60,
51.18, 47.14, 41.95, 41.66, 41.49, 39.94, 30.76, 30.49, 24.13, 24.04, 21.85, 21.81, 20.95, 20.75, 18.42, 18.31, 17.22,
17.17. HRMS calcd for [C33H55N8O6S]
















Carbamate 252 (50 mg, 97 µmol) was dissolved in 4M HCl/-
dioxane and stirred for 1 hr. before coevaporation with toluene
(3×). The residue was dissolved in DMF and cooled to -30 ◦C.
tBuONO (14 µl, 107 µmol, 1.1 equiv.) and HCl (44 µl 4M in
dioxane, 175 µmol, 1.8 equiv.) were added and the resulting
mixture stirred for 3 hr. TFA.H-Leu-EK (107 µl, 1.1 equiv.) in
DMF was added followed by DiPEA (80 µl, 485 µmol, 5 equiv.)
and the mixture was allowed to warm to RT overnight. The mixture was diluted with EA and washed with H2O
(3×). The organic layer was dried over Na2SO4 and flash column chromatography (DCM→ 5% MeOH:DCM)
afforded the title compound (22 mg, 39 µmol, 41%). LCMS: Rt 8.72 min (linear gradient 10 → 90% MeCN +
0.1% TFA, 15 min). 1H NMR (400 MHz, CD3OD, CHCl3) δ ppm 7.35 - 7.24 (m, 4H), 4.54 (dd, J = 10.6, 3.0
Hz, 1H), 4.47 - 4.30 (m, 2H), 4.32 (s, 2H), 4.04 (dd, J = 6.8, 4.8 Hz, 2H), 3.31 (d, J = 5.0 Hz, 1H), 2.91 (d, J = 5.0
Hz, 1H), 2.14 - 1.92 (m, 2H), 1.78 - 1.63 (m, 1H), 1.50 (s, 3H), 1.56 - 1.25 (m, 2H), 0.97 - 0.87 (m, 18H). 13C NMR
(101 MHz, CD3OD, CHCl3) δ ppm 207.98, 172.83, 172.78, 158.11, 137.89, 133.87, 127.81, 127.25, 58.77, 58.42,
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58.20, 53.62, 51.58, 49.87, 42.05, 38.61, 30.55, 30.50, 24.45, 22.33, 20.14, 18.37, 18.32, 17.00, 16.96, 15.74. HRMS
calcd for [C28H44N7O5]



















(256). Carbamate 253 (39 mg, 62 µmol) was dissolved in
4M HCl/dioxane and stirred for 1 hr. before coevapo-
ration with toluene (3×). The residue was dissolved in
DMF/EA 3/1 and cooled to -30 ◦C. tBuONO (9 µl, 68
µmol, 1.1 equiv.) and HCl (28 µl 4M in dioxane, 112
µmol, 1.8 equiv.) were added and the resulting mixture
stirred for 3 hr. TFA.H-Leu-EK (74 µl, 1.1 equiv.) in DMF
was added followed by DiPEA (51 µl, 310 µmol, 5 equiv.) and the mixture was allowed to warm to RT overnight.
The mixture was diluted with EA and washed with H2O (3×). The organic layer was dried over Na2SO4 and
flash column chromatography (DCM→ 4% MeOH:DCM) afforded the title compound (22 mg, 33 µmol, 53%).
LCMS: Rt 9.33 min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min).
1H NMR (400 MHz, CD3OD,
CHCl3) δ ppm 7.30 - 7.23 (m, 4H), 4.57 - 4.46 (m, 2H), 4.36 (s, 2H), 4.31 (s, 2H), 4.09 (d, J = 6.7 Hz, 1H), 4.05
(d, J = 7.1 Hz, 1H), 3.29 (d, J = 5.0 Hz, 1H), 2.90 (d, J = 5.0 Hz, 1H), 2.09 - 1.89 (m, 2H), 1.74 - 1.55 (m, 4H),
1.50 (s, 3H), 1.33 (ddd, J = 20.8, 12.6, 7.3 Hz, 2H), 0.90 (m, 24H). 13C NMR (101 MHz, CD3OD, CHCl3) δ
ppm 208.11, 172.86, 172.77, 172.33, 158.21, 137.93, 133.84, 127.84, 127.17, 58.66, 58.51, 58.09, 53.72, 51.66, 51.28,
49.94, 42.10, 40.02, 38.62, 30.84, 30.59, 24.55, 24.15, 22.41, 21.94, 21.02, 20.28, 18.39, 18.35, 17.15, 17.12, 15.86.
HRMS calcd for [C34H55N8O6]





Fmoc-Phe(4-CH2NHBoc)-VS (264). Amine 263 (613 mg, 1.73 mmol, 1 eq.) was
dissolved in a 20 mL mixture of EA and 5 drops of DMF and brought to 0◦C under
argon. DiPEA (0.45 mL, 2.60 mmol, 1.5 eq) was added followed by Fmoc-Cl (492
mg, 1.90 mmol, 1.1 eq). After stirring for 1 hr. the reaction mixture was washed
with 0.1M HCl (2×), sat. aq. NaHCO3 (1×) and brine (1×), dried with Na2SO4
and concentrated in vacuo. Crystallization with DCM/PE yielded the title com-
pound (631 mg, 1.09 mmol, 63%) as a white solid. R f = 0.3 (30% EA/Tol).
1H
NMR (400 MHz, CDCl3) δ ppm 7.78 (d, J = 7.6 Hz, 2H), 7.58 - 7.48 (m, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.32
(t, J = 7.4 Hz, 2H), 7.22 (d, J = 7.5 Hz, 2H), 7.08 (d, J = 6.7 Hz, 2H), 6.87 (d, J = 14.4 Hz, 1H), 6.32 (d, J
= 14.5 Hz, 1H), 4.85 - 4.65 (m, 2H), 4.49 (dd, J = 10.6, 6.4 Hz, 1H), 4.44 - 4.35 (m, 1H), 4.28 (d, J = 4.8 Hz,
2H), 4.17 (t, J = 6.3 Hz, 1H), 2.91 (d, J = 4.6 Hz, 2H), 2.87 (s, 3H), 1.78 (s, 1H), 1.46 (s, 9H). 13C NMR (101
MHz, CDCl3) δ ppm 156.00, 155.58, 146.78, 143.80, 143.62, 141.38, 138.09, 134.66, 130.07, 129.54, 127.87, 127.16,
124.95, 120.12, 120.09, 66.80, 52.52, 47.21, 44.28, 44.27, 44.26, 42.85, 39.87, 28.53, 28.51, 28.47. HRMS: calculated
for [C32H36N2O6S]





Fmoc-Phe(4-CH2NH3Cl)-VS (265). Vinyl sulfone 264 (856 mg, 1.48 mmol) was
dissolved in an 8 mL solution of 4M HCl in dioxane at rt under an argon atmo-
sphere. After 1 hr. of stirring the deprotection was complete and the mixture was
coevaporated with toluene (2×) yielding the title compound. 1H NMR (400 MHz,
CD3OD) δ ppm 7.80 (d, J = 7.4 Hz, 2H), 7.67 - 7.50 (m, 2H), 7.44 - 7.26 (m, 8H),
6.85 (dd, J = 15.1, 4.9 Hz, 1H), 6.54 (d, J = 15.1 Hz, 1H), 4.59 (s, 1H), 4.31 (p, J =
10.7 Hz, 2H), 4.16 - 4.09 (m, 1H), 4.04 (s, 2H), 3.00 (dd, J = 13.7, 6.0 Hz, 1H), 2.94
(s, 3H), 2.85 (dd, J = 13.0, 9.4 Hz, 1H). 13C NMR (101 MHz, CD3OD) δ ppm 157.95, 147.69, 145.27, 145.03,
142.63, 139.89, 132.89, 131.33, 131.24, 130.18, 128.86, 128.82, 128.36, 128.16, 126.13, 126.09, 120.97, 67.63, 54.30,
48.43, 43.99, 42.83, 40.49.
Wang resin p-nitrophenylcarbonate (266). Wang resin (1.1 mmol gr−1, 1 gr, 1.1 mmol) was suspended in DCM
at 0◦C. N-methyl morpholine (242 µl, 2.2 mmol, 2 equiv.) and p-nitrophenylchloroformate (443 mg, 2.2 mmol, 2










Fmoc-Phe(4-CH2-NH-C(O)-Wang resin)-VS (267). Resin 266 (251.3 mg) was al-
lowed to swell in DMF. HOBt (102 mg, 754 ţmol, 3 eq.), DiPEA (263 ţL, 1.51
mmol, 6 eq.) and vinyl sulfone 265 (257 mg, 503 ţmol, 2 eq.) were added and the
mixture was agitated at rt for 24 h. The resin was washed with DMF (3×) and
DCM (3×) and dried. Loading calculated by Fmoc-determination: 0.534 mmol/g.
A small scale cleavage test was performed in 1 mL 95% TFA/H2O for 1h, which
afforded only the starting compound 265. LCMS: Rt (min): 6.86, calculated for
[C27H28N2O4S]
+ 477.18, found 477.07.
General procedure solid phase peptide synthesis
Fmoc containing resin was treated with of 20% piperidine/DMF and agitated for 0.5 h. The resin was washed
with DMF (3×) and DCM (3×). Next, HCTU (3 equiv.), DiPEA (5 equiv.) and Fmoc-AA-OH (3 equiv) were
dissolved in 10 mL DMF and added to the resin, which was agitated at RT for 4 hr. The resin was washed
with DMF (3×) and DCM (3×) and dried. A small scale cleavage test was performed in 1 mL 95% TFA/H2O
for 1 hr, which afforded the corresponding Fmoc-AAn -Phe-(4-CH2NH2
.TFA)-VS peptide with Fmoc-AAn -OH
as a contamination. Finally, to remove unwanted esters the resin was treated with 10 mL of sat aq. LiOH in
THF/H2O (1:1) and agitated for 2 hr. The resin was washed with H2O (3×), MeOH (3×) and DCM (3×). Resin






t-Butyl 6-amino-6-oxohexanoate (274). Mono-tert-butyl adipate 266 (7.23 gr, 35.8
mmol, 1 equiv.) was dissolved in THF and cooled to -10◦C. NEt3 (4.95 ml, 35.8 mmol,
1 equiv. was added followed by dropwise addition of EtOCOCl (3.42 ml, 35.8 mmol, 1
equiv.) which caused the formation of white solids. The mixture was stirred for 15 min.
at 0◦C and NH3 (g) was bubbled through the solution for 1 hr. The mixture was filtered,
the residue washed with THF and the filtrate concentrated. Crystallisation (DCM/PE)
yielded the title compound (4.21 gr, 20.92 mmol, 59%). 1H NMR (400 MHz, CDCl3) δ ppm 6.05 (s, 1H), 5.89
(s, 1H), 2.25 (t, J = 5.9 Hz, 4H), 1.64 (s, 4H), 1.44 (s, 9H). 13C NMR (101 MHz, CDCl3) δ ppm 175.50, 172.90,










butyl ester (275). Synthesized by a procedure from Ligthart et at. 260
N-(7-chloro-1,8-naphthyridin-2-yl)acetamide 259 ((273, 222 mg, 1 mmol,
1 equiv.), tert-butyl 6-amino-6-oxohexanoate (274, 242 mg, 1.2 mmol,
1.2 equiv.) and Cs2CO3 (459 mg, 1.4 mmol, 1.4 equiv.) were suspended
in dioxane and degassed by repeated reduction of pressure and Ar bub-
bling. Xantphos (46 mg, 8 mol-%) and Pd2dba3 (18 mg, 4 mol-%) were added and the mixture was heated in a
microwave at 150◦C for 20 minutes. The reaction mixture was filtered over celite and concentrated. Column chro-
matography (DCM→ 3% MeOH/DCM followed by crystallization from DCM/PE yielded the title compound
(270 mg, 0.7 gr, 70%). LCMS: Rt 5.55 min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15 min), (ESI-MS
(m/z): 386.9 (M+H)+). 1H NMR (400 MHz, CDCl3) δ ppm 10.44 (s, 1H), 10.32 (s, 1H), 8.44 - 8.39 (m, 2H), 8.10
(d, J = 8.8 Hz, 2H), 2.43 (t, J = 7.3 Hz, 2H), 2.18 (s, 3H), 2.16 (d, J = 10.7 Hz, 2H), 1.70 - 1.48 (m, 4H), 1.42 (s,
9H). 13C NMR (101 MHz, CDCl3) δ ppm 172.94, 172.68, 170.30, 154.62, 153.21, 139.04, 117.86, 113.87, 113.73,










mono TFA salt (276). t-Butyl 6-(7-acetamido-1,8-naphthyridin-2-
ylamino)-6-oxohexanoate (275, 126 mg, 326 µmol) was stirred with 2
ml TFA for 30 minutes before being coevaporated with toluene (3×) to
yield the title compound (146 mg, quant). LCMS: Rt 2.96 min (linear
gradient 10 → 90% MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z):
331.2 (M+H)+). 1H NMR (400 MHz, CDCl3/CD3OD) δ ppm 8.46 (d, J = 8.8 Hz, 2H), 8.39 (d, J = 9.0 Hz,
2H), 2.64 (t, J = 7.2 Hz, 2H), 2.39 (t, J = 7.2 Hz, 2H), 2.36 (s, 3H), 1.95 - 1.73 (m, 4H). 13C NMR (101 MHz,
CDCl3/CD3OD) δ ppm 175.67, 173.95, 171.42, 153.57, 146.32, 141.92, 116.38, 113.69, 113.60, 36.46, 33.26,
23.84, 23.79.
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Methyl 6-aminopicolinate (279). AcCl (4.3 ml, 60 mmol, 12 equiv.) was added to MeOH
(20 ml) at 0◦C. 6-aminopicolinic acid (691 mg, 5 mmol, 1 equiv.) was added and the mix-
ture was refluxed o/n after which it was concentrated. The residue was crystallised from
MeOH/Et2O, dissolved in sat. aq. NaHCO3 and extracted with DCM. The organic lay-
ers were dried with Na2SO4 and concentrated, yielding the title compound (640 mg, 4.2
mmol, 84%). LCMS: Rt 1.82 min (linear gradient 0→ 20% MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z): 152.87
(M+H)+). 1H NMR (400 MHz, CDCl3) δ ppm 7.54 - 7.48 (m, 1H), 7.44 (dd, J = 7.3, 0.8 Hz, 1H), 6.68 (dd, J =










Methyl 6-(3-pyridin-2-ylureido)picolinate (280). pyridine-2-carbonyl azide 261
(322 mg, 2.17 mmol, 1 equiv.) was dissolved in toluene (3 ml) and heated to 100◦C
until gas evolution had stopped and TLC (1:1 EA:PE) indicated complete consump-
tion of the starting material (2 hr.). Methyl 6-aminopicolinate (279, 248 mg, 1.63
mmol, 0.75 equiv.) in toluene was added and the mixture heated at 100◦C o/n. The
mixture was concentrated and crystallized from CHCl3/PE to yield the title com-
pound (409 mg, 1.5 mmol, 92%). LCMS: Rt 4.29 min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15 min),
(ESI-MS (m/z): 272.93 (M+H)+). 1H NMR (400 MHz, DMSO) δ ppm 10.67 (s, 1H), 10.16 (s, 1H), 8.30 (d, J
= 4.9 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.96 (t, J = 7.9 Hz, 1H), 7.77 (d, J = 3.8 Hz, 2H), 7.71 (d, J = 7.7 Hz,
1H), 7.08 - 7.02 (m, 1H), 3.89 (s, 3H). 13C NMR (101 MHz, DMSO) δ ppm 164.67, 152.34, 152.20, 151.85, 147.57,









(6-(3-pyridin-2-ylureido)picolinic acid (281). Methyl 6-(3-pyridin-2-
ylureido)picolinate (280, 279 mg, 1.02 mmol) was dissolved in 10 ml THF
and 10 ml 0.1 M NaOH was added and the mixture stirred for 2 hr after which
the THF was evaporated. 0.1 M HCl was added until crystallization commenced
at pH 3. The solids were collected by centrifugation and the pellet was washed
with 1 mM HCl (2x) and dried overnight at 40◦C under vacuum to yield the title
compound (188 mg, 0.73 mmol, 71%). LCMS: Rt 3.43 min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15
min), (ESI-MS (m/z): 258.93 (M+H)+). 1H NMR (400 MHz, DMSO) δ ppm 13.29 - 13.19 (m, 1H), 10.69 (s,
1H), 10.14 (s, 1H), 8.32 - 8.28 (m, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.94 (t, J = 7.9 Hz, 1H), 7.81 - 7.71 (m, 2H), 7.70










(Naphthyridine-alkyn (277). Carboxylic acid 276 (45 mg, 100
µmol), HBTU (42 mg, 110 µmol, 1.1 equiv.) and DiPEA (59 µl,
330 µmol, 3.3 equiv.) were dissolved in DMF and propargylamine
(13 µl, 200 µmol, 2 equiv) was added and the mixture stirred for 1
hr. after which the mixture was concentrated. Column chromato-
graphy (5% MeOH:DCM→ 10% MeOH:DCM) afforded the title
compound (39 mg, 99 µmol, 99%). LCMS: Rt 3.81 min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15 min),
(ESI-MS (m/z): 368.07 (M+H)+). 1H NMR (400 MHz, CD3OD) δ ppm 8.29 (d, J = 8.8 Hz, 2H), 8.03 (d, J = 8.7
Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 3.93 (s, 2H), 2.55 (s, 1H), 2.52 - 2.47 (m, 2H), 2.22 (s, 3H), 2.21 - 2.17 (m, 2H),
1.76 - 1.53 (m, 4H). 13C NMR (101 MHz, CD3OD) δ ppm 175.30, 175.19, 172.69, 168.47, 155.09, 154.68, 140.61,











(Dipyridylurea-alkyn (282). Carboxylic acid 363 (26 mg, 100 µmol), HBTU
(42 mg, 110 µmol, 1.1 equiv.) and DiPEA (36 µl, 220 µmol, 2.2 equiv.) were
dissolved in DMF and propargylamine (13 µl, 200 µmol, 2 equiv) was added
and the mixture stirred for 1 hr. after which the mixture was concentrated.
The residue was dissolved in DCM and washed with sat. aq. NaHCO3 (3×),
H2O (3×), brine and dried with Na2SO4. Column chromatography (DCM→
4% MeOH:DCM) afforded the title compound (16 mg, 54 µmol, 54%). 1H NMR (400 MHz, CDCl3:CD3OD
1:1) δ ppm 8.36 (d, J = 4.5 Hz, 1H), 8.01 (br s, 1H), 7.91 - 7.81 (m, 2H), 7.73 (t, J = 7.5 Hz, 1H), 7.45 (s, 1H), 7.05
(dd, J = 6.7, 5.7 Hz, 1H), 4.29 (d, J = 2.4 Hz, 2H), 2.43 (t, J = 2.4 Hz, 1H). 13C NMR (101 MHz, CDCl3:CD3OD




























(Bis-(dipyridineurea)-PEG (283). Alkyne 282 (16 mg, 54 µmol, 2.2 equiv.) and tetraethyleneglycol diazide 262 (7
mg, 24.5 µmol, 1 equiv.) were dissolved in 2:1:1 tBuOH:MeCN:H2O and degassed with Ar. Sodium ascorbate (54
µl 1 M stock in degassed H2O, 2.2 equiv.) and CuSO4 (54 µl 0.2 M stock in degassed H2O, 0.44 equiv.) were added
and the mixture stirred o/n. The mixture was concentrated and the residue dissolved in MeOH and subjected to
LH20 Sephadex size exclusion chromatography to yield the title compound (10 mg, 11 µmol, 46%). LCMS: Rt
4.58 min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z): 879.20 (M+H)+). 1H NMR
(400 MHz, CD3ODCDCl3) δ ppm 8.95 (s, 2H), 8.27 (s, 2H), 8.02 (s, 2H), 7.97 (d, J = 11.3 Hz, 2H), 7.86 (t, J =
7.8 Hz, 2H), 7.78 (d, J = 7.4 Hz, 2H), 7.74 - 7.66 (m, 2H), 7.39 (s, 2H), 7.05 - 6.97 (m, 2H), 4.73 (s, 4H), 4.53 (t, J


























(Bis-(naphthyridine)-PEG (284). Alkyne 277 (28 mg, 76 µmol, 2.2 equiv.) and tetraethyleneglycol diazide 262
(10 mg, 34 µmol, 1 equiv.) were dissolved in DMF and degassed with Ar. Sodium ascorbate (80 µl 1 M stock in
degassed H2O, 2.2 equiv.) and CuSO4 (80 µl 0.2 M stock in degassed H2O, 0.44 equiv.) were added and the mixture
stirred 3 hr. Column chromatography (5% MeOH:DCM→ 20% MeOH:DCM) yielded the title compound (12
mg, 11 µmol, 64%). LCMS: Rt 5.24 min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z):
1023.47 (M+H)+). 1H NMR (400 MHz, DMF-d7) δ ppm 10.78 (s, 2H), 10.73 (s, 2H), 8.37 - 8.32 (m, 8H), 8.29 -
8.24 (m, 2H), 7.96 (s, 2H), 4.55 (t, J = 5.2 Hz, 4H), 4.41 (d, J = 5.6 Hz, 4H), 3.85 (t, J = 5.3 Hz, 4H), 3.57 - 3.48




Boc-Leu-2-furan (285). Furan (1.88 ml, 25.9 mmol, 2.5 equiv.) was dissolved in 100 ml
THF and cooled to 0◦C. nBu-Li (16.8 ml 1.6M in pentane, 26.9 mmol, 2.6 equiv.) was
added dropwise and the mixture was stirred at 0◦C for 90 min. The mixture was cooled
to -78◦C and a solution of Boc-leucine weinreb amide (2.84 gr, 10.35 mmol, 1 equiv.) in
THF (50 mL) was added dropwise and the mixture was stirred at -78◦C for 3 hr after
which it was allowed to warm to -30◦C. The mixture was quenched with 1M HCl and
EA was added and the mixture was washed with 1M HCl (3×), brine and dried with
MgSO4. Column chromatography (PE→ 11% EA:PE) yielded the title compound (2.39 gr, 8.5 mmol, 82%).
1H
NMR (400 MHz, CDCl3) δ ppm 7.66 (d, J = 1.0 Hz, 1H), 7.35 (d, J = 3.4 Hz, 1H), 6.58 (dd, J = 3.4, 1.5 Hz, 1H),
5.49 (d, J = 8.9 Hz, 1H), 5.11 (td, J = 9.4, 3.7 Hz, 1H), 1.86 - 1.74 (m, 1H), 1.69 - 1.45 (m, 2H), 1.43 (s, 9H), 1.05
(d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ ppm 188.21, 155.18, 150.65, 146.68,










Boc-Leu3-2-furan (286). Carbamate 285 (1.6 gr, 5.69 mmol, 1.1 equiv.) was
dissolved in 1:1 TFA:DCM and stirred for 30 min before coevaporation with
toluene (3× yielded TFA.H-Leu-2-furan. Boc-Leu2-NHNH2 (148, 1.85 gr,
5.2 mmol, 1. equiv.) was dissolved in DCM/DMF 9/1 and cooled to -40◦C.
tBuONO (0.76 ml, 5.69 mmol, 1.1 equiv.) and HCl (3.64 ml 4M sln. in 1,4-
dioxane, 14.6 mmol, 2.8 equiv.) were added, and the mixture was stirred for
3hr. at -30◦C after which TLC analysis (10% MeOH/DCM) showed complete
consumption of the starting material. TFA.H-Leu-furan in DMF and DiPEA
(4.3 ml, 26 mmol, 5 equiv.) was added to the reaction mixture, and this mixture was allowed to warm to RT slowly
overnight. The mixture was diluted with EA and extracted with H2O (3 ×). The organic layer was dried over
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MgSO4 and purified by flash column chromatography (tol. → 30% EA:tol.) yielded the title compound (2.33 gr,
4.6 mmol, 88%). 1H NMR (400 MHz, CDCl3) δ ppm 7.63 (d, J = 1.1 Hz, 1H), 7.32 (d, J = 3.6 Hz, 1H), 6.62 (s,
1H), 6.57 (dd, J = 3.6, 1.7 Hz, 1H), 6.47 (d, J = 8.1 Hz, 1H), 5.36 (td, J = 9.6, 3.6 Hz, 1H), 4.86 (s, 1H), 4.47 (td, J
= 8.5, 5.5 Hz, 1H), 4.17 - 4.02 (m, 1H), 1.74 - 1.46 (m, 4H), 1.44 (s, 3H), 1.01 (d, J = 6.0 Hz, 1H), 0.98 - 0.85 (m,
5H). 13C NMR (101 MHz, CDCl3) δ ppm 187.51, 172.23, 171.69, 155.20, 150.89, 147.10, 119.15, 112.28, 79.06,
53.17, 52.14, 51.53, 41.80, 41.26, 40.92, 27.91, 24.78, 24.53, 23.17, 22.72, 22.59, 22.36, 22.14, 21.73.
TFA.H-Leu3-2-furan (287). Carbamate 286 (2.33 gr, 4.6 mmol) was dissolved in 1:1 TFA:DCM and stirred for 30
min before coevaporation with toluene (3× yielded TFA.H-Leu3-2-furan, which was used without purification.
Boc-Ahx3-OMe (288). Boc-Ahx2-OH
267 (2 gr, 5.8 mmol, 1 equiv.) was dissolved in DCM. HCl.H-Ahx-OMe
(1.08 gr, 6.4 mmol, 1.1 equiv.), HBTU (2.7 gr, 7.0 mmol, 1.2 equiv.) and DiPEA (3.3 ml, 20 mmol, 3.5 equiv.)
were added and the mixture stirred o/n. The mixture was washed with 1M HCl (2×), sat. aq. NaHCO3 (4×),
brine and dried with MgSO4 to yield Boc-Ahx3-OMe which was used without purification.
1H NMR (400 MHz,
CD3OD) δ ppm 3.67 (s, 3H), 3.18 (dd, J = 12.8, 6.9 Hz, 4H), 3.04 (t, J = 7.0 Hz, 2H), 2.35 (t, J = 7.4 Hz, 2H),
2.23 - 2.16 (m, 4H), 1.69 - 1.59 (m, 6H), 1.58 - 1.47 (m, 6H), 1.45 (s, 9H), 1.42 - 1.31 (m, 6H).
Boc-Ahx3-OH (289). The crude Boc-Ahx3-OMe was dissolved in MeOH (10 ml) and KOH (10 ml 4 M in H2O, 40
mmol, 7 equiv.) was added and the mixture stirred for 3 hr. Methanol was evaporated and the residue acidified with
3M HCl to pH 3 and extracted with CHCl3 (3×). The organic layers were dried over MgSO4 and concentrated
to yield Boc-Ahx3-OH (2.6 gr, 5.6 mmol, 97% over two steps).
1H NMR (400 MHz, CD3OD) δ ppm 3.19 - 3.11
(m, 4H), 3.01 (t, J = 7.0 Hz, 2H), 2.28 (t, J = 7.4 Hz, 2H), 2.19 - 2.13 (m, 4H), 1.66 - 1.55 (m, 6H), 1.55 - 1.39 (m,
6H), 1.42 (s, 9H), 1.38 - 1.27 (m, 6H). 13C NMR (101 MHz, CD3OD) δ ppm 177.34, 175.96, 175.91, 158.46, 79.74,
41.17, 40.27, 40.14, 37.00, 36.95, 34.77, 30.63, 30.08, 28.80, 27.51, 27.46, 27.41, 26.73, 26.67, 25.69.
Boc-Ahx5-OMe (290). Boc-Ahx3-OMe (946 mg, 2 mmol, 1 equiv.) was dissolved in TFA:DCM 1:1 and stirred for
2 hr. The mixture was coevaporated with toluene (3×). Boc-Ahx2-OH
267 (689 mg, 2 mmol, 1 equiv.) was dissolved
in DMF. HBTU (834 mg, 2.2 mmol, 1.1 equiv.) and DiPEA (1.16 ml, 7 mmol, 3.5 equiv.) were added and the
mixture stirred for 10 min. before the mixture was added to TFA.H-Ahx3-OMe and the resulting mixture stirred
o/n. After evaporation, the residue was dissolved in CHCl3/MeOH and addition of EA induced crystallisation
of the title product (1.13 gr, 1.64 mmol, 71%). LCMS: Rt 6.78 min (linear gradient 10 → 90% MeCN + 0.1%
TFA, 15 min), (ESI-MS (m/z): 698.20 (M+H)+). 1H NMR (400 MHz, DMSO) δ ppm 3.58 (s, 3H), 3.04 - 2.96
(m, 8H), 2.87 (dd, J = 12.9, 6.6 Hz, 2H), 2.28 (t, J = 7.4 Hz, 2H), 2.07 - 1.97 (m, 8H), 1.56 - 1.42 (m, 10H), 1.37 (s,
9H), 1.41 - 1.30 (m, 10H), 1.28 - 1.14 (m, 10H).
Boc-Ahx5-OH (291). Boc-Ahx5-OMe (376 mg, 539 µmol) was dissolved in MeOH (50 ml) and KOH (10 ml 4
M in H2O) was added and the mixture stirred for 3 hr. Methanol was evaporated and the residue acidified with
3M HCl to pH 3, which caused precipitation of Boc-Ahx5-OH (358 mg, 523 µmol, 97%).
1H NMR (400 MHz,
DMSO) δ ppm 3.05 - 2.95 (m, 8H), 2.87 (dd, J = 13.0, 6.5 Hz, 2H), 2.18 (t, J = 7.3 Hz, 2H), 2.02 (t, J = 7.3 Hz,














Boc-Ahx3-Leu3-2-furan (292). Boc-Ahx3-OH (224 mg, 490
µmmol, 1 equiv.) was dissolved in DMF HBTU (233 mg, 588
µmol, 1.2 equiv.) and DiPEA (283 µl, 1.72 mmol, 3.5 equiv.)
were added, followed by compound 287 (281 mg, 539 µmol,
1.1 equiv.), and the mixture stirred o/n. The mixture was
concentrated, the residue dissolved in DCM and washed with
1M HCl (2×), sat. aq. NaHCO3 (4×), brine and dried with
MgSO4. Column chromatography (3% MeOH:EA → 10%
MeOH:EA) yielded the title compound (330 mg, 390 µmol, 79%. 1H NMR (400 MHz, CD3OD) δ ppm 7.83 (d,
J = 1.0 Hz, 1H), 7.42 (d, J = 3.6 Hz, 1H), 6.66 (dd, J = 3.5, 1.6 Hz, 1H), 5.24 (dd, J = 9.7, 4.7 Hz, 1H), 4.52 (dd, J
= 8.9, 6.0 Hz, 1H), 4.47 (t, J = 7.5 Hz, 1H), 3.14 (t, J = 6.9 Hz, 4H), 3.01 (t, J = 6.9 Hz, 2H), 2.28 - 2.21 (m, 2H),
2.16 (t, J = 7.4 Hz, 4H), 1.77 - 1.39 (m, 20H), 1.41 (s, 9H), 1.37 - 1.22 (m, 7H), 1.01 - 0.84 (m, 18H). 13C NMR
(101 MHz, CD3OD) δ ppm 188.94, 175.72, 175.65, 174.45, 174.22, 158.30, 152.21, 148.97, 120.01, 113.63, 79.59,
54.18, 52.80, 52.62, 41.95, 41.48, 41.12, 40.12, 40.10, 36.96, 36.91, 36.60, 30.58, 30.05, 28.83, 27.48, 27.36, 26.68,
















Boc-Ahx5-Leu3-2-furan (293). Boc-Ahx5-OH (137 mg, 200
µmmol, 1 equiv.) was dissolved in DMF HBTU (83 mg, 220
µ, 1.1 equiv.) and DiPEA (116 µl, 0.7 mmol, 3.5 equiv.) were
added, followed by compound 287 (110 mg, 210 µmol, 1.05
equiv.), and the mixture stirred 3 hr. The mixture was concen-
trated, dissolved in MeOH and subjected to LH20 Sephadex
size exclusion chromatography yielded the title compound
(192 mg, 184 µmol, 92%.) 1H NMR (400 MHz, CD3OD) δ ppm 7.85 (d, J = 1.2 Hz, 1H), 7.43 (d, J = 3.6
Hz, 1H), 6.70 (dd, J = 3.6, 1.7 Hz, 1H), 5.25 (dd, J = 9.8, 4.6 Hz, 1H), 4.60 - 4.45 (m, 1H), 4.43 (t, J = 7.6 Hz,
1H), 3.18 (t, J = 7.0 Hz, 8H), 3.04 (t, J = 7.0 Hz, 2H), 2.26 (t, J = 7.4 Hz, 2H), 2.19 (t, J = 7.4 Hz, 8H), 1.72
- 1.42 (m, 29H), 1.45 (s, 9H), 1.40 - 1.30 (m, 10H), 1.05 - 0.88 (m, 18H). 13C NMR (101 MHz, CD3OD) δ ppm
189.07, 175.98, 175.89, 174.66, 174.38, 158.48, 152.30, 149.01, 120.01, 113.67, 79.74, 54.32, 53.00, 52.76, 41.94,
41.81, 41.55, 41.18, 40.29, 40.16, 37.02, 36.98, 36.64, 30.64, 30.11, 28.81, 27.53, 27.43, 26.76, 26.70, 26.60, 26.10,


















pound 287 (26 mg, 50 µmol) was dissolved in
DMF and 276 (33 mg, 100 µmol, 2 equiv.),
HBTU (38 mg, 100 µmol, 2 equiv.) and DiPEA
(50µl, 300 µmol, 6 equiv.) were added and the
mixture stirred for 3 hr. after which the mix-
ture was concentrated. Column chromatogra-
phy (DCM → 6% MeOH:DCM) afforded the
title compound (10 mg, 14 µmol, 28%). LCMS: Rt 7.19 min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15
min), (ESI-MS (m/z): 720.33 (M+H)+). 1H NMR (400 MHz, CDCl3) δ ppm 8.45 (s, 2H), 8.07 (s, 2H), 7.78 (d, J
= 7.6 Hz, 1H), 7.69 - 7.62 (m, 2H), 7.42 - 7.32 (m, 3H), 6.60 (s, 1H), 5.49 - 5.38 (m, 1H), 5.23 - 4.86 (m, 2H), 2.73



















Naphthyridine-Ahx3-Leu3-2-furan (295). Compound 292 (52 mg, 66 µmol) was dissolved TFA:DCM 1:1 and
stirred for 30 min. before being coevaporated with toluene (3×). The residue was dissolved in DMF and 276
(44 mg, 132 µmol, 2 equiv.), HBTU (50 mg, 132 µmol, 2 equiv.) and DiPEA (55 µl, 330 µmol, 6 equiv.) were
added and the mixture stirred for 2 hr. after which the mixture was concentrated. The residue was dissolved in
MeOH and subjected to LH20 Sephadex size exclusion chromatography followed by column chromatography
(5% MeOH:DCM → 10% MeOH:DCM) afforded the title compound (60 mg, 57 µmol, 86%). LCMS: Rt 7.06
min (linear gradient 10→ 90% MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z): 1059.53 (M+H)+). 1H NMR (400
MHz, CD3OD) δ ppm 8.30 - 8.22 (m, 4H), 7.82 (d, J = 1.2 Hz, 1H), 7.40 (d, J = 3.5 Hz, 1H), 6.67 (dd, J = 3.6, 1.7
Hz, 1H), 5.24 (ddd, J = 10.1, 7.8, 4.4 Hz, 1H), 4.56 (p, J = 7.5 Hz, 2H), 3.14 (dd, J = 13.3, 6.4 Hz, 6H), 2.63 - 2.49
(m, 2H), 2.22 (s, 3H), 2.29 - 2.12 (m, 8H), 1.89 - 1.43 (m, 25H), 1.42 - 1.23 (m, 6H), 1.03 - 0.75 (m, 18H). 13C NMR
(101 MHz, CD3OD) δ ppm 189.33, 176.09, 175.96, 175.91, 175.68, 175.04, 174.85, 172.58, 155.63, 155.00, 152.31,
149.04, 140.24, 140.20, 120.04, 119.32, 114.98, 114.86, 113.72, 54.60, 53.17, 52.99, 43.74, 41.87, 41.52, 40.33, 40.20,




















Naphthyridine-Ahx5-Leu3-2-furan (296). Compound 293 (16 mg, 15 µmol) was dissolved TFA:DCM 1:1 and
stirred for 30 min. before being coevaporated with toluene (3×). The residue was dissolved in DMF and 276
128
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(10 mg, 30 µmol, 2 equiv.), HBTU (12 mg, 30 µmol, 2 equiv.) and DiPEA (12 µl, 75 µmol, 5 equiv.) were
added and the mixture stirred for 2 hr. after which the mixture was concentrated. The residue was dissolved in
MeOH and subjected to LH20 Sephadex size exclusion chromatography followed by column chromatography
(5% MeOH:CHCl3) afforded the title compound (5 mg, 4 µmol, 27%). LCMS: Rt 7.01 min (linear gradient 10→
90% MeCN + 0.1% TFA, 15 min), (ESI-MS (m/z): 1285.80 (M+H)+). 1H NMR (400 MHz, CD3OD) δ ppm
8.30 - 8.23 (m, 2H), 7.99 - 7.89 (m, 2H), 7.82 (s, 1H), 7.40 (d, J = 3.6 Hz, 1H), 6.66 (dd, J = 3.4, 1.5 Hz, 1H), 5.25 -
5.20 (m, 1H), 4.53 - 4.37 (m, 2H), 3.22 - 3.08 (m, 10H), 2.23 (s, 3H), 2.31 - 2.10 (m, 12H), 1.83 - 1.43 (m, 25H), 1.43

















Dipyridylurea-Leu3-2-furan (297). Compound 287 (26 mg,
50 µmol) was dissolved in DMF and 363 (26 mg, 100 µmol, 2
equiv.), HBTU (38 mg, 100 µmol, 2 equiv.) and DiPEA (50µl,
300 µmol, 6 equiv.) were added and the mixture stirred for 3
hr. after which the mixture was concentrated. The residue
was dissolved in DCM:CHCl3 1:1 and washed with sat. aq.
NaHCO3 (3×), H2O (3×) and dried with Na2SO4. Column
chromatography (DCM→ 3% MeOH:DCM) afforded the ti-
tle compound (17 mg, 26 µmol, 52%). LCMS: Rt 7.89 min (linear gradient 10 → 90% MeCN + 0.1% TFA, 15
min), (ESI-MS (m/z): 648.20 (M+H)+). 1H NMR (400 MHz, CDCl3) δ ppm 8.31 (d, J = 4.4 Hz, 1H), 8.21 (d, J
= 7.5 Hz, 1H), 7.97 (br s, 1H), 7.84 (d, J = 7.5 Hz, 1H), 7.75 (t, J = 7.8 Hz, 1H), 7.68 - 7.58 (m, 2H), 7.58 - 7.30
(m, 3H), 7.00 - 6.93 (m, 1H), 6.60 - 6.54 (m, 1H), 5.39 (td, J = 9.4, 3.9 Hz, 1H), 4.72 (q, J = 7.5 Hz, 1H), 4.67 - 4.60
(m, 1H), 2.09 - 1.46 (m, 9H), 1.08 - 0.75 (m, 18H). 13C NMR (101 MHz, CDCl3) δ ppm 187.66, 172.21, 171.95,
164.37, 152.13, 151.27, 150.91, 147.10, 146.98, 139.37, 138.55, 118.82, 118.34, 117.40, 116.97, 112.85, 112.50, 52.80,





















Compound 292 (37 mg, 44 µmol) was
dissolved TFA:DCM 1:1 and stirred for
30 min. before being coevaporated with
toluene (3×). The residue was dissolved in
DMF and a mixture of carboxylic acid 363
(17 mg, 66 µmol, 1.5 equiv.), HBTU (27 mg,
70 µmol, 1.6 equiv.) and DiPEA (29µl, 176
µmol, 4 equiv.) dissolved in DMF was added. This mixture was stirred for 1.5 hr. after which the mixture was
concentrated. The residue was dissolved in MeOH and subjected to LH20 Sephadex size exclusion chromatogra-
phy followed by column chromatography (5% MeOH:DCM→ 7.5% MeOH:DCM) afforded the title compound
(21 mg, 21 µmol, 49%). 1H NMR (400 MHz, CD3OD) δ ppm 8.37 (dd, J = 5.0, 1.0 Hz, 1H), 8.02 (d, J = 8.1 Hz,
1H), 7.96 - 7.90 (m, 1H), 7.84 (d, J = 1.1 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.50 (d, J = 7.6 Hz, 1H), 7.42 (d, J = 3.3
Hz, 1H), 7.11 - 7.06 (m, 1H), 6.68 (dd, J = 3.6, 1.7 Hz, 1H), 5.25 (dd, J = 9.8, 4.7 Hz, 1H), 4.53 - 4.47 (m, 1H),
4.43 (t, J = 7.6 Hz, 1H), 3.48 (t, J = 7.0 Hz, 2H), 3.19 - 3.13 (m, 4H), 2.21 (ddd, J = 19.7, 15.1, 7.5 Hz, 6H), 1.78
- 1.54 (m, 16H), 1.54 - 1.41 (m, 6H), 1.40 - 1.26 (m, 5H), 1.03 - 0.87 (m, 18H). 13C NMR (101 MHz, CD3OD) δ
ppm 189.13, 176.06, 175.93, 174.76, 174.46, 166.30, 154.07, 153.82, 152.93, 152.34, 149.27, 149.02, 148.21, 140.77,
139.91, 120.02, 119.52, 117.96, 117.40, 113.78, 113.67, 54.36, 53.04, 52.82, 41.94, 41.82, 41.56, 40.48, 40.18, 37.00,





















Compound 293 (30 mg, 28 µmol) was
dissolved TFA:DCM 1:1 and stirred for
30 min. before being coevaporated with
toluene (3×). The residue was dissolved in
DMF and a solution of carboxylic acid 363
(11 mg, 45 µmol, 1.5 equiv.), HBTU (17 mg,
45 µmol, 1.6 equiv.) and DiPEA (19µl, 112
µmol, 4 equiv.) in DMF was added. This mixture was stirred for 3 hr. after which the mixture was concentrated.
The residue was dissolved in MeOH and subjected to LH20 Sephadex size exclusion chromatography followed
by column chromatography (5% MeOH:DCM → 7.5% MeOH:DCM) afforded the title compound (26 mg, 21
µmol, 75%). 1H NMR (400 MHz, CD3OD) δ ppm 8.37 (d, J = 4.4 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.93 (t, J =
7.9 Hz, 1H), 7.85 (s, 1H), 7.81 - 7.75 (m, 2H), 7.50 (d, J = 7.4 Hz, 1H), 7.42 (d, J = 3.5 Hz, 1H), 7.09 (dd, J = 6.9,
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5.4 Hz, 1H), 6.69 (dd, J = 3.5, 1.7 Hz, 1H), 5.25 (dd, J = 9.8, 4.6 Hz, 1H), 4.50 (t, J = 7.5 Hz, 1H), 4.43 (t, J = 7.5
Hz, 1H), 3.48 (t, J = 7.0 Hz, 2H), 3.16 (dd, J = 11.5, 6.8 Hz, 8H), 2.32 - 2.12 (m, 10H), 1.82 - 1.41 (m, 30H), 1.41 -
1.27 (m, 9H), 1.06 - 0.86 (m, 18H). 13C NMR (101 MHz, CD3OD) δ ppm 189.11, 176.04, 175.92, 174.73, 174.44,
166.27, 154.05, 153.81, 152.92, 152.32, 149.26, 149.03, 148.20, 140.76, 139.90, 120.03, 119.52, 117.94, 117.40,
113.77, 113.68, 54.36, 53.04, 52.81, 41.93, 41.81, 41.55, 40.48, 40.19, 36.99, 36.65, 30.28, 30.12, 27.55, 26.77, 26.71,
26.61, 26.12, 25.94, 25.76, 23.67, 23.44, 23.41, 22.18, 22.04, 21.88.
Competition experiments in cell lysate
HEK293T cells were cultured on DMEM supplemented with 10% Fetal Calf Serum (FCS), 10 units/ml penicillin
and 10 µg/ml streptomycin in a 7% CO2 humidified incubator at 37
◦C. Cells were harvested, washed 2×with PBS
and permeated in digitonin lysis buffer (4× pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl2, 5
mM DTT, 0.025% digitonin) for 15 min. on ice and centrifuged at 16.100 rcf. for 20 min at 4◦C. The supernatant
containing the cytosolic fraction was collected and the protein content was determined by Bradford assay (Biorad).
15 µg (HEK293T) total protein per experiment was exposed to the inhibitors (10× solution in DMSO) for 1 hr. at
37◦C prior to incubation with MVB003 (500 nM) for 1 hr. at 37◦C. Reaction mixtures were boiled with Laemmli’s
buffer containing β-mercaptoethanol for 3 min. before being resolved on 12.5% SDS-PAGE. In-gel detection of
fluorescently labelled proteins was performed in the wet gel slabs directly on the Typhoon Variable Mode Imager
(Amersham Biosciences) using the Cy3/Tamra settings (λex 532 nm, λem 560 nm).
Fluorogenic substrate hydrolysis assay
26S proteasomes were purified from rabbit muscle as described. 169 To determine inhibition of purified protea-
somes, proteasome (∼ 10ng/ml) in assay buffer (50 mM Tris-HCl pH 7.5, 40 mM KCl, 2 mM EDTA, 1 mM DTT,
100 µM ATP, 50 µg/mL BSA) was incubated with inhibitors for 30 min. at 37◦C followed by assay of activity
with 100 µM fluorogenic substrates Suc-LLVY-AMC (chymotrypsin-like site), Ac-RLR-AMC (trypsin-like site),
and Ac-nLPnLD-AMC (caspase-like site). Fluorescence of released AMC was measured (λe x 350 nm, λe m 430 nm)
continuously for 30 min at 37◦C. Residual activity was determined from the slope of the reaction progress curves
as a mean value from 3 experiments. 147
Induction of immunoproteasome
3T3 cells (5×105) were seeded and grown for 6 hr in a 12-well plate. The medium was replaced for 1 ml fresh
medium containing 100 units INF-γ per well. The cells were cultured for 48 hr. before inhibitor (1000× stock
in DMSO) was added and incubated for 2 hr. The cells were washed 2× with PBS and harvested. Cell pellets
were resuspended in hypotonic lysis buffer (50 mM Tris pH 7.4, 5 mM MgCl2, 5 mM DTT) for 15 min at 0
◦C
and centrifuged at 16.100 rcf. for 20 min at 4◦C. Lysate (20 µg protein) was incubated with MVB003 (0.5 µM
end concentration) 1 hr. at 37◦C before being treated as described above. For western blot analysis, cell lysate
(100 µg protein) was treated with biotin phosphane (154, 200 µM end concentration) for 1 hr. at 37◦C before the
reaction was stopped by chloroform/methanol precipitation. 248 The pellet was redissolved in 20 µl 2x Laemli’s
sample buffer. 10 µl of these samples was resolved on 12.5% SDS-PAGE gel. Proteins were electrotransferred to
nitrocellulose membranes. The blots were blocked with BSA (1%) in TBS-Tween 20 (0.1% Tween 20) for 1 hr. at
RT, hybridized for 1 hr. with streptavidin/HRP (1:3000) in blocking buffer, washed, and visualised with the aid
of an ECL+ kit (Amersham Biosciences).
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Samenvatting
Op weg naar subunit-specifieke proteasoomremmers
De kwaliteit en hoeveelheid van elk eiwit is van cruciaal belang voor het overleven van
een cel. Het proteasoom speelt een onmisbare rol in het afbreken van de meeste eiwit-
ten in de menselijke cel. Het proteasoom, een groot eiwitcomplex dat strak gereguleerd
wordt, is daarvoor uitgerust met subunits met verschillende proteolytische activiteiten die
bij elkaar in het eiwitcomplex zitten. Het constitutieve proteasoom bevat subunits met
caspase-achtige activiteit (β1), trypsine-achtige activiteit (β2) en chymotryptische activiteit
(β5). Elk van deze activiteiten prefereert het knippen van een eiwitketen op andere plekken.
Dit wordt gestuurd door het aminozuur naast de te knippen plek in een eiwit. Afhankelijk
van het celtype kunnen nog eens vier verschillende subunits met proteolytische activiteiten
de plek van β1, β2 of β5 van het proteasoom innemen. Op een gecontroleerde manier
worden doeleiwitten door het proteasoom afgebroken tot korte peptiden. De meeste van
deze peptiden worden verder afgebroken tot losse aminozuren. Een deel van de peptiden
wordt echter geselecteerd voor presentatie op het celoppervlak en door het immuunsysteem
bestudeerd. Op deze manier stelt het immuunsysteem vast of een cel lichaamsvreemde ei-
witten bevat en wordt er zo nodig een immuunreactie opgewekt. Het proteasoom is dus
een belangrijk studieobject in de immunologie. Daarnaast is het proteasoom een doelwit
voor medicijnen tegen kanker.
Op basis van antiontstekings- of antitumoractiviteit zijn veel natuurstoffen gevonden
die een remmende werking vertonen op proteolytische activiteiten van het proteasoom.
Tegelijkertijd zijn er vele proteasoomremmers gesynthetiseerd en op het moment wordt de
proteasoomremmer bortezomib in de kliniek gebruikt als medicijn tegen leukemie. Een
aantal andere remmers wordt aan klinisch onderzoek onderworpen. De rol van elke afzon-
derlijke proteolytische activiteit in gezonde cellen of kankercellen of hun rol in het ontstaan
van auto-immuunziekten is nog niet geheel duidelijk. Selectieve remmers die elke activiteit
van het proteasoom afzonderlijk kunnen stilleggen zijn handig gereedschap om de rol van
elk van deze activiteiten te onderzoeken. Om gebruikt te kunnen worden om proteasoom-
functies in cellen te bestuderen moeten deze selectieve remmers wel celpermeabel zijn. Veel
proteasoomremmers bestaan uit een electrofiele val (om aan het katalytisch actieve residu
van de proteolytische activiteit van het proteasoom te binden), een peptidensequentie (ver-
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antwoordelijk voor herkenning), en een N-terminale extensie. Dit proefschrift beschrijft
de ontwikkeling van enkele specifieke remmers van individuele proteasoomactiviteiten.
Hoofdstuk 1 geeft een overzicht van natuurlijk voorkomende en synthetische klassen
proteasoomremmers. Daarnaast wordt een overzicht gegeven van proteasoomremmers die
selectief zijn voor bepaalde proteolytische activiteiten van het proteasoom.
Hoofdstuk 2 beschrijft de synthese van drie proteasoomremmers die de chymotrypti-
sche activiteit van het proteasoom (β5) remmen. Door het epoxyketon-electrofiel in deze
drie stoffen, verantwoordelijk voor binding aan het nucleofiele katalytische residu van de
proteasoomactiviteit, te vervangen door een vinylsulfon, werden drie analoga verkregen.
Met behulp van een fluorescent epoxomicin-analoog werd het inhibitieprofiel van de zes
stoffen in cellysaat bepaald. Door gebruik van een fluorogeen substraathydrolyse-assay met
gezuiverd constitutief proteasoom en immunoproteasoom werd de activiteit op immuno-
subunits onderzocht. De activiteit van de drie vinylsulfon-analogen is lager dan die van
de epoxyketon-gebaseerde remmers, maar twee van de vinylsulfon-analogen vertonen meer
selectiviteit voor β5. De electrofiele val beïnvloedt dus de selectiviteit van proteasoomrem-
mers.
Hoofdstuk 3 beschrijft de synthese van tien electrofiele vallen die in staat zijn Michael-
additie te ondergaan. Deze electrofielen werden gekoppeld aan drie verschillende pepti-
dedelen en dit leidde tot een dertigtal verbindingen. Geen van deze stoffen vertoonde po-
tente inhibitie van proteasoomactiviteit. De cellulaire doelwitten van twee azide bevattende
stoffen werd bepaald door middel van een bioorthogonale twee-staps labelingstrategie. De
stoffen werden met cellen geïncubeerd, waarna de azide selectief gemodificeerd werd met
biotine door middel van de Staudinger-ligatie. De gemodificeerde cellulaire doelwitten wer-
den gescheiden op basis van de aanwezigheid van biotine en geanalyseerd met massaspec-
trometrie. Onder de teruggevonden eiwitten waren katalytisch actieve subunits van het
proteasoom, ondanks het onvermogen van de gebruikte stoffen het proteasoom potent te
remmen. Daarnaast werden cathepsines gevonden, een familie cysteïne-proteases die in
staat zijn Michael-additie te ondergaan.
Syringolin A is een potente proteasoomremmer die wordt uitgescheiden door een
plantenpathogeen wanneer deze een plant binnendringt. Syringolin A is ook een potente
remmer van het menselijke proteasoom. Hoofdstuk 4 behandelt de inbouw van het bij-
zondere valine-ureum-valine motief, aanwezig in syringolin A, in een bibliotheek peptide-
gebaseerde vinylsulfonen en epoxyketonen. Het inhibitieprofiel van de bibliotheek werd
vastgesteld met een fluorescente analoog van epoxomicin. Stoffen waarbij de ureumband
op een korte afstand van de electrofiele val is ingebouwd remmen de caspase-achtige ac-
tiviteit (β1) van het proteasoom. Een epoxyketon-gebaseerde remmer uit deze korte serie
kwam naar voren als de meest potente selectieve remmer van β1 in levende cellen tot nu
toe beschreven. Remmers met een iets langere afstand tussen electrofiel en ureumband ver-
tonen juist selectiviteit voor de chymotryptische proteasoomactiviteit (β5). Verscheidene
stoffen uit de in dit hoofdstuk beschreven bibliotheek zijn potenter dan syringolin A.
Hoofdstuk 5 beschrijft de vergelijking van twee-staps labeling door cyclooctynen en de
Staudinger-Bertozzi ligatie. Proteasomen werden gelabeld met een proteasoomremmer die
een BODIPY-fluorofoor en een azide bevat. De reactie-efficiëntie van drie cyclooctynen,
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bevestigd aan biotine, werd bestudeerd aan de hand van de verschuiving van proteasoom-
signalen na gel-electroforese. De concentratie die nodig is om alle azide-BODIPY gemod-
ificeerde proteasomen te decoreren met biotine is voor cyclooctynen veel lager dan voor
de fosfine van de Staudinger-Bertozzi-ligatie. Bij het uitlezen van het signaal van biotine
blijkt dat de cyclooctyn-ligatie gepaard gaat met veel ongewenste achtergrondlabeling, in
tegenstelling tot de Staudinger-Bertozzi-ligatie.
In Hoofdstuk 6 wordt de synthese van een serie proteasoomremmers met basische
aminozuurzijketens beschreven. Het inhibitieprofiel van deze stoffen in cellysaat en le-
vende cellen werd bepaald met behulp van een fluorescente epoxomicinanaloog. Selec-
tiviteit voor de tryptische activiteit van het proteasoom (β2) wordt verkregen wanneer
een bij fysiologische pH positief geladen zijketen op P1 wordt gebruikt. Het inbouwen
van een 4-aminomethyleen fenylalanine op de P1- en P3-positie van een tetrapeptide vinyl-
sulfon levert een potente remmer met hoge selectiviteit voor β2 op. Bevestiging van een
BODIPY-fluorofoor aan dit molecuul resulteerde in een activiteits-gebaseerde probe voor
β2. Door de aanwezigheid van twee basische zijketens komen deze twee moleculen echter
niet efficiënt de cel binnen.
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